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Abstract 
Lysostaphin (EC.3.4.24.75) is an extracellular glycylglycine endopeptidase produced 
exclusively by Staphylococcus simulans biovar staphylolyticus (ATCC 1362, NRRL 
B-2628). The zinc-containing endopeptidase demonstrates specific and potent 
staphylolytic activity therefore shows great promise for the treatment of blood-borne 
and biofilm-associated staphylococcal infections. The gene encoding mature 
lysostaphin has therefore been cloned and expressed using Escherichia coli, the 
most widely used expression host for recombinant protein production.  
This research demonstrated that when recombinant lysostaphin is expressed in E. 
coli BL21(DE3), the resulting catalytically-active product exhibits considerable micro-
and macro-heterogeneity. Using a variety of chromatographic modes, including IEX, 
GF, IMAC, HIC and RP, several variants of recombinant lysostaphin were resolved 
indicating differences in charge, mass and hydrophobicity. The degree of charge 
heterogeneity observed was influenced by a number of factors, including expression 
temperature, amino acid sequence, optical density at point of induction and duration 
of culture.  Rapid analysis of N-terminally His-tagged recombinant lysostaphin 
demonstrated that charge variant formation occurred in a time-dependent manner, 
whereby basic protein variants became steadily converted to more acidic variants.  
LC-MS analysis of N-terminally His-tagged recombinant lysostaphin indicated that 
the protein was likely to have become truncated during expression. Comparison of 
WCX and LC-MS analysis suggested that amino acids were lost from the N-terminus 
to produce basic variants, whilst loss of C-terminal lysine16 may have explained the 
detection of more acidic variants.  As intact mass measurements acquired during LC-
MS analysis of N-terminally His-tagged recombinant lysostaphin did not match 
exactly with theoretical intact protein masses, it was thought that the protein variants 
were also subject to enzymatic or chemical PTMs. These conclusions were made 
using supporting evidence that was acquired during GF, SDS-PAGE and CXC 
analysis.  
Overall these findings are of concern for the production of recombinant protein 
production using E. coli.  However this research suggested that chromatography can 
be used to sensitively detect and monitor product heterogeneity, so that a more 
homogeneous product could be produced by careful adjustment of expression, 
harvest and formulation conditions. 
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1 Introduction 
 
1.1 Escherichia coli 
Escherichia coli is a rod-shaped, Gram-negative bacterium, which was first described 
as Bacterium coli in 1885 by Theodor Escherich.  The bacterium became officially 
recognised as Escherichia coli in 1958, to acknowledge its discoverer (Kuhnert et al., 
2000). E. coli is a widespread bacterial species, which includes a wide range of 
strains which can be highly pathogenic, leading to considerable morbidity through 
localised and systemic infections (Kuhnert et al., 2000).  Alternatively E. coli strains 
can be avirulent strains, contributing to the normal flora of the intestine.  Many 
avirulent strains have been characterised and are used as safe laboratory strains for 
genetic, molecular biological and biotechnological purposes. Due to the widespread 
nature and versatility of E. coli, the structure of this bacterium has been studied 
extensively  
As a Gram-negative bacterium, E. coli possess a three-layer envelope which adjoins 
the cytoplasmic space.  This envelope consists of an outer membrane and an inner 
plasma membrane which surround the periplasmic space.  E. coli was one of the first 
microorganisms to be genome sequenced, which provided enhanced knowledge of 
gene expression in this organism. The 4.6 Mbp genome of E. coli K12 was published 
in 1997 and was found to encode 4288 proteins (Blattner et al., 1997).  Although the 
exact function of around 30% of the open reading frames (ORFs) which encode the 
E. coli genome are unknown, knowledge of E. coli genetics has provided an insight 
into how the organism grows, replicates and responds within environmental 
conditions (Richmond et al., 1999).  Prior advances in knowledge of E. coli genetics 
also lead to the development of recombinant DNA technology, which has 
revolutionised the large-scale production of specific, biologically important proteins.  
 
1.1.1 Recombinant protein expression in E. coli 
In 1982, recombinant insulin, the very first therapeutic protein derived from E. coli 
was approved for therapeutic use in the treatment of insulin-dependent diabetes 
(Johnson, 1983).  Using recombinant DNA technology, the mature gene sequence 
encoding insulin could be efficiently expressed within E. coli, providing large amounts 
of recombinant insulin.  Due to high yields and efficiency, E. coli rapidly became 
popular for the production of a variety of recombinant proteins used for industrial 
purposes, such as amylases, cellulases and proteases, or therapeutic purposes, 
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such as hormones, monoclonal antibodies (mAbs), cytokines and interferons 
(Schellekens, 2005, Swartz, 2001, Eiteman and Altman, 2006, Bylund et al., 2000). 
Long-term use of E. coli has led to improvements in genetic handling and therefore 
the organism has well-characterised genetics, which can be exploited to full potential 
during recombinant protein expression (Ghosh Moulick et al., 2007).  
E. coli provides economical protein production due to being able to grow rapidly in 
inexpensive media (Zhang and Greasham, 1999).  Host expression strains have 
been genetically engineered to enhance recombinant protein production, through 
improvements in DNA transcription, RNA translation, protein expression and stability 
(Eiteman and Altman, 2006). The versatility of heterologous expression is increased 
further by advances in gene cloning which has permitted periplasmic expression and 
expression of recombinant fusion proteins, to facilitate protein purification or enhance 
solubility. Provided that expression conditions are selected appropriately, E. coli 
replicates rapidly leading to an increased cell density and high yields of recombinant 
product within a short period of time. The success and extent of protein expression is 
however dependent on a number of factors, such as expression media conditions, 
the mode and scale of culture, expression host strains and bacterial growth kinetics. 
Stringent monitoring is essential to ensure reproducibility of recombinant protein 
manufacture, especially as the complexity of the prokaryotic cellular milieu and small 
alterations in culture conditions can alter the yield, stability and structure of a 
recombinant protein (Jenzsch et al., 2006).    
E. coli remains the most commonly used expression host for the production of 
recombinant proteins derived from eukaryotic or prokaryotic origins for industrial, 
therapeutic, diagnostic and research purposes (Eiteman and Altman, 2006, Xu et al., 
2008).  Although other prokaryotic expression hosts, such as and Lactococcus lactis, 
Bacillus subtilis or Campylobacter jejuni are available for recombinant protein 
production, E. coli remains the most dominant prokaryotic expression host (Georgiou, 
1988, Chou, 2007, Mierau et al., 2005a, Westers et al., 2004, Wacker et al., 2002, 
Linton et al., 2005).  Eukaryotic expression hosts also exist from yeast species such 
as Pichia pastoris or Saccharomyces cervisiae or using insect or mammalian cells, 
such as Chinese hamster ovary (CHO) (Kang et al., 2000, Choi et al., 2006, Leonard 
et al., 1990).  Despite the availability of a variety of expression hosts, nine out of a 
total of 31 therapeutic proteins approved between 2003 and 2006 were derived from 
E. coli, demonstrating the popularity and importance of the organism as a prokaryotic 
expression host (Chou, 2007, Ioannou, 2006). 
3 
 
1.1.2 Quality control during recombinant protein production 
Following expression, the recombinant protein is purified from cellular contaminants 
as part of good manufacturing practice (GMP) as such impurities may impinge on the 
safety of therapeutic proteins (Rathore et al., 2003). Protein purification typically 
requires the application of a number of preparative techniques to achieve an 
acceptable level of purity and therefore increases the duration and cost of 
recombinant protein production. Once purified, the protein may undergo formulation, 
through the addition of buffering agents and excipients which enhance the stability of 
the recombinant protein. In addition, the yield and quality of the recombinant product 
must be assessed so that culture conditions and expression systems can be 
optimised if required (DePhillips et al., 1994). 
The quality of recombinant protein products is paramount, especially in the case of 
protein therapeutics which are strictly regulated by drug quality standards.  
Regulatory authorities, such as the Medicines and Healthcare products Regulatory 
Agency (MHRA) or European Medicines Agency (EMEA) publish guidelines which 
specify the levels of purity, stability, safety and efficacy that a recombinant product 
must satisfy. As recombinant proteins are derived from living organisms, quality 
control is a much more complex affair due to variable influence of cell physiology and 
growth conditions upon the integrity of the expressed protein. It is therefore essential 
that the structure and formulation of a recombinant protein is thoroughly 
characterised to ensure that drug immunogenicity is not encountered during clinical 
trials or following therapeutic administration (Pavlovic et al., 2008).   
When producing recombinant proteins, it is therefore desirable to produce 
homogeneous proteins which ideally display identical activity and conformational 
structure to that of the native protein.  Many eukaryotic proteins typically undergo 
post-translational modification (PTM) to achieve their native state.  As prokaryotic 
systems are regarded as being much simpler than eukaryotic systems, it has been 
reported that E. coli is not able to produce more complex, modified or processed 
forms of recombinant proteins (Sugase et al., 2008, Demain and Vaishnav, 2009). 
Therefore E. coli is regarded as the preferred host for the expression of therapeutic 
proteins that do not require PTM to achieve biological function (Jenzsch et al., 2006, 
Choi and Lee, 2004).   
Despite past reports, growing evidence has demonstrated that recombinant proteins 
expressed in E. coli can display considerable product heterogeneity, which occurs as 
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a result of post-translational processing events which follow expression.  
Recombinant proteins can also undergo chemical modifications or aggregation 
during purification, storage or formulation.  Such structural alterations can result in 
micro- and macro-heterogeneity, which could interfere with the function or stability of 
the protein. It is also concerning that greater product complexity could lead to 
unexpected immunogenicity during therapeutic use. 
 
1.2 Post-translational modifications (PTMs) 
PTMs are covalent modifications, which occur following the transcription of DNA into 
RNA and the translation of RNA into proteins. The polypeptide chains that compose 
a protein structure are constructed of unique sequences of amino acid residues.  The 
translated protein structure can exhibit further variability due to sequence alterations, 
such as amino acid substitutions or splicing variations that can occur during 
translation.  The nascent or folded polypeptide can then be subjected to co- or post-
translational modifications following chemical or enzyme-catalysed reactions (Walsh 
et al., 2005).  PTMs increase the complexity of the protein structure further and 
greatly expand the proteome of an organism. In addition to increasing biological 
diversity, PTMs alter the biophysical and biochemical properties of a protein and 
therefore have important implications for cellular processes that the protein governs.  
The structural changes imposed by PTMs can control or lead to induction of 
enzymatic activity, direction of intra- or extra-cellular translocations and can influence 
protein stability and degradation (Arfin and Bradshaw, 1988).  Such PTMs are 
reversible, allowing greater control of cellular processes, whilst other modifications 
are permanent and can only be removed through replacement of the modified 
molecule.  
 
1.2.1 Types of PTM 
PTMs can occur following the covalent addition of a chemical group to a side chain 
residue of a protein or through covalent cleavage of the peptide backbone.  Electron 
rich, nucleophilic side chains of amino acids possess the propensity to undergo 
covalent addition of electrophilic fragments of cosubstrates (Figure 1.1) (Walsh et al., 
2005). Amino acids containing nitrogen, oxygen or sulphur atoms can, depending on 
their ionization state, function as nucleophiles during covalent modification.  The 
nucleophilic group chemically mediates the transfer of the electrophile, during 
derivatization of the protein side chains. The terminal regions of a protein also 
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possess nucleophilic groups which have the potential to undergo covalent 
modification, with the amino group at the N-terminus and the carboxyl group at the C-
terminus (Walsh and Jefferis, 2006).  
 
Figure 1.1: Chemical mechanism of covalent modification.  Nucleophilic amino 
acid side chains become covalently modified by an electrophilic fragment of a 
cosubstrate (Walsh et al., 2005) 
Nucleophilic groups promote terminal and side chain modifications; however the 
incidence of such covalent interactions is facilitated by the existence of enzymes that 
efficiently catalyse the formation or removal of specific PTMs.  Through the action of 
a variety of modification-specific enzymes, a diverse range of electrophilic fragments 
can be transferred by nucleophilic attack, leading to an array of PTMs.  Common 
PTMs include phosphorylation, glycosylation, methylation and oxidation, however 
more than 200 kinds of PTM can occur following covalent addition of electrophilic 
groups (Polevoda and Sherman, 2007, Walsh, 2006).  At present it is unknown 
exactly how many of these modifications can occur within E. coli, however it  is 
already evident that a significant number can readily occur, influencing the structure 
of native and recombinant proteins.  Consequently sequence variants and PTMs 
have been found to occur at nucleophilic groups at the N-terminus or side chain of 
recombinant proteins, through chemical or enzyme-catalysed reactions (Xie et al., 
2009).  
   
1.2.1.1 N-terminal modifications of recombinant proteins expressed in E. coli 
N-terminal heterogeneity is not uncommon following expression of a recombinant 
protein within E. coli (Table 1.1).  The heterogeneity appears to arise as a 
consequence of prokaryotic protein synthesis and associated N-terminal processing 
mechanisms.  Recombinant protein expression can exacerbate the heterogeneity of 
N-terminal sequences, due to the heightened synthetic demands that heterologous 
expression imposes on the expression host.   
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Table 1.1: N-terminal modifications of recombinant proteins expressed in E. 
coli 
Modification Recombinant Protein Reference 
Retention of N-terminal 
methionine 
Interleukin-1 beta Wingfield et al., 1987a 
Growth hormone (hGH) Nakagawa et al., 1987 
Interleukin 2 (IL-2) Nakagawa et al., 1987 
Proapolipoprotein A-I Moguilevsky et al., 1993 
Growth hormone  Nishimura et al., 1998 
Retention of N-
formylmethionine 
Growth hormone II (EGH) Sugimoto et al., 1990 
Granulocyte colony-stimulating factor  Clogston et al., 1992 
Interleukin-5 Rose et al., 1992 
Histone A (hmfA) Sandman et al., 1995  
Cytochrome P450 (5 mutants)  Dong et al., 1996 
Fatty acid-binding protein (H-FABP) Specht et al., 1994 
N
α
-Acetylation Eglin C Grutter et al., 1985  
Leukocyte interferon A Takao et al., 1987 
Interferon-γ Honda et al., 1989 
Interleukin-1β (mrIL-1 β) Lischwe et al., 1993 
Stathmin-like domains RB3 and RB3’ 
(RB3SLD and RB3SLD’) 
Charbaut et al., 2002 
Tissue inhibitor of metalloproteinases-4 
(TIMP-4)  
Troeberg et al., 2002 
Prothymosin α Wu et al., 2006 
F1-V Bariola et al., 2007 
N-terminal domain of TIMP (N-TIMP-1) Van Doren et al., 2008 
Thymosin α 1-L12 (Tα1-L12) Fang et al., 2010 
N
α
-Methylation Ag1624 Lahnstein et al., 1993 
Haemoglobin (rHb1.1) Apostol et al., 1995 
Histidine-rich protein II Schneider et al., 2005 
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1.2.1.2 Enzyme-mediated side chain modifications of recombinant proteins 
expressed in E. coli 
Recombinant protein expressed in E. coli can also be susceptible to a number of 
enzyme-mediated side chain modifications.  Acetylation, phosphorylation and 
methylation are the most frequently reported of these modifications (Table 1.2).  
 
Table 1.2: Enzymatic modifications of recombinant proteins expressed in E. 
coli 
Modification Recombinant Protein Reference  
Acetylation Somatotropin (Bovine) Violand et al., 1994 
Somatotropin (Porcine) Violand et al., 1994 
Placental lactogen Violand et al., 1994 
Tissue factor pathway inhibitor (TFPI) Violand et al., 1994 
Basic fibroblast growth factor (hbFGF) 
mutein CS23 (CS23) 
Suenaga et al., 1999 
RANTES S24F d'Alayer et al., 2007 
Phosphorylation Aurora A catalytic domain Du et al., 2005a 
PAK1 catalytic domain Du et al., 2005a 
PAK7 catalytic domain Du et al., 2005a 
PKA catalytic subunit Du et al., 2005a 
Aurora 2 catalytic domain Du et al., 2005a 
StkSA1 Lomas-Lopez et al., 2008 
NE2398 CBS domain She et al., 2010 
RPA3416 CBS domain She et al., 2010 
PH0267 CBS domain She et al., 2010 
Atu1752 CBS domain She et al., 2010 
AF0847 CBS domain She et al., 2010 
TV1335 CBS domain She et al., 2010 
MJ0653 CBS domain She et al., 2010 
Atu1337 ABM domain She et al., 2010 
Methylation Growth hormone (Genotropin
®
) Hepner et al., 2005 
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1.2.1.3 Chemical side chain modifications of recombinant proteins expressed 
in E. coli 
In the absence of enzyme-mediated catalysis, side chain modification of nucleophilic 
groups of amino acids can occur readily through nucleophilic attack.  Deamidation, 
glycation and oxidation of recombinant proteins has been most frequently reported to 
occur (Table 1.3). 
 
Table 1.3:  Non-enzymatic modifications of recombinant proteins expressed in 
E. coli 
Modification Recombinant Protein Reference 
Deamidation Interleukin-1 α (IL-1α)  Wingfield et al., 1987b 
Growth hormone II (EGH)  Sugimoto et al., 1990 
Neu differentiation factor Hara et al., 1996 
Stem cell factor (rhSCF) Hsu et al., 1998 
Serine hydroxymethyltransferase Solstad and Flatmark, 2000 
Lymphotoxin (rhLT) Xie et al., 2003 
Growth hormone (Genotropin
®
)  Hepner et al., 2005 
Growth hormone (Nutropin AQ
®
)  Jiang et al., 2009 
Immunoglobulin G Fc fusion protein Ren et al., 2009 
Glycosylation GRK-2 Geoghegan et al., 1999 
ZAP-70  Geoghegan et al., 1999 
Phosphatidylinositol-3 kinase (c-P85) Geoghegan et al., 1999 
Spo0F  Yan et al., 1999b 
FKBP Yan et al., 1999a 
Src tyrosine kinase (SH3 domain)  Kim et al., 2001 
Interferon γ (rhIFN- γ) Mironova et al., 2001, Mironova 
et al., 2003 
Interferon alfacon-1 Mironova et al., 2008 
Oxidation Insulin-like growth factor I (IGF-I) Forsberg et al., 1990 
Growth hormone II (EGH) Sugimoto et al., 1990 
Interleukin-5 Rose et al., 1992 
Neu differentiation factor Hara et al., 1996  
Growth hormone (Genotropin
®
) Hepner et al., 2005 
Growth hormone (Norditropin
®
) Hepner et al., 2006 
N-terminal domain of TIMP (N-TIMP-1) Van Doren et al., 2008 
Growth hormone (Nutropin AQ
®
) Jiang et al., 2009 
Immunoglobulin G Fc fusion protein Ren et al., 2009 
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1.3 Heterogeneity of recombinant proteins expressed in E. coli 
It is evident that recombinant proteins expressed in E. coli are susceptible to a wide 
range of PTMs, which can occur as a consequence of post-translational processing, 
the nucleophilicity of amino acid groups and enzyme-mediated modification 
mechanisms.  In the majority of studies, particular modifications were specifically 
detected or reported in isolation, however more recent studies suggest that 
recombinant proteins expressed in E. coli can be susceptible to a combination of 
multiple modifications (Hepner et al., 2005, Hepner et al., 2006).  Furthermore it is 
unclear how many different kinds of modification can occur in E. coli and as a result 
recent studies have reported the detection of less common or novel modifications, 
such as succinylation or S-thiolation (Zhang et al., 2011, Liu et al., 2009) .  
 
1.3.1 Sequence variation  
In addition to PTM, proteins may exhibit sequence variation through loss or 
substitution of amino acids. Such sequence variation can occur under normal growth 
conditions, however it seems probable that hyper-expression of a recombinant 
protein could increase the likelihood of translational errors by overwhelming the 
translational apparatus and proof-reading mechanisms of E. coli (Schneider et al., 
2005, Scorer et al., 1991).  The physiological stress associated with recombinant 
protein expression may therefore adversely affect translational fidelity (McNulty et al., 
2003).  Mis-translational events can also arise due to genetic mutation or codon bias, 
which can lead to processing errors such as protein truncation, protein elongation or 
amino acid substitutions.  
Due to nature of recombinant DNA technology, errors in sequence information can 
occur at any stage of gene expression (Scorer et al., 1991).  For instance, point 
mutations, insertions or deletions within a recombinant gene sequence could alter the 
subsequent amino acid sequence of the translated recombinant protein. Nucleotide 
insertions, deletions or point mutations can lead to frame-shifting or amino acid 
substitution depending on where the mutation occurs. Frame-shift mutations and 
deletions are thought to occur more frequently than amino acid exchanges however  
(Hepner et al., 2005).  The implications of a mutation are less severe if the mutation 
happens at the third base encoding a particular codon, due to the “Wobble 
hypothesis” for codon-anti-codon pairing. If a mutation occurs within one of the first 
two bases of a codon then the amino acid is likely to become substituted.  
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Sequence variation can also arise due to codon bias, which can occur when 
expressing a foreign recombinant gene that originates from a host whose codon 
utilization preferences differ markedly from that of E. coli. During normal protein 
expression, different organisms have a bias towards a specific subset of codons, 
which have evolved according to cellular gene expression levels (Bonekamp and 
Jensen, 1988). During recombinant protein expression, translation of the target 
protein may be complicated by an absence of rare codons which are required to 
translate the protein in its desired form.  Codon bias can therefore lead to 
misincorporation errors, as the lack of rarer tRNA molecules leads to ribosomal 
stalling, frame-shifting and misincorporation of more abundant tRNA molecules 
(McNulty et al., 2003, Kane et al., 1992).  The degree of mis-translation is also 
dependent on the amino acid sequence of the recombinant protein being expressed. 
Furthermore expression culture conditions can influence the synthesis and 
subsequent availability of essential codons (Kane et al., 1992) .     
The incidence of amino acid substitution has been reported several times during 
recombinant protein expression (Table 1.4). Amino acid substitutions alter the 
primary structure of a protein, which can have implications for secondary and tertiary 
protein structure, in addition to potentially influencing the biological activity of a 
protein (McNulty et al., 2003).  The exchange of amino acids may therefore affect the 
quality of a recombinant biopharmaceutical as substituted residues may lead to 
product heterogeneity (Hepner et al., 2005) .    
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Table 1.4:  Recombinant proteins with amino acid substitutions when 
expressed in E. coli 
 
As shown in Table 1.5, a variety of amino acid residues can be substituted within the 
amino acid sequence of a recombinant protein. Methionine, glutamine and arginine 
appear to have been most frequently reported as having undergone substitution. 
Translation of arginine residues in E. coli is known to be problematic as the arginine 
codons are considered rare, occurring at a frequency of less than 1% (McNulty et al., 
2003).  In addition, rarer arginine codons, such as AGG are translated much slower 
than more abundant arginine codons, such as CGU (Bonekamp and Jensen, 1988).  
 
  
Recombinant 
Protein 
Origin E. coli  
Strain 
Detection 
Methods 
Reference 
Interleukin-2 Human K12 Edman degradation 
FAB-MS 
Amino acid analysis 
Tsai et al., 1988 
Somatotropin Bovine W3110G IEF 
RP-HPLC 
Amino acid analysis 
Bogosian et al., 
1989 
Growth hormone Human Not specified HIC 
Edman degradation 
Gellerfors et al., 
1990 
Haemoglobin Human Not specified Amino acid analysis 
ESI-MS  
Edman degradation 
Apostol et al., 
1997 
Foot protein type 5 
(Mgfp-5) 
Mytilus 
galloprovincialis 
BL21(DE3) MALDI-TOF  Hwang et al., 2004 
Growth hormone 
(Genotropin
®
)  
Human K12  ESI-LC-MS/MS Hepner et al., 
2005 
 Growth hormone 
(Norditropin
®
) 
Human MC1061 ESI-LC-MS/MS Hepner et al., 
2006 
Histidine-rich 
protein II 
Plasmodium 
falciparum 
BL21(DE3) MS Schneider et al., 
2005 
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Table 1.5: Amino acid substitutions observed in recombinant proteins 
expressed in E. coli 
Recombinant 
Protein 
Expected 
Amino Acid 
Observed 
Amino Acid 
Reference 
Interleukin-2 Methionine Norleucine Tsai et al., 1988 
Somatotropin Methionine Norleucine Bogosian et al., 1989 
Growth hormone Glutamine Valine Gellerfors et al., 1990  
Glutamine Lysine 
Haemoglobin Leucine Norvaline Apostol et al., 1997 
Foot protein type 5  
(Mgfp-5) 
Alanine Threonine Hwang et al., 2004 
Growth hormone 
(Genotropin
®
) 
Arginine Lysine or 
Glutamine 
Hepner et al., 2005 
Arginine Glycine 
Methionine Isoleucine 
Growth hormone 
(Norditropin
®
) 
Methionine Valine Hepner et al., 2006 
Histidine-rich protein II Histidine Glutamine Schneider et al., 2005 
 
Amino acid substitutions typically involve misincorporation of regular amino acids, 
however non-usual amino acids, such as norleucine, norvaline and isoleucine have 
also been incorporated into recombinant proteins (Kane et al., 1992).  Norleucine, an 
analogue of methionine is known to substitute for internal and N-terminal methionine 
residues (Tsai et al., 1988). At high intracellular norleucinyl tRNA levels, the 
analogue competes with methionyl tRNA for formylation and incorporation during 
protein translation (Bogosian et al., 1989).  Similarly norvaline is an analogue of 
leucine and can be misincorporated into recombinant proteins following intracellular 
accumulation.  Both norvaline and norleucine arise as a consequence of branched-
chain amino acid biosynthetic pathways in E. coli (Soini et al., 2008). 
Codon bias may also result in premature termination of protein synthesis, whereby a 
truncated nascent polypeptide dissociates from the ribosome (McNulty et al., 2003).  
Protein truncation can also occur as a result of proteolytic processing.  E. coli 
possesses several proteases, which are located within different intracellular 
compartments and are responsible for maintaining the cellular proteome. Proteases 
degrade abnormal or foreign recombinant proteins to ensure that the location and 
activities of native cellular proteins remain regulated (Narayanan and Chou, 2009, 
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Walsh et al., 2005).  Recombinant proteins often become truncated or degraded 
through the action of cellular proteases (Table 1.6), however such sequence variants 
are only typically investigated when the biological activity of therapeutic proteins 
become compromised.  
 
Table 1.6: Truncated recombinant proteins expressed in E. coli 
 
1.3.2 Protein instability 
Further product heterogeneity can also result from physical or chemical instabilities. 
Chemical instabilities occur as a consequence of making or breaking covalent bonds 
in the intra- and inter-molecular protein structure, whilst physical instabilities do not 
change the chemical composition of the protein but rather result in denaturation and 
aggregation (Manning et al., 2010). Protein instability is covered in further detail in 
Section 4.3. 
 
1.4 Recombinant lysostaphin 
Post-translational modification or processing of recombinant proteins can only 
become apparent through analytical characterisation of protein structure and 
function.  As only a limited selection of recombinant proteins have been 
characterised in such a manner, it is currently unclear whether all recombinant 
proteins are likely to display heterogeneity upon expression in E. coli or whether this 
phenomenon is only related to a small subset of proteins.  
Recombinant lysostaphin is one such protein which had been found to demonstrate 
product heterogeneity upon expression in E. coli (Kara et al., 2006). The protein is 
Recombinant Protein Origin E. coli Strain Detection Methods Reference 
Interleukin-6 (IL-6) Human JM83 Circular dichroism 
Edman degradation 
Proudfoot et al., 
1993 
Phenylalanine hydroxylase 
(hPAH) 
Human HMS174(DE3) 
BL21(DE3) 
IEF  
Edman degradation 
Martinez et al., 
1995 
β2-microglobulin Human BL21(DE3) ESI-MS Esposito et al., 
2000 
Growth hormone  
(Nutropin AQ
®
) 
Human Not specified LC-MS/MS 
FT-ICR MS 
Jiang et al., 
2009 
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produced by heterologous expression after cloning the gene sequence encoding 
mature lysostaphin, which is derived from the genome of Staphylococcus simulans 
biovar staphylolyticus (ATCC 1362, NRRL B-2628). The gene sequence of 
lysostaphin (EC.3.4.24.75) is encoded as a preproenzyme, which is processed by S. 
staphylolyticus to produce a mature, monomeric glycylglycine endopeptidase. 
Lysostaphin is exclusively produced by S. staphylolyticus and mediates specific 
hydrolysis of the pentaglycine cross-bridges present within peptidoglycan cell walls 
(Heath Farris et al., 2003, Surovtsev et al., 2007). As lysostaphin selectively targets 
the pentaglycine cross-links of peptidoglycan, only staphylococcal strains are 
susceptible to lysis, whilst other genera are resistant (Turner et al., 2007, Huber and 
Huber, 1989, Boyle-Vavra et al., 2001).  The mechanisms of catalysis are described 
further in Section 4.1.1. 
 
1.4.1 Applications of lysostaphin 
 
Lysostaphin has been shown to lyse over fifty strains of S. aureus, regardless of 
phage type, antibiotic resistance, cell wall condition or degree of bacterial capsulation 
(Trayer and Buckley, 1979). In addition to S. aureus, the endopeptidase can also 
target the cell walls of other staphylococcal species that have cell walls featuring 
pentaglycine residues, such as S. simulans, S. epidermidis and S. carnosus 
(Bardelang et al., 2009, Mierau et al., 2005a, Wu et al., 2003).  As lysostaphin 
demonstrates selective lysis of staphyloccal strains, the enzyme is used for a number 
of clinical and therapeutic applications.  As a prototypical peptidase, lysostaphin is 
also commonly employed as a research tool in biotechnology (Firczuk et al., 2005).  
Staphylococcal cells are resistant to conventional lysis methods, therefore the action 
of lysostaphin can be used to liberate cellular constituents, such as intracellular 
enzymes, nucleic acids and cell membrane components (Park et al., 1995). Cell wall 
lysis is also useful when differentiating staphylococcal strains or during genetic 
studies in which DNA is isolated from staphylococcal strains (Thumm and Götz, 
1997).  
 
Due to its potent anti-staphylococcal activity, lysostaphin has been considered as an 
antibacterial agent for over 40 years.  The prevalence of other antibiotics and 
difficulties in achieving protein purity restricted widespread use and development of 
lysostaphin as an antibacterial agent.  However developments in recombinant DNA 
technology and the emergence of multi-drug resistant bacteria lead to renewed 
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interest in lysostaphin for clinical and therapeutic purposes.  Due to the enzyme’s 
ability to lyse S. aureus regardless of resistance to other antibiotics, recombinant 
lysostaphin has been shown to kill multi-drug resistant strains, such as methicillin 
resistant S. aureus (MRSA), oxacillin-resistant S. aureus (ORSA) and vancomycin-
intermediate susceptible S. aureus (VISA) (Yang et al., 2007, Climo et al., 2001, 
Walsh et al., 2004).  
 
The growing emergence of antibiotic-resistant staphylococcal infections poses a 
major problem in clinical settings, particularly amongst immunosuppressed and 
immunocompromised individuals affected by cutaneous and blood-borne infections.  
Many studies have therefore been performed on animal, but also human models to 
assess the efficacy of recombinant lysostaphin in the therapy of localised and 
systemic infections (Table 1.7). Such investigations have indicated that lysostaphin 
can effectively kill Staphylococcal cells at low minimal inhibitory concentration (MIC) 
values of between 0.0039 and 15.4 µg/ml, depending on staphylococcal strain (Dajcs 
et al., 2000, Climo et al., 1998, Wu et al., 2003, Harrison and Zygmunt, 1967, Patron 
et al., 1999, McCormick et al., 2006, Oluola et al., 2007).  These values indicate that 
lysostaphin can inhibit the visible growth of staphylococcal cells at extremely low 
concentrations, suggesting that the enzyme offers extremely sensitive and potent cell 
lysis.    
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Table 1.7: Studies in which lysostaphin has been administered topically or 
parenterally to human or animal models with successful suppression or 
eradication of localised or systemic staphylococcal infections. 
Reference Animal 
Model 
Target  
infection 
Mode of 
Administration 
MIC value† 
(µg/ml) 
Schuhardt and 
Schindler, 1964 
Mouse Systemic Intraperitoneal 
or subcutaneous 
Not specified 
Harris et al, 1967 Human Nasal 
colonisation 
Topical Not specified 
Harrison et al, 1967 Mouse Renal Intravenous 0.095 
Dixon et al, 1968 Mouse Renal Intravenous Not specified 
Quickel et al, 1971 Human Nasal 
colonisation 
Topical Not specified 
Stark et al, 1974  Human Systemic Intravenous Not specified 
Oldham and Daley, 
1992 
Cow Mastitis Sub-cutaneous Not specified 
Climo et al, 1998 Rabbit Aortic valve 
endocarditis 
Intravenous 0.015-0.030 
Patron et al, 1999 Rabbit Aortic valve 
endocarditis 
Intravenous 0.0039 
Dajcs et al, 2000 Rabbit Keratitis Topical 0.031-0.063 
Dajcs et al, 2001 Rabbit Endophthalmitis Topical Not specified 
Dajcs et al, 2002 Rabbit Keratitis Topical Not specified 
Kokai-Kun et al, 2003 Rat Nasal 
colonisation 
Topical Not specified 
Walsh et al, 2004 Mouse Nasal 
colonisation 
Topical Not specified 
McCormick et al, 2006 Rabbit Endopthalmitis Topical 0.74-15.4 
Kokai-Kun et al, 2007 Mouse Systemic Intravenous Not specified 
Oluola et al, 2007 Rat Systemic Intraperitoneal 0.125 
† MIC values were determined against single or multiple lysostaphin-susceptible 
bacterial strains.  In some cases where the MIC values were not specified, the 
applied lysostaphin concentrations were deliberately augmented to enhance 
therapeutic efficacy.  
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Table 1.7 details a number of studies in which lysostaphin has demonstrated 
efficacious suppression or eradication of localised and systemic staphylococcal 
infections.  Lysostaphin preparations can be administered topically or via 
intraperitoneal, subcutaneous or intravenous injection. Topical application of 
lysostaphin to nasal or ocular infections has demonstrated considerable success in a 
number of studies indicating that effective formulations exist to tackle and prevent 
cutaneous infections, not only in research but also clinical trials (Yang et al., 2007, 
Cisani et al., 1982, Dajcs et al., 2000, Dajcs et al., 2002). Intravenous administration 
of lysostaphin has also been shown to eradicate localised and systemic 
staphylococcal infections in a number of animal models.  However Walsh et al (2004) 
found that greater than 95% of the enzyme is cleared from serum circulation within 
an hour of administration (Walsh et al., 2004).  In order to maintain serum protein 
concentrations and minimise the requirement for frequent dosing, the protein 
formulation may require optimisation to extend serum half-life.   
 
Lysostaphin has also been applied to treat staphylococcal infections of the mammary 
glands (mastitis) in animals.  Mastitis has major economic implications for dairy 
farming, by adversely influencing animal welfare and reducing overall dairy yields.  
Lysostaphin has been used to successfully treat bovine mastitis, without 
encountering resistance.  The endopeptidase treatment has traditionally been 
administered through sub-cutaneous injection of lysostaphin purified following 
expression in either bacterial or mammalian cells (Williamson et al., 1994).  However 
in recent years, lysostaphin has been expressed transgenically in the mammary 
glands of animals (Fan et al., 2004, Klein et al., 2006, Donovan et al., 1996, Kerr et 
al., 2001, Mitra et al., 2003, Fan et al., 2002). This approach was found to effectively 
protect livestock against intra-mammary staphylococcal infections as the lysostaphin 
gene remains functional in mammalian cells, despite its prokaryotic origins 
(Williamson et al., 1994).   
 
In addition to the treatment of staphylococcal infections, recombinant lysostaphin has 
also been used to suppress biofilm formation, particularly on medical devices, such 
as catheters (Turner et al., 2007).  Like many other bacterial strains, staphylococcal 
cells have a tendency to form a multi-layered population of cells known as biofilms.  
Biofilms are 1000-1500 times more resistant to antibiotics than their more dispersed 
counterparts, therefore are much more difficult to eradicate and often necessitate 
removal of indwelling medical devices (Wu et al., 2003).  However lysostaphin has 
been found to be active against S. aureus within biofilms, but is also known to rapidly 
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disrupt the extracellular matrix of biofilms colonizing plastic and glass surfaces (Wu 
et al., 2003). Shah et al (2004) found that lysostaphin-coated catheters were less 
readily colonized by several strains of S. aureus and therefore could be used 
prophylactically to prevent the incidence of catheter-related staphylococcal infections 
(Shah et al., 2004).  
 
Although lysostaphin shows great promise as an anti-staphylococcal agent, the 
activity of the enzyme may ultimately become compromised by the development of 
endopeptidase resistance. S. staphylolyticus renders itself resistant to the action of 
lysostaphin through modification of the polyglycine cross-bridges within 
peptidoglycan. Some staphylococcal species also demonstrate complete resistance 
to lysostaphin, whilst others exhibit decreased susceptibility, such as S. epidermidis 
and S. haemolyticus.  Lysostaphin-resistant staphylococcal strains exhibit similar 
modifications of the poly-glycine cross-links as S. staphylolyticus, in that glycine 
residues become substituted with serine or alanine residues.  This resistance can 
arise following mutations of the femA gene, which typically mediates the addition of 
the glycine residues within the cross-bridge. Essentially mutation of this gene results 
in production of a monoglycine cross-linker, which however renders the cells 
susceptible to the action of β-lactam antibiotics (Kiri et al., 2002, DeHart et al., 1995, 
Climo et al., 2001). 
 
The incidence of reduced susceptibility to lysostaphin highlights the importance of 
using lysostaphin, in combination with other antibacterial agents to achieve maximal 
cell lysis during therapeutic interventions.  For instance, using lysostaphin in 
combination with lysozyme, a endo-β-muramidase, can potentiate the anti-
staphylococcal efficacy of lysostaphin (Cisani et al., 1982). Lysostaphin has been 
used in combination with other antibiotic agents, such as vancomycin to provide 
enhanced elimination of staphylococcal infections or biofilms (Climo et al., 1998, 
Walencka et al., 2005, Walencka et al., 2006).  Furthermore recombinant lysostaphin 
has been used in combination with antimicrobial peptides, such as ranalexin or 
monoclonal antibodies raised against staphylococcal cell wall components with 
increased efficiency of infection eradication (Walsh et al., 2004).  
 
The efficacy of lysostaphin applied alone and in combination with other anti-
staphylococcal agents has exemplified the biopharmaceutical importance of 
recombinant lysostaphin production. However the purity and potential 
immunogenicity of all recombinant biopharmaceuticals must be considered prior to 
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clinical use in the interests of drug safety.  The studies in Table 1.7 indicated that 
lysostaphin retains biological activity in vivo without eliciting immune responses 
following administration.  In addition, the enzyme was thought to be digested by 
intestinal proteinases, without demonstrating oral toxicity (Williamson et al., 1994).  
Also Dajcs et al, (2002) did not observe immunogenicity, even following immunization 
of rabbits with anti-lysostaphin antibodies (Dajcs et al., 2002).   
 
In the majority of studies, immunogenicity has not been notably observed following 
topical or parenteral administration of lysostaphin to human subjects (Quickel et al., 
1971, Climo et al., 1998). A few isolated cases have reported immunogenicity 
following administration, however due to the emergence of more stringent clinical trial 
regulations, lysostaphin has not been readily administered to human models, which 
limits the availability of data concerning the potential immunogenicity of the protein 
(Daley and Oldham, 1992, Stark et al., 1974).  Sensitisation experiments performed 
in animals indicated that lysostaphin did not elicit an immune response until 18-21 
administrations had been performed (Daley and Oldham, 1992). It is therefore 
possible that individuals who have been previously exposed to lysostaphin may have 
only become sensitized if an excessive dosing regime was prescribed.  
Recombinant lysostaphin may elicit greater immunogenicity due to product impurity 
or heterogeneity following purification after expression in prokaryotic or eukaryotic 
hosts. Immunogenicity would be a major concern due to the production of antibodies 
which could neutralize enzyme activity or increase drug clearance (Walsh et al., 
2004).    
 
1.4.2 Chromatographic analysis of recombinant lysostaphin expressed in E. 
coli 
Recombinant lysostaphin shows great promise as an anti-staphylococcal agent and 
therefore high level production of such a therapeutically important protein is 
essential. The protein has been shown to be express at high levels in E. coli, 
however this has been associated with product heterogeneity (Kara et al., 2006). As 
the quality and homogeneity of recombinant protein preparations must be closely 
controlled and regulated, it was imperative that the extent and origins of this 
heterogeneity was investigated.  
This research therefore aimed to provide an insight into the heterogeneity of 
recombinant lysostaphin following cloning and expression in E. coli (Kara et al., 
20 
 
2006).  Through purification and separation of protein isoforms using LC it was 
possible to assess the heterogeneity of recombinant lysostaphin, before 
characterising the activity, stability and structure of protein variants using LC 
separation and LC-MS analysis. Due to the implications of sequence variation, post-
translational processing and modifications upon protein structure function and 
heterogeneity, it was imperative that structure of recombinant lysostaphin was 
appropriately characterised.  This research therefore had a number of aims.  
Aims:  
 To clone the gene encoding recombinant lysostaphin using E. coli cloning 
vectors. 
 To express recombinant lysostaphin in E. coli expression hosts. 
 To purify recombinant lysostaphin from E. coli using single or multiple 
chromatographic modes. 
 To separate recombinant lysostaphin isoforms using chromatography. 
 To evaluate the extent of product heterogeneity following expression in E. coli 
using single or multi-dimensional chromatographic separation. 
 To assess the influence of culture conditions upon the heterogeneity of 
recombinant lysostaphin preparations.  
 To characterise the functional and structural properties of recombinant 
lysostaphin, through activity assays, chromatographic and mass 
spectrometric analysis.  
 To identify post-translational processing events or modifications that may 
have contributed to the heterogeneity of recombinant lysostaphin.  
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2 Cloning, Expression and Purification of Recombinant Lysostaphin 
 
2.1 Introduction  
 
In order to investigate the heterogeneity of recombinant lysostaphin, the protein had 
to be produced and purified prior to chromatographic analysis. The gene encoding 
lysostaphin was therefore cloned in E. coli following identification and amplification of 
the appropriate gene sequence from within the genomic DNA of Staphylococcus 
staphylolyticus. The amplified gene sequence was firstly cloned into pCR-Blunt, 
before sub-cloning the insert DNA into pET-vector cloning systems. Appropriate pET-
vectors were selected to permit subsequent expression of recombinant lysostaphin 
with or without additional N- or C-terminal hexahistidine tags, which facilitate 
subsequent purification. In addition PelB leader sequences were incorporated into 
some of the gene constructs to permit translocation of recombinant lysostaphin to 
periplasm of E. coli.  
 
Following cloning, the recombinant lysostaphin gene constructs were expressed in E. 
coli BL21(DE3) to allow subsequent purification and characterisation of the resulting 
recombinant protein. Although the expression host strain was kept constant, 
expression conditions such as induction conditions, cultures volumes, media 
composition, temperature and expression location were varied during the course of 
research to establish which factors could influence the expression of recombinant 
lysostaphin.  Once expressed, a variety of chromatographic techniques were tested 
to achieve efficient purification of recombinant lysostaphin so that protein 
heterogeneity could be investigated.  Rapid recovery of target protein was essential 
to minimise potential proteolysis or modification caused by enzymes or reactive 
intermediates present within the cell lysate.  
Aims:  
 To clone the gene encoding recombinant lysostaphin using pCR-Blunt and 
pET-vector cloning systems. 
 To express recombinant lysostaphin in E. coli BL21(DE3). 
 To efficiently purify recombinant lysostaphin from E. coli using single or 
multiple chromatographic modes. 
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2.2 Methods 
 
2.2.1 Bacterial strains  
 
Bacterial strain information, storage and culture is described in Appendix 7.1-
Appendix 7.7. 
 
2.2.2 Chemicals 
 
All chemicals used in this research and their preparation are outlined in Appendix 7.8 
and Appendix 7.9. 
 
2.2.3 Equipment 
 
All key pieces of laboratory equipment and chromatographic columns required at 
each stage of the research are outlined in Appendix 7.10 and Appendix 7.11.  
 
2.2.4 Buffers and solutions 
 
All buffer and solution compositions are outlined in Appendix 7.12. 
 
2.2.5 Agarose gel electrophoresis  
 
DNA preparations were analysed using analytical agarose gel electrophoresis to 
assess molecular weight or purity (Appendix 7.13), whilst preparative agarose gel 
electrophoresis was used to separate and extract DNA (Appendix 7.14).   
 
2.2.6 Polyacrylamide gel electrophoresis (PAGE)  
SDS-PAGE was performed under denaturing conditions to assess the purity and 
molecular weight of proteins following recombinant expression, purification, 
separation or digestion (Appendix 7.15).  
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2.2.7 Quantitation and detection of DNA and protein 
 
DNA and protein concentrations were established using UV spectrometry (Appendix 
7.23). The presence of protein was determined using Bradford’s reagent (Appendix 
7.24). 
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2.3 Cloning of the gene encoding lysostaphin 
 
2.3.1 Introduction 
 
Lysostaphin (EC.3.4.24.75) is an extracellular glycylglycine endopeptidase, produced 
exclusively by Staphylococcus simulans biovar staphylolyticus (ATCC 1362, NRRL 
B-2628).  The zinc-containing endopeptidase can lyse staphylococcal cells by 
specifically cleaving the pentaglycine cross-links in their peptidoglycan cell walls 
(Firczuk et al., 2005, Fedorov et al., 2003). Lysostaphin was originally isolated from 
cell-free filtrates of Staphylococcus staphylolyticus by Schindler and Schuhardt 
(1960) and the gene encoding lysostaphin was subsequently identified and 
sequenced by Recsei et al (1987) (Schindler and Schuhardt, 1964, Trayer and 
Buckley, 1979, Recsei et al., 1987). 
 
The lysostapin gene is carried on pACK1, a β-lactamase expressing plasmid which is 
the largest of the five plasmids of S. staphylolyticus (Sharma et al., 2006). The 
pACK1 plasmid also carries an endopeptidase resistance gene (epr), which renders 
S. staphylolyticus resistant to the lytic action of lysostaphin (Chan, 1996). Resistance 
is acquired by modification of pentaglycine cross-links of peptidoglycan, through the 
substitution of glycine residues with serine residues. The expression of epr is 
regulated, therefore cell cultures are known to be susceptible during the early 
exponential phase but resistant during the post-exponential phase.  However as S. 
staphylolyticus synthesises lysostaphin as a preproenzyme, there is time during the 
processing of preprolysostaphin to acquire resistance (DeHart et al., 1995).    
 
The entire coding region of the lysostaphin gene is comprised of 1482 bp that encode 
preprolysostaphin, which is 493 amino acids (aa) in length. The sequence encodes 
three distinct domains: a secretory signal peptide (36 aa) at the N-terminus; a 
hydrophilic propeptide (211 aa) from which there are 15 conserved repetitive 
sequences (13 aa each) and the hydrophobic mature lysostaphin (246 aa) (Thumm 
and Götz, 1997, Recsei et al., 1987) (Figure 2.1).  
 
 
Figure 2.1: A schematic representation of the three domains of the uncleaved 
lysostaphin preproenzyme (adapted from Klein et al., 2006) 
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At the N-terminus of the sequence, the signal peptide region consists of a hydrophilic 
region (6 aa) and a hydrophobic region (21 aa), which forms a β-pleated sheet 
(Heinrich et al., 1987). The exact site of signal peptide cleavage is not yet known, 
however the entire sequence of the gene has been elucidated (Appendix 7.35).  
Unlike the signal peptide sequence, the repetitive sequences within the hydrophilic 
propeptide region have a strong tendency to undergo α-helix formation. The 
repetitive sequences are 13 aa long and whilst the first 14 identical repeats encode 
for A-E-V-E-T-S-K-A-P-V-E-N-T, the 15th repeat encodes A-E-V-E-T-S-K-A-L-V-Q-N-
R (Heinrich et al., 1987).  The amino acid sequence and structure of mature 
lysostaphin is discussed further in Chapter 4 .   
 
During expression in S. staphylolyticus, the 42 kDa preprolysostaphin is exported 
from the bacterial cytoplasm by signal peptide-mediated translocation.  During cell 
wall secretion, the N-terminal 36 aa signal peptide is cleaved by a signal peptidase to 
produce catalytically active prolysostaphin (Fedorov et al., 2003).  However mature 
lysostaphin is around 4.5 fold more active than prolysostaphin, therefore the mature 
peptide is produced by extracellular cleavage of the propeptide following 
translocation (Thumm and Götz, 1997). In S. staphylolyticus, the conversion of 
prolysostaphin to lysostaphin is catalysed by a cysteine protease that is entrapped 
within the cell wall matrix or non-covalently associated with cell wall polymers 
(Grundling et al., 2006, Bunn et al., 1998). Extracellular cleavage of prolysostaphin 
yields the mature and catalytically-active 27 kDa protein, lysostaphin (Szweda et al., 
2001).  
 
2.3.1.1 Cloning of the lysostaphin gene 
Due to the importance of lysostaphin as a therapeutic agent, the lysostaphin gene 
has been cloned and expressed using a variety of expression hosts. Recombinant 
lysostaphin preparations are commercially available and have been used extensively 
for research purposes (Kokai-Kun et al., 2003, Kokai-Kun et al., 2007). The gene 
encoding lysostaphin has been cloned and the encoded product expressed using 
both eukaryotic and prokaryotic cloning and expression systems (Klein et al., 2006, 
Mierau et al., 2005b, Recsei et al., 1987). The gene has primarily been cloned in E. 
coli vectors, as described in  
 
Table 2.1, but has also been cloned using the NICE cloning system in Lactococcus 
lactis (Mierau et al., 2005a, Mierau et al., 2005b).  
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Table 2.1: Cloning of recombinant lysostaphin in E. coli 
E. coli Strain Cloning Vector Restriction sites Reference 
JM83 pUC19 Not specified Heinrich et al., 1987 
JM105 pUC8 MboI 
BamHI 
Recsei et al., 1987 
HB101 pBR322 MboI 
BamHI 
Williamson et al., 1994 
JM83 pET-29b(+) NdeI 
BamHI 
Chan, 1996 
TOP10F pTYB12 BamHI Szweda et al., 2001 
 
 
2.3.1.2 Cloning of the gene encoding lysostaphin in E. coli 
In order to investigate the homogeneity of recombinant lysostaphin expressed in E. 
coli, the lysostaphin gene was cloned in E. coli TOP10 and XL1-Blue, in preparation 
for expression in E. coli BL21(DE3). Prior to cloning, the lysostaphin gene sequence 
was amplified from the genomic DNA of S. staphylolyticus using PCR. PCR primers 
were synthesised in order to facilitate directional cloning of the insert DNA into pET-
vector cloning systems. However, following PCR, the amplified gene sequence was 
first cloned into the cloning vector, pCR-Blunt.   
 
Following cloning in pCR-Blunt, the cloned lysostaphin gene was then subcloned into 
pET-22b or pET-28a depending on the requirement for fusion tag sequences. The N-
terminally His-tagged regions of recombinant proteins can exhibit phosphorylation, 
gluconoylation and phosphogluconoylation when in expressed in E. coli (Du et al., 
2005a, Du et al., 2005b, She et al., 2010). Therefore recombinant lysostaphin was 
cloned in pET-22b and pET-28a allowing expression of the protein without a His-tag 
sequence, but also expression with an N-terminal or a C-terminal His-tag sequence.  
This cloning strategy was designed to allow investigation of the effects of terminal 
His-tag sequences on recombinant protein heterogeneity, with a view to identification 
of possible terminal modifications.     
 
Lysostaphin gene constructs were also created to allow expression of the 
recombinant protein in different cellular locations within E. coli.  The lysostaphin gene 
was therefore subcloned into pET-22b and pET-28a allowing cytoplasmic expression 
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of recombinant lysostaphin or expression within the periplasm, following PelB 
mediated transfer of the expressed protein to the periplasm.  This cloning strategy 
was developed to ultimately allow assessment of the influence of expression location 
upon the heterogeneity of recombinant lysostaphin.    
 
Aims: 
 
 To amplify the gene sequence encoding mature lysostaphin using PCR.  
 To clone the gene sequence into pCR-Blunt. 
 To clone the gene sequence into the appropriate pET vector.  
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2.3.2 Methods 
 
2.3.2.1 Media 
All media compositions are outlined in Appendix 7.25. 
 
2.3.2.2 Enzyme and buffer composition  
Enzyme and buffer compositions are outlined in Appendix 7.26. 
 
2.3.2.3 Bacterial strains 
E. coli TOP10 and E. coli XL1 Blue were cultured for the preparation of chemically 
and electrocompetent cells for transformation with recombinant plasmids containing 
the lysostaphin gene.  Staphylococcus staphylolyticus, biovar of Staphylococcus 
simulans (DSM 20723, NRRL B-2628) was grown for the extraction of genomic DNA 
for cloning of the lysostaphin gene.  
 
2.3.2.4 Vectors 
Cloning of the lysostaphin gene was achieved using the cloning systems described in 
Table 2.2. Vector maps for all of the plasmids are shown in Appendix 7.29, Appendix 
7.30 and Appendix 7.31.   
 
Table 2.2: Cloning systems used during gene cloning 
 
Vector System Application Supplier 
Zero Blunt Cloning System Cloning of lysostaphin gene 
using pCR-Blunt 
Invitrogen Ltd, UK 
pET Vector Cloning System Cloning of lysostaphin gene 
using pET-28a and pET-22b 
Merck4Biosciences, UK 
 
 
 
 
29 
 
2.3.2.5 Kits  
Gene cloning procedures were performed using a number of molecular biology kits, 
as described in Table 2.3.  The composition of buffers used in each kit is provided in 
Appendix 7.32.  
 
Table 2.3: Molecular biology kits used during gene cloning  
 
Kit Application Supplier 
DNeasy Mini Spin Kit  Extraction of genomic DNA from S. 
staphylolyticus  
Qiagen Ltd, UK 
QIAprep Spin MiniPrep Kit Plasmid DNA extraction  Qiagen Ltd, UK 
QIAquick Gel Extraction Kit Gel extraction of DNA Qiagen Ltd, UK 
Plasmid Maxi Kit Plasmid DNA extraction Qiagen Ltd, UK 
 
2.3.2.6 PCR amplification of the lysostaphin gene  
In order to clone the lysostaphin gene, S. staphylolyticus was cultured (Appendix 
7.33) and the genomic DNA of the organism extracted using a DNeasy mini spin kit 
(Appendix 7.34) to allow PCR amplification of the lysostaphin gene.    
 
2.3.2.7 Primer design and plasmid DNA constructs 
Primers were synthesised (MWG Biotech AG, Germany) to allow amplification of the 
section of the gene that encodes the mature lysostaphin ORF (Gen Bank Accession 
No. X06121) (Appendix 7.35).  Primers were designed to contain restriction sites at 
their 5’ ends. In addition, the primers were designed to enable cloning of the 
lysostaphin gene with or without fusion tags (N-terminal His-tags, C-terminal His-tags 
and PelB leader sequences) (Table 2.4).  PCR was performed as described in 
Appendix 7.36 and Appendix 7.37. The resulting PCR products were firstly cloned in 
pCR-Blunt vector using the Zero Blunt® Cloning system and then subcloned in the 
pET vector cloning system using pET-22b or pET-28a vectors  
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Table 2.4: Primer sequences, pET-vectors, fusion tags and expression locations of lysostaphin constructs
Construct Primer Sequences Vector Restriction 
Sites 
Fusion 
Tags 
Expression 
Location 
1 LSNdeIFP: 5’-CAT ATG GCT GCA ACA CAT GAA CAT TCA-3’ 
 
LSXhoISRP: 5’-CTC GAG TCA CTT TAT AGT TCC CCA AAG-3’ 
pET-28a NdeI 
XhoI 
N-terminal His-tag Cytoplasmic 
2 LSNdeIFP: 5’-CAT ATG GCT GCA ACA CAT GAA CAT TCA-3’ 
 
LSXhoISRP: 5’-CTC GAG TCA CTT TAT AGT TCC CCA AAG-3’ 
pET-22b NdeI 
XhoI 
None Cytoplasmic 
3 LSNdeIFP: 5’-CAT ATG GCT GCA ACA CAT GAA CAT TCA-3’ 
 
LSXhoINSRP: 5’-CTC GAG CTT TAT AGT TCC CCA AAG AAC-3’ 
pET-22b NdeI 
XhoI 
C-terminal His-tag Cytoplasmic 
4 LSNcoIFP: 5’-CCA TGG CTG CAA CAC ATG AAC ATT CA-3’ 
 
LSXhoINSRP: 5’-CTC GAG CTT TAT AGT TCC CCA AAG AAC-3’ 
pET-22b NcoI 
XhoI 
C-terminal His-tag 
PelB leader sequence 
Periplasmic 
5 LSNcoIFP: 5’-CCA TGG CTG CAA CAC ATG AAC ATT CA-3’ 
 
LSXhoISRP: 5’-CTC GAG TCA CTT TAT AGT TCC CCA AAG-3’ 
pET-22b NcoI 
XhoI 
PelB leader sequence Periplasmic 
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2.3.2.8 Cloning using the Zero Blunt® cloning system 
Following PCR, the lysostaphin ORF was cloned into pCR-Blunt through ligation of the PCR 
product (744bp) with pCR-Blunt vector (3.5 Kb) (Appendix 7.38). E. coli TOP10/ XL1-BLUE 
were grown (Appendix 7.39) for the preparation of electrocompetent cells (Appendix 7.40).  
The electrocompetent cells were then transformed with the ligated vector DNA by 
electroporation (Appendix 7.41).  Following transformation and overnight incubation, plasmid 
DNA was extracted from pCR-Blunt clones (Appendix 7.42) and was subjected to restriction 
digestion to establish whether the extracted DNA contained the appropriate insert DNA 
fragment (Appendix 7.43).  
 
2.3.2.9 Cloning into pET-vector system 
In order to clone the mature lysostaphin domain encoding sequence into pET-28a or pET-
22b, plasmid DNA isolated from the pCR-Blunt clones was restriction digested (Appendix 
7.43), subjected to preparative gel electrophoresis (Appendix 7.14) and the DNA insert 
fragment gel extracted using a QIAquick® gel extraction kit (Appendix 7.44). E. coli 
transformed with pET-vector DNA were cultured (Appendix 7.45), so that pET vector DNA 
could be prepared (Appendix 7.46) and restriction digested (Appendix 7.43) prior to ligation 
with the insert DNA fragment.  Recombinant pET vector DNA was then used to transform E. 
coli BL21 (DE3) cells for protein expression as described in Appendix 7.73.  Plasmid DNA 
was extracted from transformed cells and sequenced to ensure that the mature lysostaphin 
domain encoding sequence was encoded correctly (Appendix 7.42 and Appendix 7.48). 
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2.3.3 Results 
 
2.3.3.1 Purification of genomic DNA from S. staphylolyticus   
Genomic DNA was extracted from S. staphylolyticus and agarose gel electrophoresis was 
used to confirm that the genomic DNA had been extracted successfully (Figure 2.2).  
 
Figure 2.2: 1% (w/v) agarose gel electrophoresis of purified genomic DNA from S. 
staphylolyticus. Lane 1: Bioline 10 Kb Hyperladder size standard; Lane 2: Purified 
genomic DNA  
 
2.3.3.2 PCR amplification of mature lysostaphin domain encoding sequence from S. 
staphylolyticus genomic DNA 
The mature lysostaphin gene sequence was amplified from S. staphylolyticus genomic DNA 
using PCR. Primers were designed to allow amplification of the mature lysostaphin domain 
encoding sequence to permit cloning of the sequence and expression of mature lysostaphin 
without or with fusion tags.  Following PCR, the PCR products were analysed by agarose gel 
electrophoresis to ensure that the amplified products were the correct size. As shown in 
Figure 2.3A, PCR products for constructs 1, 2, 4 and 5 amplified successfully on the first 
attempt, however amplification of the PCR product for construct 3 was unsuccessful initially. 
Repetition of PCR using the same conditions was successful and the PCR product for 
construct was amplified correctly (Figure 2.3B).  
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Figure 2.3: PCR amplification of the section of lysostaphin gene encoding mature 
lysostaphin from S. staphylolyticus genomic DNA. A) Lane 1: Bioline 10 Kb 
Hyperladder size standard; Lane 2: PCR product for construct 1 and 2, Lane 3: 
Unsuccessful amplification of PCR product for construct 3; Lane 4: PCR product for 
construct 4; Lane 5: PCR product for construct 5. B) Lane 1: Bioline 10 Kb 
Hyperladder size standard; Lane 2: PCR product for construct 3 
 
2.3.3.3 Cloning of the mature lysostaphin domain encoding sequence using the Zero 
Blunt® cloning system  
Following PCR, the amplified mature lysostaphin domain encoding sequences were ligated 
into the 3.5 Kb pCR-Blunt vector and transformed into E. coli TOP10.  Plasmid DNA was 
extracted from overnight cultures of E. coli TOP10 inoculated using transformed colonies.  
The extracted plasmid DNA was restriction digested with NdeI and XhoI or NcoI and XhoI 
depending on which PCR product had been ligated into the pCR-Blunt vector (Figure 2.4). 
 
 
34 
 
 
Figure 2.4: Restriction digestion of pCR-Blunt recombinants.  A) Lane 1: Bioline 10 Kb 
Hyperladder size standard; Lanes 2-5: pCR-Blunt construct 1 and 2 (NdeI and XhoI 
digest); Lane 6: pCR-Blunt construct 4 (NcoI and XhoI digest).  B) Lane 1: Bioline 10 
Kb Hyperladder size standard; Lane 2: pCR-Blunt construct 3 (NdeI and XhoI digest).  
C) Lane 1: Bioline 10 Kb Hyperladder size standard; Lane 2: pCR-Blunt construct 5 
(NcoI and XhoI digest). 
 
As shown in Figure 2.4, each PCR product was cloned successfully in pCR-Blunt vector.  
Restriction digestion using NdeI and XhoI released the insert DNA from the 3.5 Kb pCR-
Blunt vector. Due to internal NcoI restriction sites in the pCR-Blunt vector, digestion with 
NcoI and XhoI yielded the insert DNA fragment and two pCR-Blunt vector fragments of 500 
bp and 1500 bp. Following restriction digestion and gel extraction, the insert DNA fragment 
from each pCR-Blunt construct was ligated into appropriately restriction digested pET vector 
DNA.    
 
2.3.3.4 Cloning of the lysostaphin gene using pET vector cloning system 
Following ligation, the recombinant pET vector DNA was transformed into E. coli TOP10 or 
E. coli XL-1 Blue.  Plasmid DNA was extracted from overnight cultures, which had been 
inoculated with transformed E. coli colonies. The plasmid DNA was restriction digested with 
NdeI and XhoI or NcoI and XhoI depending on which insert DNA fragment had been 
subcloned into the pET vector (Figure 2.5).  
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Figure 2.5: Restriction digestion of pET vector recombinants.  A) Lane 1: Bioline 10 
Kb Hyperladder size standard; Lane 2: pET construct 1 in pET-28a (NdeI and XhoI 
digest).  B) Lane 1: Bioline 10 Kb Hyperladder size standard; Lane 2: pET-22b without 
insert DNA (NdeI and XhoI digest), Lane 3: pET construct 2 in pET-22b (NdeI and XhoI 
digest). C) Lane 1: Bioline 10 Kb Hyperladder size standard; Lane 2: pET construct 3 
in pET-22b (NdeI and XhoI digest). D) Lane 1: Bioline 10 Kb Hyperladder size 
standard; Lane 2: pET construct 4 in pET-22b (NcoI and XhoI digest). E) Lane 1: 
Bioline 10 Kb Hyperladder I size standard; Lane 2: pET construct 5 in pET-22b (NcoI 
and XhoI digest); Lane 3: pET construct 5 in pET-22b (NcoI and XhoI digest). 
 
As shown in Figure 2.5 (A-E), each insert DNA fragment was successfully subcloned in pET-
22b or pET-28a. Restriction digestion using NdeI and XhoI or NcoI and XhoI released the 
insert DNA fragment from the pET-22b vector (5493 bp) or the pET-28a vector (5369 bp), 
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providing confirmation of gene cloning.  pET constructs 1-3 were then sequenced to 
establish the accuracy of the cloned lysostaphin gene sequence.  
 
2.3.3.5 Sequencing of plasmid DNA  
pET constructs 1-3 were sequenced to ensure that the mature lysostaphin gene was 
accurately encoded. The quality of the sequenced data was generally very high and 
chromatographic representation of the sequence data demonstrated largely non-overlapping 
and evenly-spaced peaks (Appendix 7.49, Appendix 7.50 and Appendix 7.51). To establish if 
the acquired sequence data matched with the expected nucleotide sequences (Appendix 
7.52, Appendix 7.53, Appendix 7.54, Appendix 7.55, Appendix 7.56 and Appendix 7.57) 
ClustalW alignments were performed to identify any nucleotide mis-matches.  
 
2.3.3.6 ClustalW alignment of the known mature lysostaphin domain encoding 
sequence (with an N-terminal His-tag encoding sequence added) and the 
acquired DNA sequence from pET construct 1  
The known mature lysostaphin domain encoding sequence (with N-terminal His-tag 
encoding sequence added) is presented in Appendix 7.52.  The sequence acquired from 
construct 1 is presented in Appendix 7.53. The known and acquired sequences were then 
compared by ClustalW analysis and the results are presented in Figure 2.6. 
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Figure 2.6: ClustalW alignment of the known mature lysostaphin domain encoding 
sequence (with N-terminal His-tag encoding sequence added) and the acquired DNA 
sequence from pET construct 1 
 
As shown in Figure 2.6, a number of mis-matched nucleotides were found within the initial 
part of the sequence data.  However further examination of the sequence chromatographic 
data, as shown in Figure 2.7 indicates that the mis-matched bases occurred within a region 
of the sequence where the chromatographic trace was particularly noisy.  The correct 
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nucleotide bases could be identified within the noisy region, suggesting that the mis-matches 
bases were falsely identified during sequencing.  
 
 
Figure 2.7: Mis-indentification of bases during sequencing of pET construct 1.  Mis-
identified bases are indicated. 
 
Apart from mis-matches in the initial region of sequence data, ClustalW alignment also 
identified two other mis-matched nucleotides at positions 203 and 563. Inspection of the 
chromatographic sequence data revealed the genuine presence of guanine rather than 
cytosine at both mis-matched positions (Figure 2.8).  
 
 
Figure 2.8: Sequence data supporting base differences supported by ClustalW.  The 
positions of substituted bases are marked by an asterisk. 
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ClustalW analysis of sequence data obtained following sequencing of pET constructs 2 and 
3 (Appendix 7.58 and Appendix 7.61 respectively) also revealed a number of mis-matched 
bases within the initial part of the sequence data.  Further examination of the 
chromatographic data acquired during sequencing of pET constructs 2 and 3 also indicated 
that the mis-matched bases occurred within a region of the sequence where the 
chromatographic trace was particularly noisy (Appendix 7.59 and Appendix 7.62). The 
correct nucleotide bases could therefore be identified within the noisy region suggesting that 
the mis-matched bases were falsely identified during sequencing. In addition to mis-matches 
in the initial region of sequence data, ClustalW alignment also identified two other mis-
matched nucleotides at positions 147 and 507 for pET construct 2 (Appendix 7.60 A and B) 
and positions 148 and 508 for pET construct 3 (Appendix 7.63 A and B). In both cases, 
examination of the chromatographic sequence data revealed the genuine presence of 
guanine rather than cytosine at each of the mis-matched positions.  
 
2.3.3.7 Identification of mis-matched nucleotides within the mature lysostaphin 
domain encoding sequence 
 
Sequencing of plasmid DNA encoding the mature lysostaphin domain (pET constructs 1-3) 
revealed the presence of two apparent nucleotide mis-matches.  Both changes involved the 
genuine identification of guanine rather than expected cytosine nucleotides.  These mis-
matched bases could be identified as occurring at cytosines at position 96 and 456 within the 
sequence of the mature lysostaphin domain encoding sequence (Figure 2.9). The corrected 
sequence of the mature lysostaphin domain encoding sequence is presented in Appendix 
7.65.  
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Figure 2.9: DNA sequence encoding the mature lysostaphin domain.  Cytosine bases 
which appear to have been substituted in plasmid DNA sequences are indicated 
(position 96 and 456). 
 
To assess how these nucleotide mis-matches influenced the resulting amino acid sequence 
of the mature lysostaphin domain, the expected and sequenced DNA sequences were 
translated in silico to derive the anticipated amino acid sequences (Appendix 7.67) and 
compared using ClustalW analysis (Figure 2.10).  Incorporation of guanine rather than 
cytosine at position 456 did not alter the translation of proline152, whilst incorporation of 
guanine rather cytosine at position 96 resulted in the translation of methionine32 rather than 
isoleucine32. 
 
 
Figure 2.10: ClustalW alignment of the expected amino acid sequences of the mature 
lysostaphin domain obtained following incorporation of guanines rather than 
cytosines at position 96 and 456. Exchange of cytosine at position 456 did not alter 
the translation of proline152, whilst exchange of cytosine at position 96 resulted in the 
translation of methionine32 rather than isoleucine32. 
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2.3.4 Discussion  
 
Using a combination of PCR and gene cloning techniques, the mature lysostaphin domain 
encoding sequence was successfully amplified and cloned in E. coli.  DNA sequencing was 
used to provide more accurate confirmation that the exact nucleotide sequence had been 
cloned.  However a number of nucleotide mis-matches were observed following sequencing 
of pET constructs 1-3, which were attributable to some false and true nucleotide differences. 
  
Processed sequencing data is typically represented by chromatographic traces consisting of 
evenly spaced, non-overlapping peaks that correspond to labelled fragments that terminate 
at a specific nucleotide in the sequence  (Ewing et al., 1998).  However the chromatographic 
traces may deviate from this pattern in some regions of the sequence. For instance, the 
chromatographic trace commonly becomes noisy within the first 50-70 bases of a sequence, 
resulting in mis-identification of nucleotides. Noisy traces and unevenly spaced peaks tend 
to occur as a consequence of the detection of unreacted dye-primer or dye-terminator 
molecules and the anomalous migration of very short DNA fragments (Ewing et al., 1998).  
Therefore following examination of sequencing chromatograms, it was possible to establish 
that nucleotide mis-matches occurring between the first 60 and 80 bases of the sequence 
could be attributable to chromatographic noise.  
 
Sequencing data obtained from the subsequent 400-500 bases is typically of high quality, 
with an error rate of around 4% (Lipshutz et al., 1994, Kelley et al., 2010).  The quality of 
sequencing data acquired after the first 80 nucleotides was high, with a chromatographic 
distribution of even, non-overlapping peaks.  However the obtained sequence data also 
demonstrated two incidences of base mis-identification, whereby nucleotide positions 96 and 
456 were composed of guanine rather than cytosine bases.  The credibility of these mis-
matches was augmented by their presence in all three sets of sequencing data.  These 
nucleotide mis-matches could be explained by a number of factors including mis-
amplification of the gene sequence during PCR or simply inaccurate gene sequence 
information.    
 
PCR is known to occasionally introduce mutations into the amplified DNA sequence through 
mis-incorporation of nucleotides by the polymerase (Wendland, 2003). In this work, PCR 
amplifications were performed using KOD Hot Start Polymerase, which offers efficient and 
high-fidelity amplification of DNA, due to the possession of 3’-5’ exonuclease-dependent 
proofreading activity. It was therefore less likely that the apparent base changes observed 
during sequencing arose due to errors during PCR amplification. Furthermore it is unlikely 
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that DNA extension errors could account for the observed errors which occurred at the 
exactly the same nucleotides, despite the DNA being generated in separate PCR reactions. 
 
Primers were designed to allow amplification of the DNA sequence encoding the mature 
lysostaphin sequence within the preprolysostaphin gene.  The preprolysostaphin gene 
sequence (X06121) (Appendix 7.35) was acquired from the nucleotide database maintained 
by the National Centre for Biotechnology Information (NCBI) and was submitted by Heinrich 
et al (1987) after initial identification of the lysostaphin gene sequence.  The accuracy of the 
sequence is therefore dependent on database maintenance by NCBI and the accuracy of 
DNA sequencing performed by Heinrich et al (Heinrich et al., 1987). Heinrich et al performed 
dideoxy-DNA sequence analysis as described by Sanger et al, 1977 which was reported to 
achieve reasonably accurate determination of sequences ranging between around 15 and 
200 nucleotides (Sanger et al., 1977, Gargis et al., 2010).  Given the “reasonable accuracy” 
of DNA sequence analysis used to determine the sequence of lysostaphin, it seemed 
probable that the determined nucleotide sequence may not have been entirely accurate.  
 
This theory is supported by the work of Gargis et al (2010), who sequenced the pACK1 
plasmid of S. staphylolyticus, but did not acknowledge nucleotide mis-matches within the 
lysostaphin gene sequence (Gargis et al., 2010).  As the pACK1 plasmid contains the gene 
for lysostaphin, the sequence of pACK1 was compared to the sequence of the mature 
lysostaphin by ClustalW analysis. ClustalW analysis revealed that the lysostaphin-encoding 
region of the pACK1 plasmid contained guanine rather than cytosine at nucleotide positions 
96 and 456 (Appendix 7.64). Therefore the sequence data acquired in this work and the 
sequence of pACK1 clearly demonstrate that cytosine bases at 96 and 456 of lysostaphin 
were incorrectly determined during sequence analysis by Heinrich et al (1987).  Changes in 
the expected nucleotide sequence consequently influenced the resulting amino acid 
sequence following expression of the recombinant protein.  Whilst incorporation of guanine 
rather than cytosine at position 456 would not alter translation of proline152, incorporation of 
guanine rather than cytosine at position 96 would result in the translation of methionine32 
rather than isoleucine32.  Methionine has a mass of 149 Da which is greater than the mass of 
isoleucine (131 Da), therefore this amino acid difference will have slightly increased the 
predicted mass of recombinant lysostaphin following expression.   
 
Although this single amino acid difference was not likely to have interfered with the activity of 
recombinant lysostaphin, it would have interfered with characterisation of the primary 
structure of lysostaphin. With this knowledge, the pET constructs encoding the mature 
lysostaphin domain were expressed in E. coli so that the structure and function of 
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recombinant lysostaphin could be characterised to ensure that the cloned gene sequence 
encoded the desired product.  
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2.4 Expression of recombinant lysostaphin in E. coli 
 
2.4.1 Introduction 
 
As described in Section 2.3.1, the lysostaphin gene encodes a proproenzyme, which is 
processed by S. staphylolyticus to produce a mature, monomeric glycylglycine 
endopeptidase.  The native mature lysostaphin is composed of 246 amino acids and has a 
molecular weight of around 25 kDa (Recsei et al., 1987). The endopeptidase achieves 
optimal staphylolytic activity at pH 7.5 and is a basic protein with an isoelectric point (pI) of 
9.5 (Heinrich et al., 1987).  The mature lysostaphin domain expressed in E. coli will now be 
referred to as recombinant lysostaphin in this thesis. Recombinant lysostaphin exhibits the 
same activity as the native protein.   
Recombinant lysostaphin has been produced using eukaryotic expression hosts, such as 
mammalian cells and transgenic animals (Klein et al., 2006, Williamson et al., 1994, Wall et 
al., 2005, Kerr et al., 2001). Recombinant lysostaphin is more frequently produced using 
prokaryotic expression hosts, including E. coli, L. lactis, Bacillus subtilis and Lactobacillus 
casei (Gaier et al., 1992, Mierau et al., 2005a, Mierau et al., 2005b, Mitra et al., 2003). 
Higher amounts of recombinant lysostaphin can be yielded from E. coli, therefore E. coli is 
frequently used to express recombinant lysostaphin for research and commercial purposes, 
as demonstrated in Table 2.5 (Kokai-Kun et al., 2007, Oddone et al., 2007). 
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Table 2.5: Expression conditions for the production of recombinant lysostaphin in E. 
coli 
 
Expression 
Strain 
Expression 
System 
Vector Inducer Expression 
Media 
Fusion 
Proteins 
Reference 
JM105 pUC pUC8 None L Not specified Recsei et al., 
1987 
JM83 pET pET-29b(+) IPTG LB Not specified Chan, 1996 
ER2566 IMPACT-
CN 
 
pTYB12 IPTG LB Chitin-bound 
intein tag 
Szweda et 
al., 2001 
BL21(DE3) pET pET-23b(+) IPTG LB C-terminal 
His-tag 
Szweda et 
al., 2005 
BL21(DE3) pBAD pBAD/Thio-TOPO IPTG LB N-terminal 
His-tag 
Thioredoxin 
tag 
Szweda et 
al., 2005 
BL21(DE3) pET pET-15b IPTG LB N-terminal 
His-tag 
Sharma et 
al., 2006 
 
As shown in Table 2.5, recombinant lysostaphin has been expressed in a number of 
expression strains and vectors, with incorporation of various fusion tags.  In the majority of 
cases, E. coli was propagated in LB and protein expression was induced through the 
addition of IPTG. Recombinant lysostaphin was expressed and harvested from the 
cytoplasm of E. coli, although Chan, 1996 reported that lysostaphin activity could also be 
detected in the periplasmic and extracellular fractions of recombinant E. coli (Chan, 1996).  
 
2.4.1.1 Expression of recombinant lysostaphin in E. coli 
Following cloning, the recombinant lysostaphin gene constructs were expressed in E. coli to 
permit subsequent purification and characterisation of the resulting recombinant protein.  
The recombinant plasmid DNA was transformed into E. coli BL21(DE3) to see if recombinant 
lysostaphin could be successfully expressed. The recombinant lysostaphin gene constructs 
were engineered to permit expression in the cytoplasm or periplasm.  As lysostaphin 
displays activity against staphylococcal strains only, expression of recombinant lysostaphin 
in E. coli was unlikely to result in cell toxicity or death of host cells.  As expression of 
recombinant lysostaphin has previously been achieved in E. coli BL21(DE3) using pET 
vectors, it was expected that the lysostaphin gene constructs would express successfully in 
this work (Szweda et al., 2005, Sharma et al., 2006).   
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Once expression had been established, expression experiments were performed to establish 
which factors could influence expression of recombinant lysostaphin.  Expression variables 
such as different expression media, induction conditions and culture volumes were 
assessed. Recombinant protein expression was performed using rich and minimal media in 
shake-flasks. Depending on the amount of recombinant lysostaphin required for protein 
analysis, culture volumes varied between 50 ml and 1 L.  To achieve higher amounts of 
recombinant lysostaphin, cell lysates were pooled from multiple batch cultures and 
expression levels upon scale up were assessed. Sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE) analysis was used to provide an initial assessment of the 
molecular weight and solubility of recombinant lysostaphin.   
Aims:  
The initial aim of this work was:  
  To establish whether the recombinant lysostaphin gene constructs could be 
successfully expressed within the cytoplasm or periplasm of E. coli using SDS-PAGE 
analysis.  
If recombinant lysostaphin was expressed correctly then further experiments could be 
performed:   
 To assess the solubility of expressed recombinant lysostaphin using SDS-PAGE and 
solubilising buffer analysis.  
 To evaluate expression in minimal and complex media.  
 To assess expression levels upon scale-up of cell culture.  
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2.4.2 Methods 
 
2.4.2.1 Media  
All media compositions are outlined in Appendix 7.68. 
 
2.4.2.2 Chemicals 
All chemical compositions are outlined in Appendix 7.69. 
 
2.4.2.3 Buffers 
All buffer compositions are outlined in Appendix 7.70 
 
2.4.2.4 Bacterial strains 
Recombinant protein expression was performed following transformation of E. coli 
BL21(DE3).  
2.4.2.5 Media supplementation 
All cultures were supplemented with an antibiotic, according to the antibiotic selectivity of the 
pET vector used during recombinant protein expression. During IPTG-based induction of 
protein expression, the lactose analogue, IPTG was added to the culture to induce protein 
expression. Antibiotics and IPTG were added to cultures at the concentrations reported in 
Table 2.6.  The media supplements were prepared by dissolving the required chemical in 
sterile 18.2 M/cm H2O, before storing at 4°C for up to one week.  
Table 2.6: Antibiotic and chemical supplements used during the expression of 
recombinant lysostaphin 
Chemical Media Working 
Concentration 
(µg/ml) 
Stock 
Concentration 
(mg/ml) 
Dilution 
Kanamycin LB 50 10 1/200 
Kanamycin AIM 100 10 1/100 
Ampicillin LB/AIM 100 10 1/100 
IPTG LB/AIM/TB/MM 240 24 1/100 
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2.4.2.6 Bioinformatic prediction of expected molecular weight 
To establish the predicted amino acid sequence following translation from each recombinant 
lysostaphin gene construct, nucleotide sequences were submitted to the Translate tool 
(Expasy Proteomics Server, Swiss Institute of Bioinformatics), available at 
http://expasy.org/tools/dna.html.  The submitted nucleotide sequences were based on the 
corrected lysostaphin gene sequence as determined by sequencing data, as described in 
Section 2.3.3.7. The predicted amino acid sequence was then submitted to the ProtParam 
tool (Expasy Proteomics Server, Swiss Institute of Bioinformatics), available at the 
http://expasy.org/tools/protparam.html. The theoretical molecular weight and other 
physiochemical properties of each recombinant lysostaphin construct were determined using 
the results of ProtParam analysis.  Theoretical masses were calculated based on the 
assumption that the zinc binding domain was not occupied.  
2.4.2.7 Expression from recombinant lysostaphin gene constructs  
After cloning of the mature lysostaphin gene sequence, extracted recombinant pET vector 
DNA was transformed into chemically competent E. coli BL21(DE3) to permit protein 
expression. Chemically competent cells were prepared (Appendix 7.72) and transformed 
(Appendix 7.73).  Transformed E. coli were then inoculated into media which was carefully 
prepared prior to recombinant protein expression in shake flask cultures (Appendix 7.74). 
Recombinant protein expression was achieved following autoinduction (Appendix 7.75) or 
IPTG induction (Appendix 7.76) and the expressed protein was extracted following 
cytoplasmic (Appendix 7.77) or periplasmic protein expression (Appendix 7.78).  
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2.4.3 Results 
 
2.4.3.1 Expression of recombinant lysostaphin gene constructs in E. coli  
Following cloning in Chapter 1, the recombinant plasmid DNA was transformed into E. coli 
BL21(DE3) and a number of expression experiments were performed to assess how 
efficiently the recombinant lysostaphin gene constructs were expressed during culture and 
under a variety of expression conditions.  Initial experiments focused on whether induction of 
protein expression resulted in the successful and soluble expression of recombinant 
lysostaphin in the cytoplasm or following signal peptide-mediated translocation to the 
periplasmic space.  Bioinformatics analysis was performed to establish the theoretical 
molecular weight of each of the recombinant lysostaphin gene constructs following 
expression (Table 2.7). The expected nucleotide and amino acid sequences and ProtParam 
analysis results are presented in Appendix 7.80-Appendix 7.94.  
Unfortunately ProtParam could only provide the theoretical masses of the apoprotein form of 
recombinant lysostaphin, which does not have a bound zinc molecule.  At this stage of 
analysis, it was unclear whether recombinant lysostaphin was expressed in an apoprotein or 
holoprotein form or how the addition of zinc would influence the mass of recombinant 
lysostaphin. Therefore theoretical apoprotein masses were used to assess the masses of 
expressed proteins during SDS-PAGE analysis, until further characterisation of recombinant 
lysostaphin could be performed and theoretical metalloprotein masses obtained (Chapter 4).   
Table 2.7: Theoretical molecular weight and number of amino acids encoding 
recombinant lysostaphin gene constructs. 
Construct Fusion Tags Number of 
Amino Acids 
Apoprotein 
Mass (kDa) 
1 N-terminal His-tag 267 29337.8 
2 None 247 27075.4 
3 C-terminal His-tag 255 28140.5 
4 C-terminal His-tag 
PelB leader sequence 
255 28140.5 
5 PelB leader sequence 247 27075.4 
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2.4.3.2 Cytoplasmic expression of N-terminally His-tagged recombinant lysostaphin 
(construct 1) 
Cytoplasmic expression of N-terminally His-tagged recombinant lysostaphin was induced in 
E. coli BL21(DE3) and the cell lysate containing the resulting recombinant protein was 
harvested and analysed by PAGE. The cell lysate was found to contain a hyper-expressed 
protein with a molecular weight of around 29 kDa that was indicative of the presence of N-
terminally His-tagged recombinant lysostaphin, which has a theoretical molecular weight of 
29337.8 kDa (Figure 2.11).  
 
 
Figure 2.11: Cytoplasmic expression of N-terminally His-tagged recombinant 
lysostaphin (construct 1) in E. coli BL21(DE3) cultured in AIM. Cell-free extract (CFE) 
was analysed by 12% (v/v) SDS-PAGE. Lane 1: Sigma low molecular weight markers; 
Lane 2: CFE (1:10); Lane 3: CFE (1:100); Lane 4: Sigma high molecular weight 
markers. 
 
PAGE analysis revealed that N-terminally His-tagged recombinant lysostaphin could be 
hyper-expressed within the cytoplasm of E. coli and therefore this form of recombinant 
lysostaphin was expressed many times to produce recombinant lysostaphin for subsequent 
analysis and characterisation.  Following expression, the solubility of proteins within the 
harvested cell lysate was tested by adding solubilising buffer to cell lysate, before PAGE 
analysis.  As shown in Figure 2.12, the solubilised cell lysate sample contained a stronger 
protein band at 29 kDa, than was detected in cell lysate that was not treated with solubilising 
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buffer. This indicated that a small proportion of N-terminally His-tagged recombinant 
lysostaphin may have become insoluble upon cytoplasmic expression.    
 
Figure 2.12: Cytoplasmic expression of N-terminally His-tagged recombinant 
lysostaphin in E. coli BL21 (DE3) cultured in AIM. CFE was analysed by 12% (w/v) 
SDS-PAGE. Lane 1: Sigma low molecular weight markers; Lane 2: CFE (neat); Lane 3: 
CFE (1:10); Lane 4: CFE (1:100); Lane 5: CFE in solubilising buffer; Lane 6: Sigma 
high molecular weight markers. 
 
2.4.3.3  Expression of recombinant lysostaphin (constructs 2, 3, 4 and 5) 
PAGE analysis of cell lysate following cytoplasmic expression of recombinant lysostaphin 
(constructs 2 and 3) demonstrated hyper-expression of protein with a molecular weight 
corresponding with the expected values, indicating the presence of recombinant lysostaphin 
(Appendix 7.95 and Appendix 7.96 respectively).  Both forms of the protein appeared to 
remain soluble upon expression in E. coli BL21(DE3).   
 
PAGE analysis of cell lysate following periplasmic expression of recombinant lysostaphin 
(constructs 4 and 5) demonstrated hyper-expression of protein with a molecular weight 
corresponding with the expected values, indicating that the PelB leader sequence effectively 
translocated recombinant lysostaphin across the inner membrane to the periplasmic space 
(Appendix 7.97 and Appendix 7.99 respectively). Repeated expression of both forms of the 
protein indicated that recombinant lysostaphin remained soluble upon expression in E. coli 
BL21(DE3) (Appendix 7.98 and Appendix 7.100).  However PAGE analysis also revealed 
that the periplasmic lysate also featured over-expression of other proteins, with molecular 
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weights of around 36 and 45 kDa, which may have had a detrimental effect on the 
expression levels of recombinant lysostaphin through their activity or interference with 
translocation.    
 
2.4.3.4 Expression of recombinant lysostaphin using different expression media 
Initial expression experiments suggested that the recombinant lysostaphin gene constructs 
could be transcribed and translated in E. coli BL21(DE3), yielding a protein with a molecular 
weight that corresponded with the molecular weight of recombinant lysostaphin. Initially 
expression experiments were performed by culturing the E. coli in AIM, whereas in 
subsequent experiments E. coli was optionally fermented using either LB, minimal media 
(MM) or terrific broth (TB), whilst protein expression was induced through the addition of 
IPTG. 
Expression of N-terminally His-tagged recombinant lysostaphin (construct 1) was 
demonstrated in AIM, LB, TB and MM (Appendix 7.101), though greater expression levels 
were observed in more complex media (LB and TB) or semi-defined media (AIM) and protein 
solubility appeared highest when the protein was expressed in LB (Appendix 7.102). 
Expression of recombinant lysostaphin (construct 2) and C-terminally His-tagged 
recombinant lysostaphin was found to occur to a greater extent in AIM than LB (Appendix 
7.103 and Appendix 7.104 respectively).  However due to the popularity and convenient 
formulation of LB media, LB became the preferred media type for preparation of recombinant 
lysostaphin during the optimisation of preparative and analytical chromatographic methods.  
 
2.4.3.5 Expression of recombinant lysostaphin using different expression media 
volumes 
The yield of recombinant lysostaphin (construct 1) could be increased by augmenting 
expression media volume from 50 ml to 1 L, without compromising expression levels. Protein 
yield could be increased further by harvesting cell lysate originating from 1, 5 and 15 L of 
culture (Figure 2.13).  Although there were no major discernible differences between protein 
expression levels with increased expression media volumes, it was unclear whether pooling 
shake flask cultures increased protein heterogeneity if individual cultures suffered from 
batch-to-batch variability.   
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Figure 2.13: PAGE analysis of cytoplasmic cell lysates resulting from overall culture 
volumes during the expression of N-terminally His-tagged recombinant lysostaphin 
(construct 1) in E. coli BL21(DE3) cultured in AIM. Overexpression of a protein with a 
molecular weight of around 29 kDa was observed in cell lysates derived from 1 L 
batch culture or after pooling 5 or 15 x 1L batch cultures, indicating successful 
expression of N-terminally His-tagged recombinant lysostaphin. A) CFE resulting from 
1L batch culture; Lane 1: Sigma low molecular weight markers; Lane 2: CFE (neat); 
Lane 3: CFE (1:10). B) CFE resulting from 5 x 1L batch cultures; Lane 1: Sigma low 
molecular weight markers; Lane 2: CFE (neat); Lane 3: CFE (1:10).  C) CFE resulting 
from 15 x 1L batch cultures. Lane 1: Sigma low molecular weight markers; Lane 2: 
CFE (neat); Lane 3: CFE (1:10). 
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2.4.4 Discussion 
 
Following protein expression in E. coli, it was evident that all five recombinant lysostaphin 
gene constructs could be successfully expressed in E. coli BL21(DE3).  Each recombinant 
lysostaphin gene construct appeared to have been expressed efficiently within the 
cytoplasm.  Successful expression was indicated by SDS-PAGE, through the observation of 
protein bands that corresponded with the expected molecular weights of proteins encoded 
by the recombinant lysostaphin gene constructs.  Furthermore recombinant lysostaphin with 
pelB leader sequences (constructs 3 and 4) appeared to undergo effective translocation 
from cytoplasm to periplasm, which is not always guaranteed (Malik et al., 2006, Chou, 
2007).  PelB leader sequences are cleaved by signal peptidases upon translocation through 
the inner membrane.  PAGE analysis suggested that pelB leader sequence had been 
effectively removed, as the observed protein bands matched the expected molecular weight 
of N-terminally processed recombinant lysostaphin, in the presence and absence of a C-
terminal His-tag.    
Recombinant lysostaphin was expressed exclusively using E. coli BL21(DE3), however the 
cloned plasmids harbouring the lysostaphin gene could have been transformed into 
alternative E. coli strains.  Alternative E. coli B or K-12 strains are often employed when 
expression is problematic, however in this work E. coli BL21(DE3) was shown to provide 
efficient expression of recombinant lysostaphin therefore the use of alternative expression 
strains was not deemed necessary.  Furthermore, the influence of strain diversity upon the 
expression of recombinant lysostaphin was not investigated in this work, as the chemical 
and enzymatic modifications described in Section 1.2.1 were not found to be strain-specific, 
occurring in variety of popular E. coli expression strains. 
All of the expression experiments indicated that the recombinant lysostaphin gene constructs 
could be used to express recombinant lysostaphin in a largely soluble form.  A crude test of 
solubility was performed by treating cellular proteins with solubilising buffer prior to PAGE 
analysis.  Solubilising buffer treatment solubilised any insoluble fractions of the recombinant 
protein preparation, however in the majority of instances, recombinant lysostaphin appeared 
to remain soluble following expression, which is desirable during recombinant protein 
production.   
However on several occasions, PAGE analysis revealed that N-terminally His-tagged 
recombinant lysostaphin (construct 1) appeared to be produced in soluble and insoluble 
fractions.  The insolubility of N-terminally His-tagged occurred intermittently and became 
apparent through frequent expression of this particular construct.  It was likely that the 
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apparent insolubility probably arose as a consequence of hyper-expression of recombinant 
lysostaphin and therefore could probably be minimised through alteration of culture 
temperatures or the addition of lower concentrations of IPTG during induction.  Protein 
insolubility can lead to undesirable protein aggregation, therefore N-terminally His-tagged 
recombinant lysostaphin was analysed by gel filtration, as described in Section 4.3, as a test 
of protein aggregation.     
All of the recombinant lysostaphin gene constructs appeared to express well in different 
types of expression media. Expression experiments were primarily performed using AIM or 
LB, however due to convenience and popularity, LB became the preferred choice of 
expression media.  Recombinant lysostaphin appeared to remain soluble when expressed in 
LB, whereas insoluble fractions were frequently observed upon expression in AIM.  
Furthermore, the use of LB and IPTG-based induction may have provided greater control 
over induction conditions, than auto-induction of protein expression. Auto-induction is 
dependent on cellular metabolism therefore induction occurs during growth saturation at a 
point which is determined by intrinsic cell physiology. IPTG-based induction therefore 
provides greater knowledge and control over the optical density at which protein expression 
is induced within a culture. 
Most expression experiments were performed using 50-1000 ml of expression media, 
however when larger yield of recombinant lysostaphin were required, the cell lysates from up 
to 15 L of culture were combined. Pooling of cell lysates from multiple batch cultures proved 
to be a successful method of providing larger amounts of recombinant lysostaphin, in the 
absence of a continuous culture strategy.  PAGE analysis of cell lysates resulting from the 
combination of multiple batch cultures suggested that batch-to-batch variability did not 
appear to dramatically increase the overall heterogeneity of the cell lysate.  However this 
strategy may have increased the heterogeneity of recombinant lysostaphin through the 
combination of different protein isoforms, therefore this strategy was avoided where 
possible.   
Due to the reactive nature of the cellular compartments of E. coli, recombinant lysostaphin 
would have been exposed to a cellular milieu which may have been detrimental to its 
structure, stability or function.  It was therefore desirable to rapidly isolate the recombinant 
protein from the cell lysate by protein purification, as described in Section 2.5.  
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2.5 Purification of recombinant lysostaphin  
 
2.5.1 Introduction  
A protein purification strategy typically aims to purify a target protein in a rapid and efficient 
manner, whilst retaining biological activity and structural integrity.  An optimised purification 
strategy can permit maximal recovery of pure and active protein from the complex starting 
material from which the protein was derived.  Cell lysates, such as those obtained from E. 
coli contain a mixture of macromolecules, including several thousand proteins, from which 
the target protein must be purified (Marshak, 1996).  As recombinant DNA technology, 
enables high level expression of a target protein, it has become simpler to isolate a target 
protein.  Nevertheless it is imperative that the hyper-expressed target protein is separated 
from active cellular proteases that could detrimentally affect protein structure upon their 
release by cellular disruption.   
Careful preparation of cell lysate is  therefore important to ensure the target protein does not 
undergo proteolysis prior to purification. Cell lysate preparation should be optimised to 
ensure that protein stability and activity is appropriately influenced by pH, ionic strength, 
temperatures and reducing agents.  Cell lysate is therefore typically prepared at low 
temperatures using buffers which are compatible with the target protein, but also with 
subsequent assay measurements or chromatographic analysis.  Such downstream 
applications often determine the level of purification required, as proteins with therapeutic 
uses must be purified to a very high level, whilst protein used in industrial applications can 
be of lower purity.   
As proteins are composed of different numbers and sequences of amino acids, they tend to 
differ in their physical and chemical characteristics.  Furthermore, polypeptides are folded to 
create distinct tertiary structures, which influences the size, shape and reactivity of the 
protein (Marshak, 1996). Unique biochemical properties, such as mass, charge, stability, 
solubility, hydrophobicity or affinity are exploited during protein purification to isolate the 
target protein. A number of these techniques were employed during the separation or 
purification of recombinant lysostaphin, as presented in Table 2.8. Many of these separation 
techniques are dependent on molecular interactions, involving hydrogen bonds, hydrophobic 
and ionic interactions, which vary with temperature, pH and ionic strength. An understanding 
of the nature and strength of these molecular interactions can therefore facilitate protein 
purification, through optimisation of purification conditions.   
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Table 2.8: Modes and principles of separation techniques used in protein purification 
Separation Process Separation Mode Principle of Separation 
Precipitation  Ammonium sulphate Solubility  
Acetate Solubility 
Trichloroacetic acid  Solubility 
Chromatography  Immobilised metal affinity chromatography Specific ligand binding 
Hydrophobic Interaction Hydrophobicity  
Reversed-Phase    Hydrophobicity, size  
Ion Exchange  Charge 
Gel Filtration (Size exclusion)  Size, shape  
Filtration Ultrafiltration  Size, shape 
Dialysis Size, shape 
 
2.5.1.1 Purification of recombinant lysostaphin 
Following expresssion of recombinant lysostaphin, it was imperative that the target protein 
was recovered from the cell lysate as swiftly and efficiently as possible, to minimise 
proteolysis or modification of the recombinant product. To achieve this, a protein purification 
strategy for the isolation of recombinant lysostaphin was identified and optimised. Complete 
protein purification often requires the application of several separative techniques, however 
in this instance purification of recombinant lysostaphin in a single purification step was 
desirable.  
By minimising the number of purification steps, the yield and activity of purified recombinant 
lysostaphin could also be maximised and maintained. To ensure that the activity of 
recombinant lysostaphin had been preserved during purification, the staphylolytic activity 
was assayed (Section 4.1). To confirm that protein yields and purity were maintained 
through the course of purification, protein concentration was monitored by UV spectrometry, 
whilst purity was determined by SDS-PAGE analysis.  Maximal retention of expressed 
recombinant lysostaphin was essential to ensure that enough protein was available for 
subsequent analysis and characterisation, as described in Chapters 3 and 4.  Whilst some 
analytical techniques such as mass spectrometry, theoretically only required femtomolar 
amounts for protein identification, biological assays and chromatographic separation of 
protein isoforms required larger, micromolar amounts of protein to accomplish analysis.  
During the optimisation of a purification strategy, a number of purification techniques were 
employed, including ammonium sulphate fractionation (ASF), immobilised metal affinity 
chromatography (IMAC), ion exchange chromatography (IEX), hydrophobic interaction 
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chromatography (HIC), gel filtration (GF) and ultrafiltration.  Some techniques were selected 
according to convenience, such as ASF, due to its ease and compatibility with HIC. ASF was 
also used on several occasions to concentrate protein sample prior to chromatographic 
purification. Ultrafiltration was used to effectively desalt and concentrate samples prior to 
and following a chromatographic separation.  Recombinant lysostaphin expressed in E. coli 
has traditionally been purified using affinity chromatography, however in this work a variety 
of chromatographic separations were performed to assess whether recombinant lysostaphin 
could be successfully isolated by different chromatographic mechanisms (Chan, 1996, 
Szweda et al., 2001, Sharma et al., 2006).   
The success of chromatographic separation was ultimately influenced by the 
physicochemical properties of each of the expressed recombinant lysostaphin constructs.  
Following bioinformatic analysis of the amino acid sequences of recombinant lysostaphin 
constructs, certain biochemical properties could be predicted, as described in Table 2.9. 
Evidently, recombinant lysostaphin constructs harbouring His-tag sequences could 
theoretically be purified efficiently and directly using IMAC. Recombinant lysostaphin 
constructs without affinity fusion tags had to be purified using alternative chromatographic 
approaches, such as IEX, HIC and GF. As PTMs have been known to occur at His-tag 
sequences of proteins, His-tagged recombinant lysostaphin constructs were also purified 
using these techniques, to establish whether modified protein isoforms were excluded from 
purified recombinant lysostaphin preparations during IMAC.  
 
Table 2.9: Expected physicochemical properties of expressed recombinant 
lysostaphin gene constructs, as determined by ProtParam analysis. 
Construct Fusion Tags Apoprotein 
Mass (kDa) 
Theoretical 
isoelectric point 
(pI) 
1 N-terminal His-tag 29337.8 9.72 
2 None 27075.4 9.59 
3 C-terminal His-tag 28140.5 9.52 
4 C-terminal His-tag and 
PelB leader sequence 
28140.5 9.52 
5 PelB leader sequence 27075.4 9.59 
 
The theoretical isoelectric points of the recombinant lysostaphin constructs indicate that 
recombinant lysostaphin is a fairly basic protein. This trait would essentially lead to the 
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protein bearing an overall negative charge at neutral pH, suggesting that the protein would 
be purified more succesfully using CXC rather than AXC.  
The aims of this work were: 
 To sucessfully isolate recombinant lysostaphin from extracted cell lysates using a 
single or multiple chromatographic techniques. 
 To purify maximal amounts of the expressed recombinant protein.  
 To create an optimised purification strategy allowing rapid purification of recombinant 
lysostaphin.   
 To retain the biological activity of recombinant lysostaphin. 
 To produce His-tagged recombinant lysostaphin preparations, purified using affinity 
purification or non-affinity based chromatography, for comparison of product 
heterogeneity.   
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2.5.2 Methods  
 
2.5.2.1 Buffers  
All buffer compositions are outlined in Appendix 7.105. 
 
2.5.2.2 Chemicals 
All chemical compositions are outlined in Appendix 7.106.  
 
2.5.2.3 Equipment  
All equipment used during the purification of recombinant lysostaphin is outlined in Appendix 
7.107. 
 
2.5.2.4 Purification of recombinant lysostaphin  
Recombinant lysostaphin was purified from cell-free extract (CFE) following protein 
extraction. ASF was tested as an initial differential purification technique and was 
occasionally used to concentrate protein samples during the course of protein purification 
(Appendix 7.109). Harvested cell lysate was applied to ion exchange columns during AXC 
(Appendix 7.112) and CXC (Appendix 7.113).  Recombinant lysostaphin constructs 
expressed without His-tags were purified in one-step using CXC or two-steps, using HIC 
(Appendix 7.110) and GF (Appendix 7.111).  Constructs expressed with His-tags were 
purified in one-step with IMAC, but were also purified by CXC to ensure that potential protein 
isoforms harbouring His-tag modifications were not eliminated from the final purified protein 
preparation.   
IMAC was performed using Chelating Sepharose™ Fast Flow columns in conjunction with 
an ÄKTA™ prime plus purification system (Appendix 7.114) or Eyela microtube peristaltic 
pump during large-scale purification (Appendix 7.115). Dialysis (Appendix 7.118) and 
lyophilisation (Appendix 7.119) was used to concentrate purified protein following large-scale 
purification. Alternatively IMAC purification was performed using ProPac® IMAC-10 columns 
and an Ultimate™ 3000 Titanium system (Appendix 7.116 and Appendix 7.117). Following 
small-scale purifications, resulting fractions were analysed by PAGE and fractions containing 
the target protein were concentrated by ultrafiltration (Appendix 7.120).  
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2.5.3 Results 
Following expression of the recombinant lysostaphin gene constructs in E. coli BL21(DE3), 
experiments were performed to purify the recombinant protein from other contaminating 
cellular proteins from E. coli.   
 
2.5.3.1 Ammonium sulphate fractionation 
ASF was tested as an initial crude differential purification technique to remove less 
hydrophilic contaminating proteins from the protein preparation. Following expression in E. 
coli BL21(DE3), harvested cell lysate was analysed by SDS-PAGE (Appendix 7.121) and 
precipitated using between 20 and 60% (w/v) ammonium sulphate. SDS-PAGE analysis of 
resuspended protein suggested that recombinant lysostaphin became insoluble at 20% (w/v) 
ammonium sulphate and therefore ASF could not provide differential purification on the 
grounds of solubility (Figure 2.14). Precipitation of recombinant lysostaphin with 50-60% 
(w/v) ammonium sulphate was subsequently used to provide sample concentration, however 
this was found to have detrimental effects on protein solubility during resuspension, as 
described in Sections 2.5.3.3 and 2.5.3.8. 
Figure 2.14: ASF of recombinant lysostaphin (construct 2).  Lane 1: Sigma low 
molecular weight markers; Lane 2: 20% (w/v) ammonium sulphate (pellet); Lane 3: 
30% (w/v) ammonium sulphate (pellet); Lane 4: 40% (w/v) ammonium sulphate (pellet); 
Lane 5: 60% (w/v) ammonium sulphate (pellet); Lane 6: 60% (w/v) ammonium sulphate 
(supernatant); Lane 7: Sigma high molecular weight markers.  
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2.5.3.2 HIC using Phenyl Sepharose™ high performance media and an ӒKTA™ 
purification system 
Following ASF, the pelleted protein was subjected to HIC, which resulted in the elution of a 
series of poorly separated peaks (Figure 2.5). According to SDS-PAGE, these peaks 
reflected the retention of recombinant lysostaphin and other E. coli cellular proteins (Figure 
2.15). 
 
Figure 2.15: Purification of recombinant lysostaphin (construct 2) using HIC.  Cell 
lysate extracted from recombinant E. coli BL21(DE3) cultured in AIM was applied to 
the Phenyl Sepharose™ high performance column.  Bound protein was eluted by 
applying a decreasing ammonium sulphate concentration (1.5-0 M).  Fractions 73-80 
contained recombinant lysostaphin.  
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Figure 2.16: SDS-PAGE analysis of fractions eluted during HIC of cell-lysate 
containing recombinant lysostaphin (construct 2). Lane 1: Sigma low molecular 
weight markers; Lane 2: Fraction 73; Lane 3: Fraction 74; Lane 4: Fraction 75; Lane 5: 
Fraction 76; Lane 6: Fraction 77; Lane 7: Fraction 78; Lane 8: Fraction 79; Lane 9: 
Fraction 80; Lane 10: Sigma low molecular weight markers. 
 
HIC was performed again following application of cell lysate containing C-terminally His-
tagged recombinant lysostaphin (construct 3) (Appendix 7.126), which resulted in the 
resolution of a number of peaks that reflected the presence of recombinant lysostaphin and 
contaminating E. coli proteins (Figure 2.17 and Figure 2.18). 
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Figure 2.17: Purification of C-terminally His-tagged recombinant lysostaphin 
(construct 3) using HIC. Cell lysate extracted from recombinant E. coli BL21(DE3) 
cultured in AIM was applied to the Phenyl Sepharose™ high performance column.  
Bound protein was eluted by applying a decreasing ammonium sulphate 
concentration (1.5-0 M).  
 
 
Figure 2.18: SDS-PAGE analysis of fractions eluted during HIC of cell-lysate 
containing C-terminally His-tagged recombinant lysostaphin (construct 3). Fractions 
70-80 were pooled and precipitated by ammonium sulphate fractionation prior to 
concentration by ultrafiltration. Lane 1: Fraction 70; Lane 2: Fraction 72; Lane 3; 
Fraction 74; Lane 4: Fraction 76; Lane 5: Fraction 78; Lane 6: Fraction 80; Lane 7: 
Fraction 82; Lane 8: Fraction 84; Lane 9: Sigma high molecular weight markers.  
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2.5.3.3 GF using HiLoad™ 16/60 Superdex 200 media and a FPLC system 
Following HIC, the fractions containing recombinant lysostaphin (construct 3) were pooled 
and subjected to ASF before resuspending the pellet and concentrating the protein by 
ultrafiltration. Sample concentration was hindered by protein solubility issues, however the 
sample was ultimately concentrated and injected onto a GF column (Figure 2.19). GF 
resulted in the elution of a number of peaks, one of which contained recombinant 
lysostaphin, as confirmed by SDS-PAGE (Figure 2.20). 
 
Figure 2.19:  Purification of C-terminally His-tagged recombinant lysostaphin 
(construct 3) using GF. Concentrated protein purified using HIC was applied to 
HiLoad 16/60 Superdex 200 prep grade column.  Bound protein was eluted by 
isocratic elution.  
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Figure 2.20: SDS-PAGE analysis of fractions eluted during GF of protein eluted during 
HIC. Fractions 19-26 were pooled and concentrated by ultrafiltration. Lane 1: Fraction 
18; Lane 2: Fraction 19; Lane 3; Fraction 20; Lane 4: Fraction 21; Lane 5: Sigma low 
molecular weight markers; Lane 6: Sigma low molecular weight markers; Lane 7: 
Fraction 22; Lane 8: Fraction 23; Lane 9: Fraction 24; Lane 10: Fraction 25; Lane 11: 
Fraction 26.  
The fractions containing recombinant lysostaphin were pooled and concentrated prior to 
SDS-PAGE (Figure 2.21). Whilst HIC and GF provided high-level purification of recombinant 
lysostaphin, the purified sample was of low concentration and may have degraded during the 
course of purification and storage. 
 
Figure 2.21: SDS-PAGE analysis of the recombinant protein preparation after HIC and 
following HIC and GF. Lane 1; Sigma low molecular weight markers; Lane 2; Protein 
sample following HIC; Lane 3: Protein sample following HIC and GF. 
 
67 
 
2.5.3.4 AXC using Source™ 30Q media and an ӒKTA™ purification system  
As HIC could not provide complete purification of recombinant lysostaphin, IEX was 
performed with the intention of directly purifying the recombinant protein from the cell lysate. 
Cell lysate was subjected to AXC, which resulted in retention of multiple proteins (Figure 
2.22); however SDS-PAGE analysis revealed that the detected peaks represented retention 
of E. coli cytoplasmic proteins instead of recombinant lysostaphin (Figure 2.23). AXC was 
repeated following application of cell lysate containing recombinant lysostaphin (constructs 4 
and 5) (Appendix 7.122 and Appendix 7.124), however once again SDS-PAGE analysis 
revealed that the target protein was not retained (Appendix 7.123 and Appendix 7.125) and 
therefore AXC could not be used to purify recombinant lysostaphin.  
 
Figure 2.22: Purification of recominant lysostaphin (construct 2) using AXC. Cell 
lysate extracted from recombinant E. coli BL21(DE3) cultured in AIM was applied to 
the Source™ 30Q column.  Bound protein was eluted by applying an increasing NaCl 
concentration (0-1.0 M) 
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Figure 2.23: SDS-PAGE analysis of fractions eluted during AXC of cell-lysate 
containing recombinant lysostaphin (construct 2).  Lane 1: Sigma low molecular 
weight markers; Lane 2: Fraction 28; Lane 3: Fraction 30; Lane 4: Fraction 32; Lane 5: 
Fraction 34; Lane 6: Fraction 36; Lane 7: Fraction 38; Lane 8: Fraction 40; Lane 9: 
Fraction 42; Lane 10: Sigma high molecular weight markers; Lane 11: Sigma low 
molecular weight markers; Lane 12: Fraction 44; Lane 13: Fraction 46; Lane 14: 
fraction 48. 
 
2.5.3.5 CXC using Source™ 30s media and an ӒKTA™ purification system  
Cell lysate was also subjected to CXC, which resulted in the resolution of a single major 
peak (Figure 2.24).  SDS-PAGE analysis revealed that CXC efficiently separated 
recombinant lysostaphin (construct 2) from E. coli cytoplasmic proteins, providing a high 
degree of purification (Figure 2.25). CXC also provided efficient purification of N-terminally 
His-tagged recombinant lysostaphin (construct 1) on two separate occasions (Appendix 
7.127 and Appendix 7.129). Once again SDS-PAGE of eluted fractions revealed that CXC 
could selectively purify the target protein from the cell lysate (Appendix 7.128 and Appendix 
7.130).  
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Figure 2.24: Purification of recombinant lysostaphin (construct 2) using CXC.  Cell 
lysate extracted from recombinant E. coli BL21(DE3) cultured in AIM was applied to 
the Source™ 30s column.  Bound protein was eluted by applying an increasing NaCl 
concentration (0-1.0 M). 
 
Figure 2.25: SDS-PAGE analysis of CXC fractions and purified recombinant 
lysostaphin (construct 2).  A) Fractions eluted during CXC of cell-lysate containing 
recombinant lysostaphin (construct 2). Eluted CXC fractions 35-41 were pooled and 
concentrated by ultrafiltration.  Lane 1: Sigma low molecular weight markers; Lane 2: 
Fraction 34; Lane 3: Fraction 36; Lane 4: Fraction 38; Lane 5: Fraction 40; Lane 6: 
Fraction 42; Lane 7: Fraction 43. B) Concentrated protein after pooling and 
ultrafiltration of fractions eluted during CXC of cell-lysate containing recombinant 
lysostaphin (construct 2). Lane 1: Sigma low molecular weight markers; Lane 2: 
concentrated protein (neat); Lane 3: concentrated protein (1:10); Lane 4: concentrated 
protein (1:100); Lane 5: Sigma high molecular weight markers.  
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2.5.3.6 IMAC using Chelating Sepharose™ Fast Flow media and an ӒKTA™ 
purification system  
As three of the five expressed recombinant lysostaphin gene constructs featured His-tag 
sequences, recombinant lysostaphin (constructs 1, 3 and 4) could be purified using IMAC.  
Initial IMAC purifications were performed using an ӒKTA™ prime plus purification system, 
whilst later purifications were performed using an Ultimate™ 3000 Titanium system. IMAC 
purification of cell lysate containing recombinant lysostaphin (construct 3) resulted in elution 
of a narrow, well resolved peak, suggesting purification of the target protein (Figure 2.26).  A 
high degree of protein purification was confirmed following PAGE analysis of the fractions 
eluted during IMAC (Figure 2.27).  
 
 
Figure 2.26: Purification of C-terminally His-tagged recombinant lysostaphin 
(construct 3) using IMAC.  Cell lysate extracted from recombinant E. coli BL21(DE3) 
cultured in AIM was applied to the Chelating Sepharose™ Fast Flow media column.  
Bound protein was eluted by applying an increasing imidazole concentration (20-500 
mM).  
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Figure 2.27: SDS-PAGE analysis of fractions following IMAC purification of C-
terminally His-tagged recombinant lysostaphin (construct 3). Lane 1: Sigma low 
molecular weight markers; Lane 2: Fraction 41; Lane 3: Fraction 43: Lane 4: Fraction 
45; Lane 5: Fraction 47; Lane 6: Fraction 49; Lane 7: Fraction 51; Lane 8: Fraction 53; 
Lane 9: Sigma high molecular weight markers.   
 
To remove low molecular weight contaminants, fractions containing purified recombinant 
lysostaphin were concentrated and subjected to GF (Figure 2.28). SDS-PAGE of eluted 
fractions demonstrated that recombinant lysostaphin has been purified to a very high degree 
(Figure 2.29). Further IMAC purifications of recombinant lysostaphin (construct 1 and 
construct 4) were performed (Appendix 7.131 and Appendix 7.133) leading to a high-level of 
purification which was confirmed by SDS-PAGE (Appendix 7.132 and Appendix 7.134).  As 
IMAC provided a high degree of purification within a single chromatographic step, secondary 
purification with GF was not considered efficient or necessary.  
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Figure 2.28:  Purification of C-terminally His-tagged recombinant lysostaphin 
(construct 3) using GF.  Concentrated protein purified using HIC was applied to 
HiLoad 16/60 Superdex 200 prep grade column.  Bound protein was eluted by 
applying an isocratic gradient.  
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Figure 2.29: SDS-PAGE analysis of fractions following IMAC and GF purification of C-
terminally His-tagged recombinant lysostaphin (construct 3) derived from E.coli 
BL21(DE3) cultured in AIM. Lane 1: Sigma low molecular weight markers; Lane 2: 
Fraction 17; Lane 3: Fraction 18: Lane 4: Fraction 19; Lane 5: Fraction 20; Lane 6: 
Fraction 21; Lane 7: Fraction 22; Lane 8: Fraction 23; Lane 9: Fraction 24; Lane 10: 
Sigma high molecular weight markers.   
 
2.5.3.7 Large-scale purification of recombinant lysostaphin by IMAC using Chelating 
Sepharose™ Fast Flow media and an ӒKTA™ purification system 
When cell lysate was harvested from multiple batch cultures, multiple IMAC purifications 
were performed consecutively to ensure that the increased concentration of recombinant 
protein did not overwhelm the binding capacity of the IMAC stationary phase.  Due to shared 
usage, it was more practical to perform multiple IMAC purifications rather than re-pack the 
chelating sepharose column and re-program the ӒKTA™ chromatographic program to 
accommodate the larger bed volume of the stationary phase. Therefore cell lysate containing 
recombinant lysostaphin (construct 3) was applied to the IMAC column over two consecutive 
separations (Figure 2.30). PAGE analysis suggested that recombinant lysostaphin was 
purified effectively from cell lysate from 4 L of culture; however this approach was not 
practical when purifying the target protein from larger culture volumes (Figure 2.31).  
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Figure 2.30: Purification of N-terminally His-tagged recombinant lysostaphin 
(construct 1) using IMAC.  Cell lysate extracted from recombinant E. coli BL21(DE3) 
cultured in 4 x 1 L AIM was applied to the Chelating Sepharose™ Fast Flow media 
column.  Bound protein was eluted by applying an increasing imidazole concentration 
(20-500 mM). A) First application of CFE, B) Second application of CFE.  
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Figure 2.31: SDS-PAGE analysis of C-terminally His-tagged recombinant lysostaphin 
(construct 3). A) Expression of construct 3 in E. coli BL21(DE3) grown in AIM (4L 
culture volume).  Lane 1: Sigma low molecular weight markers; Lane 2: CFE (neat). B) 
Concentrated purified recombinant lysostaphin following multiple IMAC purifications. 
Lane 1: Sigma low molecular weight markers; Lane 2: concentrated protein (neat); 
Lane 3: concentrated protein (1:10); Lane 4: concentrated protein (1:100); Lane 5: 
Sigma high molecular markers   
 
2.5.3.8 Large-scale purification of recombinant lysostaphin by IMAC using Chelating 
Sepharose™ Fast Flow media and a peristaltic pump  
To purify larger amounts of recombinant protein in an efficient manner, IMAC purification 
was performed using a peristaltic pump and a chelating sepharose column with greater 
binding capacity. Cell lysate containing recombinant lysostaphin (construct 1) (Appendix 
7.101 B and Figure 2.13.C) was applied to a nickel column and purification was achieved by 
step elution using a peristaltic pump. SDS-PAGE analysis suggested that the highest 
concentration of protein was eluted following application of elution buffer containing 300 and 
400 mM imidazole (Figure 2.32). The eluted protein was concentrated by lyophilisation, 
however following resuspension, recombinant lysostaphin protein did not regain full 
solubility, which interfered with the effectiveness of subsequent chromatographic analysis 
(Section 3.4.3.3).    
 
76 
 
 
Figure 2.32: SDS-PAGE analysis of IMAC fractions following IMAC purification of N-
terminally His-tagged recombinant lysostaphin (construct 1) produced in E.coli 
BL21(DE3). A) IMAC purification of recombinant lysostaphin derived from 15 x 1 L 
shake-flask cultures of AIM. Lane 1: Sigma low molecular weight markers; Lane 2: 200 
mM imidazole elution; Lane 3: 300 mM imidazole elution; Lane 4: 400 mM imidazole 
elution; Lane 5: Sigma high molecular weight markers. B) IMAC purification of 
recombinant lysostaphin derived from 14 x 1 L shake-flask cultures of LB. Lane 1: 
Sigma low molecular weight markers; Lane 2: 200 mM imidazole elution (A); Lane 3: 
200 mM imidazole elution (B): Lane 4: 300 mM imidazole elution; Lane 5: 400 mM 
imidazole elution; Lane 6: 500 mM imidazole elution; Lane 7: Sigma high molecular 
weight markers.   
 
2.5.3.9 Purification of recombinant lysostaphin from E. coli cell lysate using an 
Ultimate™ 3000 system and a ProPac® IMAC-10 column 
As IMAC purification using the ӒKTA™ system was fairly time consuming ( Figure 2.33), 
IMAC purifications were also performed using an Ultimate™ 3000 system with a ProPac® 
IMAC-10 (4 x 250 mm) column (Figure 2.34). SDS-PAGE analysis of fractions eluted during 
comparative IMAC purifications demonstrated that the ProPac® IMAC column provided a 
higher degree of protein purification than the Chelating Sepharose™ Fast Flow column did 
(Figure 2.35).  Due to operating at a lower flow rate (0.5 ml/min) than the Chelating 
Sepharose™ Fast Flow column (5 ml/min), total elution volumes were reduced, which 
beneficially reduced the duration of sample concentration. The ability to rapidly purify His-
tagged proteins was explained in further depth in a Dionex customer application note, 
entitled “Rapid His-tag Purification of Recombinant Proteins using Dionex ProPac IMAC 
columns” (Appendix 7.135). 
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 Figure 2.33: IMAC purification of recombinant lysostaphin (construct 1) using a 
Chelating Sepharose™ Fast Flow column and ӒKTA™ purification system.  
 
 
Figure 2.34: IMAC purification of recombinant lysostaphin (construct 1) using a 
ProPac® IMAC-10 column (4.0 x 250 mm) and Ultimate™ 3000 system.  Fractions were 
collected by time between 48 and 98 min and fractions 7, 11, 15, 19, 23, 27, 31 and 35 
were analysed by SDS-PAGE. The increasing imidazole concentration was detected at 
280 nm, as indicated.  This background absorbance was removed in subsequent 
chromatograms, through arithmetic combination against a blank UV trace. 
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Figure 2.35: SDS-PAGE analysis of IMAC fractions following purification of N-
terminally His-tagged recombinant lysostaphin (construct 1) derived from E.coli 
BL21(DE3) cultured in LB. A) IMAC purification performed using an ӒKTA™ 
purification system. Lane 1: NZY molecular size markers; Lane 2: Fraction 34 (neat); 
Lane 3: Fraction 38 (neat): Lane 4: Fraction 42 (neat); Lane 5: Fraction 46 (neat); Lane 
6: NZY molecular size markers; Lane 7: Fraction 50 (neat); Lane 8: Fraction 54 (neat); 
Lane 9: Fraction 58 (neat); Lane 10: Fraction 62 (neat). B) IMAC purification performed 
using an Ultimate™ 3000 purification system. Lane 1: Fraction 7 (1:10); Lane 2: 
Fraction 11 (1:10); Lane 3: Fraction 15 (1:10); Lane 4: NZY molecular size markers; 
Lane 5: NZY molecular size markers; Lane 6: Fraction 19 (1:10); Lane 7: Fraction 23 
(1:10); Lane 8: Fraction 27 (1:10); Lane 9: NZY molecular size markers; Lane 10: 
Fraction 31 (1:10); Lane 11: Fraction 35 (1:10).  
 
2.5.3.10 IMAC using ProPac® IMAC columns (2 x 250 mm) 
ProPac® IMAC-10 columns were also available in a 2 x 250 mm format which permitted 
faster IMAC purification due to a reduced column volume.  The overall binding capacity of 
the column was initially unknown, however injection of varying amounts of purified 
recombinant lysostaphin, demonstrated that the column could comfortably bind 8 µg and 40 
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µg of protein with minimal flow-through of non-binding protein (Figure 2.36).  However the 
application of 40 µg resulted in considerable band broadening due to longitudinal diffusion. 
 
Figure 2.36: Comparison of peak height following application of 8 and 40 µg of 
purified N-terminally His-tagged recombinant lysostaphin. 
 
2.5.3.11 IMAC using ProPac® IMAC columns (4 x 250 mm) 
To achieve a greater binding capacity, IMAC purification was performed using a ProPac® 
IMAC-10 column with a 4 mm diameter.  The chromatographic method was modified to allow 
CFE loading and the capacity of the 4 x 250 mm column was assessed by applying cell 
lysate harvested from 2 L of culture expressing recombinant lysostaphin (construct 3), with 
the intention that the capacity of the column would be exceeded. The first application of cell 
lysate resulted in a single peak with a high UV absorbance reading at 280 nm (Figure 2.37). 
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Figure 2.37: Purification of recombinant lysostaphin (construct 3) from E. coli cell 
lysate (1) using an Ultimate™ 3000 System and ProPac® IMAC-10 (4 x 250 mm).  A 
single peak reflecting purified recombinant lysostaphin (construct 3) was observed 
(peak A). Unbound cell lysate (2) was collected manually as indicated and re-applied 
to the column.  
 
The unbound cell lysate (2) was collected manually (outside of the fraction collection period) 
and re-applied to the ProPac® IMAC column to purify any recombinant lysostaphin which 
was still left in the unbound cell lysate.  Figure 2.38 demonstrates that application of 
unbound cell lysate (2) to the column resulted in another single peak (Peak B). The peak 
height of Peak B was very similar to that of Peak A suggesting that the column capacity of 
the ProPac® IMAC column was reached at a peak height of 3000 mAU. The total amount of 
purified recombinant lysostaphin eluted within peak B was determined to be 9.72 mg. PAGE 
analysis confirmed that both peaks A and B contained a protein with the same molecular 
weight as recombinant lysostaphin (construct 3), regardless of differences in peak retention 
times (Figure 2.39).  
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Figure 2.38: Comparison of elution peaks following the application of cell lysate (1) 
and re-application of unbound cell lysate (2) flow-through.  The re-application of 
unbound cell lysate resulted in elution of a single peak (B) at a retention time which 
was longer than that of the elution of peak A after initial application of cell lysate.   
 
Figure 2.39: SDS-PAGE analysis of IMAC fractions and concentrated purified protein 
following IMAC purification of C-terminally His-tagged recombinant lysostaphin 
(construct 3) derived from E.coli BL21(DE3) cultured in LB. A) IMAC fraction collected 
during elution of peak A. Lane 1: Sigma low molecular weight markers; Lane 2: 
Fraction 5; Lane 3: Fraction 11: Lane 4: Fraction 14; Lane 5: Fraction 17; Lane 6: 
Fraction 20; Lane 7: Fraction 23; Lane 8: Sigma high molecular weight markers; Lane 
9: Fraction 27. B) Concentrated protein pooled from IMAC fractions 31-34 collected 
during elution of peak B. Lane 1: Sigma low molecular weight markers; Lane 2: 
concentrated protein (neat).  
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2.5.4 Discussion  
After testing a number of protein purification techniques, it was evident that recombinant 
lysostaphin could be efficiently and successfully separated from contaminating E. coli 
proteins following recombinant protein expression.  By performing protein purification it 
became apparent that sufficient amounts of recombinant lysostaphin could be recovered 
following batch culture, permitting subsequent separation and characterisation of the 
recombinant product.  In addition, it became clear that recombinant lysostaphin could be 
effectively purified using single chromatographic separations, which was extremely desirable 
given the increased potential for protein modifications or degradation to occur over extended 
periods of time.  
Despite its ease and convenience, ASF did not offer differential purification of recombinant 
lysostaphin on the grounds of solubility. Though recombinant lysostaphin was predicted to 
be a relatively hydrophilic protein, this putative hydrophilicity did not prevent precipitation of 
recombinant lysostaphin at fairly low concentrations of ammonium sulphate. Although ASF 
was not effective for purification, ammonium sulphate precipitation was also employed as a 
mode of sample concentration during protein purification.  Recombinant lysostaphin could be 
effectively precipitated, however it was found that the recombinant protein could not be 
successfully resuspended following precipitation in two instances, prior to GF and following 
large-scale IMAC purification.   
These findings indicated that ammonium sulphate precipitation had a detrimental influence 
on the solubilisation of recombinant lysostaphin. In order to achieve solubilisation, the 
precipitated protein molecules must regain monomolecular dispersion, without participating 
in non-native intra- or inter-molecular interactions (Tsumoto et al., 2003).  Full solubilisation 
can often require the addition of inorganic salts, such as sodium chloride, which increases 
ionic strength and encourages protein solubility (Vuillard et al., 1995).  Whilst resuspension 
of precipitated protein in buffers containing inorganic salts may have resolubilised 
recombinant lysostaphin, this approach was not desirable given that the presence of fairly 
high salt concentrations can interfere with consequent biological assays, electrophoresis or 
IEX.   
Although ASF cannot provide successful purification of recombinant lysostaphin, the 
technique is highly compatible with HIC.  However HIC also did not offer efficient separation 
of recombinant lysostaphin from contaminating E. coli proteins.  SDS-PAGE analysis 
revealed that a second chromatographic purification step was required to achieve protein 
purification.  Subsequent GF provided a high degree of protein purification following HIC, 
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indicating that recombinant lysostaphin could be successfully purified using a combination of 
HIC and GF. However, GF offers low productivity and high resolution that is only once the 
protein sample has been concentrated to a volume which reflects less than 5% of the total 
column volume (Jungbauer, 2005).  Prior sample concentration increases the length of time 
taken to recover recombinant lysostaphin from contaminating protein, which could have 
increased the incidence of protein degradation or modification during handling and storage.    
As HIC could not offer purification in a single chromatographic step, IEX was performed 
using AXC to see if recombinant lysostaphin could be efficiently purified.  As ProtParam 
analysis revealed that all of the recombinant lysostaphin constructs had a theoretical pI of 
between 9.52 and 9.72, it was expected that as a basic protein, recombinant lysostaphin 
would be unlikely to bind at neutral pH during AXC.  This prediction was confirmed following 
AXC of cell lysates containing recombinant lysostaphin (constructs 2, 4 and 5), which did not 
appear to bind to the anion exchange resin.  As the majority of cellular proteins are acidic, a 
very high number of proteins bound to the anion exchange resin, as revealed by SDS-
PAGE.  It therefore would have been extremely difficult to isolate recombinant lysostaphin 
from the E. coli cellular proteins had the protein been successfully retained during AXC.  
Whilst recombinant lysostaphin could not be successfully purified during AXC, CXC was 
found to provide an excellent degree of protein purification. SDS-PAGE analysis revealed 
that fractions eluted during CXC contained very few contaminating proteins, suggesting that 
only a limited number of proteins present within the E. coli cell lysate could be retained on 
the cation exchange resin. CXC therefore provided fairly rapid, one-dimensional 
chromatographic purification of recombinant lysostaphin in the presence and absence of His-
tag sequences, a trait which was exploited to further advantage in Chapter 3.   
His-tagged recombinant lysostaphin was also purified using IMAC which was performed 
using an ӒKTA™ purification system or an Ultimate™ 3000 Titanium system. Both 
chromatographic systems offered preparative purification of recombinant lysostaphin, 
however the Ultimate™ 3000 system was primarily developed for analytical separations, as 
described in Chapter 3.  Initial preparative purifications performed using the ӒKTA™ system 
and a chelating fast-flow sepharose column generally resulted in a high degree of 
purification, without the need for any additional purification steps prior to protein analysis.  In 
one instance, IMAC was followed by GF to remove a few low molecular weight 
contaminants, however it was found that the extra purification provided by GF was not 
worthwhile given the additional time and cost of purification.  
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When producing larger amounts of recombinant lysostaphin, it was still possible to 
successfully purify recombinant lysostaphin using consecutive IMAC purifications. However 
this approach extended the duration of purification which was not desirable. Large-scale 
IMAC purification using a greater capacity chelating sepharose column and peristaltic pump 
was therefore performed and provided high quality purification.  However due to the use of 
step elution, recombinant lysostaphin was recovered in fractions of a large volume, which 
meant that lengthy sample concentration was required using dialysis and lyophilisation. The 
analytical quality of the lyophilised recombinant lysostaphin was examined in Section 3.4.3.3 
and 4.3.3.2.  
To reduce the duration of purification, IMAC purification was also performed using ProPac® 
IMAC-10 columns and an Ultimate™ 3000 system.  After performing comparative IMAC 
purifications using the chelating sepharose and ProPac® IMAC-10 columns, SDS-PAGE 
analysis revealed that a greater degree of purity could be obtained using the ProPac® IMAC-
10 columns, over a shorter purification period (Appendix 7.135).  The duration of purification 
could be reduced further by using a 2.0 mm diameter ProPac® IMAC column, however 
greater binding capacity could be achieved using a ProPac® IMAC column with a 4.0 mm 
diameter.  In testing column capacity, it became apparent that the chromatographic peaks 
were subject to retention time shifting.  This phenomenon often arises due to variation in 
mobile phase pH or ionic strength, though in this instance may have been explained by N-
terminal His-tag heterogeneity as discussed in Section 4.2.  
This work demonstrated that recombinant lysostaphin could be purified to near homogeneity 
using CXC.  His-tagged recombinant lysostaphin could also be purified to a high degree 
using IMAC via ӒKTA™ or Ultimate™ 3000 systems.  The ability to purify recombinant 
lysostaphin was imperative to prevent PTM of the expressed protein by enzymes or reactive 
intermediates present in the cell lysate.  Following purification, recombinant lysostaphin 
could be effectively desalted and concentrated by ultrafiltration, which is commonly used for 
pre-concentration prior to protein analysis (Eykamp, 1991).  Although ultrafiltration devices 
have been developed to allow rapid desalting and concentration of proteins, current 
ultrafiltration membranes are fairly thick and therefore it often takes hours or days for 
unwanted molecules to pass through the membranes (Striemer et al., 2007).  During which 
time the recombinant protein may become aggregated or undergo non-enzymatic 
modifications, such as glycation or deamidation, which often propagate upon extended 
processing or storage (Mironova et al., 2003, Ren et al., 2009).      
During protein purification, protein yield and activity are typically monitored during and 
following chromatographic steps.  The overall amount of purified protein was dependent on 
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the recombinant lysostaphin construct, expression media composition and volume and the 
chosen purification strategy.  Following purification, 1-60 mg of recombinant lysostaphin was 
recovered from litre batch cultures.  Evidently increased protein amounts were obtained 
following purification of cell lysate derived from larger culture volumes.  In addition, 
purifications performed using preparative resins tended to provide higher yields due to 
providing greater binding capacity.  However analytical ProPac® IMAC-10 columns offered 
faster purification and a better degree of protein purification than preparative IMAC columns.    
The activity of purified recombinant lysostaphin preparations was regularly monitored to 
ensure staphylolytic activity was retained following protein processing and purification, as 
described in Section 4.1.  Purified recombinant lysostaphin was also subjected to 
chromatographic separation with the intention of separating and identifying distinct protein 
isoforms, as documented in Chapter 3.  
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2.6 Discussion 
 
The gene sequence encoding the mature lysostaphin domain from S. staphylolyticus was 
amplified and cloned in E. coli using a combination of PCR and gene cloning techniques.  
Cloning of the mature lysostaphin domain was uneventful and lead to the production of five 
pET vector constructs, which could be used to express recombinant lysostaphin with or 
without N- or C-terminal His-tags, within the cytoplasm or the periplasm of E. coli 
BL21(DE3). However sequencing of the pET vector constructs 1, 2 and 3 lead to the 
elucidation of two nucleotide mis-matches within the lysostaphin gene sequence published 
by Heinrich et al, (1987).  These nucleotide mis-matches were confirmed by the work of 
Gargis et al (2010), who sequenced the pACK1 plasmid of S. staphylolyticus, which encodes 
the lysostaphin gene (Gargis et al., 2010, Heinrich et al., 1987).  
Whilst the mis-identification of cytosine at position 456 was not found to alter the translation 
of proline152, mis-identification of cytosine at position 96, was found to result in the 
translation of methionine32 rather than isoleucine32.  The presence of a guanine rather than 
cytosine at position 96 was unlikely to have significantly altered the physicochemical 
properties of recombinant lysostaphin, however increased the predicted mass of the protein 
by 18 Da.  This mass increment was not particularly significant; however knowledge of this 
amino acid substitution was useful during characterisation of recombinant lysostaphin, in 
which the correct amino acid sequence was required (Section 4.4).  
Once transformed into E. coli BL21(DE3), all five pET vector constructs were found to 
express a recombinant protein with a molecular weight that corresponded with the expected 
weight of cloned recombinant lysostaphin (with or without N- or C-terminal His-tag 
sequences). Expression of pET constructs 4 and 5, which featured pelB leader sequences, 
were also found to lead to effective translocation of recombinant lysostaphin to the 
periplasmic space. In the majority of experiments recombinant lysostaphin was hyper-
expressed in a largely soluble form, even when E. coli BL21(DE3) was cultured in different 
expression media.  
Following expression, it was found that recombinant lysostaphin could be successfully 
purified using IMAC, HIC, GF and CXC to achieve a high level of purity.  However the most 
efficient purification could be achieved using IMAC or CXC in a single chromatographic step. 
Single-stage purification was essential to ensure that purified recombinant lysostaphin could 
be obtained rapidly so as to prevent sample degradation or modification during purification or 
storage. CXC provided selective purification of recombinant lysostaphin from contaminating 
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anionic proteins present within the cell lysate. This trait was exploited to further advantage in 
Chapter 3. 
N-terminally His-tagged recombinant lysostaphin (construct 1) was most commonly 
expressed and was purified using IMAC due to the high purity that the technique could 
provide. However this technique was used with caution as several recombinant proteins 
expressed in E. coli have exhibited N-terminal His-tag heterogeneity (She et al., 2010, Du et 
al., 2005a, Du et al., 2005b). Unusual retention behaviour was observed during IMAC 
purification of recombinant lysostaphin, therefore retention behaviour was examined further 
(Section 4.2) to assess whether potential His-tag modifications interfered with the efficiency 
of purification.   
Once purified, the structure and heterogeneity of recombinant lysostaphin could be 
investigated further by using a variety of chromatographic approaches to separate 
recombinant protein isoforms for further high-resolution characterisation using proteomic 
techniques, as described in Chapters 3 and 4. 
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3 Separation of Recombinant Lysostaphin Isoforms 
 
3.1 Introduction 
 
Following protein purification, a recombinant protein preparation should be assessed to 
establish whether the protein population is homogeneous. In the biotechnological and 
pharmaceutical industry, assessment of product heterogeneity is critical to ensure that the 
resulting protein demonstrates stability and consistency.  However, as reported in Chapter 1, 
recombinant protein preparations may be composed of protein variants which demonstrate 
considerable charge heterogeneity.  Such charge variants arise during expression or 
purification, as a consequence of chemical or enzymatic reactions (Pabst et al., 2008, 
Weitzhandler et al., 2001).  The separation of protein charge variants is therefore of growing 
importance and can be achieved using a number of electrophoretic and chromatographic 
techniques. As charge variants differ in their pI, electrophoretic separations featuring 
isoelectric focusing (IEF) such as 2D-PAGE and capillary electrophoresis (CE) can be used 
to separate protein variants.   
 
High-resolution HPLC is commonly used to detect protein variants, as the technique can 
reveal subtle modifications of protein structure (Jacobson et al., 1997).  IEX is particularly 
popular due to its ability to separate and resolve charge variants (Weitzhandler et al., 2001, 
Ren et al., 2009).  The charge heterogeneity of recombinant proteins is typically assessed 
using CXC.  CXC separates proteins according to surface charge distribution and can 
resolve protein isoforms according to localised charge differences, caused by the presence 
or absence of chemical or enzymatic modifications.  For instance, CXC is commonly used to 
assess the charge heterogeneity of recombinant monoclonal antibody variants which exhibit 
local charge differences and elution profiles due to the presence or absence of 
oligosaccharides (Gaza-Bulseco et al., 2008, Lyubarskaya et al., 2006).    
 
Once separated, chromatographic fractions containing resolved charge variants can be 
isolated for subsequent analysis more conveniently than when using electrophoretic 
techniques. Due to the ability of IEX to provide high-resolution separation of recombinant 
protein variants, IEX was used to assess the charge heterogeneity of purified recombinant 
lysostaphin. This research was performed with a number of aims:  
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Aims:  
 
 To resolve and separate recombinant lysostaphin isoforms using an appropriate 
analytical ion exchange column.  
 To optimise chromatographic separation of recombinant lysostaphin isoforms   
 To investigate factors affecting charge heterogeneity of recombinant lysostaphin 
during recombinant protein expression 
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3.2 Methods  
 
3.2.1 Buffers  
 
All buffer compositions are outlined in Appendix 7.136. 
 
3.2.2 Equipment 
 
All equipment used during the separation of recombinant lysostaphin isoforms is outlined in 
Appendix 7.137. 
 
3.2.3 Sample preparation 
 
Sample preparation is described in Appendix 7.139.  
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3.3 Column selection  
 
3.3.1 Introduction  
 
In Section 2.5.3.5, CXC was shown to provide efficient purification of recombinant 
lysostaphin. During purification, conditions were optimised to provide capture and purification 
of the target protein. Such preparative chromatography achieved resolution using columns 
that provided low efficiency, yet high selectivity (Jungbauer, 2005). However during 
analytical chromatography, protein separation is optimised for informative purposes by using 
columns which provide maximum efficiency. Following the success of CXC during 
purification, it was therefore hoped that recombinant lysostaphin isoforms could be 
separated effectively using analytical IEX. In this section, chromatographic separations were 
performed using a number of IEX columns developed to provide high-resolution protein 
separation.  Recombinant lysostaphin was applied to ProPac™ and ProSwift™ ion 
exchange columns to establish which type of stationary phase composition and ion 
exchange functionality could provide separation of recombinant lysostaphin variants.   
 
Chromatographic separations were initially performed using ProPac® WCX-10, SCX-10 and 
SAX-10 columns, however a ProPac® MAb SCX beta test column also became available for 
separations in the later stages of this research. ProPac™ IEX columns are composed of a 
non-porous, tentacle-type polymeric stationary phase, which consists of 10 µm diameter 
polystyrene particles (55% cross-linked).  Polymeric supports can tolerate a wide pH range 
and offer high mechanical stability which is beneficial during IEX.  Furthermore, the 
polymethacrylate stationary phase is coated in a hydrophilic film to prevent non-specific 
hydrophobic interactions with the analyte (Weitzhandler et al., 2001).  Minimisation of non-
specific interactions ultimately leads to higher yields (Melter et al., 2007).  
 
To provide ion exchange functionality, the pellicular stationary phase particles of ProPac® 
SCX-10 and MAb SCX were grafted with sulphonate functional groups, whilst the ProPac® 
WCX-10 and SAX-10 were derivatised with carboxylate and quaternary amine groups 
respectively. These grafted functional groups confer high selectivity upon the column, 
however the nature of pellicular stationary phase composition reduces the surface area for 
derivatisation and therefore decreases column capacity (Melter et al., 2007).    
 
Chromatographic separations were also performed using ProSwift™ ion exchange columns 
which are composed of polymethacrylate monoliths.  Recombinant lysostaphin was applied 
to ProSwift® WCX-1S and SCX-1S columns, which had been chemically grafted with 
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carboxylate and sulphonate groups respectively (Evenhuis et al., 2008). ProSwift™ columns 
offer high resolution yet faster mass transfer and high loading capacity than their ProPac™ 
counterparts (Rao et al., 2010).  Like ProPac™ ion exchange columns, ProSwift™ columns 
also exhibit stability over a wide range of pH due to their polymethacrylate composition 
(Nordborg and Hilder, 2009). 
 
ProPac™ Ion Exchange columns have previously been used to provide high-resolution 
separation of monoclonal antibody (mAb), cytochrome C, ribonuclease A and haemoglobin 
variants (Melter et al., 2007, Heckenberg et al., 2002). It has also been reported that protein 
isoforms differing by a single charged residue can be resolved using ProPac™ ion exchange 
columns, permitting evaluation of protein micro- and macro-heterogeneity (Heckenberg et 
al., 2002).  Monolithic ion exchange columns, such as ProSwift™ Ion Exchange can also be 
used to resolve protein isoforms, however they tend to be less frequently employed during 
IEX applications than particle columns, despite sharing the same advantages (Nordborg et 
al., 2009).  
 
Aims:  
 
 To confirm that recombinant lysostaphin does not bind to analytical anion exchange 
columns. 
 To establish whether recombinant lysostaphin isoforms can be resolved using strong 
or weak cation exchange columns.  
 To compare the degree of separation and resolution of protein isoforms provided by 
weak or strong ion exchange functionalities.  
 To assess whether ProPac™ or ProSwift™ ion exchange columns provided better 
resolution and separation of protein isoforms.  
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3.3.1 Methods  
 
3.3.1.1 Column selection 
A number of initial separations were performed to assess the separative capacity and 
resolution of ProPac® SAX-10, SCX-10 and WCX-10 columns using the DX500 
chromatography system (Appendix 7.168) or an Ultimate™ 3000 chromatography system 
(Appendix 7.169). The performance of the ProPac® WCX-10 (4 x 500 mm) column was also 
validated (Appendix 7.170). Additional separations were performed using the ProSwift® 
SCX-1S (Appendix 7.171) and ProSwift® WCX-1S columns (Appendix 7.172). Separations 
were also performed using ProPac® MAb SCX beta test columns to provide column 
validation (Appendix 7.173) and separation of recombinant lysostaphin variants (Appendix 
7.174). 
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3.3.2 Results  
 
In this section, chromatographic separations were performed using a number of IEX columns 
developed to provide high-resolution protein separation.  Recombinant lysostaphin was 
applied to ProPac™ and ProSwift™ ion exchange columns to establish which type of 
stationary phase composition and ion exchange functionality could provide separation of 
recombinant lysostaphin variants.   
 
3.3.2.1 Protein separation using ProPac® SAX-10 column and DX500 chromatography 
system 
Purified recombinant lysostaphin was applied to a variety of ion exchange columns to 
establish, whether the protein would bind to the resin.  In Section 2.5.3.4, it was determined 
that recombinant lysostaphin was not retained during AXC and could only be retained by a 
preparative CXC column.  To provide extra confirmation of this finding, recombinant 
lysostaphin was injected onto an analytical ProPac® SAX-10 (4 x 250 mm) column.  As 
shown in Figure 3.1, recombinant lysostaphin did not bind to the column and the sample 
appeared to elute from the column at the start of the separation without being retained. The 
chromatogram also showed two spikes which probably occurred as a result of the air 
bubbles passing through the UV detector.  
 
 
Figure 3.1: Separation of 5.5 mg of C-terminally His-tagged recombinant lysostaphin 
(construct 4; preparation 1) using a ProPac® SAX column (4 x 250 mm).  Recombinant 
lysostaphin did not bind to this column as demonstrated by a breakthrough peak at 
the start of the separation.  Absorbance was recorded at a wavelength of 280 nm.  
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3.3.2.2 Protein separation using ProPac® SCX-10 column and DX500 chromatography 
system 
As recombinant lysostaphin did not bind to a SAX column, the purified sample was applied 
to a ProPac® SCX (4 x 250 mm) column.  As Figure 3.2 shows, recombinant lysostaphin 
bound to a strong cation exchange resin.  Despite being retained on the column, 
recombinant lysostaphin isoforms were not resolved by the SCX column.  
 
 
Figure 3.2: Separation of 5.5 mg of C-terminally His-tagged recombinant lysostaphin 
(construct 4; preparation 1) using a ProPac® SCX-10 column (4 x 250 mm).  
Recombinant lysostaphin bound to this column, resulting in a large peak eluting 
between 6.0 and 20.0 minutes. Absorbance was recorded at a wavelength of 280 nm.    
 
3.3.2.3 Protein separation using ProPac® WCX-10 column and DX500 
chromatography system 
Consequently purified recombinant lysostaphin was applied to a ProPac WCX® (4 x 250 
mm) column to establish if protein variants could be resolved using a WCX column.  As 
demonstrated in Figure 3.3, recombinant lysostaphin was retained by the WCX column and 
it appeared that charge-distinct protein isoforms could be resolved as shoulder peaks during 
the WCX separation.  SDS-PAGE analysis provided further confirmation that the peak 
observed during WCX separation reflected the presence of purified recombinant lysostaphin 
(Figure 3.4).  
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Figure 3.3: Separation of 5.5 mg of C-terminally His-tagged recombinant lysostaphin 
(construct 4; preparation 1) using a ProPac® WCX-10 column (4 x 250 mm).  
Recombinant lysostaphin bound to this column, resulting in a large peak eluting 
between 16.0 and 21.5 minutes. Additional shoulder peaks present within this peak 
indicated the resolution of protein isoforms. Absorbance was recorded at a 
wavelength of 280 nm.    
 
 
Figure 3.4: PAGE analysis of fractions eluted during WCX separation of purified C-
terminally His-tagged recombinant lysostaphin (construct 4; preparation 1).  
Recombinant lysostaphin was expressed in E. coli BL21(DE3) cultured in AIM and was 
preparatively purified using IMAC prior to WCX separation. Following WCX 
separation, the eluted fractions were analysed by 12% (v/v) SDS-PAGE at neat 
concentration and whilst fraction collection is not indicated in Figure 3.3, 
corresponding retention times are provided in brackets.  Lane 1: Sigma low molecular 
weight markers; Lane 2: Fraction 15 (15 min); Lane 3: Fraction 16 (16 min); Lane 4: 
Fraction 17 (17 min); Lane 5: Fraction 18 (18 min); Lane 6: Fraction 19 (19 min); Lane 
7: Fraction 20 (20 min); Lane 8: Fraction 21 (21 min); Lane 9: Sigma high molecular 
weight markers.    
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Due to the success of this initial WCX separation, C-terminally His-tagged recombinant 
lysostaphin (construct 3) was also applied to the column as further assessment of the 
degree of separation and resolution provided by the ProPac® WCX-10 column.  Figure 3.5 
provided further evidence that the presence of protein isoforms could be established using 
this WCX column. During the early stages of the WCX separation (3-22 min), the UV trace at 
280 nm appeared to be fairly erratic, suggesting interference by low level baseline noise, 
potentially due to mobile phase contaminants. Between 22 and 31 min, more authentic 
chromatographic peaks were observed indicating the presence of multiple protein isoforms. 
Further peaks were observed at retention times of 32 and 34 min indicating the resolution 
and separation of recombinant lysostaphin or protein contaminants.    
 
 
Figure 3.5: Separation of 0.8 mg of C-terminally His-tagged recombinant lysostaphin 
(construct 3; preparation 2) using a ProPac® WCX-10 column (4 x 250 mm). 
Recombinant lysostaphin bound to this column, resulting in the elution of multiple 
peaks between 22.0 and 39.0 minutes. The presence of multiple peaks indicates 
resolution of recombinant lysostaphin isoforms or possibly the presence of basic 
protein contaminants. The erratic UV trace between 6 and 22 min is likely to have 
reflected low level of baseline noise. UV absorbance was recorded at a wavelength of 
280 nm.    
 
Another preparation of C-terminally His-tagged recombinant lysostaphin (construct 3) which 
had been purified using preparative HIC and GF was also applied to the ProPac® WCX-10 
column to separate protein variants.  As shown in Figure 3.6, multiple peaks were resolved 
during WCX separation indicating the presence of recombinant lysostaphin isoforms.  The 
wide distribution of peaks indicates that recombinant lysostaphin may have started to 
degrade, producing a greater number of charge variants.  This theory is supported by PAGE 
analysis of the purified protein preparation (Figure 2.21) which demonstrated the presence of 
lower molecular weight bands which were likely to represent protein degradation.  As the 
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protein preparation had been purified to near homogeneity using HIC and GF it was less 
likely that many of peaks represented protein contaminants.  Unfortunately the protein 
concentration within fractions was not high enough to permit successful SDS-PAGE analysis 
of the eluted protein. 
 
 
Figure 3.6: Separation of 0.1 mg of C-terminally His-tagged recombinant lysostaphin 
(construct 3; preparation 3) using a ProPac® WCX-10 column (4 x 250 mm).  
Recombinant lysostaphin bound to this column, resulting in the elution of multiple 
peaks between 12.0 and 36.0 min. The presence of multiple peaks indicated 
degradation of recombinant lysostaphin or possibly the presence of basic protein 
contaminants. UV absorbance was recorded at a wavelength of 280 nm.    
 
3.3.2.4 Protein separation using ProPac® WCX-10 column and Ultimate™ 3000 
chromatography system 
To permit optimisation of flow rates, fraction collection and data acquisition, WCX separation 
was also performed using an Ultimate™ 3000 system.  As shown in Figure 3.7, the ProPac® 
WCX-10 column provided resolution of multiple protein isoforms when performing 
chromatography using the Ultimate™ 3000 chromatography system. A number of protein 
isoforms were observed, in addition to a number of peaks which may have reflected the 
presence of recombinant lysostaphin or other contaminating basic proteins. In addition the 
UV trace was subject to slight baseline shifting, possibly due to issues with mobile phase 
composition or instrumental operation, which was not desirable.  
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Figure 3.7: Separation of 0.1 mg of N-terminally His-tagged recombinant lysostaphin 
(construct 1; preparation 4) using a ProPac® WCX-10 column (4 x 250 mm).  
Recombinant lysostaphin bound to this column, resulting in the elution of multiple 
peaks between 10 and 16 min.  The UV trace increased after 16 min revealing further 
peaks, which may have reflected recombinant lysostaphin or the presence of 
contaminating proteins.  The UV trace also displayed base line drifting, which was 
indicative of instrumental or mobile phase composition issues. UV absorbance was 
recorded at a wavelength of 280 nm.    
 
To establish whether the eluted peaks contained recombinant lysostaphin, selected WCX 
fractions were concentrated using TCA precipitation, as indicated in Figure 3.8.  The 
concentrated fractions were the analysed by SDS-PAGE which revealed that the majority of 
the peaks contained recombinant lysostaphin (Figure 3.9).  Due to loss of protein during 
TCA precipitation, recombinant lysostaphin could not be detected in some of the analysed 
fractions.  
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Figure 3.8: Separation of 0.1 mg of N-terminally His-tagged recombinant lysostaphin 
(construct 1; preparation 4) using a ProPac® WCX-10 column (4 x 250 mm).  Fractions 
9, 13, 14, 16, 17, 18, 23 and 24 were concentrated by TCA precipitation and subjected 
to SDS-PAGE analysis.  
 
 
Figure 3.9: PAGE analysis of fractions eluted during WCX separation of purified N-
terminally His-tagged recombinant lysostaphin (construct 1; preparation 4).  
Recombinant lysostaphin was expressed in E. coli BL21 (DE3) cultured in AIM and 
was preparatively purified using IMAC prior to WCX separation.  Lane 1: Sigma low 
molecular weight markers; Lane 2: Fraction 9; Lane 3: Fraction 13; Lane 4: Fraction 
14; Lane 5: Fraction 16; Lane 6: Fraction 23; Lane 7: Fraction 24; Lane 8: Sigma low 
molecular weight markers; Lane 9: Sigma low molecular weight markers; Lane 10: 
Fraction 18; Lane 11: Fraction 17.  
 
3.3.2.5 Validation of ProPac® WCX-10 column 
Following chromatographic issues during the separation of recombinant lysostaphin, the 
ProPac® WCX-10 was validated by applying a cytochrome C protein standard to the column.  
As shown in Figure 3.10, cytochrome C variants were separated and resolved effectively 
using ProPac® WCX-10.  Repeated injection of cytochrome C demonstrated that the 
5  10  15  20  25  30  
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ProPac® WCX-10 can provide very reproducible separations under optimal operational 
conditions.  
 
 
Figure 3.10: Separation of a cytochrome C standard protein solution during validation 
of a ProPac® WCX column (4 x 250 mm) . Cytochrome C was applied to the column 
three times and was separated efficiently and reproducibly by the ProPac® WCX 
column.  Peaks representing cytochrome C are indicated. UV absorbance was 
recorded at a wavelength of 280 nm.    
 
3.3.2.6 Protein separation using ProSwift® SCX-1S column and an Ultimate™ 3000 
system 
Recombinant lysostaphin could evidently bind to ProPac® SCX and WCX columns, therefore 
the purified protein was also applied to ProSwift™ ion exchange column to establish whether 
recombinant lysostaphin isoforms could be effectively resolved using monolithic ion 
exchange columns as well. Recombinant lysostaphin was initially applied to a ProSwift® 
SCX-1S column and the protein bound to the column (Figure 3.11).  Whilst recombinant 
lysostaphin was strongly retained by the column, protein eluted during the wash phase 
rather than the linear gradient. Separation of protein isoforms could therefore not be 
achieved.   
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Figure 3.11: Separation of 0.2 mg of N-terminally His-tagged recombinant lysostaphin 
(construct 1; preparation 4) using a ProSwift® SCX-1S column (4.6 x 500 mm).  
Recombinant lysostaphin bound strongly to this column however charge isoforms 
were not resolved within the main peak.  UV absorbance was recorded at a 
wavelength of 214 nm.    
 
3.3.2.7 Protein separation using ProSwift® WCX-1S column and an Ultimate™ 3000 
system 
Due to previous successful resolution of protein isoforms using the ProPac® WCX-10 
column, purified recombinant lysostaphin was also applied to a single ProSwift® WCX-1S 
column.  Figure 3.12 demonstrates that the ProSwift® WCX-1S provided successful 
separation of protein isoforms within the linear gradient elution phase of the separation. 
However protein also eluted during the wash phase of the separation indicating that 
recombinant lysostaphin was strongly retained by the column, without achieving further 
resolution of protein isoforms.   
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Figure 3.12: Separation of 0.1 mg of C-terminally His-tagged recombinant lysostaphin 
(construct 3; preparation 4) using a ProSwift® WCX column (2 x 50 mm). Purified 
recombinant lysostaphin was applied to the column and appeared to be retained on 
the column, with multiple peaks eluting during the course of separation. A large 
proportion of the sample eluted during the wash phase minimising the efficiency of 
separation. UV absorbance was recorded at a wavelength of 280 nm.  
 
3.3.2.8 Validation of ProPac® MAb SCX beta test column 
Later in the course of this research, a ProPac® MAb SCX beta test column became available 
for the separation of protein variants.  The column was initially validated by performing 
multiple separations of a protein standard mix.  As shown in Figure 3.13, RNase A, 
cytochrome C and lysozyme were resolved efficiently and reproducibly using the beta test 
ProPac® MAb column.  
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Figure 3.13: Separation of standard proteins during beta testing of a ProPac® MAb 
SCX column (4 x 250 mm).  Peaks representing RNase A, cytochrome C, lysozyme are 
indicated.  UV absorbance was recorded at a wavelength of 280 nm.    
 
3.3.2.9 Protein separation using ProPac® MAb SCX beta test column and an 
Ultimate™ 3000 system   
Following validation of the beta test ProPac® MAb SCX, a sample of purified recombinant 
lysostaphin was applied to the column (Figure 3.14).  The ProPac® SCX MAb column 
provided excellent separation of the lysostaphin isoforms, with fairly narrow peak width and 
separation of peaks.  The degree of separation achieved using the ProPac® SCX MAb 
column was comparable and if not better than that achieved using the ProPac® WCX, even 
following method development as described in Section 3.4. 
 
 
Figure 3.14: Separation of 16 µg of C-terminally his-tagged recombinant lysostaphin 
(construct 3; preparation 5) using a single ProPac MAb SCX column (4 x 250 mm) 
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3.3.3 Discussion  
 
Initial separations performed using ProPac™ and ProSwift™ columns provided an insight 
into the separation and resolving powers of analytical ion exchangers.  As expected, 
recombinant lysostaphin was not retained by the ProPac® SAX column and therefore could 
not provide separation of protein variants.  However recombinant lysostaphin was retained 
by ProPac® SCX and WCX columns and whilst the SCX column did not provide resolution of 
protein isoforms, the WCX column did.  Initial separations using the ProPac® WCX indicated 
that the column could separate and resolve a number of protein isoforms, which had a 
molecular weight corresponding with that of recombinant lysostaphin. This result indicated 
that recombinant lysostaphin preparations are indeed heterogeneous, emphasising the 
importance of the resolution, separation and characterisation of protein isoforms.   
 
Whilst the ProPac® WCX separation provided good resolution and separation of protein 
isoforms, separation of recombinant lysostaphin was complicated by the quality of the 
recombinant protein preparation and initial chromatographic issues, which lead to baseline 
drifting.  Purified protein preparations which had undergone lengthy purification appeared to 
have been affected by degradation, interfering with successful analysis of protein 
heterogeneity.  To prevent this, subsequent separations were performed using recombinant 
lysostaphin preparations which had only been purified using a single purification step.  
Baseline drifting also interfered with the quality of analysis by complicating the identification 
of resolved peaks.  Optimisation of chromatographic separations led to correction of baseline 
drifting.  
 
Protein separations were also performed using monolithic ProSwift™ columns, with the 
intention of achieving rapid, high-resolution separation of protein variants.  Recombinant 
lysostaphin was strongly retained by the ProSwift® SCX column, however resolution and 
separation was not accomplished. The ProSwift® WCX column also retained recombinant 
lysostaphin and whilst the column provided resolution of protein isoforms, it did not provide 
efficient separation.  Overall ProSwift™ ion exchange columns did not appear to offer 
appropriate separation or resolution of recombinant lysostaphin variants, therefore 
subsequent separations were primarily focused on the use of ProPac™ ion exchange 
columns. 
 
Development and availability of a beta-test ProPac® MAb column in the later stages of this 
research provided further evidence that ProPac™ ion exchange columns could provide 
effective separation and resolution of protein isoforms. The ProPac® MAb provided excellent 
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resolution of recombinant lysostaphin isoforms, therefore this column was employed during 
culture studies, as described in Section 3.5.3.13.  Like the ProPac® WCX column, the 
ProPac® MAb column demonstrated very good reproducibility between separations as 
shown during column validation.  
 
During this work, separations were performed using either a DX500 or an Ultimate™ 3000 
chromatography system. Whilst both systems could be used to provide chromatographic 
separation during initial column selection, the single gradient pump setup of DX500 
chromatography system did not offer the flexibility and versatility of operation that was 
required for the optimisation of protein separation and subsequent chromatographic 
characterisation of protein isoforms.  For instance, unlike the DX500 system, the Ultimate™ 
3000 system permitted microflow rates, which facilitated optimisation of protein separation 
and a variety of fraction collection modes, assisting the collection of resolved protein variants 
in an appropriate manner.  In addition, the availability of dual pumps and switching valves on 
the Ultimate™ 3000 system provide the ability to perform multidimensional separations, as 
described in Section 3.4.3.7.    
 
Ultimate™ 3000 chromatography systems were therefore used to optimise the separation of 
recombinant lysostaphin isoforms so that the heterogeneity of the recombinant expression 
products could be investigated. At this stage it was not possible to make definitive 
conclusions about the nature of recombinant lysostaphin variants, due to the variability of the 
obtained results.  The variability of results was augmented by the separation of different 
recombinant lysostaphin constructs, which influenced the charge and inherent structure of 
the analysed protein. It was however known that the heterogeneity of recombinant 
lysostaphin could be further investigated through application and optimisation of protein 
separation using ProPac™ ion exchange columns.  
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3.4 Optimisation of protein isoform separation  
 
3.4.1 Introduction 
 
Unlike other analytical techniques, chromatographic separations must be developed for 
specific applications in order to maximise performance, reliability and reproducibility. It was 
therefore essential that the chromatographic performance of protein separation was 
optimised for the separation of recombinant lysostaphin variants.  Optimal chromatographic 
performance can be achieved by empirical optimisation of mobile phase conditions, such as 
pH or stationary phase conditions, such as column length and diameter. In addition gradient 
functions, fraction collection, sample concentration and formulation must also be optimised 
to ensure that the protein isoforms are separated efficiently and in a manner which prevents 
sample degradation and facilitates downstream analysis and characterisation.   
 
It was evident that recombinant lysostaphin charge variants could be separated using 
ProPac™ ion exchange columns, however, it was unclear whether alternative column 
dimensions could enhance the analysis of recombinant lysostaphin variants. Protein 
separations were primarily performed using 4 mm i.d ProPac® WCX-10 columns, which 
provided high-resolution separation of larger amounts of recombinant lysostaphin. To 
enhance resolution and efficiency of separation, column diameter should be reduced to 
achieve higher and faster sample permeability (Gu et al., 2007). Unfortunately a 2 mm 
version of the ProPac® WCX-10 column was not initially available; however separation of 
isoforms could be performed using a ProPac® SCX-10 column (2 x 250 mm) due to the 
lower flow rates used.  ProPac® WCX-10 columns (2 x 250 mm) were later acquired, in 
addition to a further ProPac® WCX-10 column (4 x 250 mm), therefore separations could 
also be performed over an extended column length, which should provide increased 
resolution and capacity.  
 
Initial protein separations were performed using sodium phosphate buffers adjusted to pH 
7.0.  As IEX is dramatically influenced by protein charge which is inherently affected by pH,  
it was important that protein separation was also tested using mobile phase buffers adjusted 
to pH 6.0 or pH 8.0 to establish whether separation was enhanced.  In addition, altering 
mobile phase buffering agents can enhance resolution in a quicker and more economical 
manner than stationary phase optimisation.  Careful optimisation of mobile phase gradients 
could also improve chromatographic performance by increasing separation efficiency and 
reducing the retention of strongly bound compounds.  Extension of chromatographic 
gradients could enhance separation, however would increase duration of separation and 
108 
 
mobile phase consumption, which could be problematic if a large number of samples had 
been prepared. 
 
Chromatographic conditions were initially established for the binding and separation of 
recombinant lysostaphin after applying purified protein to the column.  It was unclear how 
much protein should be applied to the column to obtain sufficient concentrations of 
separated protein isoforms for subsequent analysis. Therefore experiments were performed 
to assess appropriate sample loading concentrations without over-loading the column and 
decreasing peak resolution.  Recombinant lysostaphin had also been prepared in a 
lyophilised state, which could remain stable in the long-term, but tended to precipitate upon 
resuspension. Chromatographic separations were therefore performed on the resuspended 
protein to see whether sample precipitation interfered with protein separation. Furthermore 
protein separation was also performed upon cell lysate to establish whether recombinant 
lysostaphin isoforms could be directly purified and separated using analytical CXC columns, 
rather than preparative columns, as described in Section 2.5.3.5. 
 
Fraction collection also required optimisation to ensure that all resolved protein isoforms 
were collected in an appropriate manner, whilst minimising co-elution of protein isoforms.  
Due to the availability of an autosampler with fractionation capabilities it was possible to 
evaluate the performance of fraction collection by time or peak recognition. Subsequent 2D-
LC analysis of separated protein isoforms could also be performed using second-
dimensional reverse phase separation to assess the purity and heterogeneity of separated 
protein isoforms.   
 
Through the course of chromatographic optimisation it was also possible to gain insight into 
the chromatographic behaviour of recombinant lysostaphin isoforms and the heterogeneity 
of alternative cationic recombinant proteins.  Factors influencing the heterogeneity of 
recombinant lysostaphin, such as culture temperature and expression media could also be 
investigated.  
 
Aims:  
 To assess the influence of column length and diameter upon the efficiency and 
resolution of protein isoform separation.  
 To evaluate the influence of mobile phase pH, mobile phase composition and 
gradient functions upon protein isoform separation. 
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 To optimise sample preparation by testing whether the heterogeneity of recombinant 
lysostaphin could be monitored most efficiently by direct separation of purified, 
lyophilised or crude preparations.   
 To assess the influence of sample concentration upon the separation, resolution and 
abundance of protein isoforms.  
 To optimise fraction collection by time or peak recognition.  
 To perform 2D-LC analysis to assess purity and heterogeneity of separated protein 
isoforms.  
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3.4.2 Methods  
 
3.4.2.1 Optimisation of protein isoform separation 
All separations were performed using the Ultimate™ 3000 Titanium system unless specified 
otherwise. Separations were performed to permit optimisation of sample loading conditions 
(Appendix 7.175), sample preparation (Appendix 7.176), gradient conditions (Appendix 
7.177), mobile phase conditions (Appendix 7.178), column length (Appendix 7.179) and 
column diameter (Appendix 7.180).  Experiments were also performed to optimise fraction 
collection by time (Appendix 7.181) or peak recognition (Appendix 7.182). 
 
3.4.2.2 Separation of protein isoforms using optimised conditions 
Once chromatographic separation had been optimised, various experiments were performed 
to analyse purified recombinant lysostaphin (Appendix 7.183) and the influence of culture 
temperature upon the charge heterogeneity of recombinant lysostaphin (Appendix 7.184).  
The optimised conditions were also used to analyse the charge heterogeneity of alternative 
recombinant protein preparations (Appendix 7.186). 
 
3.4.2.3 Optimisation of protein separation using ProPac® MAb SCX columns 
Separations were performed to permit optimisation of sample loading conditions (Appendix 
7.187), gradient conditions (Appendix 7.188), mobile phase conditions (Appendix 7.189) and 
column length (Appendix 7.190).  
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3.4.3 Results  
 
3.4.3.1 Optimisation of protein isoform separation using the ProPac® WCX column 
As the ProPac® WCX columns provided good resolution separation of protein isoforms in 
initial experiments, further experiments were performed to optimise chromatographic 
conditions to achieve greater resolution.  These experiments focused on optimising sample 
loading conditions, sample preparation, mobile phase conditions and gradient functions.  
 
3.4.3.2 Optimisation of sample loading conditions 
Initial applications of recombinant lysostaphin to ProPac® WCX columns resulted in the 
resolution and separation of lysostaphin isoforms.  During these separations anywhere 
between 0.1 and 14 mg of recombinant lysostaphin was applied to the column.  Each 
application provided separation and resolution of protein isoforms, however it was unclear 
how much protein should be applied to the column to allow not only detection of protein 
isoforms, but also their subsequent characterisation.  Following the application of 9.1 mg of 
recombinant lysostaphin, it was evident that a fairly high concentration of lysostaphin should 
be applied to the column to permit resolution of low abundance protein isoforms. As shown 
in Figure 3.15, nine low abundance protein isoforms could be resolved during the separation, 
in addition to two more abundant protein variants.    
 
 
Figure 3.15: Separation of N-terminally His-tagged recombinant lysostaphin 
(construct 1) using a ProPac® WCX-10 column (4 x 250 mm).  The application of 9.1 
mg of recombinant lysostaphin (preparation 9) resulted in the elution of multiple 
peaks between 24 and 44 min.  Eleven peaks were resolved during the separation, as 
indicated.  
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To increase the concentration of low abundance protein isoforms, the amount of applied 
protein was increased further. However Figure 3.16 indicates that an increased amount of 
protein resulted in substantial peak broadening, leading to decreased resolution of protein 
isoforms, particularly in the case of highly abundant isoforms.  Peak broadening was not 
desirable as it interfered with the visualisation of protein variants and decreased the 
separative capacity provided by the column.  
 
 
Figure 3.16: Separation of N-terminally His-tagged recombinant lysostaphin 
(construct 1) using a ProPac® WCX-10 column (4 x 250 mm).  The application of 14.0 
mg of recombinant lysostaphin (preparation 8) resulted in the elution of multiple 
peaks between 24 and 47 min.  Eleven peaks were resolved during the separation, as 
indicated.  
 
As these results provided evidence to support the application of either lower or higher 
amounts of recombinant lysostaphin, further comparative separations were performed to 
directly assess the resolution of protein isoforms following the application of different 
amounts of protein (Figure 3.17). Figure 3.17 indicates that the injection of lower amounts of 
protein resulted in better resolution and peak width following elution of highly abundant 
isoforms, though poor resolution of less abundant isoforms. As shown in previous 
separations, the injection of higher amounts of recombinant lysostaphin provided better 
resolution of less abundant isoforms, however peak broadening lead to decreased resolution 
of highly abundant isoforms.    
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Figure 3.17: Comparative separation of N-terminally His-tagged recombinant 
lysostaphin (construct 1) using a ProPac® WCX-10 column (4 x 500 mm).  The 
application of 14.0 mg and 1.4 mg of recombinant lysostaphin (preparation 8) resulted 
in the elution of multiple peaks, however the resolution and peak width of high 
abundance isoforms was better following application of a smaller amount of protein. 
Conversely, the resolution of low abundance isoforms was enhanced by the 
application of larger amounts of protein. 
 
3.4.3.3 Optimisation of sample preparation 
The majority of protein separations were performed using recombinant lysostaphin 
preparations which had been purified and concentrated via ultrafiltration.  As described in 
Section 2.5.3.8, recombinant lysostaphin was purified from multiple batch cultures using 
large-scale IMAC purification and the resulting protein was dialysed and lyophilised.  The 
lyophilised purified protein was resuspended to allow separation of protein isoforms. PAGE 
analysis indicated that the lyophilised protein preparation was reasonably pure, with signs of 
only slight degradation (Appendix 7.191).  
 
The resuspension of lyophilised recombinant lysostaphin was complicated by poor solubility, 
which lead to sample precipitation upon resuspension in 18.2 MΩ/cm H2O.  Prior to 
chromatography, the resuspended protein samples were briefly centrifuged to remove visible 
precipitates from the sample.  Due to the insolubility of the lyophilised recombinant 
lysostaphin it was difficult to achieve a high protein sample concentration, which meant that 
it was not possible to visualise less abundant protein isoforms without increasing the sample 
injection volume (Figure 3.18).  In addition, the WCX separation of the resuspended sample 
resulted in an atypical peak distribution and peak broadening, suggesting that sample 
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preparation influenced the the charge of the expressed protein, potentially through 
aggregation or degradation.   
 
 
Figure 3.18: Comparison of WCX separations following injection of increasing 
amounts of N-terminally His-tagged recombinant lysostaphin (construct 1; 
preparation 10).   
 
Each separation was performed in duplicate by applying injection volumes containing 4.5, 
5.0 or 5.8 mg of resuspended recombinant lysostaphin. Low abundance isoforms were not 
resolved until at least 5.0 mg of sample was applied to the column.  More abundant peaks 
appeared to be poorly resolved due to peak broadening.  Injection of larger amounts of 
recombinant lysostaphin appeared to provide enhanced resolution of protein isoforms, 
however the separation still resulted in a broad, atypical peak (Figure 3.19).  These results 
indicated that the separation of recombinant lysostaphin isoforms should be performed with 
freshly prepared protein preparations which have not undergone lengthy sample preparation 
by dialysis or lyophilisation.   
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Figure 3.19: WCX separation following injection of 8.3 mg of N-terminally His-tagged 
recombinant lysostaphin (construct 1; preparation 10).  
 
3.4.3.4 Optimisation of gradient conditions  
Altering the duration of a linear gradient alters gradient steepness which can alter the degree 
of separation of protein isoforms.  The duration of the 0 -50% linear gradient was altered so 
that the effect could be assessed.  Recombinant lysostaphin was applied to the WCX 
column and separations were performed where the gradient ranged between 60 and 240 
minutes (Figure 3.20 and Figure 3.21).  As shown in Figure 3.20, increasing the gradient 
duration from 60 to 90 min resulted in marginally increased separation of protein isoforms.  
 
 
Figure 3.20: Effect of linear gradient duration on separation of 0.2 mg of N-terminally 
His-tagged recombinant lysostaphin (construct 1; preparation 4) using a ProPac WCX-
10 (2 x 250 mm). Linear gradients of 60, 70 and 90 min were examined.   
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The gradient duration was increased further to 120 and 240 min respectively. Figure 3.21 
indicates that the greatest degree of separation could achieved with a 240 min linear 
gradient, however this extended gradient also lead to peak broadening and therefore 
resulted in reduced peak resolution.  Overall the 60 min linear gradient provided the least 
separation of protein isoforms, whilst 70, 90 and 120 minute linear gradients provided a 
slightly greater degree of separation with minimal loss of resolution.  To minimise the total 
duration of separation, a 70 min linear gradient was applied in subsequent optimised 
separations to provide optimal separation and resolution within a reasonable amount of time.  
 
 
Figure 3.21: Effect of linear gradient duration on separation of 0.2 mg of N-terminally 
His-tagged recombinant lysostaphin (construct 1; preparation 4) using a ProPac WCX-
10 (2 x 250 mm). Linear gradients of 90, 120 and 240 min were examined.   
 
These initial gradient experiments were performed whilst applying a 0-50% B elution 
gradient, therefore recombinant lysostaphin was also separated using a steeper elution 
gradient to assess the influence upon separation and resolution of protein isoforms.  
Recombinant lysostaphin was therefore separated under a 0-90% B elution gradient, as 
shown in Figure 3.22.  The application of a steeper elution gradent decreased retention 
times, however also decreased the resolution of protein isoforms.   
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Figure 3.22: Effect of linear gradient steepness upon upon separation of 0.1 mg of N-
terminally His-tagged recombinant lysostaphin (construct 1; preparation 7) using a 
ProPac WCX-10 (4 x 250 mm).  
 
3.4.3.5 Optimisation of mobile phase conditions 
IEX separations were initially performed using mobile phase buffers containing sodium 
phosphate buffered to pH 7.0.  Whilst successful separation of protein isoforms could be 
achieved at pH 7.0, separations were also performed using mobile phase which had been 
buffered to pH 6.0 or pH 8.0, to establish how the utilisation of more acidic or basic mobile 
phase influenced the separation of recombinant lysostaphin isoforms.  
 
 
Figure 3.23: Comparative separation of 9.5 mg of N-terminally His-tagged recombinant 
lysostaphin (construct 1; preparation 4) using mobile phase buffered to pH 6.0, pH 7.0 
or pH 8.0.  WCX separation performed at pH 8.0 resulted in earlier elution and better 
separation of recombinant lysostaphin isoforms. WCX separation performed at pH 6.0 
resulted in later elution and poorer separation of protein isoforms.  
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As shown in Figure 3.23, reduction of mobile phase pH lengthened peak retention time and 
did not enhance peak separation, whilst increasing mobile phase pH decreased peak 
retention time and enhanced resolution of protein isoforms.  As pH 8.0 buffers provided more 
efficient separation of protein isoforms than pH 7.0 buffers, pH 8.0 buffers were used during 
subsequent WCX separations.  
 
3.4.3.6 Optimisation of column length  
To enhance sample loading capacity and resolution, comparative WCX separations were 
performed using a single ProPac® WCX-10 (4 x 250 mm) column or two ProPac® WCX-10 (4 
x 500 mm) columns. As shown in Figure 3.24, WCX separation using a longer 500 mm 
column provided slightly enhanced resolution of protein isoforms and increased sample 
capacity.  Two ProPac® WCX-10 (4 x 250 mm) columns were therefore used in subsequent 
experiments to provide higher resolution investigation of protein heterogeneity under 
different culture conditions.  
 
 
Figure 3.24: Comparative separation of 14.0 mg of N-terminally His-tagged 
recombinant lysostaphin (construct 1; preparation 8) using a ProPac® WCX-10 (4 x 
250 mm) column or ProPac® WCX-10 (4 x 500 mm) column. WCX separation 
performed using the ProPac® WCX-10 (4 x 500 mm) column provided slightly 
enhanced resolution of protein isoforms and greater sample capacity than the 
ProPac® WCX-10 (4 x 250 mm) column. 
 
3.4.3.7 Optimisation of column diameter  
Peak resolution can be further enhanced by the use of a column with a narrower internal 
diameter, which minimises sample diffusion and therefore band broadening during 
chromatography.  A 2.0 mm version of the ProPac® WCX-10 column was not available 
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initially, therefore some experiments were performed using a ProPac® SCX-10 (2 x 250 mm) 
column.  Although the ProPac® SCX-10 (4 x 250 mm) column had not demonstrated 
separation of protein isoforms, it was hoped that the 2.0 mm version of the column would 
have provided better separation and resolution of protein isoforms.  Figure 3.25 shows that 
improved resolution of protein isoforms was indeed achieved using the ProPac® SCX-10 (2 x 
250 mm) column.  
 
 
Figure 3.25: Separation of 7.8 mg of purified recombinant lysostaphin (construct 1; 
preparation 11) using a ProPac® SCX (2 x 250 mm) column.  
 
The use of a lower flow rate increased the efficiency of separation, which could be achieved 
over a much shorter gradient. Furthermore fractionation could be easily performed within the 
system auto sampler, which permitted subsequent 2D-LC analysis of the fractions eluted 
during SCX separation (Figure 3.26). As shown by the 2D retention map, the eluted peaks 
appeared to be composed entirely of recombinant lysostaphin isoforms, which was not 
surprising considering that the separations were performed on a purified recombinant 
lysostaphin preparation.   
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Figure 3.26: 2D-LC separation of 7.8 mg of purified recombinant lysostaphin 
(construct 1; preparation 11).  Charge variants were separated using a ProPac® SCX (2 
x 250 mm) column. Fractions collected during SCX separation were separated using a 
ProSwift™ RP-4H (1 x 250 mm) column.  
 
Closer examination of RP separations performed in the 2nd dimension largely indicated that 
the WCX fractions contained protein isoforms which did not differ significantly in their 
hydrophobicity (Figure 3.27). However peak broadening observed upon RP separation of 
fractions 7, 8, and 9 indicated that slightly less hydrophobic protein isoforms were partially 
resolved during the separation.  
 
 
Figure 3.27: Comparison of RP separations performed on SCX fractions 5-10 using a 
ProSwift™ RP-4H (1 x 250 mm) column. 
 
In a later experiment, cell lysate was applied directly to the ProPac® SCX (2 x 250 mm) 
column to establish whether recombinant lysostaphin could be purified and separated 
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straight from cell lysate without prior purification. Figure 3.28 indicates that recombinant 
lysostaphin protein isoforms could be separated directly from cell lysate without prior 
purification. This efficient mode of sample preparation was used extensively in subsequent 
separations to eliminate purification and storage stages, which could have contributed to the 
development of increased sample heterogeneity.  
 
Figure 3.28: Separation of recombinant lysostaphin (construct 1) from E. coli cell 
lysate using a ProPac® SCX (2 x 250 mm) column.  Cellular constituents, which could 
not bind to the SCX column, eluted within the first few minutes of the separation. 
Protein isoforms appeared to elute during the linear elution gradient, however the 
elution of some peaks following column washing suggested that some of the protein 
or UV-absorbing cationic contaminants were retained more strongly. 
 
2D-LC analysis of fractions collected during SCX separation revealed that the resulting 
fractions were largely composed of a single protein type, however some protein 
contaminants were resolved in the later eluting fractions (Figure 3.29).  Considering that 
crude cell lysate was applied to the column, it was remarkable that so few cationic protein 
contaminants were resolved during 2D-LC analysis. This result therefore demonstrated the 
high selectivity of CXC for the separation of basic proteins, such as recombinant lysostaphin.   
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Figure 3.29: 2D-LC separation of recombinant lysostaphin (construct 1) from E. coli 
cell lysate. Recombinant lysostaphin was directly purified from cell lysate and charge 
variants were separated using a ProPac® SCX (2 x 250 mm) column. Fractions 
collected during SCX separation were separated using a ProSwift™ RP-4H (1 x 250 
mm). The first RP separation had an elevated baseline which led to mis-representation 
of fraction 1 in the 2D retention map.  
 
A 2.0 mm version of the ProPac® WCX-10 (2 x 250 mm) column was acquired later and 
proved to provide high resolution separation of recombinant lysostaphin isoforms than the 
ProPac® SCX-10 (2 x 250 mm) column could (Figure 3.30).  
 
 
Figure 3.30: Separation of 0.3 mg of purified N-terminally His-tagged N-terminally His-
tagged recombinant lysostaphin (construct 1; preparation 12) using a ProPac® WCX (2 
x 250 mm) column.    
 
A second ProPac® WCX (2 x 250 mm) column was obtained to create a ProPac® WCX (2 x 
500 mm) column with greater capacity and resolving power. This longer column was 
1  2  
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employed for the rapid high-resolution separation of recombinant protein isoforms contained 
within purified preparations or within cell lysate, as demonstrated in Figure 3.31.   
 
 
Figure 3.31: Separation of cell lysate containing recombinant lysostaphin (construct 
1) using a ProPac® WCX (2 x 500 mm) column. 
 
Overall these experiments indicated that high-resolution separation of recombinant 
lysostaphin isoforms could be achieved using a ProPac® WCX-10 (2 x 500 mm) column or 
ProPac® WCX-10 (4 x 500 mm) column.  The ProPac® WCX-10 (2 x 500 mm) column was 
therefore used to provide rapid analysis of purified recombinant lysostaphin or cell lysate, 
whilst the ProPac® WCX-10 (4 x 500 mm) column was frequently employed to separate 
larger quantities of recombinant lysostaphin present within a purified preparation or cell 
lysate.  
 
3.4.3.8 Optimisation of fraction collection  
CXC separations were performed using fraction collection on the basis of time or peak-
recognition.  Fraction collection was complicated by the complexity of recombinant 
lysostaphin as protein isoforms did not necessarily elute as distinct peaks. A number of 
experiments were therefore performed to establish whether timed or peak recognition 
provided the most appropriate mode of collection.  
 
3.4.3.9 Timed fraction collection  
When performing fractionation by time it was essential that the onset and termination of 
fraction collection was triggered appropriately. The duration of timed fraction collection was 
selected in accordance with the duration of the linear elution gradient but also after 
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observing the elution of peaks during previous separation experiments.  As shown in Figure 
3.32, the duration of fraction collection was generally performed over an extended period of 
time to ensure that all of the resolved protein isoforms were appropriately collected.  The 
duration of collection was also determined by the heterogeneity of the protein preparation, 
which was shown to vary considerably between separate batch cultures of recombinant 
lysostaphin, even following expression of the same gene construct.  The onset of 
fractionation was often reduced to an earlier retention time to ensure that more acidic, less 
abundant protein isoforms were collected.  
  
Figure 3.32: Fraction collection based upon time during the separation of different 
preparations of N-terminally His-tagged recombinant lysostaphin (construct 1).  WCX 
analysis resulted in the separation of differently charged protein isoforms, which 
eluted at different retention times. During the separation of 2.4 mg of preparation 10, 
timed fraction collection was performed between 15 and 55 min to ensure that less 
abundant protein variants were collected. During the separation of 3.0 mg of 
preparation 9, timed fraction collection was performed between 20 and 55 min as the 
preparation appeared to contain fewer acidic, low-abundance protein isoforms.  
 
3.4.3.10 Peak recognition 
Peak recognition fraction collection could be performed according to UV absorbance 
readings acquired at 214 or 280 nm. Monitoring of absorbance at 214 nm provided the most 
sensitive detection of protein absorbance, through detection of the peptide backbone but 
also other UV-absorbing contaminants.  Measurement of absorbance at 280 nm detects 
protein molecules according the presence of aromatic residues, therefore offers more 
specific detection of protein absorbance, rather than UV-absorbing contaminants. Peak 
recognition fraction collection was initially performed based on absorbance at 214 nm.  As 
shown in Figure 3.33, this lead to sensitive peak recognition collection of low abundance 
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isoforms, however the presence of UV contaminants interfered with appropriate fraction 
collection of more abundant protein isoforms.  
 
 
Figure 3.33:  Fraction collection based upon UV absorbance at 214 nm during the 
separation of 0.7 mg of C-terminally His-tagged recombinant lysostaphin (construct 3; 
preparation 13).  Collection was based upon peak recognition, which provided 
sensitive collection at low absorbance reading, yet lost detection sensitivity upon the 
elution of broad peaks with a higher absorbance.  However peak recognition at 214 
nm permitted collection of less abundant protein isoforms between 13 and 21 min. 
 
When peak recognition fraction collection was based upon absorbance at 280 nm, fraction 
collection of protein isoforms was performed more appropriately.  Figure 3.34 demonstrates 
that the most abundant protein isoforms were collected in separate fractions, however less 
abundant protein isoforms were not collected as their absorbance level did not trigger 
automated collection, suggesting that the peak recognition parameters required modification. 
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Figure 3.34: Fraction collection based upon UV absorbance at 280 nm during 
separation of 0.7 mg of C-terminally His-tagged recombinant lysostaphin (construct 3; 
preparation 13).  Collection was based upon peak recognition, which provided 
sensitive detection of peak elution and permitted collection of protein isoform peaks 
within separate fractions. However peak recognition at 280 nm did not permit 
collection of less abundant protein isoforms. 
 
A number of WCX separations were performed using slightly adjusted peak recognition 
parameters with the intention of achieving sensitive collection of eluted peaks. Despite 
modifying peak recognition parameters in a systematic manner, it was found that fraction 
collection could not be achieved correctly. This was due to an intrinsic programming error 
associated with the Chromeleon Version 6.8 software, which prevented the correct 
performance of peak recognition fraction collection.  As demonstrated in Figure 3.35, fraction 
collection was inappropriately triggered in the absence of peak elution.  Inappropriate and 
spurious fraction collection was not desirable as the hyper-functioning of the auto-sampler 
module resulted in missed collection of eluted peaks.  
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Figure 3.35: Inappropriate peak recognition fraction collection during separation of 
0.7 mg of C-terminally His-tagged recombinant lysostaphin (construct 3; preparation 
13).  This was caused by a software fault which was subsequently corrected by 
Dionex Corporation.  
 
This issue was reported to Dionex Corporation and the fault was subsequently rectified.  
However it was decided that time-based fraction collection would be applied in subsequent 
separations due to the fact that it would have been very difficult to optimise peak recognition 
parameters to recognise and collect small or poorly resolved peaks. Timed fraction collection 
was known to provide more reliable and consistent collection, regardless of peak height or 
resolution, therefore reducing the likelihood of missed collection of peaks during WCX 
separation.  
 
3.4.3.11 Analysis of recombinant lysostaphin using optimised conditions 
During the optimisation of WCX separation many experiments were performed to evaluate 
recombinant lysostaphin variants.  It was apparent that multiple peaks could be resolved 
during WCX separation, reflecting the presence of protein isoforms. However it may have 
been possible that the detection of multiple peaks may have occurred as an artefactual 
phenomenon associated with separation.  Therefore an eluted fraction was collected and re-
applied to the column to demonstrate that the protein contained in the fraction displayed the 
same retention time as it did during the initial separation (Figure 3.36).  
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Figure 3.36:  Re-application of fractions eluted during WCX separation of 0.7 mg of C-
terminally His-tagged recombinant lysostaphin (construct 3; preparation 13). Fraction 
25 was collected and re-applied to the column, as indicated.  
 
Re-application of the collected fraction indicated that the eluted protein demonstrated a 
similar retention time as it did during the initial separation. Slight shifting in retention time 
was likely to reflect the fact that the protein had been eluted in an increased salt 
concentration, which may have influenced protein retention during the second separation.     
 
3.4.3.12 Influence of culture temperature upon charge heterogeneity of recombinant 
lysostaphin  
To assess whether culture temperature influenced charge heterogeneity of recombinant 
lysostaphin, three cultures were divided at the point of induction and fermented at either 20 
or 30°C.  SDS-PAGE analysis revealed that recombinant lysostaphin was hyper-expressed 
in all cultures (Appendix 7.191).  As shown in Figure 3.37, Figure 3.38 and Figure 3.39, 
greater charge heterogeneity was observed amongst recombinant lysostaphin which had 
been expressed in cultures incubated at 30°C.  SDS-PAGE analysis of selected fractions 
collected during WCX separation demonstrated that the major peaks were attributable to the 
presence of a protein with a molecular weight corresponding to that of recombinant 
lysostaphin (construct 1) (Appendix 7.193 - Appendix 7.204).   
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Figure 3.37: Comparison of WCX separations performed on cell lysate containing 
recombinant lysostaphin (construct 1) following expression at 20 or 30°C (Culture 1).    
 
 
 
Figure 3.38: Comparison of WCX separations performed on cell lysate containing 
recombinant lysostaphin (construct 1) following expression at 20 or 30°C (Culture 2).    
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Figure 3.39: Comparison of WCX separations performed on cell lysate containing 
recombinant lysostaphin (construct 1) following expression at 20 or 30°C (Culture 3). 
 
The presence of particular protein isoforms appeared to remain fairly consistent between all 
three cultures, however greater cell density at the point of induction appeared to increase 
sample heterogeneity during the expression of recombinant lysostaphin at 20°C (Figure 
3.40) rather than at 30°C (Figure 3.41). 
 
 
Figure 3.40: Comparison of WCX separations performed on cell lysate containing 
recombinant lysostaphin (construct 1) following expression at 20°C (Cultures 1, 2 and 
3). 
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Figure 3.41: Comparison of WCX separations performed on cell lysate containing 
recombinant lysostaphin (construct 1) following expression at 30°C (Cultures 1, 2 and 
3). 
 
As a reduced culture temperature and a moderate optical density at the point of induction 
appeared to minimise the occurrence of more acidic protein isoforms, further experiments 
were performed under these conditions.  The experiments were also performed using 
recombinant lysostaphin without His-tags (construct 2) rather than N-terminally His-tagged 
recombinant lysostaphin (construct 1) as this form of the protein was later found to exhibit 
less charge heterogeneity (Section 4.2.3.1).  As shown in Figure 3.42 and Figure 3.43, the 
presence of particular protein isoforms remained fairly constant between cultures incubated 
at the same temperature and induced at similar optical densities.  However the abundance 
of the more acidic isoform (observed at 42 min) was diminished in cultures incubated at 
16°C (Figure 3.44 and Figure 3.45).  Cell lysate harvested from cultures incubated at 16°C 
was also analysed by SDS-PAGE to confirm hyper-expression of recombinant lysostaphin 
(Appendix 7.205).   
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Figure 3.42: Comparison of WCX separations performed on cell lysate containing 
recombinant lysostaphin (construct 2) following expression at 20°C (Cultures 4 and 
5). 
 
 
Figure 3.43: Comparison of WCX separations performed on cell lysate containing 
recombinant lysostaphin (construct 2) following expression at 16°C (Cultures 4 and 
5). 
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Figure 3.44: Comparison of WCX separations performed on cell lysate containing 
recombinant lysostaphin (construct 2) following expression at 16°C and 20°C (Culture 
4). 
 
 
Figure 3.45: Comparison of WCX separations performed on cell lysate containing 
recombinant lysostaphin (construct 2) following expression at 16°C and 20°C (Culture 
5). 
 
Recombinant lysostaphin (construct 2) expressed in E. coli fermented at 16°C was produced 
as a fairly homogeneous preparation, with the resolution of a single major peak during WCX 
separation.  However the broad width and asymmetry of the resolved single peak, suggested 
that protein eluted within this peak could still be fairly homogeneous.  As the heterogeneity of 
the recombinant lysostaphin preparation was likely to increase with increased duration of 
culture, an additional experiment was performed to establish whether recombinant 
lysostaphin would demonstrate a lesser degree of heterogeneity if cell lysate was harvested 
after a shorter period of culture.   
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During the previous experiment cell lysate was harvested at 17.5 h post-induction, therefore 
in the subsequent experiment cell lysate was harvested at 14.0 h post-induction.  Figure 
3.46 however demonstrated that recombinant lysostaphin harvested at 14.0 h post-induction 
did not in fact demonstrate greater homogeneity.  
 
 
Figure 3.46: Comparison of WCX separations performed on cell lysate containing 
recombinant lysostaphin (construct 2) following expression at 16°C and harvest at 
14.0 h post-induction (Culture 6). 
 
3.4.3.13 Separation of alternative recombinant protein preparations 
As WCX separation provided resolution of protein isoforms within recombinant lysostaphin 
preparations, the optimised WCX method was used to analyse alternative recombinant 
protein preparations to establish whether charge heterogeneity may be a common 
occurrence when recombinant proteins are expressed in E. coli.  As WCX columns could 
only separate proteins which were basic at pH 8.0, two basic proteins were selected for 
analysis in the form of recombinant oxidoreductase from Clostridium acetobutylicum and 
recombinant NADPH-dependent 1-acyl dihydroxyacetone phosphate reductase (Ayr1p) from 
Saccharomyces cerevisiae.  
 
ProtParam analysis of amino acid sequences (Appendix 7.206 and Appendix 7.207) 
revealed that the recombinant proteins had theoretical pI of 8.62 and 9.23 respectively 
(Appendix 7.208 and Appendix 7.209) and therefore were predicted to bind to the WCX 
column. In addition ClustalW analysis confirmed that the amino acid sequences did not 
share sequence homology with the amino acid sequence of recombinant lysostaphin 
(Appendix 7.210).  Both recombinant proteins were initially expressed in E. coli BL21(DE3) 
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cultured in LB , before harvesting the cell lysate and performing SDS-PAGE analysis 
(Appendix 7.211). The cell lysates were then subjected to WCX analysis (Figure 3.47 and 
Figure 3.48).  
 
 
Figure 3.47: WCX separation of cell lysate containing recombinant oxidoreductase 
using a ProPac® WCX (4 x 500 mm) column.  Cell lysate was harvested from E. coli 
BL21(DE3) which had been cultured in LB. Arrows indicate the presence of resolved 
charge variants.  
 
 
Figure 3.48: WCX separation of cell lysate containing recombinant Ayr1p using a 
ProPac® WCX (4 x 500 mm) column. Cell lysate was harvested from E. coli BL21(DE3) 
which had been cultured in LB.  Arrows indicate the presence of resolved charge 
variants.  
 
As shown in Figure 3.47 and Figure 3.48, WCX separation revealed that both recombinant 
protein preparations contained a predominant peak, within which minor charge variants 
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could be resolved.  SDS-PAGE analysis confirmed that the peaks resolved during WCX 
separation (Appendix 7.212 and Appendix 7.214) reflected the presence of protein with a 
molecular weight which corresponded to the masses of recombinant oxidoreductase (28.5 
kDa) and recombinant Ayr1p (32.8 kDa) (Appendix 7.213 and Appendix 7.215). Both 
recombinant proteins were also expressed in E. coli BL21(DE3) cultured in AIM and 
harvested cell lysates (Appendix 7.216) were subjected to WCX analysis, as shown in Figure 
3.49 and Figure 3.50.  Once again PAGE analysis confirmed that the peaks resolved during 
WCX separation (Appendix 7.217 and Appendix 7.219) reflected the presence of protein with 
molecular weights which corresponded to the masses of recombinant oxidoreductase (28.5 
kDa) and recombinant Ayr1p (32.8 kDa) (Appendix 7.218 and Appendix 7.220). 
 
 
Figure 3.49: WCX separation of cell lysate containing recombinant oxidoreductase 
using a ProPac® WCX (4 x 500 mm) column. Cell lysate was harvested from E. coli 
BL21(DE3) which had been cultured in AIM. Arrows indicate the presence of resolved 
charge variants.  
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Figure 3.50: WCX separation of cell lysate containing recombinant Ayr1p using a 
ProPac® WCX (4 x 500 mm) column. Cell lysate was harvested from E. coli BL21(DE3) 
which had been cultured in AIM. Arrows indicate the presence of resolved charge 
variants.  
 
WCX separation of recombinant oxidoreductase and recombinant Ayr1p expressed in E. coli 
cultured in AIM clearly demonstrated that charge heterogeneity is not only exhibited by 
recombinant lysostaphin, but also by other cationic recombinant proteins. Expression of 
recombinant oxidoreductase and recombinant NADPH-dependent 1-acyl dihydroxyacetone 
phosphate reductase (Ayr1p) by E. coli cultured in AIM appeared to result in greater charge 
heterogeneity, which may have been attributable to the expression media (Figure 3.51 and 
Figure 3.52). However it was more likely that the greater charge heterogeneity was 
attributable to differences in culture duration as recombinant proteins expressed by E. coli 
cultured in AIM were harvested at 16.0 h post-induction, whilst recombinant proteins 
expressed by E. coli cultured in LB were harvested at 19.5 h post-induction.   
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Figure 3.51: Comparison of WCX separations performed on cell lysate containing 
recombinant oxidoreductase expressed in E. coli BL21(DE3) cultured in LB or AIM. 
PAGE analysis revealed that the presence of an additional peak at 49 min (indicated 
by arrow) represented the presence of a large cationic E. coli protein (66-97 kDa) 
which was expressed upon growth in AIM. 
 
 
Figure 3.52: Comparison of WCX separations performed on cell lysate containing 
recombinant Ayr1p expressed in E. coli BL21(DE3) cultured in LB or AIM. PAGE 
analysis revealed that the presence of an additional peak at 49 min (indicated by 
arrow) represented the presence of a high molecular weight cationic E. coli protein 
(66-97 kDa) which was expressed upon growth in AIM. 
 
PAGE analysis confirmed that the peaks resolved between 24 and 34 min during WCX 
separation reflected the presence of protein with molecular weight which corresponded to 
the masses of recombinant oxidoreductase (28.5 kDa) (Appendix 7.213 and Appendix 
7.218) and recombinant Ayr1p (32.8 kDa) (Appendix 7.215 and Appendix 7.220). 
Interestingly cell lysates harvested from E. coli cultured in AIM appeared to contain more 
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contaminating cationic proteins, which were detectable during WCX separation and SDS-
PAGE. This finding demonstrates that expression media can significantly influence cellular 
proteomic expression profiles.   
 
3.4.3.14 Optimisation of protein isoform separation using the beta-test ProPac® MAb 
column 
Although the ProPac® MAb column provided excellent resolution of protein isoforms, 
experiments were performed to establish whether separation could be optimised further by 
slight modification of sample loading, column length, gradient and mobile phase conditions.  
 
3.4.3.15 Optimisation of sample loading conditions 
This initial application of recombinant lysostaphin resulted in excellent resolution and 
separation of lysostaphin isoforms, however only a small amount of lysostaphin (16.8 µg) 
had been applied to the column.  Consequently comparative separations were performed 
following injection of higher amounts of lysostaphin to establish if this would result in peak 
broadening and a reduction in isoform resolution and separation (Figure 3.53). 
   
 
Figure 3.53: Comparison of chromatograms after injection of increasing amounts of 
C-terminally His-tagged recombinant lysostaphin (construct 3; preparation 5).  Arrows 
indicate additionally resolved peaks. 
 
Figure 3.53 demonstrates that peak height increases with the application of increasing 
amounts of lysostaphin, as would be expected.  Adding a ten-fold higher amount of 
lysostaphin (1.63 mg) resulted in a very similar pattern of separation to that achieved after 
application of a ten-fold lower amount of lysostaphin (0.16 mg), with only slight peak 
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broadening observed.  Application of a twenty-fold higher amount of lysostaphin (3.3 mg) 
also resulted minimal peak broadening and increased peak height as expected.  This third 
application of lysostaphin was subject to slight chromatographic shifting as shown in Figure 
3.53, however it is interesting to observe that additional protein isoforms were resolved with 
the application of a higher amount of recombinant lysostaphin (see arrows on Figure 3.53).  
This result highlighted the importance of optimising the amount of sample protein that was 
applied to the column.     
 
3.4.3.16 Optimisation of chromatographic gradient conditions  
Excellent separations of recombinant lysostaphin were achieved using the beta-testing 
gradient conditions suggested by Dionex.  As the gradient conditions had been optimised 
extensively for the ProPac® WCX column, the optimised gradient conditions were applied in 
conjunction with the ProPac® MAb column to see if the optimised method for the ProPac® 
WCX-10 column could provide even greater resolution of isoforms using the beta test 
column.  However, Figure 3.54 demonstrates that the optimised gradient conditions did not 
provide significantly better separation of peaks than the gradient conditions recommended 
during beta testing.     
 
 
Figure 3.54: Comparison of separation efficiency of chromatographic gradient 
conditions during the separation of 0.3 mg of C-terminally His-tagged recombinant 
lysostaphin (construct 3; preparation 5) As indicated, there is very little difference in 
the separation efficiency of both chromatographic gradient methods.    
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3.4.3.17 Optimisation of mobile phase conditions  
The beta test program advocated the use of MES-buffered mobile phase conditions and 
these conditions demonstrated very promising results. However optimised ProPac® WCX-10 
separations gave an improved elution profile with sodium phosphate-buffered mobile phase 
conditions, therefore ProPac® MAb SCX separations were carried out using MES and 
sodium phosphate- buffered mobile phase conditions to compare the separation efficiency of 
the buffer conditions being employed (Figure 3.55).  
 
Figure 3.55 demonstrated that separations using sodium phosphate buffers resulted in early 
elution of the recombinant lysostaphin isoforms, which suggested that the total 
chromatographic program time could be reduced considerably.  However despite the 
benefits of early elution, the separation efficiency of the lysostaphin isoforms was 
significantly poorer using sodium phosphate buffers than for MES buffers. Recombinant 
lysostaphin isoforms were retained for an additional 10 minutes on the ProPac® MAb SCX 
column, however MES buffers demonstrated a much higher separation efficiency and 
resolution of the protein isoforms.   
 
 
Figure 3.55: Comparison of mobile phase conditions during separation of 0.3 mg of C-
terminally His-tagged recombinant lysostaphin (construct 3; preparation 5). 
Separations 1 and 2 were performed using an elution buffer containing 20 mM sodium 
phosphate, pH 8.0 and 1M NaCl, whilst separations 3 and 4 were performed using an 
elution buffer containing 20 mM MES, pH 6 and 1M NaCl.   
 
3.4.3.18 Optimisation of column length  
As described in Section 3.5.3.6, the in-line coupling of two 2 x 250 mm ProPac® WCX-10 
columns to create a larger weak cation exchange matrix (2 x 500 mm), resulted in significant 
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improvements in column capacity, separation efficiency and resolution of protein isoforms.  
Therefore two ProPac® MAb SCX (4 x 250 mm) columns were coupled together to create a 
longer ProPac® MAb SCX (4 x 500 mm) column, with the expectation that the longer column 
volume would result in further enhancement of peak resolution. As a result of column length 
extension, the chromatographic method was also extended appropriately.   
 
 
Figure 3.56: Comparison of separations of 0.7 mg of C-terminally His-tagged 
recombinant lysostaphin (construct 3; preparation 5) using a ProPac® MAb SCX (4 x 
250 mm) or a ProPac® MAb SCX (4 x 500 mm) column. An additional isoform was 
resolved using the longer 4 x 500 mm column.  
 
Figure 3.56 indicates that the longer ProPac® MAb SCX (4 x 500 mm) column does not offer 
significant improvements in isoform separation efficiency, however the additional column 
length has resolved an additional peak which was not identified using the ProPac® MAb SCX 
(4 x 250 mm) column. By reflecting on Figure 3.53 and Figure 3.54, it became apparent that 
this additional peak could not be resolved by the single ProPac® MAb SCX (4 x 250 mm) 
column, but was visibly present and represented by peak broadening or peak shouldering of 
the second major eluted peak, as shown in Figure 3.57. 
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Figure 3.57: Examples of peak broadening and peak shouldering. Chromatograms 
show the separation of 0.2 mg (black trace) and 0.3 mg (blue trace) of C-terminally 
His-tagged recombinant lysostaphin (construct 3; preparation 5) on the ProPac® MAb 
SCX (4 x 500 mm) beta test column.  
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3.4.4 Discussion 
 
Optimisation of protein separation was a lengthy process, which was complicated by the 
dynamic nature of recombinant protein production.  It was only by performing many 
optimisation separations that greater insight into the heterogeneity of recombinant 
lysostaphin preparations could be achieved.  For instance, the separation of higher 
concentrations of recombinant lysostaphin revealed that many low abundance protein 
isoforms could be resolved by the ProPac® WCX-10 (4 x 250 mm) column.  However the 
application of larger amounts of recombinant lysostaphin could decrease the resolution of 
more abundant protein isoforms due to band broadening.  It therefore became apparent that 
more abundant protein isoforms should be separated following the application of lower 
sample concentrations, to avoid column overloading and band broadening. Whilst separation 
and resolution of low abundance isoforms required the application of much higher amounts 
of recombinant lysostaphin.  
 
The majority of protein separations were performed following application of recombinant 
lysostaphin which had been purified and stored in a liquid state prior to analysis.  Lyophilised 
recombinant lysostaphin was produced following large-scale production of the protein and 
whilst this formulation provided long-term protein stability, it was found that sample 
precipitation interefered with the separation of protein isoforms, through atypical peak 
resolution and peak broadening.  The separation of recombinant lysostaphin isoforms 
directly from cell lysate was found to provide efficient and high-resolution separation of 
protein isoforms however. 2D-LC analysis of protein isoforms separated from cell lysate  
also demonstrated that recombinant lysostaphin could be selectively purified from the cell 
lysate using CXC and therefore no prior purification stages were actually required, providing 
more efficient, real-time analysis of harvested recombinant lysostaphin preparations.  
 
Optimisation of mobile phase conditions and gradient functions for protein separation using 
the ProPac® WCX-10 (4 x 250 mm) column indicated that greater separation could be 
achieved by extending gradient duration.  Optimal separation was achieved using a 70 min 
gradient, which provided a good compromise between separation efficiency and peak 
resolution, which diminished with more extended gradients of 120-240 min.  Increasing the 
steepness of the elution gradient also did not enhance resolution or separation, therefore the 
gradient was maintained at 0-50% of elution buffer. Altering the pH of mobile phase buffers 
to pH 8.0, did however increase the efficiency of protein separation by decreasing peak 
retention times. Therefore the pH of mobile phase buffers was increased from pH 7.0 to pH 
8.0 to increase the overall efficiency of separation.  
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Resolution and separation power could be increased by performing separation using an 
extended ProPac® WCX-10 (4 x 500 mm) column.  This extended column format provided 
high resolution separation of protein isoforms, but also provided the capacity to separate 
protein obtained from 1 L batch cultures.  However  separation could not be performed in an 
rapid manner which prevented high-throughput analysis of multiple samples. The efficiency 
of protein separation could however be increased by decreasing internal diameter of the 
column from 4 mm to 2 mm.   
 
Although the ProPac® SCX-10 (4 x 250 mm) column did not provide good resolution of 
protein isoforms, the ProPac® SCX-10 (2 x 250 mm) column was found to provide higher 
resolution separation of recombinant lysostaphin variants within purified and crude lysate 
samples.  2D-LC could be performed efficiently using the smaller elution volumes achieved 
during SCX separation. Furthermore second dimensional RP analysis indicated that peaks 
eluted during SCX reflected the presence of a single protein with very few contaminants. The 
presence of additional protein isoforms that could not be separated by charge, could also be 
observed following RP analysis.  
 
A ProPac® WCX-10 (2 x 250 mm) column was later acquired and was found to provide 
superior resolution of protein isoforms than the ProPac® SCX-10 (2 x 250 mm) column.  The 
use of an extended ProPac® WCX-10 (2 x 500 mm) column provided more enhanced 
resolution and separation of protein isoforms from cell lysate within 50 min.  The speed at 
which recombinant lysostaphin isoforms could be separated from cell lysate provided a 
means by which recombinant protein expression could be monitored by rapid analysis, as 
described in Section 3.5.3.6.  Protein separation by the ProPac® WCX-10 (2.0 x 250 mm) 
columns was however limited by column capacity and therefore larger amounts of 
recombinant protein would have to be separated using the ProPac® WCX-10 (4 x 500 mm) 
column to achieve higher amounts of separated protein variants for characterisation 
experiments.  
 
The ProPac® MAb SCX-10 (4 x 250 mm) column had already demonstrated excellent 
resolution of protein isoforms, however a few experiments were performed to establish 
whether resolution could be increased any further.  Beta testing gradients and mobile phase 
conditions were found to offer better or similar separation and resolution of protein isoforms 
and the column possessed the capacity to separate moderate concentrations of recombinant 
lysostaphin. The use of an extended ProPac® MAb SCX-10 (4 x 500 mm) column was also 
found to provide slightly enhanced resolution of charge variants, however did not increase 
the separation efficiency.  The ProPac® MAb SCX-10 columns did however provide rapid, 
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high-resolution separation of protein isoforms, which could facilitate rapid analysis of multiple 
samples harvested during the course of protein expression.  
 
Due to the heterogeneity and differential abundance of recombinant lysostaphin variants, 
optimisation of fraction collection was essential to ensure that resolved proteins were 
appropriately fractionated. Whilst peak recognition-based fraction collection should have 
provided sensitive collection of resolved peaks, programming errors prevented appropriate 
fractionation. Peak recognition conditions were also difficult to optimise given that some 
peaks were resolved but not separated and therefore were not recognised upon elution.  
Time-based fraction collection was therefore found to offer more reliable collection of protein 
isoforms during separation .  
 
During the course of optimisation of chromatographic conditions, it was possible to gain 
further insight into the influence of expression conditions upon the heterogeneity of 
recombinant lysostaphin. The studies provide further evidence of the variable heterogeneity 
within recombinant lysostaphin preparations.  Repeated separation of protein eluted within a 
single WCX provided confirmation that the observed heterogeneity was real and that the 
resolution of multiple peaks did not occur as an artefactual phenomenon.  However the 
ability to make conclusions about the origins or nature of charge heterogeneity, based on 
comparison of chromatograms, was limited by frequent alterations of chromatographic 
conditions during optimisation.  It was however possible to investigate the influence of some 
expression conditions whilst optimising chromatographic conditions.  
 
Investigation of the influence of incubation temperature upon product heterogeneity, 
revealed that higher incubation temperatures were associated with greater charge 
heterogeneity. An additional acidic variant was observed in cultures incubated at 30°C or 
cultures in which expression had been induced at higher optical densities. This observation 
was not especially surprising considering that post-translational processing or modification 
would occur faster at elevated temperatures following Arrhenius kinetics.  Following this 
finding, incubation temperatures were reduced to 16°C which lead to the production of a 
more homogeneous protein preparation.  Whilst WCX separation of cell lysate harvested 
from cultures incubated at 16°C revealed the presence of fewer protein isoforms, peak width 
and asymettry suggested that the protein preparation still contained a number of charge 
isoforms.  Nevertheless, these experiments demonstrated that the degree of product 
heterogeneity could be manipulated by careful selection of culture conditions.  
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These experiments demonstrated that the charge heterogeneity of recombinant lysostaphin 
was evident, however it was not clear whether other recombinant proteins expressed in E. 
coli could also exhibit charge variation. WCX separation of cell lysate containing 
recombinant oxidoreductase or recombinant NADPH-dependent 1-acyl dihydroxyacetone 
phosphate reductase (Ayr1p) suggested that the expressed protein did demonstrate micro-
heterogeneity in the form of charge variants which were resolvable using the ProPac® WCX-
10 (4 x 500 mm) column. Charge heterogeneity appeared to increase further upon 
expression of the recombinant proteins in AIM rather than LB, which indicated that 
expression media could influence the rate or extent of post-translational processing or 
modification. Furthermore investigation of the influence of expression media would be 
desirable as it was unclear whether the observed differences in charge heterogeneity were 
attributable to expression media or the duration of propagation.  
 
Overall these experiments demonstrated that protein separation, performed under optimised 
chromatographic conditions could be used evaluate the charge heterogeneity of recombinant 
lysostaphin and other cationic recombinant proteins expressed in E. coli.  The availability of 
a number of ProPac™ IEX columns provided the flexibility to perform rapid or high capacity, 
high-resolution separation of protein isoforms through appropriate selection of column 
diameter. The ability to perform rapid analysis is particularly desirable to permit culture 
monitoring during recombinant protein expression.  Whilst one-off separations performed on 
whole recombinant protein preparations proved to be informative, the presence of particular 
charge variants could not be predicted or did not seem to follow any conclusive patterns.  It 
was therefore thought that the charge variability could transition over time or according to 
culture optical density. Monitoring the influence of optical density and time could therefore be 
most effectively achieved by performing rapid analysis during recombinant protein 
expression.  
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3.5 Rapid analysis of recombinant lysostaphin isoforms 
 
3.5.1 Introduction 
 
Industrial recombinant protein production in E. coli is typically performed over a short, 
defined period of time, in which bacterial growth parameters and expression conditions are 
strictly controlled (Garnick et al., 1988).  Due to the time and cost invested in large-scale 
recombinant protein production it is essential that culture conditions, protein yields and 
product homogeneity are monitored throughout expression.  By monitoring a recombinant 
protein production, any slight deviation in culture parameters, yields or homogeneity can be 
swiftly detected and addressed by adjustment and correction of culture conditions to achieve 
optimal expression (Dalmora et al., 1997, DePhillips et al., 1994).  Alternatively culture 
analysis may demonstrate extensive product heterogeneity or poor expression yields, which 
would advocate termination of culture prior to performing expensive protein purification 
procedures.  
 
In addition to optimisation of expression, culture analysis is desirable to establish when it is 
most appropriate for a recombinant product to be harvested.  If a protein is harvested 
prematurely or too late, product yield can be dramatically reduced due to under-expression 
or degradation during culture (Baker et al., 2002).  Changes in recombinant protein 
expression levels are commonly assessed using techniques such as SDS-PAGE or ELISA, 
however these techniques do not necessarily provide accurate determination of protein 
concentration, particularly when analysing heterogeneous protein populations (Paasch et al., 
1996).  Whilst SDS-PAGE and ELISA can be repeated during the course of expression, the 
techniques cannot be automated and do not provide real-time culture analysis. Therefore 
culture conditions cannot be sensitively adjusted and controlled to ensure optimal expression 
(Liu et al., 2005, DePhillips et al., 1994). 
 
The detection and assessment of product homogeneity during recombinant protein 
production can only be achieved using more sensitive analytical techniques, which can 
provide resolution of protein variants. The assessment of the macro- and micro-
heterogeneity of a recombinant protein preparation provides an insight into the consistency 
and stability of the recombinant product which is essential for quality control purposes 
(Jacobson et al., 1997).  Furthermore culture analysis can facilitate further investigation of 
protein modifications, leading to elucidation of their origin, nature, incidence and influence 
upon the structure and function of a recombinant protein (Dalmora et al., 1997).  By 
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identifying the source of a protein variant, measures can be taken to limit or prevent its 
occurrence, thereby increasing yields of the desired, unmodified recombinant protein.  
 
Sensitive and reproducible techniques, such as HPLC and capillary electrophoresis have 
been commonly employed to monitor recombinant protein expression and heterogeneity.  
These techniques are often used to analyse a recombinant protein following its expression 
and purification, but are often too slow to provide on-line, real-time analysis of expression 
products (Baker et al., 2002).  However optimisation of sample preparation and analytical 
conditions has demonstrated that HPLC and CE can be effectively used to provide rapid and 
accurate detection of protein variants, as and when they occur during culture (Dalmora et al., 
1997, McNerney et al., 1996).  Due to its sensitivity, HPLC has been more commonly 
applied than CE during expression studies and therefore a number of rapid analysis 
methods have been described (Dalmora et al., 1997, Londo et al., 1998, Hummel et al., 
1989, Strege and Lagu, 1995).  
 
In order to monitor recombinant protein expression in real-time, protein harvesting and 
purification procedures must be rapid enough to achieve analytical data which reflects the 
current state of expression.  Such an optimised real-time analysis workflow would involve 
simple extraction of the expressed recombinant protein and a single separation stage which 
provides direct purification and analysis of the protein of interest.  In addition, the rate of 
sample analysis is important as it dictates how many samples can be processed within the 
course of expression.  Rapid analysis of samples is therefore desirable to permit high 
sample through-put and provide more information during each expression study.    
 
Rapid harvesting of the recombinant protein is essential to ensure that host proteases, 
modifying enzymes and reactive intermediates that are present within E. coli do not degrade 
or alter the recombinant protein prior to rapid analysis.  Direct recovery of a recombinant 
protein from a crude cell lysate is advantageous as it significantly reduces processing time 
and costs.  Cell lysates that are acquired using cellular disruption methods, such as 
sonication or osmotic shock provide the best medium for reliable evaluation of protein 
concentration and homogeneity.  Cellular disruption can be achieved fairly rapidly, therefore 
a cell lysate can be acquired within less than hour and subjected to rapid analysis, following 
one-step capture of the recombinant protein using an appropriate chromatographic or 
electrophoretic technique.  
 
The selection of an appropriate analytical technique is complicated by the complex nature of 
crude cell lysates, which contains numerous host molecules that can interfere with 
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separation and detection of the target protein (Jacobson et al., 1997).  For instance, host 
contaminants may interfere with adsorption interactions or exhibit similar chromatographic 
behaviour as the target protein, resulting in co-elution (Viloria-Cols et al., 2004).  Co-elution 
can lead to mis-interpretation of detected peaks and may interfere with the accuracy of 
subsequent biological assays.  It is therefore imperative that the target recombinant protein 
is efficiently isolated by a separation method that offers high specificity and selectivity (Kroef 
et al., 1989).   
 
Direct analysis of crude cell lysates may also result in column fouling, whereby cellular 
constituents bind to the adsorbent matrix. Fouling occurs due to electrostatic interactions 
between the column stationary phase and cell particulates such as nucleic acids, proteins, 
lipids, cellular debris and cells (Viloria-Cols et al., 2004). The non-specific binding of 
macromolecular cell particulates can lead to aggregation which can hinder purification of the 
target protein, destabilize column fluidisation and reduce overall process efficiency (Feuser 
et al., 1999). The fouled adsorbent matrix can be regenerated by extensive washing, 
however harsh regeneration procedures often lead to only partial recovery of column 
performance and therefore column fouling significantly affects the performance and life 
expectancy of a column (DePhillips et al., 1994).   
 
To reduce the risk of column fouling, chromatographic conditions should be carefully 
selected to ensure that there is ample opportunity for cellular constituents to be washed from 
the column without interfering with separation of the target recombinant protein.  Unlike 
techniques such as SDS-PAGE, chromatographic separation can be developed and 
optimised to provide optimal performance during rapid and reproducible separation. 
Development of stationary phase chemistries, such as the introduction of non-porous 
particles and perfusive supports has further enhanced the applicability of HPLC for real-time 
culture analysis (Londo et al., 1998). 
 
3.5.1.1 Rapid analysis of recombinant lysostaphin  
As described in Section 3.4, protein analysis was performed after following a number of 
harvesting and purification steps had been undertaken (Figure 3.58).  Depending on culture 
capacity, protein harvesting could be achieved within a few hours.  However protein 
purification, subsequent analysis and concentration stages took longer, often days to 
complete, delaying protein analysis and characterisation significantly.  Delayed analysis was 
undesirable as the protein preparation may have been affected by degradation or chemical 
modifications which occurred artifactually during the course of sample preparation. 
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Figure 3.58: A culture analysis workflow from expression to characterisation. 
 
However the ability of CXC to purify cationic proteins directly from cell lysate could be 
exploited to provide a rapid analysis workflow (Figure 3.59).  The elimination of additional 
protein purification stages dramatically reduced the time taken to prepare recombinant 
lysostaphin before analysing charge heterogeneity using CXC. Depending on the volume of 
culture being harvested, analysis of product heterogeneity could be performed within a few 
hours of protein expression by applying this rapid analysis workflow.  Further analysis and 
characterisation of the recombinant protein could then be performed immediately or following 
proteolytic digestion, concentration and/or buffer exchange.  
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Figure 3.59: A rapid culture analysis workflow from expression to characterisation. 
 
As chromatographic conditions had already been optimised for the binding and separation of 
purified recombinant, chromatographic conditions were systematically varied to permit 
optimised separation of crude lysate. Optimisation involved reassessment of sample 
preparation and chromatographic conditions. 
 
3.5.1.2 Optimisation of sample preparation during rapid analysis  
To develop a protocol for rapid analysis of recombinant protein heterogeneity, the 
preparation of cell lysate and the amount of recombinant lysostaphin being separated 
needed to be assessed and optimised.  During culture analysis, it was essential that 
harvested samples contained enough recombinant lysostaphin to allow detection of protein 
isoforms using CXC. In addition to optimising cell lysate preparation, it was desirable to 
ensure that high sample-throughput was achieved during rapid analysis. The frequency of 
analysis itself was dependent on the rate of sample through-put provided by 
chromatographic analysis and sample throughput was ultimately limited by the duration of 
chromatographic separation.  To circumvent this inherent limitation, different modes of 
sample preparation were considered to establish whether recombinant lysostaphin could be 
preserved in its harvested state, so that rapid analysis could be delayed until a more 
convenient time (Section 3.5.1.3).    
153 
 
3.5.1.3 Maximising sample through-put during rapid analysis  
As sample throughput was limited by the duration of chromatographic separation, different 
modes of sample preparation were considered to permit analysis of an increased number of 
samples. Cell lysate was typically prepared and analysed within hours of its extraction, which 
became very labour intensive if multiple samples were being analysed during the course of 
expression, which typically spanned several days. The option of freezing samples during 
sample preparation was therefore considered, to allow more flexible expression analysis or 
repeated analysis of a sample extracted at a specific time point. For instance, pelleted E. coli 
cells could be frozen following initial extraction and centrifugation, as shown in Figure 3.60.  
This approach permits samples to be stored until a time when the remaining sample 
preparation and chromatographic analysis could be conveniently performed.   
 
 
Figure 3.60: Work-flow diagram for analysis of cell lysate harvested from fresh and 
frozen cells.  Samples of culture were extracted in duplicate, centrifuged and the 
resulting cell pellets were resuspended with an appropriate buffer.  One of the 
samples was processed immediately (1), whilst the other sample was frozen (2) and 
processed at a convenient time.  
 
Alternatively, additional subsequent sample preparation could be avoided by freezing a cell 
lysate, which could be thawed prior to chromatographic separation (Figure 3.61).  As the 
recombinant protein remained in a reactive cellular environment, it was imperative that the 
samples were frozen immediately and analysed immediately after thawing to prevent any 
further modification or alteration of protein structure between analysis of fresh and thawed 
samples.  
154 
 
 
Figure 3.61: Work-flow diagram for analysis of cell lysate harvested from fresh and 
frozen cell lysate. Samples of culture were extracted in duplicate, centrifuged and the 
resulting cell pellets was resuspended with an appropriate buffer. Both samples were 
sonicated and centrifuged to yield cell lysate. One of the resulting cell lysates was 
analysed immediately (1), whilst the other sample was frozen (2) and analysed at a 
convenient time. 
 
3.5.1.4 Optimisation of chromatographic conditions 
In order to create an effective method for rapid analysis, chromatographic conditions 
required optimisation to permit real-time analysis of protein expression as it occurred during 
culture. Although chromatographic conditions applied whilst using the ProPac® WCX (4 x 
500 mm) had been optimised for the separation of recombinant lysostaphin variants, these 
conditions could not be applied during rapid culture analysis for a number of reasons. 
 
Firstly analytical separations performed using the ProPac® WCX (4 x 500 mm) were 
performed over an extended gradient to provide optimal separation of protein isoforms. This 
extended duration of separation was not suitable for rapid analysis, therefore it was essential 
that analysis was performed using columns with a narrower internal diameter, such as 
ProPac® SCX or WCX (2 x 250 mm) columns. Due to bearing a smaller internal diameter, 
greater resolution could be achieved whilst applying lower flow rates and shorter gradient, 
wash and equilibration phases, therefore increasing the speed of analysis. The application of 
lower flow rates was also advantageous, as eluted protein could be collected as more 
concentrated fractions during separation.  Alternatively rapid separation could be performed 
using a column which could provide high resolution separation over a short duration of 
separation, such as the ProPac® MAb SCX (4 x 250 mm).  
 
Secondly, chromatographic conditions required modification to accommodate the injection of 
crude cell lysate rather than purified, concentrated recombinant lysostaphin preparations. As 
cell lysate contains many cellular contaminants, sample loading stages required optimisation 
to ensure that interactions between cellular contaminants and the stationary phase, such as 
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column fouling and chromatographic interference could be avoided as much as possible. 
Fortunately E. coli cell lysate has less of a tendency to bind to chromatographic matrices 
than lysates harvested from eukaryotic expression hosts do (Feuser et al., 1999). Cation 
exchange resins are also less susceptible column fouling than anion exchange resins 
(Londo et al., 1998).  Furthermore polymeric stationary phase materials, such as those used 
in ProPac™ IEX columns, provide increased column stability and are less prone to 
degradation in the presence of crude samples (DePhillips et al., 1994).  In addition ProPac™ 
IEX columns are protected from secondary interactions due to the polymeric beads being 
covered in a hydrophilic coating (Dainiak et al., 2002). 
 
The aims of this work were: 
 
 To optimise chromatographic conditions and sample preparation for the rapid 
separation of protein isoforms directly from cell lysate.  
 To validate a rapid analysis strategy for the direct determination of recombinant 
lysostaphin expression levels and charge heterogeneity from cell lysate using CXC.   
 To study the expression of recombinant lysostaphin over the course of bacterial 
culture. 
 To monitor the charge heterogeneity of recombinant lysostaphin throughout 
expression. 
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3.5.2 Methods 
 
All separations were performed using an Ultimate™ 3000 Titanium system  
 
3.5.2.1 Optimisation of rapid analysis  
Initial rapid analysis separations were performed using a ProPac® SCX (2 x 250 mm) column 
as described in Appendix 7.221. This rapid analysis method was used to investigate the 
influence of optical density at the point of induction upon charge heterogeneity (Appendix 
7.222). The performance of the ProPac® SCX (2 x 250 mm) and ProPac® WCX (4 x 500 
mm) columns were then compared (Appendix 7.223).  
 
Rapid analysis was then performed using the ProPac® WCX (2 x 500 mm) column 
(Appendix 7.225) after optimising cell lysate preparation (Appendix 7.224) and trying to 
maximise sample through-put (Appendix 7.226). Chromatographic conditions were optimised 
further (Appendix 7.228) before investigating the influence of optical density at the point of 
induction again (Appendix 7.227). Using the optimised method, the influence of time upon 
the charge heterogeneity of recombinant lysostaphin was investigated (Appendix 7.229 and 
Appendix 7.230). Rapid analysis was also performed using the ProPac® MAb SCX (4 x 250 
mm) column (Appendix 7.231).  
 
  
157 
 
3.5.3 Results  
 
3.5.3.1 Rapid analysis of recombinant lysostaphin using a ProPac® SCX (2 x 250 mm) 
column 
Due to the availability of a 2 mm diameter cation exchange column, initial rapid analysis 
separations were performed using a ProPac® SCX (2 x 250 mm) column.  E. coli cell lysate 
harvested during the expression of recombinant lysostaphin was injected onto column and 
several peaks were separated and resolved from cellular constituents which could not bind 
to the SCX column (Figure 3.62). The separation was performed over 35 min, which could 
allow analysis of cell lysates that were harvested hourly during culture.  The majority of the 
separated peaks were observed during the linear gradient elution, however resolved peaks 
were also observed following the column wash phase. As UV data was only acquired at 214 
nm, it was not clear whether these peaks represented strongly retained protein or other UV-
absorbing molecules.   
Figure 3.62: Separation of E. coli cell lysate containing expressed N-terminally His-
tagged recombinant lysostaphin (construct 1) using a ProPac® SCX (2 x 250 mm) 
column.  Cellular constituents which could not bind to the SCX column eluted within 
the first few minutes of the separation. Protein isoforms appeared to elute during the 
linear elution gradient, however the elution of some peaks following column washing 
suggested that some of the protein or UV-absorbing cationic contaminants were 
retained more strongly. UV data was acquired at a wavelength of 214 nm.  
 
Following successful capture of cationic protein isoforms using this column, a series of 
separations were performed at regular intervals during the expression of recombinant 
lysostaphin.  As shown in Figure 3.63, culture analysis could be performed in a reproducible 
manner, with fairly consistent sample loading and peak heights observed between 
separations.  However some of the separations were subject to chromatographic shifting,  
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which slightly compromised the quality of the results.  
 
Figure 3.63: Culture analysis during the expression of N-terminally his-tagged 
recombinant lysostaphin (construct 1) in E. coli BL21(DE3). Cell lysates were 
harvested between 2.0 and 27.0 h after the induction of protein expression and 
applied to a ProPac® SCX (2 x 250 mm) column. Separations could be performed in a 
reproducible manner, however the separations were subject to chromatographic 
shifting.   
 
This preliminary culture analysis provided an insight into the expression levels and charge 
heterogeneity of recombinant lysostaphin over the course of expression.  SCX separations 
performed on cell lysates harvested early in the course of culture revealed that recombinant 
lysostaphin was hyper-expressed within 2 h of the induction of protein expression (Figure 
3.64).  This finding correlated with over-expression observed following SDS-PAGE analysis 
(Appendix 7.242). Even at this early stage of expression, several peaks were resolved 
indicating that the charge distribution of the separated recombinant lysostaphin was not 
homogeneous.  Separation of cell lysate harvested 3 h after the induction of expression, 
demonstrated the emergence of an acidic protein variant.  
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Figure 3.64: Culture analysis during the early expression of N-terminally His-tagged 
recombinant lysostaphin (construct 1) in E. coli BL21(DE3). SCX separation resolved 
a number of peaks which indicated that hyper-expression of recombinant lysostaphin 
had commenced within 2 h of the induction of protein expression.  The resolved 
protein isoforms also demonstrated the presence of basic variants and the 
emergence of an acidic variant by 3 h post-induction.  
 
Following an interval of 16 h, cell lysate was harvested again at 19.0 h post-induction and 
separated by SCX (Figure 3.66).  SCX analysis indicated that recombinant lysostaphin was 
being constitutively hyper-expressed in E. coli, which was in concurrence with SDS-PAGE 
findings (Appendix 7.242). By 19 h post-induction, the most predominant peak was observed 
at a retention time of 11.5 min.  This observation indicated that a more acidic protein variant 
had become more prevalent than the original peak observed at a retention time of 12.5 min 
in cell lysates harvested at 2 and 3 h.  This original peak was still evident in cell lysates 
harvested between 19 and 22 h, however the relative abundance of this protein isoform 
appeared to have decreased.    
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Figure 3.65: Culture analysis during the expression of N-terminally His-tagged 
recombinant lysostaphin (construct 1) in E. coli BL21(DE3). SCX separation resolved 
a number of peaks which confirmed that recombinant lysostaphin was still being 
expressed. An acidic peak at 11.5 min marked the emergence of a more prevalent 
protein isoform. The more basic original protein isoform could still be observed at 
12.5 min, however the height of this peak was reduced, indicating a decreased protein 
abundance.  
 
Continued analysis of cell lysates harvested after 23 h post-induction demonstrated 
sustained expression of recombinant lysostaphin, with continued presence of the two most 
prevalent protein variants (Figure 3.66).  By 27 h post-induction the abundance of both 
protein variants appeared to have been slightly diminished indicating that expression of 
recombinant lysostaphin may have reduced or ceased. A reduction in protein expression, 
concomitant to protein degradation could have led to the observed reduction in the amount 
of recombinant lysostaphin present in the cell lysate.    
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Figure 3.66: Culture analysis during later stages of expression of N-terminally His-
tagged recombinant lysostaphin (construct 1) in E. coli BL21(DE3). SCX separation 
resolved a number of peaks which confirmed that recombinant lysostaphin was still 
being expressed. An acidic peak at 11.5 min marked the emergence of a more 
prevalent protein isoform. The more basic original protein isoform could still be 
observed at 12.5 min, however the height of this peak was reduced, indicating a 
decreased protein abundance.  
 
This initial culture analysis demonstrated that the ProPac® SCX (2 x 250 mm) column could 
be used to provide real-time monitoring of recombinant protein.  As recombinant lysostaphin 
is a basic protein, it binds to cation exchange columns at neutral pH and therefore this 
technique can be used to selectively purify the protein directly from cell lysate during culture 
analysis.  The benefits of this technique were explained in further depth in a customer 
application note, entitled “Rapid Analysis of Recombinant Protein Production during 
Fermentation Using Dionex ProPac IMAC columns” (Appendix 7.291).  
 
3.5.3.2 Influence of optical density at point of induction upon charge heterogeneity  
Due to the success of initial culture analysis using the ProPac® SCX (2 x 250 mm) column, 
the method was used to provide further investigation of the influence of culture conditions 
upon product heterogeneity.  The influence of optical density at the point of induction upon 
the expression and heterogeneity of recombinant lysostaphin was therefore investigated. 
The expression of recombinant lysostaphin in twenty four batch cultures which had been 
induced at various cell densities was monitored by SDS-PAGE (Appendix 7.253). SDS-
PAGE demonstrated that hyper-expression of recombinant lysostaphin generally occurred 
regardless of optical density and could be detected in the majority of samples harvested at 4, 
10 or 20 h post-induction.   
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After harvesting, the extracted cell lysates were subjected to rapid SCX analysis to assess 
the charge heterogeneity of the expressed recombinant lysostaphin.  As shown in Figure 
3.67, the presence of protein isoforms could be observed in cultures which had been 
induced at an OD600 nm of less than 0.6 and harvested at 4 h post-induction. Whilst low-level 
expression of recombinant protein expression prevented clear detection of protein isoforms 
in cultures which had been induced at very low optical densities (less than 0.06), the 
presence of protein variants could be detected in cultures that were induced at higher optical 
densities (greater than 0.06).   
 
Figure 3.67: SCX analysis of cell lysates harvested 4 h after the induction of protein.  
Protein expression was induced at optical densities lower than the standard induction 
densities.   
 
Induction of protein expression within the standard expression range (OD600 nm = 0.6-1.0) 
appeared to result in higher expression levels as expected, however the heterogeneity of the 
protein preparation did not appear to significantly differ from that observed in cultures 
induced at a lower optical density (Figure 3.68).  The relative abundance of protein isoforms 
did however appear to vary as the optical density at the point of induction increased.    
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Figure 3.68: SCX analysis of cell lysate harvested 4 h after the induction of protein 
expression.  Protein expression was induced at an optical density within the standard 
range. 
 
SCX analysis of cultures harvested at 10 h post-induction revealed a similar pattern of 
separation, however greater expression levels could be observed in cultures in which protein 
expression had been induced at very low optical densities (less than 0.06) (Figure 3.69). 
This result was to be expected as a longer incubation time would have allowed time for a 
greater cell density to be reached and therefore enhanced capacity for recombinant protein 
production.  Changes in the relative abundance of protein isoforms appeared to become 
more pronounced as the expression levels and the optical density at point of induction 
increased.  
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Figure 3.69: SCX analysis of cell lysates harvested 10 h after the induction of protein 
expression.  Protein expression was induced at optical densities lower than the 
standard induction densities. Arrows indicate increased prevalence of more acidic or 
basic protein isoforms.   
  
The difference in abundance of the more acidic protein isoform, observed at a retention time 
of 18 min, became increasingly evident as cell lysates induced at higher optical densities 
were analysed (Figure 3.70).  However SDS-PAGE and SCX analysis both confirmed that 
recombinant lysostaphin was not expressed in a culture induced at an OD600 nm of 0.991.  
 
Figure 3.70: SCX analysis of cell lysate harvested 10 h after the induction of protein 
expression.  Protein expression was induced at an optical density within the standard 
range.  The arrow indicates the increased prevalence of a more acidic protein isoform.   
 
When SCX analysis was performed on cell lysates harvested at 20 h post-induction of 
protein expression, over-expression of recombinant lysostaphin was observed in cultures 
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which had been induced at a low optical density (less than 0.2) (Figure 3.71).  SDS-PAGE 
and SCX analysis revealed that there was reduced expression of recombinant lysostaphin in 
cultures induced at an OD600 nm of 0.4.  These results were thought to be anomalous due to 
evidence of increased expression in cultures that were induced a slightly higher optical 
densities.   
 
Figure 3.71: SCX analysis of cell lysates harvested 20 h after the induction of protein 
expression.  Protein expression was induced at optical densities lower than the 
standard induction densities. 
 
Hyper-expression of recombinant lysostaphin was observed in cultures which had been 
induced within the standard induction range (OD600 nm = 0.6-1.0).  SCX analysis 
demonstrated the presence of two peaks representing more acidic or basic protein isoforms 
(Figure 3.72). The abundance of each of these isoforms varied with differences in the optical 
density at point of induction, as observed during analysis of cell lysates harvested at 4 or 10 
h post-induction.  
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Figure 3.72: SCX analysis of cell lysate harvested 20 h after the induction of protein 
expression.  Protein expression was induced at an optical density within the standard 
range. 
 
Overall the results of these studies indicate that the optical density at which protein 
expression was induced was not critical to achieve expression of recombinant lysostaphin.  
SCX analysis indicated that the expressed protein was indeed heterogeneous, however 
there was no clear correlation between optical density at the point of induction and the 
greater prevalence of the more acidic or basic protein isoforms.  
 
3.5.3.3 Comparative analysis of cell lysate using ProPac® SCX (2 x 250 mm) and 
ProPac® WCX (4 x 500 mm) columns 
Although the previous experiments provided further evidence that the ProPac® SCX (2 x 250 
mm) column could provide rapid separation of recombinant lysostaphin, it was also evident 
that this column provided less resolution of protein isoforms than was demonstrated by the 
ProPac® WCX (4 x 500 mm) column, despite possessing a larger internal diameter.  
Differences in the resolving power of the two types of column were exemplified during 
investigation of the influence of colony or glycerol stock-based inoculation of starter cultures 
upon the charge heterogeneity of expressed recombinant lysostaphin. SDS-PAGE analysis 
demonstrated that expression of recombinant lysostaphin could be observed in cell lysates 
harvested from cultures inoculated from colony or glycerol stock (Appendix 7.254).  
 
Figure 3.73 demonstrates duplicate separations of cell lysate derived from colony or glycerol 
stock-based starter cultures using the ProPac® SCX (2 x 250 mm) column.  The separations 
suggested that the charge heterogeneity of recombinant lysostaphin was very similar in cell 
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lysates extracted from cultures derived from colony- and glycerol stock-inoculated starter 
cultures.   
 
 
Figure 3.73: SCX separation of cell lysates derived from cultures inoculated from 
starter cultures, which had been inoculated from a colony or glycerol stock.  The 
colony and glycerol stock contained E. coli BL21(DE3) transformed with a plasmid 
harbouring N-terminally His-tagged recombinant lysostaphin (construct 1).  Starter 
cultures inoculated from glycerol stock or colony were inoculated into flasks 
containing 500 ml of LB.  Protein expression was induced at an OD600 nm of 1.060 in the 
culture derived from a colony, whilst expression was induced at an OD600 nm of 1.041 in 
the culture derived from a glycerol stock.  Each resulting cell lysate was analysed in 
duplicate.  
 
However WCX separations performed using a ProPac® WCX (4 x 500 mm) column 
demonstrated that there were clear differences in the charge distribution of protein isoforms 
present in cell lysates extracted from cultures derived from colony- and glycerol stock-
inoculated starter cultures (Figure 3.74).  This enhanced resolution was desirable during 
rapid analysis, however the use of the ProPac® WCX (4 x 500 mm) column and the 
extended duration of separation did not support rapid analysis. At this point, the acquisition 
of a ProPac® WCX (2 x 250 mm) column became extremely desirable so as to permit higher-
resolution, rapid analysis of recombinant lysostaphin charge variants.  
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Figure 3.74: WCX separation of cell lysates derived from cultures inoculated from 
starter cultures, which had been inoculated from a colony or glycerol stock.  The 
colony and glycerol stock contained E. coli BL21(DE3) transformed with a plasmid 
harbouring N-terminally His-tagged recombinant lysostaphin (construct 1).  Starter 
cultures inoculated from glycerol stock or colony were inoculated into flasks 
containing 500 ml of LB.  Protein expression was induced at an OD600 nm of 1.060 in the 
culture derived from a colony, whilst expression was induced at an OD600 nm of 1.041 in 
the culture derived from a glycerol stock.   
 
The observed differences in the charge variants present in cell lysates extracted from 
cultures derived from colony- and glycerol stock-inoculated starter cultures appeared initially 
to be of concern. This concern was with regard to whether it was more appropriate to 
inoculate starter cultures using transformed colonies or transformed glycerol stocks and the 
implications of each inoculation mode upon consistency between different batch cultures and 
experiments. The results demonstrated in Figure 3.74 indicate that both inoculation modes 
could lead to different charge variants, however it was more probable that the observed 
differences occurred as a result of growth phase and optical density variability at the multiple 
points of inoculation or point of induction. Therefore glycerol-stock based inoculation 
remained the preferred mode of inoculation due to convenience and the fact that more 
cultures could be consistently inoculated using a single glycerol stock rather than a single 
colony.    
 
3.5.3.4 Rapid analysis of recombinant lysostaphin using a ProPac® WCX (2 x 250 
mm) column  
In Section 3.4.3.7, ProPac® WCX (2 x 250 mm) columns were found to provide efficient, high 
resolution separation of recombinant lysostaphin isoforms within purified and crude 
preparations therefore could be used to perform rapid culture analysis. To improve the 
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quality of culture analysis it was important that sample preparation was considered and 
optimised to ensure that as much information could be obtained during separation of protein 
isoforms and during subsequent characterisation of the separated variants.  A number of 
experiments were therefore performed to establish how much culture should be harvested at 
a specific time point during culture analysis to ensure that protein isoforms could be 
detected, but also characterised using activity assays or further LC separations. 
 
Furthermore experiments were performed to establish whether sample through-put could be 
increased by freezing harvested E. coli or cell lysate during sample preparation (Section 
3.5.3.7).  Whilst such strategies could be used to enhance sample through-put, it was 
essential that cell lysates derived from frozen samples could be separated to achieve 
identical resolution of protein isoforms and charge heterogeneity, to ensure the accuracy of 
results.    
 
3.5.3.5 Optimisation of cell lysate preparation during rapid analysis using a ProPac® 
WCX (2 x 250 mm) column 
WCX separation of cell lysate harvested from 1 ml of culture yielded several distinct peaks 
representing the expressed isoforms of recombinant lysostaphin.  However, the most 
abundant peak had a peak height of 55 mAU, which did not correlate with a high protein 
concentration. As a consequence, the separated WCX fractions could not be used for 
subsequent proteolytic digestion and reproducible mass spectrometric analyses.  In addition, 
some of the less abundant isoforms were represented by peaks, which due to low 
absorbance readings were hard to distinguish from minor chromatographic baseline drifts 
(Figure 3.75).  
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Figure 3.75: WCX separation of N-terminally His-tagged recombinant lysostaphin 
(construct 1) from cell lysate harvested from 1 ml of culture. The elution of the most 
abundant protein isoform was represented by a peak with a peak height of 55 mAU. 
The peak heights of less abundant isoforms were very low and therefore the 
distinction between peaks and UV base-line drifting was less clear. 
 
Further WCX separations were performed using cell lysate harvested from larger volumes of 
culture (25 and 100 ml). Comparison of the WCX separations in Figure 3.76 clearly shows 
that higher concentrations of recombinant lysostaphin isoforms could be obtained by 
applying cell lysate derived from 100 ml of culture.  
 
 
Figure 3.76: Comparison of WCX separations of N-terminally His-tagged recombinant 
lysostaphin (construct 1) from cell lysate harvested from 1, 25 and 100 ml volumes of 
culture. 
 
Closer inspection of the WCX separation of recombinant lysostaphin harvested from 100 ml 
of culture shows that the peak representing the most abundant isoform has a peak height of 
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1228 mAU, which corresponds with a protein concentration which is more than adequate for 
proteolytic digestion and repeatable MS analysis (Figure 3.77). However harvesting 100 ml 
of culture would lead to volumetric depletion of 1 L batch culture after the analysis of only ten 
time-points, which could be problematic if protein expression lasts for several days.   
 
 
Figure 3.77: WCX separation of N-terminally His-tagged recombinant lysostaphin 
(construct 1) from cell lysate harvested from 100 ml of culture. The elution of the most 
abundant protein isoform was represented by a peak with a peak height of 1228 mAU. 
The peak heights of less abundant isoforms were also high enough to permit 
proteolytic digestion and reproducible MS analysis.  
 
WCX separation of recombinant lysostaphin harvested from 25 ml of culture also provides 
distinct peaks representing protein isoforms which are present in high quantities (Figure 
3.78). The peak representing the most abundant isoform has a peak height of 295 mAU 
which also corresponds with a protein concentration which would be sufficient for 
subsequent analysis.  Harvesting 25 ml of culture would only lead to volumetric depletion of 
1 L batch culture after the analysis of forty time-points, which would allow routine analysis 
over an extended period of protein expression. 
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Figure 3.78: WCX separation of N-terminally His-tagged recombinant lysostaphin 
(construct 1) from cell lysate harvested from 25 ml of culture. The elution of the most 
abundant protein isoform was represented by a peak with a peak height of 295 mAU. 
The peak heights of less abundant isoforms were also high enough to permit 
proteolytic digestion and reproducible MS analysis.  
 
3.5.3.6 Rapid analysis of recombinant lysostaphin using a ProPac® WCX (2 x 500 
mm) column 
Following the acquisition of a second ProPac® WCX (2 x 500 mm) column, both WCX 
columns were coupled to create a ProPac® WCX (2 x 500 mm) column.  Cell lysate 
containing N-terminally His-tagged recombinant lysostaphin (construct 1) was applied to the 
column and separation resulted in the resolution of multiple protein isoforms (Figure 3.79).  
Due to the presence of two columns, the duration of column wash and equilibration phases 
was increased to accommodate the increased stationary phase capacity.  The separation 
could still be achieved within 65 min, however produced enhanced resolution of protein 
isoforms.   
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Figure 3.79: Separation of cell lysate containing N-terminally His-tagged recombinant 
lysostaphin (construct 1) using a ProPac® WCX (2 x 500 mm) column.   
 
Repeated application of cell lysate containing N-terminally His-tagged recombinant 
lysostaphin (construct 1) demonstrated that reproducible separations could be obtained 
using the ProPac® WCX (2 x 500 mm) column and modified chromatographic method 
(Figure 3.80). 
 
Figure 3.80: Separation of cell lysate containing N-terminally His-tagged recombinant 
lysostaphin (construct 1). Duplicate applications of the cell lysate demonstrated the 
reproducibility of the separation. 
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3.5.3.7 Maximising sample through-put during rapid analysis using a ProPac® WCX 
(2 x 500 mm) column 
Whilst chromatographic separation methods were developed to provide rapid separation of 
recombinant lysostaphin, this process was ultimately delayed by the time taken to harvest 
cell lysate and to perform all stages of chromatographic operation, such as column elution, 
washing and equilibration.  Rapid analysis could be performed as frequently as every hour 
during culture which was found to provide a good insight into the transitory nature of charge 
heterogeneity during protein expression. However it was not possible to perform repeated 
analysis of sample harvested at a specific time point, due to the continuous nature of 
analysis when performing hourly analysis of culture.  It was therefore desirable to find a way 
of preserving recombinant lysostaphin in its harvested state, whilst delaying analysis for 
several hours or days until it became convenient to perform analysis.  
 
As described in Section 3.5.1.3, this could theoretically have been achieved by freezing 
freshly harvested E. coli cells and resuming sample harvesting at a more convenient time. 
To test this strategy, cell lysates were prepared from fresh or frozen E. coli cell suspensions 
and analysed by WCX analysis to establish whether the freeze-thaw process affects the 
reproducibility of WCX separation results.  WCX separations of recombinant lysostaphin 
from cell lysates derived from fresh and frozen cells were compared in Figure 3.81 and 
Figure 3.82. The results clearly show that the freeze-thaw process did not detrimentally 
affect the concentrations of protein within the samples, with no major differences in peak 
heights being observed between fresh and frozen preparations.  However the results 
suggested that the freeze-thaw process subtly affected the charge of protein isoforms in the 
recombinant protein preparations.  
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Figure 3.81: Mirrored-comparison of WCX separations of N-terminally His-tagged 
recombinant lysostaphin (construct 1) harvested from fresh and frozen E. coli 
(example 1).  All of the isoforms appeared to be present in cell lysate harvested from 
both fresh and frozen E. coli, however the relative abundance of some of the 
conjoined peaks shifted between samples.    
 
Comparison of WCX separations in example 1 (Figure 3.81) demonstrated that there is a 
shift in the relative abundance of some of the conjoined peaks between samples. In Figure 
3.82, evaluation of WCX separations revealed the appearance of a double peak in the 
sample derived from frozen cells that was not present in the sample derived from fresh cells. 
Unfortunately these subtle differences between WCX separation of fresh and frozen 
preparations precluded the use of frozen samples in a rapid analysis protocol, as the results 
did not match the results obtained from fresh preparations.    
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Figure 3.82: Mirrored-comparison of WCX separations of N-terminally His-tagged 
recombinant lysostaphin (construct 1) harvested from fresh and frozen E. coli 
(example 2).  A major difference between the WCX separations was the appearance of 
a double peak (+) in the sample derived from frozen cells that was not present in the 
sample derived from fresh cells. Comparison of WCX separations also demonstrated 
a chromatographic shift in the retention times between the two separations which 
complicated comparison of peaks. 
 
As N-terminally His-tagged recombinant lysostaphin (construct 1) was not preserved in its 
expressed state after freezing harvested E. coli cells, comparative WCX separations were 
performed using freshly prepared cell lysate and cell lysate which had been frozen following 
preparation. However, as shown in Figure 3.83, separation of the frozen cell lysate resulted 
in loss of several protein isoforms that were observed following separation of freshly 
prepared cell lysate.  In addition, the abundance of the isoforms that were observed in 
freshly prepared cell lysate appeared to have increased, leading to the detection of two 
predominant isoforms following separation of the frozen cell lysate.   
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Figure 3.83: Comparison of WCX separations of N-terminally His-tagged recombinant 
lysostaphin (construct 1) harvested from fresh and frozen cell lysate (Example 1).  All 
of the isoforms appeared to be present in cell lysate harvested from both fresh and 
frozen E. coli BL21(DE3), however the relative abundance of some of the conjoined 
peaks shifted between samples.    
 
A second comparative WCX experiment also revealed differences in the charge 
heterogeneity of protein isoforms detected in fresh and frozen cell lysate.  Once again, 
several protein isoforms were not detected within the frozen cell lysate, with two 
predominant peaks being retained (Figure 3.83). These results indicated that frozen cell 
lysate, could not be used to accurately represent the heterogeneity of recombinant 
lysostaphin during culture.  This inability to preserve recombinant lysostaphin reinforced the 
importance of optimising and performing rapid analysis to ensure that protein heterogeneity 
could be monitored in real-time and as frequently as possible.  
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Figure 3.84: Comparison of WCX separations of N-terminally His-tagged recombinant 
lysostaphin (construct 1) harvested from fresh and frozen cell lysate (Example 2).  All 
of the isoforms appeared to be present in cell lysate harvested from both fresh and 
frozen E. coli, however the relative abundance of some of the conjoined peaks shifted 
between samples. 
 
3.5.3.8 Culture analysis using a ProPac WCX® (2 x 500 mm) column 
Once chromatographic conditions had been optimised, multiple experiments were performed 
to provide further culture analysis, whilst taking advantage of the improved resolution 
provided by the ProPac WCX® (2 x 500 mm) column. Expression studies were focused upon 
elucidating the influence of optical density at the point of induction or time upon the resulting 
charge heterogeneity of recombinant lysostaphin.  
 
3.5.3.9 Investigation of the influence of optical density at the point of induction upon 
the charge heterogeneity of recombinant lysostaphin 
The influence of optical density upon the charge heterogeneity of recombinant lysostaphin 
was reinvestigated by performing three experiments in which recombinant protein 
expression was analysed in a total of twenty nine cultures.  Expression of recombinant 
lysostaphin was analysed by SDS-PAGE (Appendix 7.255) and by WCX analysis to provide 
further information about the influence of optical density at point of induction upon product 
heterogeneity.  Unlike the previous experiments investigating the influence of optical density 
upon expression and heterogeneity, which were performed on cell lysate extracted at 4, 10 
or 20 h, these three experiments were performed on cell lysates harvested at 20 h 
exclusively.  
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Figure 3.85 demonstrates high resolution separation of protein isoforms expressed following 
induction of protein expression at optical densities lower than the standard induction 
densities (OD600 nm = 0.6-1.0).  WCX separation of cell lysates resulting from cultures 
induced at optical densities below 0.2 did not reveal the presence of clear protein isoforms 
indicating poor expression of N-terminally His-tagged recombinant lysostaphin (construct 1). 
However WCX separation of cell lysates harvested from cultures induced at optical densities 
at 0.2 and above, demonstrated clear separation of several protein isoforms. As 
demonstrated, in previous culture analysis experiments, the abundance of the most basic 
protein isoform appeared to decrease as the optical density at point of induction increased. 
Furthermore the abundance of the major acidic protein isoform appeared to increase with 
increasing optical density.   
 
 
Figure 3.85: WCX analysis of N-terminally His-tagged recombinant lysostaphin 
(construct 1) from cell lysates harvested 20 h after the induction of protein expression 
at varying optical densities (Experiment 1).  Protein expression was induced at optical 
densities lower than the standard induction densities. Arrows indicate changes in the 
abundance of the two major acidic or basic protein isoforms.  
 
WCX separation of cell lysates harvested from cultures induced at optical densities within 
the standard range for protein expression, resulted in the detection of two predominant 
protein isoforms (Figure 3.86).  In addition, a more acidic protein isoform, with a retention 
time of around 21.5 min, became more abundant in cultures induced at standard optical 
densities. These results indicated that the heterogeneity of recombinant lysostaphin also 
increased in cultures induced at higher optical densities. The detection of a third major 
protein isoform demonstrated how the increased resolution provided by the ProPac WCX® (2 
x 500 mm) column could allow better identification of charge variants than the ProPac SCX® 
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(2 x 250 mm) column.  It is likely that this third acidic isoform could not be resolved by the 
ProPac SCX® column, but instead led to the observed peak broadening.  
 
 
Figure 3.86: WCX analysis of N-terminally His-tagged recombinant lysostaphin 
(construct 1) from cell lysates harvested 20 h after the induction of protein expression 
at varying optical densities (Experiment 1).  Protein expression was induced at optical 
densities within the standard range. Arrows indicate changes in the abundance of the 
two major acidic or basic protein isoforms.  
 
In the second experiment, the enhanced resolution provided by the ProPac WCX® (2 x 500 
mm) column elucidated the presence of further protein isoforms which were not evident 
during the first experiment (Figure 3.87).  WCX separation of cell lysates harvested from 
cultures in which protein expression was induced at optical densities below 0.2 once again 
did not reveal any separated protein isoforms due to poor expression of N-terminally His-
tagged recombinant lysostaphin (construct 1).  Cell lysates harvested from cultures induced 
at optical densities above 0.2 demonstrated the presence of the two most predominant 
protein isoforms at retention times of 21.5 and 23.0 min.  These protein isoforms were 
detected in the first experiment, however in the second experiment additional peaks at 
retention times of 20.5 and 22.5 min were also detected leading to greater charge 
heterogeneity. It is possible that these protein isoforms represented intermediate charge 
states that occurred during post-translational processing.     
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Figure 3.87: WCX analysis of N-terminally His-tagged recombinant lysostaphin 
(construct 1) from cell lysates harvested 20 h after the induction of protein expression 
at varying optical densities (Experiment 2).  Protein expression was induced at optical 
densities lower than the standard induction densities. Arrows indicate changes in the 
abundance of the two major acidic or basic protein isoforms.  
 
WCX separation of N-terminally His-tagged recombinant lysostaphin (construct 1) from cell 
lysates harvested from cultures induced at higher optical densities demonstrated a similar 
degree of heterogeneity with two or four major protein isoforms detected in all of the samples 
(Figure 3.88).  Unlike the first experiment, the observed charge heterogeneity appeared to 
vary more considerably between cultures.  The overall abundance of the protein isoforms 
appeared to have decreased slightly in cultures induced at optical densities of 0.854 and 
1.558, which may have reflected decreased expression, in conjunction with degradation of 
recombinant lysostaphin by cellular proteases.  
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Figure 3.88: WCX analysis of N-terminally His-tagged recombinant lysostaphin 
(construct 1) from cell lysates harvested 20 h after the induction of protein expression 
at varying optical densities (Experiment 2).  Protein expression was induced at optical 
densities within the standard range. Arrows indicate changes in the abundance of the 
two major acidic or basic protein isoforms.  
 
The third experiment yielded similar results to the second experiment with at least four 
protein isoforms detected in each of the harvested cell lysates. The abundance of each of 
these protein isoforms appeared to vary with no apparent pattern between samples.  WCX 
separation of cell lysates harvested from cultures induced at OD600 nm values below 0.6 
indicated that protein isoforms with a retention time of 20.5 and 22.5 were less abundant, yet 
still detectable (Figure 3.89).  All four protein isoforms were clearly evident in cell lysates 
harvested from cultures which had been induced within the standard optical density range 
(Figure 3.90).    
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Figure 3.89: WCX analysis of N-terminally His-tagged recombinant lysostaphin 
(construct 1) from cell lysates harvested 20 h after the induction of protein expression 
at varying optical densities (Experiment 3).  Protein expression was induced at optical 
densities lower than the standard induction densities. Arrows indicate changes in the 
abundance of the two major acidic or basic protein isoforms.  
 
 
Figure 3.90: WCX analysis of N-terminally His-tagged recombinant lysostaphin 
(construct 1) from cell lysates harvested 20 h after the induction of protein expression 
at varying optical densities (Experiment 3).  Protein expression was induced at optical 
densities within the standard range.  
 
Overall these results demonstrate that more extensive visualisation of recombinant 
lysostaphin variants can be achieved using the ProPac WCX® (2 x 500 mm) column, 
providing a greater insight into the highly variable charge heterogeneity that can be observed 
following induction of protein expression at varying optical densities.  The results of these 
experiments were however of concern, when considered that the increased charge 
184 
 
heterogeneity appeared to increase in cultures which were induced within the standard 
expression range (OD600 nm = 0.6-1.0) and harvested 20 h following induction, as these 
conditions reflect those which could be routinely employed during recombinant protein 
production.   
 
Although the cultures in all three experiments were fermented for exactly 20 h, the observed 
variability may have been attributable to differences in the optical density of the starter 
culture used to inoculate the main shake-flask culture. The optical density values of the 
starter cultures at point of inoculation were controlled as much as possible, however starter 
cultures with OD600 nm values of 1.651, 1.732 and 1.578 were used to inoculate cultures in 
experiments 1, 2 and 3 respectively, therefore differences in bacterial growth phase may 
have contributed to the observed variability.   
 
To eliminate the introduction of variability from differences in starter culture optical density, a 
series of experiments were performed in which cultures were inoculated directly from a 
glycerol stock.  To investigate whether recombinant lysostaphin could be successfully 
produced following direct inoculation of shake-flask cultures from a glycerol stock, cell 
lysates were harvested from a total of fifteen cultures during three experiments. WCX 
analysis of harvested cell lysates harvested in the first experiment demonstrated the 
presence of detectable protein isoforms (Figure 3.91).  However the abundance and 
resolution of the detected peaks appeared to be detrimentally affected in some of the 
samples, due to poor expression, which was detected by SDS-PAGE analysis (Appendix 
7.243).  
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Figure 3.91: WCX analysis of N-terminally His-tagged recombinant lysostaphin 
(construct 1) from cell lysates harvested from cultures inoculated directly from a 
glycerol stock (Experiment 1).  Cultures were harvested 20 h after the induction of 
protein expression at varying optical densities.   
 
WCX analysis of cell lysates harvested in the second and third experiments also 
demonstrated the presence of detectable peaks, however poor protein expression was 
evident in some of the cell lysates (Figure 3.92 and Figure 3.93).  Interestingly the more 
basic protein isoforms appeared to be more abundant in each of the samples and 
experiments, despite differences in the optical density at the point of induction. This 
contradicted previous experiments which suggested that higher optical densities at the point 
of induction correlated the increased abundance of more acidic protein isoforms.  
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Figure 3.92: WCX analysis of N-terminally His-tagged recombinant lysostaphin 
(construct 1) from cell lysates harvested from cultures inoculated directly from a 
glycerol stock (Experiment 2). Cultures were harvested 20 h after the induction of 
protein expression at varying optical densities. 
 
Figure 3.93: WCX analysis of N-terminally His-tagged recombinant lysostaphin 
(construct 1) from cell lysates harvested from cultures inoculated directly from a 
glycerol stock (Experiment 3).  Cultures were harvested 20 h after the induction of 
protein expression at varying optical densities.   
  
3.5.3.10 Optimisation of chromatographic conditions  
As the IEX separations were frequently performed to investigate how the heterogeneity of N-
terminally His-tagged recombinant lysostaphin (construct 1) was influenced by culture 
variables, such as optical density and time, chromatographic methods often remained 
unmodified to prevent retention time differences and allow easier comparison between 
experiments.  However alterations to chromatographic methods were gradually applied 
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during the development of a rapid analysis strategy.  The first such alteration featured the 
incorporation of a sample wash period at the start of the separation to ensure that unbound 
cellular contaminants did not interfere with analysis (Figure 3.94).  However following 
separation it was evident that a 3 min wash period was not long enough to permit full elution 
of the unbound contaminants.  
 
 
Figure 3.94: Introduction of an extended sample wash during chromatographic 
separation.  During and following injection of cell lysate, 100% WCX buffer A was 
applied to the column for 3 min to ensure that any unbound cellular contaminants 
were washed from the column.  The separation was performed on cell lysate 
containing N-terminally His-tagged recombinant lysostaphin (construct 1) using a 
ProPac® WCX (2 x 500 mm) column.  
 
The wash period was therefore extended to last for 10 min following the injection of more 
concentrated cell lysates or to accommodate larger injection volumes.  As shown in Figure 
3.95, the extended sample wash period was long enough to allow unbound cellular 
constituents prior to the start of the linear elution gradient.  
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Figure 3.95: Introduction of an extended sample wash during chromatographic 
separation.  During and following injection of cell lysate, 100% WCX buffer A was 
applied to the column for 10 min to ensure that any unbound cellular contaminants 
were washed from the column.  The example separation was performed on cell lysate 
containing N-terminally His-tagged recombinant lysostaphin (construct 1) using a 
ProPac® WCX (2 x 500 mm) column.  
 
During the early development of a rapid analysis strategy, the column wash period was 
extended to 13 min to ensure that observed peaks reflected the current state of protein 
expression rather than carry-over from a previous separation.  With repeated culture 
analysis experiments, this wash period was reduced to 8 min (Figure 3.96).  The 
equilibration period was also lengthened to minimise chromatographic shifting during culture 
analysis.  
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Figure 3.96: Optimised chromatographic method applied used during culture analysis.  
In addition to an extended sample wash, the column wash phase was shortened and 
the equilibration phase was lengthened to prevent chromatographic shifting during 
repeated analysis.  The example separation was performed on cell lysate containing 
N-terminally His-tagged recombinant lysostaphin (construct 1) using a ProPac® WCX 
(2 x 500 mm) column.  
 
3.5.3.11 Investigation of the influence of time upon the charge heterogeneity of 
recombinant lysostaphin 
Expression studies focused on the influence of optical density at the point of induction 
provided an insight into the transitory nature of protein charge during the expression of 
recombinant lysostaphin. However the studies did not demonstrate a clear correlation 
between optical density at the point of induction and differences in the abundance and 
charge of particular protein isoforms.  It was therefore decided that in subsequent expression 
studies, the charge heterogeneity of recombinant lysostaphin should be monitored using 
time, rather than optical density at the point of induction, as a variable.  
 
To achieve this, the charge heterogeneity of N-terminally His-tagged recombinant 
lysostaphin (construct 1) was monitored in a single culture over a time-course of expression. 
To avoid swift volumetric depletion, 25 ml of culture was harvested from the culture at 
regular time intervals, as frequently as every 90 min. Bacterial growth during culture was 
monitored by UV spectrometry during the course of culture analysis (Appendix 7.244).  The 
growth of the E. coli BL21(DE3) followed typical bacterial growth kinetics, entering death 
phase after 28 h of culture (Appendix 7.246).  Despite entering death phase, expression of 
N-terminally His-tagged recombinant lysostaphin (construct 1) was detected by SDS-PAGE 
for at least 28 h following induction of protein expression (Appendix 7.247).  
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Cell lysate harvesting and culture analysis was performed between 1.5 and 30.0 h following 
the induction of protein expression.  As evidenced by Figure 3.97, expressed recombinant 
lysostaphin isoforms were successfully detected and separated throughout the culture 
analysis.  Due to the number of WCX separations performed, visual representation of the 
compared chromatograms was less clear, however it was evident that the presence of two 
predominant protein isoforms could be detected through the course of expression.   
 
 
Figure 3.97: WCX analysis of N-terminally His-tagged recombinant lysostaphin 
(construct 1) over an expression time-course. Cell lysate was harvested from a 1L LB 
culture at regular intervals between 1.5 h and 30.0 h post-induction.  
 
Due to the continuous nature of analysis, chromatographic issues such as retention time 
shifting or the presence of anomalous peaks could not be corrected immediately by re-
analysing the sample. For instance, WCX analysis of cell lysates harvested at 3.0, 4.5, 6.0 
and 7.5 h post-induction were subject to retention time shifting which falsely represented the 
peaks as more acidic protein isoforms (Figure 3.98).  The degree of retention time deviation 
may have been caused by slight fluctuations in system back pressure during early WCX 
separations. The presence of additional noisy peaks between 13.5 and 15.0 min provided 
further evidence that the WCX separations did not provide accurate chromatographic 
representations. The source of the noisy peaks was unknown.   
191 
 
 
Figure 3.98: Comparison of chromatograms produced by WCX separation of N-
terminally His-tagged recombinant lysostaphin (construct 1) performed during early 
culture analysis. WCX separation of cell lysates harvested at 3.0, 4.5, 6.0 and 7.5 h 
post-induction demonstrated detection of noisy peaks and retention time shifting.   
 
Due to the apparent inaccuracy of WCX separation, cell lysates harvested at 3.0, 4.5, 6.0 
and 7.5 h post-induction, were re-applied to the ProPac WCX® (2 x 500 mm) column once 
the final separation had been performed on cell lysate harvested at 30.0 h post-induction 
(Figure 3.99).  The cell lysates were stored at 4°C until analysis could be performed to 
demonstrate that the observed peaks should have displayed retention times that 
corresponded with those detected during WCX separation of cell lysates harvested at 1.5 
and 9.0 h.   
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Figure 3.99: Comparison of chromatograms produced by WCX separation performed 
following re-application of cell lysates analysed during early culture analysis. WCX 
separation of cell lysates harvested at 3.0, 4.5, 6.0 and 7.5 h post-induction 
demonstrated detection of noisy peaks and retention time shifting.   
 
Re-application of cell lysates demonstrated that noisy peaks between 13.5 and 15.0 min 
were not detected during these WCX separations, indicating that their original presence was 
anomalous.  More importantly, repeated separation demonstrated that the peaks detected in 
the cell lysates did indeed display the same retention time as peaks demonstrated in cell 
lysates harvested at 1.5 and 9.0 h post-induction. Due to the delay in re-analysis, the protein 
isoforms appear to have undergone partial degradation evidenced by reduced peak heights 
and the presence of a broad low intensity peak which eluted between 23 and 26 min.  
Degradation of recombinant lysostaphin variants would result in a gradual decrease in the 
charge of the proteolytic fragments, leading to the detection of a broad peak representing an 
extremely heterogeneous mixture of increasingly acidic molecules.  
 
To allow clearer comparison of charge variants and their relative abundance during culture, 
chromatograms produced following re-analysis of cell lysates harvested at 3.0, 4.5, 6.0 and 
7.5 h post-induction were compared against other WCX separations performed on cell 
lysates harvested between 1.5 and 30.0 h post-induction (Figure 3.100).  The compared 
chromatograms revealed a much clearer pattern of charge heterogeneity, which 
demonstrated a clear shift in the relative abundance of the two prominent acidic and basic 
protein isoforms. However due to the reduced peak height of peaks detected during re-
analysis of cell lysates harvested at 3.0, 4.5, 6.0 and 7.5 h post-expression, visualisation of 
the detected protein isoforms was less clear.  
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Figure 3.100: WCX analysis of N-terminally His-tagged recombinant lysostaphin 
(construct 1) over an expression time-course. Cell lysate was harvested from a 1L LB 
culture at regular intervals between 1.5 h and 30.0 h post-induction.  
 
To counteract differences in peak height, the predominant basic peak at 30 min detected 
during separation of cell lysate harvested at 3.0 h post-induction was normalised against the 
same basic peak eluting at approximately 30 min in the rest of the WCX chromatograms. 
Normalisation resulted in better alignment of protein isoform peaks facilitating comparison of 
WCX separations. In addition the development of more acidic peaks could be monitored as 
their presence increased during the course of expression (Figure 3.101).  
 
 
Figure 3.101: Comparison of normalised WCX chromatograms following separation of 
cell lysate containing N-terminally His-tagged recombinant lysostaphin (culture 1) 
during culture analysis. Cell lysate was harvested from a 1L LB culture at regular 
intervals between 1.5 h and 30.0 h post-induction. Separated peaks were normalised 
against the predominant basic peak at 30.25 min 
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To gain enhanced visualisation of charge variants expressed during the early stages of 
recombinant protein expression, selected WCX separations were compared in further detail 
(Figure 3.102).  At 1.5 h post-induction, WCX separation of the harvested cell lysate 
revealed the presence of a single major protein isoform (tR = 30.25) and two minor acidic 
isoforms (tR =28.15 and 29.18).  This result suggested that the major peak reflected the 
presence of N-terminally His-tagged recombinant lysostaphin (construct 1) in the form that E. 
coli preferentially produces upon induction of protein expression.  As the two minor peaks 
demonstrated much lower peak heights, the peaks reflected less abundant protein isoforms 
whose charge was attributable to synthesis by E. coli or post-translational processing or 
modification of one of the other abundant protein isoforms.   
 
 
Figure 3.102: Comparison of WCX separations of cell lysates harvested between 1.5 
and 4.5 h post-induction.  Separated peaks were normalised against the predominant 
basic peak at 30.2 min, indicated by an asterisk. A non-normalised comparative 
chromatogram is presented in Appendix 7.256. 
 
WCX separation of cell lysate harvested at 3.0 and 4.5 h post-induction revealed that the 
major protein isoform (tR = 30.25) at remained detectable, however minor acidic isoforms 
(tR = 28.15, 29.07 and 29.52) were represented by peaks of increasing height. The 
increased charge heterogeneity of the N-terminally His-tagged recombinant lysostaphin 
(construct 1) appeared to suggest increased production of alternative forms of the 
recombinant product, or more probable that the increased culture had allowed more time for 
the original basic protein isoform molecules to become steadily converted to more acidic 
variants through some form of post-translational processing. 
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As the culture progressed, the abundance of the more acidic isoforms rapidly increased, 
creating near equilibrium between the two prominent protein isoforms (Figure 3.103).  
However with time, the height of the peak representing the major acidic protein isoform (tR = 
28.9-29.1) started to increase beyond the height of the peak representing the major basic 
protein isoform (tR = 30.1).  The shift in the prevalence of the more acidic protein isoforms 
probably signified an accumulation of a recombinant lysostaphin variant which was being 
produced in a constitutive manner through post-translational processing.  The peak height of 
the major basic peak also remained high, theoretically due to continued hyper-expression of 
recombinant lysostaphin by E. coli BL21(DE3). 
 
Figure 3.103: Comparison of WCX separations of cell lysates harvested between 6.0 
and 9.0 h post-induction.  Separated peaks were normalised against the predominant 
basic peak at 30.1 min, indicated by an asterisk. A non-normalised comparative 
chromatogram is presented in Appendix 7.257 
 
The major acidic protein isoform remained the most prevalent form of N-terminally His-
tagged recombinant lysostaphin (construct 1) present in cell lysates between 7.5 and 26.5 h 
post-induction.  This extended prevalence is demonstrated in Figure 3.104, indicating that if 
the more basic peak represents a post-translationally processed form of N-terminally His-
tagged recombinant lysostaphin, the modification or structural alteration tends to remain 
consistent over time. It was evident that other minor acidic variants were present, however 
prevalence of these variants remained low, suggesting that these forms of the protein were 
not readily produced through synthesis or post-translational processing. 
  
196 
 
Figure 3.104: Comparison of WCX separations of cell lysates harvested between 10.5 
and 18.0 h post-induction.  Separated peaks were normalised against the predominant 
basic peak at 30.2 min, indicated by an asterisk.  A non-normalised comparative 
chromatogram is presented in Appendix 7.258. 
 
During the final stages of culture analysis, the major acidic protein isoform remained most 
abundant variant present within the analysed cell lysates (Figure 3.105).  WCX separation of 
cell lysate harvested at 26.5 h post-induction revealed the resolution of a shoulder peak (tR 
= 28.53), possibly signifying the emergence of a new acidic protein isoform.  However 
analysis of cell lysate harvested at 30.0 h post-induction suggested that the newly resolved 
acidic variant may have been rapidly converted to the more acidic protein isoform present 
(tR = 28.17). Furthermore, the peak height of even more acidic peak (tR = 26.62) increased 
fairly dramatically.  This peak had previously been observed in low abundance in previous 
WCX separations and was thought to reflect the presence of a degradation product or a 
much more acidic protein isoform.   
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Figure 3.105: Comparison of WCX separations of cell lysates harvested between 19.5 
and 30.0 h post-induction.  Separated peaks were normalised against the predominant 
basic peak at 30.2 min. A non-normalised comparative chromatogram is presented in 
Appendix 7.259. 
 
Further observation of Figure 3.104 indicates a slight issue with normalising peaks during 
comparison of WCX separation following culture analysis.  By normalising peaks detected 
during WCX separation of cell lysate harvested at 30 h post-induction against the basic peak 
detected during a previous WCX separation, the apparent UV trace was increased 
proportionally to values which were in accordance with previous separations.  Whilst this 
manipulation of the UV data allowed better comparison and visualisation of the resolved 
protein isoforms, it however lead to mis-representation of protein expression levels at 30.0 h 
post-induction. When non-normalised chromatograms were compared, it was evident that 
levels of recombinant lysostaphin isoforms within the cell lysate appear to have decreased 
dramatically, suggesting either poor sample loading during chromatography or that cellular 
level of recombinant lysostaphin had decreased due to reduced expression and the 
degradative action of cellular proteases (Figure 3.106). 
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Figure 3.106: Comparison of WCX separations of cell lysates harvested at 26.5 and 
30.0 h post-induction.   
 
Following culture analysis, fractions eluted during WCX separation were analysed by SDS-
PAGE to confirm that the detected peaks represented N-terminally His-tagged recombinant 
lysostaphin (construct 1). Figure 3.107 clearly indicates how a protein with a molecular 
weight of around 29 kDa was detected by SDS-PAGE after analysis of a fraction collected 
following elution of the major basic peak (tR = 30.25).  
 
Figure 3.107: Analysis of cell lysate harvested at 1.5 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma low molecular weight markers; Lane 
2: Fraction 6.     
 
SDS-PAGE of fractions eluted during other WCX separations proved to be more informative 
than initially anticipated due to the resolution of distinct molecular weight isoforms. As shown 
in Figure 3.108, Fraction 3, which was known to contain acidic protein isoforms appeared to 
contain two protein isoforms with distinct differences in molecular weight.  The presence of 
5  10  15  
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two mass distinct isoforms in Fraction 3 was likely to have been attributable to the elution of 
two peaks into the fraction. The other analysed fractions were only found to contain a single 
protein band, indicating that the fraction only contained recombinant lysostaphin molecules 
with very similar mass.    
 
Figure 3.108: Analysis of cell lysate harvested at 3.0 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma low molecular weight markers; Lane 
2: Fraction 3; Lane 3: Fraction 4: Lane 4: Fraction 5.      
 
SDS-PAGE analysis of fractions eluted during the WCX separation of cell lysates harvested 
at other time points also produced duplicate protein bands indicating that the molecular 
weight heterogeneity of expressed N-terminally His-tagged recombinant lysostaphin was 
more complex than anticipated.  WCX separations and corresponding SDS-PAGE analyses 
are presented in Appendix 7.260-Appendix 7.273.  SDS-PAGE analysis demonstrated that 
molecular weight heterogeneity was typically associated with the more acidic protein 
isoforms, however retention time variability and the elution of multiple peaks into single 
fractions did not provide a clear association between each peak and molecular weight 
heterogeneity.  
 
3.5.3.12 Extended investigation of the influence of time upon the charge heterogeneity 
of recombinant lysostaphin 
Despite issues with the presentation of the data, this study provided an excellent insight into 
the changing charge heterogeneity of N-terminally His-tagged recombinant lysostaphin 
(construct 1) over time. Therefore a second extended culture study was performed to act as 
secondary confirmation of these findings, but also to study the increasing heterogeneity of 
recombinant lysostaphin in the later stages of culture beyond 30 h post-induction.  Extended 
culture analysis was important given that the expression of recombinant lysostaphin had 
been shown to occur for as long as 85.5 h after the induction of protein expression by SDS-
5  10  15  
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PAGE analysis (Appendix 7.251). Figure 3.109 demonstrates a slightly more complex 
pattern of charge heterogeneity, nevertheless, it is still possible to see that the formation of 
basic and acidic protein isoforms followed the same pattern as in the previous time-course 
culture experiment.    
 
 
Figure 3.109: WCX analysis of N-terminally His-tagged recombinant lysostaphin 
(construct 1) over an extended culture time-course. Cell lysate was harvested from a 
1L LB culture at regular intervals between 12.0 and 85.5 h post-induction.  
 
As the study involved the analysis of cell lysate extracted at nineteen time points during 
culture, comparison of all of the WCX separations in a single chromatogram was less easy 
to interpret. Therefore Figure 3.110, Figure 3.111, and Figure 3.112 provide evidence of the 
distinct phases of protein isoform formation that were observed during the extended culture 
analysis.  In Figure 3.110, it is evident that between 12.0 and 15.0 h post-induction, the 
major basic protein isoform (tR = 30.1-30.2) was abundantly expressed. This was 
unexpected as the previous study indicated that by 12.0 h post-induction, a more acidic 
protein isoform should have become the most prevelant isoform.  The observed differences 
in protein isoform formation may have been attributable to differences in bacterial growth 
rate during culture, which was found to be much slower during UV spectrophotometric 
monitoring (Appendix 7.248, Appendix 7.249, Appendix 7.250 and Appendix 7.252). 
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Figure 3.110: Comparison of WCX separations of cell lysates harvested between 12.0 
and 15.0 h post-induction.   
 
As the culture progressed, the relative abundance of acidic and basic protein isoforms 
shifted in the same manner as observed in the previous time-course experiment.  WCX 
separation of cell lysate harvested at 22.5 h post-induction demonstrated the presence of 
duplex peak (tR = 28.72-29.04) (Figure 3.111). This was an unusual finding, which due to its 
unique appearance, may have reflected a  temporary transition state that occurred during 
the conversion of a more basic protein isoform to a more acidic one.  By 24.0 h post-
induction, the acidic protein isoform had become the most prevelant protein isoform as 
reflected by a single peak (tR = 28.9-29.1), and continued to remain most prevalant through 
the remainder of culture analysis. 
 
 
Figure 3.111: Comparison of WCX separations of cell lysates harvested between 22.5 
and 37.5 h post-induction.   
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In the latter stages of culture analysis, it became apparent that charge heterogeneity of N-
terminally His-tagged recombinant lysostaphin (construct 1) became more complex (Figure 
3.112). At 40.5 and 46.5 h post-induction, the more acidic major protein isoform (tR = 28.9-
29.1) remained the most prevalent protein isoform. By 48.0 h post-induction the abundance 
of all of the protein isoforms appeared to have dramatically reduced suggesting that the 
expression of recombinant lysostaphin may have reduced.  However the presence of 
multiple, poorly resolved peaks suggested that post-translational processing or modifications 
of N-terminally His-tagged recombinant lysostaphin (construct 1) continued to occur in the 
absence of heterologous expression. By 72.0 and 85.5 h, the harvested cell lysate appeared 
to contain a much reduced concentration of recombinant protein and therefore WCX 
separation could not clearly resolve defined protein isoforms.  It was evident that 
recombinant protein expression must have ceased and that the action of cellular proteases 
had lead to the degradation of protein isoforms at this late stage of culture.  
 
 
Figure 3.112: Comparison of WCX separations of cell lysates harvested between 40.5 
and 85.5 h post-induction.   
 
Following extended culture analysis, selected collected fractions were analysed by SDS-
PAGE to confirm that the detected peaks reflected the presence of a protein with a 
molecular weight which corresponded to the weight of N-terminally His-tagged recombinant 
lysostaphin (construct 1).  As shown in Figure 3.113, the detected peak was found to contain 
a protein with a molecular weight of less than 45 kDa.  SDS-PAGE analysis of fractions 
eluted during other WCX separations performed during culture analysis confirmed that the 
detected protein had a molecular weight of approximately 29 kDa (Appendix 7.274-Appendix 
7.290). Interestingly molecular weight heterogeneity was not evident following SDS-PAGE of 
fractions collected during this extended culture analysis experiment.  
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Figure 3.113: Analysis of cell lysate harvested at 12.0 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Fraction 7: Lane 2: Fraction 8: Lane 3: 
Sigma low molecular weight markers. 
 
3.5.3.13 Rapid analysis of recombinant lysostaphin using a ProPac® MAb SCX (4 x 250 
mm) column 
As the ProPac® MAb column had previously been shown to provide excellent resolution of 
recombinant lysostaphin isoforms within a fairly short separation time (Section 3.3.2.9), the 
column was used to perform rapid culture analysis.  Culture analysis was performed on cell 
lysates, which had previously been analysed using the ProPac® WCX (2 x 500 mm) column 
(Section 3.5.3.11).  Comparison of SCX separations demonstrated that the ProPac® MAb 
SCX column could indeed be used to provide rapid culture analysis during recombinant 
protein expression (Figure 3.114).  
 
Figure 3.114: SCX analysis of N-terminally His-tagged recombinant lysostaphin 
(construct 1) over an expression time-course. Cell lysate was harvested from a 1L LB 
culture at regular intervals between 1.5 h and 30.0 h post-induction.  
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On initial assessment of the compared chromatograms, it appeared that SCX separations 
may not have provided very good resolution of protein isoforms, due to asymmetrical and 
erratic appearance of the eluted peaks.  However further examination of the SCX 
separations revealed that the separations did in fact provide an indication of the greater 
micro-heterogeneity of N-terminally His-tagged recombinant lysostaphin (construct 1).  
Comparison of SCX chromatograms also suggested that the SCX separations were very 
reproducible, demonstrating consistent retention times and peak alignment between 
samples (Figure 3.115).    
 
Figure 3.115: Reproducibility of SCX separations over a expression time-course. Cell 
lysate was harvested from a 1L LB culture at regular intervals between 1.5 h and 30.0 
h post-induction. SCX separations showed a high degree of reproducibility.   
 
During the early stages of culture analysis, SCX analysis demonstrated the same pattern of 
protein isoform formation that was detected by WCX analysis using the ProPac® WCX (2 x 
500 mm) (Figure 3.116). Separation of cell lysate harvested at 1.5 h post-induction resulted 
in the detection of a major peak (tR= 28.48), which harboured a few minor shoulder peaks 
within the peak area. Between 3.0 and 6.0 h post-induction, analysed cell lysate was found 
to contain additional acidic protein isoforms which steadily increased in abundance over 
time.  
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Figure 3.116: Comparison of SCX separations of cell lysates harvested between 1.5 
and 6.0 h post-induction.   
 
SCX analysis of cell lysates harvested between 7.5 and 18.0 h post-induction, demonstrated 
that the observed charge heterogeneity of N-terminally His-tagged recombinant lysostaphin 
(construct 1) remained fairly constant, with only slight alterations in the micro-heterogeneity 
of each eluted peak, observed between samples (Figure 3.117). Comparison of separations 
achieved using the ProPac® MAb SCX (4 x 500 mm) and the ProPac® WCX (2 x 500 mm) 
indicated that both columns detected the presence of both major peaks, however the protein 
micro-heterogeneity within each peak was not readily resolved using the ProPac® WCX (2 x 
500 mm) column.  
 
Figure 3.117: Comparison of SCX separations of cell lysates harvested between 7.5 
and 18.0 h post-induction.   
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In the final stages of culture analysis, the emergence of minor acidic protein isoforms 
became more evident (Figure 3.118).  Overall SCX analysis confirmed earlier results of 
culture analysis observed during WCX analysis, however provided greater resolution of 
protein isoforms present within eluted peaks.  In effect SCX analysis revealed that the 
expression of recombinant lysostaphin leads to the production of a number of protein 
isoforms, which can be separated or resolved on the grounds of major or minor charge 
differences. 
 
Figure 3.118: Comparison of SCX separations of cell lysates harvested between 19.5 
and 30.0 h post-induction.   
  
207 
 
3.5.4 Discussion 
 
Separation and isolation of protein variants often requires the use of several different 
analytical techniques.  The use of multiple chromatographic stages increases overall 
processing time substantially and therefore prohibits real-time analysis of recombinant 
protein heterogeneity.  Development of a rapid, reproducible chromatographic method, 
which could permit separation of protein isoforms and elucidate small changes in protein 
concentration or heterogeneity, was therefore extremely desirable.  This work described the 
development and optimisation of a rapid and reproducible method which demonstrated a 
real-time insight into the transitioning charge heterogeneity of recombinant lysostaphin 
during its culture.   
 
Initial culture analysis was performed using a ProPac® SCX (2 x 250 mm) column, which 
provided resolution of protein isoforms using a rapid separation method.  Single-step 
isolation and purification of recombinant lysostaphin could be achieved readily following the 
application of freshly harvested cell lysate to the SCX column, due to the basicity of the 
recombinant protein.  The ProPac® SCX (2 x 250 mm) column could be used to gain an 
insight into the charge heterogeneity of recombinant lysostaphin over time, as published 
(Appendix 7.291).  In addition to monitoring charge heterogeneity over time, analysis was 
performed on cell lysates resulting from shake-flask cultures in which protein expression had 
been induced at various optical densities. Although culture analysis using the ProPac® SCX 
(2 x 250 mm) column did not really demonstrate any clear patterns of protein variant 
formation, the analysis did indicate that multiple basic and more acidic protein isoforms could 
be detected during culture.  
 
Despite successful culture analysis, the resolution of protein isoforms achieved using the 
ProPac® SCX (2 x 250 mm) was inferior to that achieved using the ProPac® WCX (4 x 500 
mm) column.  As WCX separations performed using the ProPac® WCX (4 x 500 mm) 
column could not provide rapid analysis of recombinant lysostaphin, a ProPac® WCX (2 x 
250 mm) column was acquired specifically for rapid culture analysis.  As it was not possible 
to acquire a second ProPac® WCX (2 x 250 mm) column immediately, initial separations 
were performed using a single WCX column with the intention of optimisation rapid analysis 
conditions.  Comparative separations suggested that the extraction of cell lysate from 25 ml 
of culture could provide sufficient material to achieve detectable peaks during WCX 
separation, without encountering volumetric depletion during culture analysis. WCX 
separations also demonstrated that recombinant lysostaphin derived from cell lysate which 
had been frozen or prepared from frozen cells did not demonstrate the same charge as 
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recombinant lysostaphin isolated from freshly prepared cell lysate, questioning the reliability 
of frozen samples.   
 
Once a second ProPac® WCX (2 x 250 mm) had been acquired, a ProPac® WCX (2 x 500 
mm) column was created and provided reproducible and high-resolution separation of N-
terminally His-tagged recombinant lysostaphin variants. Chromatographic conditions were 
adjusted to accommodate the loading of cell lysate and to ensure that the chromatographic 
separation featured appropriate wash and equilibration phases to reduce the risk of carry-
over and retention time shifting.  Once chromatographic conditions had been optimised, a 
number of studies were performed to provide further insight into the influence of time and 
optical density at the point of induction upon the expression and charge heterogeneity of N-
terminally His-tagged recombinant lysostaphin (construct 1).  Culture analysis using the 
ProPac® WCX (2 x 500 mm) column demonstrated that powerful evaluation of the quality, 
abundance and diversity of the expressed recombinant lysostaphin variants, in a 
reproducible and high through-put manner.   
 
Although enhanced resolution could be achieved using the ProPac® WCX (2 x 500 mm), the 
investigation of the influence of optical density upon the heterogeneity of N-terminally His-
tagged recombinant lysostaphin did not yield a clear correlation between bacterial growth 
phase and presence of particular protein isoforms.  It did however become apparent that the 
heterogeneity of recombinant lysostaphin increased with increased optical density at the 
point of induction.  Greatest heterogeneity appeared to be associated with using standard 
expression conditions, such as following prolonged culture (> 4 h) and induction of protein 
expression at an optical density within the standard range (0D600 nm =0.6-1.0).  This finding 
was particularly concerning given that many recombinant proteins could be produced using 
comparable conditions leading to similar degree of charge heterogeneity.  
 
To minimise the variability of bacterial growth phase that was introduced at each culture 
inoculation, cultures were then directly inoculated from a glycerol stock, however this 
strategy was limited by poor protein expression and therefore could not be implemented in 
further experiments.  Due to the inability to control optical density between batch cultures, 
subsequent rapid analysis experiments were performed on single batch cultures which were 
studied over a time-course.  Time-course culture analysis yielded much more informative 
results, which suggested that the charge heterogeneity of N-terminally His-tagged 
recombinant lysostaphin isoforms transitioned over time leading to the formation of 
increasingly acidic protein isoforms.  
 
209 
 
Although some retention time shifting was observed during culture analysis, normalisation of 
results provided more appropriate comparison of eluted peaks.  Whilst normalisation of 
results facilitated interpretation of detected peaks, it also led to some mis-representation of 
protein isoform abundance in the later stages of analysis. This finding emphasized that the 
culture analysis results should be interpreted carefully and appropriately to provide reliable 
data.  When data normalisation was not applied to the results, it was possible to observe 
reductions in the concentration and abundance of protein isoforms, whilst also giving an 
indication of possible degradation products that may have occurred as the culture 
progressed.  
 
Overall culture analysis performed over time, revealed a time-dependent pattern of charge 
heterogeneity in which certain acidic protein isoforms emerged with time.  This pattern was 
observed again during extended culture analysis of a second culture, providing secondary 
confirmation of a consistent pattern of variant formation. Interestingly protein variant 
formation appeared to occur at a much slower rate in the second culture, possibly due the 
decreased bacterial growth rate which was observed during UV spectrophotometric 
monitoring of growth (Appendix 7.249 and Appendix 7.252).  Further examination of protein 
variant formation is provided in Section 3.6.  
 
SDS-PAGE analysis of protein eluted during culture analysis provided confirmation that a 
protein with a molecular weight of around 29 kDa was isolated during separation, indicating 
that N-terminally His-tagged recombinant lysostaphin (construct 1) had been specifically 
retained and purified. Interestingly SDS-PAGE analysis also indicated that some of the 
eluted peaks contained protein isoforms demonstrating molecular weight heterogeneity. Due 
to the co-elution of peaks into single fractions during collection, it was not possible to 
establish exactly which peaks correlated with the observed molecular weight heterogeneity, 
however it was found to be more readily associated with more acidic protein isoforms.  This 
finding suggested that not all of the recombinant lysostaphin variants could be separated on 
the basis of charge, indicating the need for subsequent analysis by orthogonal 
chromatographic approaches and mass spectrometric analysis.  
 
The greater extent of protein heterogeneity was elucidated further during culture analysis 
performed using the ProPac® MAb SCX (4 x 250 mm) column.  Despite the ProPac® WCX (2 
x 500 mm) column providing good resolution of protein isoforms during analysis of cell 
lysates extracted periodically over a 30 h period, the ProPac® MAb SCX (4 x 250 mm) 
column was found to provide even better resolution of recombinant lysostaphin variants.  
The ProPac® MAb SCX (4 x 250 mm) column provided evidence that the peaks detected 
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during separation using the ProPac® WCX (2 x 500 mm) column were composed of a 
number of protein variants, which explained why molecular weight heterogeneity could be 
observed during the SDS-PAGE analysis of apparently homogeneous peaks.  
 
Overall these rapid analysis experiments demonstrated the importance of extensive culture 
analysis during recombinant protein expression. This work demonstrated that an insight into 
the charge heterogeneity of recombinant lysostaphin could be achieved using a variety of 
analytical cation exchange columns, with varying degrees of peak resolution. Analysis could 
be performed rapidly through optimisation of chromatographic conditions, sample 
preparation and careful selection of column stationary phase and diameter.  As extracted cell 
lysate could not be preserved for delayed analysis, the rapid, immediate separation of 
freshly prepared cell lysate became increasingly important to provide reliable and consistent 
real-time analysis.   
 
Although culture analysis was only performed upon cell lysate harbouring N-terminally His-
tagged recombinant lysostaphin (construct 1), this reproducible method could have been 
applied to the other cytoplasmically expressed recombinant lysostaphin constructs 
(constructs 2 and 3) without any alteration of the optimised conditions.  Furthermore, this 
optimised rapid analysis strategy could be used to analyse other basic recombinant proteins, 
such as recombinant oxidoreductase and recombinant NADPH-dependent 1-acyl 
dihydroxyacetone phosphate reductase (Ayr1p) which also possess the ability to bind to 
cation exchange resins..  
 
This culture analysis strategy could also be applied to the analysis of recombinant 
lysostaphin which had been targeted to the periplasmic space (Constructs 4 and 5).  As 
described in Appendix 7.78, periplasmic extraction of recombinant lysostaphin was achieved 
using a lengthy osmotic shock disruption method, which could be completed in 
approximately 1 h and therefore precluded rapid analysis of periplasmic recombinant 
proteins.  However Dalmora et al, (1997) developed an analytical method for the direct 
analysis of human growth hormone following periplasmic extraction and RP-HPLC (Dalmora 
et al., 1997).  In this method, an optimised osmotic shock extraction strategy was employed, 
permitting periplasmic extraction within 30 min.  It would therefore be possible to perform 
rapid analysis of periplasmically expressed recombinant lysostaphin using an optimised 
osmotic shock extraction method, which involved shorter centrifugation times.  
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3.6 Discussion  
 
In Chapter 3, separation of recombinant lysostaphin preparations demonstrated that the 
recombinant protein was indeed heterogeneous.  As a basic protein, recombinant 
lysostaphin was found to bind to cation exchange resins, which is unusual considering that 
most cellular proteins are anionic.  Greater resolution and separation of protein isoforms 
could be achieved using pellicular rather than monolithic stationary phase resins, and 
therefore ProPac™ IEX were selected in preference over ProSwift™ IEX columns.  The 
most superior resolution of protein isoforms was achieved using a ProPac® MAb SCX 
column, however as this column was only released in the later stages of this research, high-
resolution, reproducible separation was mainly achieved using ProPac® WCX-10 columns.  
 
Protein separation was achieved using several HPLC systems and whilst high quality 
separation of protein isoforms could be achieved using Dionex® DX500 HPLC system, 
greater flexibility and versatility during analysis could be achieved using Ultimate™ 3000 
HPLC systems. The ability to use micro and nano flow rates facilitated rapid analysis using 
narrower bore columns and characterisation using LC/MS, as described in Section 4.4.2. 
Furthermore the ability to fractionate within the autosampler provided greater flexibility during 
fraction collection and provided the opportunity to perform 2D-LC analysis. 2D-LC analysis 
provided further confirmation that CXC was highly selective for recombinant lysostaphin, but 
also indicated that recombinant lysostaphin preparations feature protein isoforms which 
differ in hydrophobicity as well as charge.   
 
Through column selection and optimisation of chromatographic conditions, it became 
apparent that separation of recombinant lysostaphin isoforms would be more complicated 
than expected.  Sample preparation was of critical concern as a significant delay between 
expression and CXC analysis could increase the heterogeneity of the preparation or 
decrease the stability of the protein. The majority of the optimisation experiments were 
performed using purified recombinant lysostaphin which had been purified by a single 
purification technique.  Multi-stage purification of recombinant lysostaphin prior to separation 
was found to be detrimental to peak resolution and therefore was avoided.  The use of 
recombinant lysostaphin which had been derived from a combination of multiple batch 
cultures was also avoided as it became clear that charge heterogeneity could vary from 
batch-to-batch.  
 
Lyophilisation of purified recombinant lysostaphin appeared to diminish protein solubility and 
it was found that sample precipitation interfered with the availability and ability of 
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recombinant lysostaphin to be separated by CXC analysis. However it was found that 
recombinant lysostaphin present within freshly harvested cell lysate could be directly and 
selectively purified and separated by analytical CXC, even in the presence of a milieu of 
contaminating cellular proteins.  This was a critical finding as recombinant lysostaphin could 
now be analysed in its expressed state, whilst eliminating concerns over protein instability or 
the occurrence of chemical modifications, such as oxidation, deamidation or glycation, which 
could potentially occur during purification or storage (Jiang et al., 2009, Mironova et al., 
2001, Mironova et al., 2003, Pikal et al., 1991, Lagerwerf et al., 1996).  
 
Frequent expression of recombinant lysostaphin within E. coli BL21(DE3) provided access to 
reasonable quantities of cell lysate and purified recombinant lysostaphin which facilitated 
optimisation of chromatographic separations.  Optimisation of mobile phase conditions, 
through the implementation of extended elution gradients and pH 8.0 mobile phase buffers 
was found to enhance the resolution and separation of protein isoforms.  In addition, 
optimisation of stationary phase conditions, through extension of column length or reduction 
of column internal diameter also helped to improve the resolution and efficiency of protein 
separation.  Ultimately the selection of column dimensions was determined by the amount of 
protein available and the speed at which separation needed to be achieved.  
 
Separation of protein isoforms present within purified recombinant lysostaphin or cell lysate 
derived from large shake-flask cultures, was readily achieved using the ProPac® WCX-10 (4 
x 500 mm) column. Separations performed using this column provided evidence that greater 
charge heterogeneity was associated with higher incubation temperatures or induction of 
protein expression at higher optical densities. Furthermore the extent of charge 
heterogeneity could be controlled by manipulation of expression and harvest conditions. 
Separation of recombinant oxidoreductase and recombinant NADPH-dependent 1-acyl 
dihydroxyacetone phosphate reductase (Ayr1p) demonstrated that charge heterogeneity 
was not restricted to recombinant lysostaphin, and suggested that a significant number of 
recombinant proteins expressed in E. coli may be subject to post-translational processing or 
modification. This critical finding therefore had wider ramifications for industrial and 
biopharmaceutical production of recombinant proteins in E. coli. 
 
Differences in charge heterogeneity could be observed following multiple separations of 
recombinant lysostaphin and also appeared to be influenced by the choice of expression 
media.  However conclusive arguments about the nature and origin of such charge 
heterogeneity could not be made given that chromatograms and peak elution profiles could 
not often be compared due to frequent adjustment of chromatographic conditions during 
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optimisation of separation.  Furthermore it was not possible to express recombinant 
lysostaphin using E. coli growing at identical growth rates or cell densities, therefore different 
optical densities at the point of inoculation or induction may have contributed to charge 
heterogeneity.  The heterogeneity of recombinant lysostaphin also varied according to the 
duration of culture propagation, which was not controlled during initial separation 
experiments.  
 
The influence of time and optical density upon charge heterogeneity only became apparent 
through rapid analysis of protein isoforms present within cell lysate using the ProPac® WCX-
10 (2 x 500 mm) column and ProPac® MAb SCX-10 (4 x 500 mm) columns.  WCX analysis 
of charge heterogeneity of N-terminally His-tagged recombinant lysostaphin (construct 1) 
expressed within cultures induced at various optical densities did not reveal any clear 
association between bacterial growth and the presence of particular charge variants.  Rapid 
analysis of recombinant lysostaphin harvested from a single culture monitored over time, did 
however reveal a time-dependent pattern of charge heterogeneity, in which particular acidic 
charge variants emerged over time.  Extended culture analysis of a second culture 
demonstrated the same pattern of variant formation, which provided secondary confirmation 
of this phenomenon.  Protein variant formation did however occur at a slower rate in the 
second culture, which may have been attributable to a slower bacterial growth rate, which 
had been observed during spectrophotometric monitoring of growth.  
 
The finding that charge variants emerged in a particular manner during the expression of 
recombinant lysostaphin provided an explanatory mechanism for how acidic and basic 
charge variants were detected during previous CXC separations (Figure 3.120).  The early 
detection of the most basic peak would suggest the expression of the protein in the “native” 
state that E. coli preferentially synthesised1. The emergence of more acidic peaks may have 
reflected conversion of the more basic “native” protein to a more acidic variant through PTM 
or truncation of N- or C-terminal amino acids.  This “conversion” theory was supported by the 
fact that abundance of the acidic variant was found to increase as the abundance of the 
basic variant decreased. 
 
The results of culture analysis would also suggest that the conversion of the basic variant to 
the acidic variant occurred in a constitutive manner, as the abundance of the acidic variant 
                                               
1
  The term “native” could only be used tentatively as it was not known whether the protein eluted within 
the basic peak corresponded with the expected mass or primary sequence of recombinant lysostaphin 
however. 
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appeared to consistently increase over time.  More acidic variants emerged in the later 
stages of culture analysis, however the production of these variants did not appear to be as 
prolific and occurred at a time when the expression of N-terminally His-tagged recombinant 
lysostaphin appeared to have decreased.  This finding would suggest that the most acidic 
peaks may have reflected acidic polypeptides generated through host cell proteolysis of the 
recombinant product.  
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Figure 3.119: Development and detection of charge variants during the expression of 
N-terminally His-tagged recombinant lysostaphin (construct 1). Stages 1-6 represent 
the development of the charge variants observed during culture analysis   
 
Whilst this proposed mechanism of charge variant formation seemed to give the most 
appropriate explanation of peaks detected during culture analysis, it was important to 
remember that this theory was fairly simplistic.  For instance, culture analysis using the 
ProPac® MAb SCX analysis demonstrated that eluted peaks displayed much more micro-
heterogeneity than culture analysis performed using the ProPac® WCX column had 
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suggested.  Therefore this theory does not explain the formation of all charge variants 
produced during the expression of recombinant lysostaphin.  This theory does however give 
a rational explanation as to why abundance of particular charge variants appeared to differ 
so dramatically during separation of recombinant lysostaphin preparations expressed and 
harvested at different times and optical densities.  
 
Assuming that the time-dependent pattern of charge heterogeneity occurred whenever 
recombinant lysostaphin was expressed in E. coli, Figure 3.120 predicts how optical density 
at the point of induction would influence the detection of particular protein isoforms. 
Expression levels of recombinant lysostaphin will have been dependent on cell density at the 
point of induction of protein expression. The high optical density associated with log or 
stationary phase cells will have led to the greatest expression of recombinant lysostaphin 
within a short space of time, whilst less expression of recombinant lysostaphin would be 
produced in lag or death phase cultures. As time progressed, recombinant lysostaphin will 
have been expressed at levels that were determined by transitioning cell growth phase 
physiology. Over time the expressed product will have undergone conversion to a more 
acidic form, with the abundance of the acidic variant dependent on initial expression levels. If 
cell lysate was harvested and analysed after a short period of expression, separation 
chromatograms would only demonstrate high abundance of acidic variants in cultures which 
had been induced at a high optical density.  
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Figure 3.120:  Charge variant formation following induction of recombinant 
lysostaphin expression at different growth phases and short expression duration.  
“Native” basic recombinant lysostaphin variants are denoted in pink, whilst converted 
acidic variants are denoted in green.  
 
If recombinant lysostaphin was harvested after moderate expression duration, lag or log 
phase cultures will have become log and stationary phase cultures, therefore enhancing the 
expression of “native” basic recombinant lysostaphin variants.  Whilst stationary and death 
phase cultures will have started to produce less of the basic recombinant lysostaphin variant.  
Increased production of recombinant lysostaphin would have ultimately lead to much greater 
abundance of the converted acidic variant within the culture at the point of harvest (Figure 
3.121). 
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Figure 3.121: Charge variant formation following induction of recombinant 
lysostaphin expression at different growth phases and moderate expression duration.  
“Native” basic recombinant lysostaphin variants are denoted in pink, whilst converted 
acidic variants are denoted in green.  
 
Analysis of recombinant lysostaphin harvested after a lengthy culture would correspond with 
lower levels of the “native” basic recombinant lysostaphin variant as its expression will have 
diminished in cultures induced at log, stationary or death phase.  However the basic variant 
would have been more abundant in cultures which were induced at lag phase. A longer 
period of expression would have been associated with greater accumulation of the converted 
product, however the accumulation of these recombinant lysostaphin variants will have 
started to diminish in cultures in which expression was induced at stationary or death phase, 
due to host cell stress responses and proteolysis (Gill et al., 2000).    
  
219 
 
 
Figure 3.122: Charge variant formation following induction of recombinant 
lysostaphin expression at different growth phases and long expression duration.  
“Native” basic recombinant lysostaphin variants are denoted in pink, whilst converted 
acidic variants are denoted in green. Proteolysis of variants is denoted by X.  
 
The pattern of charge variant formation observed during analysis could therefore explain the 
variable nature of charge heterogeneity observed during separation of N-terminally His-
tagged recombinant lysostaphin (construct 1) harvested from cultures induced at various 
optical densities.  Further analysis of cultures induced at different optical densities would 
however be desirable to provide further evidence supporting these concepts.  In addition to 
optical density, elevated temperatures during expression would increase the rate at which 
product conversion occurred.  Expression was performed at 20°C during culture analysis, 
therefore reduction of the culture temperature to 16°C would be likely to reduce the rate at 
which post-translational processing or modification occurred.  
 
The differences in protein charge could be attributable to a number of causes, including 
protein aggregation, loss of N-terminal or C-terminal amino acids or PTM of charged 
residues.  Examination of charged residues within the amino acid sequence of recombinant 
lysostaphin would suggest that there are multiple charged residues, which could be modified 
during expression (Figure 3.123). 
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Figure 3.123: Charged amino acid residues within the amino acid sequence of N-
terminally His-tagged recombinant lysostaphin. Some residues are positively 
charged, including lysine (L) and arginine(R), whilst others are negatively charged, 
such as aspartate (D) and glutamate (E).  The imidazole group of histidine (H) is less 
likely to possess a positive charge above pH 6.0 however.  
 
Closer examination of amino acid residues at the N- and C-termini suggests that cleavage of 
the C-terminal lysine16, would reduce the overall charge of the protein leading to detection of 
acidic charge variants.  The amino acids at the N-terminus of the protein do not have 
charged side chain groups therefore cleavage of the first four residues would not influence 
the charge of the protein.  As the imidazole group of histidine has a pKa value of 6.02, 
histidine residues in the N-terminal His-tag sequence would be unlikely to possess a positive 
charge at neutral pH, therefore loss of these histidine residues would not necessarily reduce 
the charge of the protein.  
 
The net charge of recombinant lysostaphin may also be influenced by N-terminal processing 
during translation.  Provided that the N-formyl group of N-formylmethionine has been 
removed by the action of PDF, the N-terminal methionine possesses a positively charged 
free α-amino group at its terminus. Depending on the action of metAPs, recombinant 
lysostaphin may or may not feature an N-terminal methionine residue; however a positive 
charge is likely to become exposed at the free α-amino group of the N-terminal residue.  
Retention of the N-formylmethionine or addition of an N-acetyl, N-methyl, N-gluconoyl or N-
phosphogluconoyl groups would neutralise the positive charge at the N-terminal amino 
group or introduce a negative charge in the case of phosphogluconoylation (Charbaut et al., 
2002).  Any of these N-terminal modifications could therefore explain loss of charge 
associated with acidic recombinant lysostaphin variants.   
 
Side chain modification of any of the charge side chain residues could also lead to the 
formation of acidic recombinant protein variants through chemical or enzymatic reactions.  
As deamidation involves the conversion of neutral asparagine residues to negatively 
charged aspartate residues, this modification could produce acidic variants that would not be 
detectable by PAGE analysis due to the 0.98 Da mass increments that the modification 
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imposes. Glycation can also produce more acidic protein variants by neutralisation of 
positively charged lysine and arginine residues (Luthra and Balasubramanian, 1993). 
Meanwhile oxidation affects most amino acids, though preferentially occurs at aromatic 
amino acid residues, such as tryptophan, histidine, phenylalanine and tyrosine.  Charged 
amino acids such as arginine and lysine can also become oxidated to produce carbonyl 
derivatives, which are known to occur during lipid peroxidation or glycation reactions 
(Requena et al., 2001). Oxidation may therefore neutralise positive charges, producing 
acidic protein variants. 
 
Enzyme-catalysed side chain modifications may have also contributed to the formation of 
acidic protein variants during culture. Acetylation of lysine residues is known to increase the 
net negative charge of a protein (Shaw et al., 2010). When mono- and di-methyl groups are 
transferred to lysine residues these alkyl amines can become protonated. The addition of a 
trimethyl group to lysine is always positively charged however (Gooley and Packer, 1997). 
Therefore depending on protonation state, methylation can also produce acidic variants 
through neutralisation of ε-amino charges or can preserve a positive charge. Often the 
overall charge of an amino acid is typically only altered by around 0.5 pKa units, therefore 
methylation often has a negligible impact upon the isoelectric point of a protein, however 
may alter the hydrophobicity of the protein (Chiang et al., 1996).  Whilst phosphorylation of 
amino acids, such as serine and threonine is known to introduce negative phosphate groups 
to the protein, leading to the development of acidic variants   
 
An additional source of charge variance could be attributable to the presence of apoprotein 
and holoprotein forms of N-terminally His-tagged recombinant lysostaphin (construct 1). It 
would seem likely that a zinc molecule would become integrated into the structure of 
recombinant lysostaphin following expression, however this is not necessarily guaranteed, 
particularly if PTMs or amino acid substitutions inhibit zinc binding (Hann et al., 2006). The 
presence of zinc would augment the charge of recombinant lysostaphin, due to the 
molecule’s 2+ charge state and conversely the apoprotein would have a reduced charge. On 
these grounds it would seem unlikely that the removal of the bound zinc molecule would lead 
to the emergence of more acidic variants over time. However this does not rule out the 
possibility that the presence of an apoprotein form of recombinant lysostaphin could be 
detected as a low abundance acidic peak during CXC separation.  Recombinant lysostaphin, 
as a zinc glycyl-endopeptidase was investigated further in Section 4.1.1.3.  
 
Although protein heterogeneity can be detected using more traditional techniques, such as 
2D-PAGE, these findings demonstrated that rapid analysis is essential to detect the time-
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dependent development of charge heterogeneity within recombinant protein preparations 
expressed in E. coli. Rapid analysis provided an important insight into the transitioning 
charge variants expressed during the production of N-terminally His-tagged recombinant 
lysostaphin (construct 1).  Further rapid analysis experiments would be desirable to establish 
whether the charge heterogeneity of C-terminally His-tagged recombinant lysostaphin 
(construct 3 and 4) and recombinant lysostaphin without His-tags (construct 2 and 5) exhibits 
the same pattern of charge variant formation.  Furthermore rapid analysis of alternative 
cationic recombinant proteins, such as recombinant oxidoreductase and recombinant 
NADPH-dependent 1-acyl dihydroxyacetone phosphate reductase (Ayr1p) would assess 
whether the observed pattern of charge isoform formation occurs upon their culture as well.  
 
Although separation of recombinant lysostaphin provided information about the development 
of charge variants, the exact structure of these variants could only be achieved through 
characterisation of the separated variants.  Characterisation of the structure of recombinant 
lysostaphin variants was essential to provide further understanding of charge variant 
formation.  The elucidation of protein mass and PTM detection could be achieved most 
sensitively using LC-MS analysis (Section 4.4). Characterisation of protein activity, retention 
behaviour and stability could also be achieved through further chromatographic analysis and 
activity assays, as described in Chapter 4.  
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4 Characterisation of Recombinant Lysostaphin  
 
Separation of recombinant lysostaphin demonstrated that the protein preparations displayed 
charge heterogeneity.  Whilst a pattern of charge variant development was identified 
following culture analysis, it was not clear how the charge variants occurred. Therefore a 
number of experiments were performed to investigate the function and biophysical 
characteristics of recombinant lysostaphin, with the hope that the nature and origins of post-
translational processing or modification could be elucidated.  
The functional activity of recombinant lysostaphin was assessed by performing turbidometric 
assays. Evidence of staphylolytic activity was essential to provide additional confirmation 
that the recombinant product displayed the activity associated with native lysostaphin. 
Turbidometric assays were also performed to establish whether separated charge variants 
possessed the desired staphylolytic activity, as the presence of fusion tags, covalent 
attachment of PTMs or C-terminal truncation may have disrupted enzyme activity.  
The biophysical characteristics of recombinant lysostaphin were investigated further through 
the application of a number of chromatographic techniques including GF, IMAC and RP (as 
part of LC-MS analysis).  GF was used to evaluate the stability of recombinant lysostaphin, 
to assess whether aggregated or mis-folded protein species may have contributed to the 
observed charged heterogeneity of recombinant lysostaphin during separation of protein 
isoforms.  IMAC purification was performed to investigate the nickel binding affinity of 
recombinant lysostaphin, after N-terminally His-tagged recombinant lysostaphin (construct  
1) demonstrated unusual retention behaviour whilst establishing the capacity of analytical 
IMAC columns (Section 2.5.3.11). The mass of recombinant lysostaphin isoforms was also 
assessed using high resolution LC-MS analysis. Intact mass measurements were 
determined to establish whether the mass of separated charge variants corresponded with 
the expected mass of recombinant lysostaphin (construct 1).  
Aims:  
 To measure the staphylolytic activity of recombinant lysostaphin preparations and 
separated recombinant lysostaphin charge variants.  
 To assess the stability of recombinant lysostaphin using GF 
 To evaluate the retention behaviour of recombinant lysostaphin during IMAC 
purification. 
 To determine intact mass measurements for separated recombinant lysostaphin 
charge variants using UHR-LC-MS.  
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4.1 Activity of recombinant lysostaphin  
 
4.1.1 Introduction  
 
As described in Section 1.4, Lysostaphin is an extracellular glycylglycine endopeptidase 
which can lyse staphylococcal cells through specific hydrolysis of the pentaglycine cross-
bridges present within peptidoglycan (Heath Farris et al., 2003, Surovtsev et al., 2007).  Cell 
walls of both Gram-positive and negative bacteria feature peptidoglycan as a major 
structural component, as it provides rigidity and strength to protect the cell from osmotic lysis 
and acts as scaffold for cell wall assembly (Grundling and Schneewind, 2006).  The catalytic 
action of lysostaphin therefore leads to cell rupture and loss of the bacterial cell wall 
envelope.  
 
Peptidoglycan is a complex molecule, which has a sugar backbone consisting of N-
acetylglucosamine (NAG) and N-acetyl-muramic acid (NAM) residues that are cross-linked 
with 1,4-glycosidic bonds (Figure 4.1) (Donovan et al., 1996). The D-lactyl moiety of NAM 
residues forms an amide bond linkage with short polypeptides, which are composed of L-and 
D-amino acids (Grundling and Schneewind, 2006). As the C-terminus of the polypeptides is 
typically composed of two D-alanine residues, neighbouring wall peptides become cross-
linked by transpeptidation, which strengthens the bacterial cell wall and generates a 3D 
network of peptidoglycan (Grundling and Schneewind, 2006).  In Gram-negative bacteria 
and some Gram-positive bacteria, such as S. aureus, these cross-links involve the 
incorporation of glycine-rich linker sequences (Bochtler et al., 2004).  
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Figure 4.1: Structure of peptidoglycan in S. aureus. The diagram demonstrates the 
sugar backbone of peptidoglycan and side chain tetrapeptides.  Adjacent wall 
peptides become cross-linked between the ε-amino group of L-Lys and the carboxyl 
group of D-Ala via a pentaglycine cross-linker. Figure taken from Warfield et al (2006).  
 
Specific peptidoglycan hydrolases exist to cleave nearly every amide bond within the 
peptidoglycan structure (Bochtler et al., 2004). These enzymes are typically categorised as 
glycosidases, amidases and endopeptidases (Donovan et al., 1996).  Lysostaphin is 
primarily regarded as a glycyl-glycine endopeptidase, but has also been reported to possess 
β-N-acetyl glucosaminidase and N-acetyl-muramyl-L-alanine amidase activities (Kumar, 
2008, Wadstrøm and Vesterberg, 1971) . The substrate specificities of these functions are 
indicated in Figure 4.2.  Lysostaphin is also reported to catalyse the transpeptidation of 
glycine peptides, therefore may participate in cell wall remodelling (Gargis et al., 2010, 
Surovtsev et al., 2007, Sloan et al., 1977, Park et al., 1995). 
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Figure 4.2: A diagram demonstrating the enzymatic activities of lysostaphin within the 
structure of peptidoglycan. Lysostaphin possesses multiple enzyme activities, acting 
as:1) endo-β-N-acetyl glucosaminidase, 2) N-acetyl-muramyl-L-alanine amidase and 3) 
glycylglycine endopeptidase. The glycylglycine endopeptidase activity leads to 
solubilisation of the pentaglycine bridges. Figure from Kumar, (2008) 
 
4.1.1.1 Staphylolytic activity of lysostaphin 
Much research involving lysostaphin has focused primarily upon the glycyl-glycine 
endopeptidase activity of the protein, which is not functionally unique as other lysostaphin-
type peptidases natively expressed in other Gram-positive bacteria can also specifically 
hydrolyse glycine-rich sequences. Due to their homology of function, glycyl-glycine 
endopeptidase orthologues, such as ALE-1 from S. capitas and LytM from S. aureus also 
share considerable sequence homology with lysostaphin.  Structural and functional analysis 
of these lysostaphin-type peptidases and their catalytic domains has therefore enhanced 
understanding of the mechanisms by which lysostaphin targets and cleaves the cell walls of 
staphylococcal strains.   
 
Mature lysostaphin consists of two domains – a C-terminal cell wall targeting domain (CWT) 
and the catalytic glycyl-glycine endopeptidase domain.  The C-terminal CWT consists of 92 
amino acids, which facilitate rapid pro-enzyme processing and selectively direct the 
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interaction between lysostaphin and the pentaglycine cross-links of peptidoglycan cell walls 
(Figure 4.3) (Climo et al., 1998, DeHart et al., 1995). The selectivity and substrate specificity 
of the CWT domain is critical for the efficacy of lysostaphin as it ensures that the protein can 
discriminate between host and target cells (Wu et al., 2003). This function is essential as S. 
staphylolyticus and S. aureus have a very similar peptidoglycan structure, which suggests 
that the selectivity of the CWT is likely require a complex interaction between the lysostaphin 
and peptidoglycan. 
  
 
Figure 4.3: Amino acid sequence of mature lysostaphin indicating the sequence 
which encodes the cell wall targeting domain (green).  The CWT domain was identified 
based on research described by Baba et al, (1996). 
 
As described in Section 2.3.1, S. staphylolyticus is rendered resistant to lysostaphin through 
co-expression of lysostaphin immunity factor (lif) encoded by an endopeptidase resistance 
gene (epr). Expression of lif results in the incorporation of serine residues into the third and 
fifth positions of each polyglycine cross-bridge (Kiri et al., 2002). As lysostaphin is unable to 
hydrolyse glycyl-serine or seryl-glycine bonds, host cells become resistant to the lytic action 
of the protein (Warfield et al., 2006). Whilst the incorporation of serine residues into cross 
bridges confers resistance to lysostaphin upon S. staphylolyticus, it is also likely that other 
cell wall structural components, such as techoic acids and carbohydrates help the CWT 
domain discriminate between host and target cells (Grundling et al., 2006, Baba and 
Schneewind, 1996).  
Once directed to the staphylococcal cell wall, the catalytic glycyl-glycine endopeptidase 
domain specifically hydrolyses the pentaglycine cross-links of the peptidoglycan, which are 
typically composed of five glycine residues (Heinrich et al., 1987). Specific lysis of 
proliferating or quiescent cells can occur, regardless of cellular metabolic state (Szweda et 
al., 2001, Yang et al., 2007).  Analysis of staphylococcal surface proteins released during 
lysostaphin catalysis has suggested that hydrolytic cleavage occurs specifically between the 
third and fourth N-terminal residues of the pentaglycine cross bridge (Fedorov et al., 2003).  
The catalytic endopeptidase domain is located at the N-terminus of the mature protein 
sequence, as indicated in Figure 4.4.  
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Figure 4.4: Amino acid sequence of mature lysostaphin indicating the sequence 
which encodes the catalytic glycyl-glycine endopeptidase domain (pink) and cell wall 
targeting domain (green).  The CWT domain was identified based on research 
described by Baba et al, (1996) and the catalytic glycyl-glycine endopeptidase domain 
was outlined by Warfield et al (2006). 
 
4.1.1.2 Elastolytic activity of lysostaphin 
Lysostaphin has also been found to exhibit elastolytic activity, by binding to and degrading 
elastin, a major component of the mammalian extracellular matrix.  When cross-linked, 
elastin is an extremely hydrophobic protein that is resistant to proteolysis and degradation. 
Glycine residues constitute one-third of the amino acids in the structure of elastin, which may 
explain the elastolytic activity of lysostaphin on the grounds of the enzyme’s preference for 
glycine-rich sequences (Park et al., 1995). Kinetic studies have indicated that elastolytic 
activity proceeds with relatively slow kinetics, is influenced by pH and can be inhibited by 
zinc chelators (Sugai, 1997, Park et al., 1995).  
 
Studies by Park et al (1995) indicate that elastolytic and staphylolytic activities of the protein 
are dependent on separate distinct binding domains, however both activities are reliant on 
the presence of zinc as lysostaphin is a zinc metalloprotease (Park et al., 1995).  Park et al., 
(1995) proposed that the Ala-Ala-Thr-His-Glu sequence of the mature lysostaphin sequence 
may be a catalytic domain for elastolysis (Figure 4.5). The identification of this sequence 
was based on sequence homology between lysostaphin, bacterial zinc metalloproteins and 
mammalian matrix metalloproteinases (MMPs) which also exhibited the ability to degrade 
elastin.   
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Figure 4.5: Amino acid sequence of mature lysostaphin indicating the Ala-Ala-Thr-His-
Glu sequence, a proposed catalytic site for elastolytic activity (blue).  
 
Further investigation of ionogenic residues within the sequence of lysostaphin indicated that 
the protein active site is likely to contain a glutamate and a histidine residue.  These residues 
are believed to participate in general acid-base catalysis, whilst under the influence of 
environmental pH, regional hydrophobicity and electrostatic effects from proximal residues 
(Surovtsev et al., 2007). Using crystal structure and sequence data from other lysostaphin-
type enzymes, such as LytM, the active site glutamate residue was localised to the 
elastolytic catalytic site proposed by Park et al. (1995) as indicated in Figure 4.6. 
Furthermore Surovtsev et al (2007) proposed that the identified active site could be involved 
in both elastolytic and staphylolytic catalysis (Surovtsev et al., 2007).  
 
  
Figure 4.6: Amino acid sequence of mature lysostaphin indicating the proposed active 
site glutamate and histidine residues (orange). The residues occur within the putative 
elastolytic catalytic site domain (blue) and are thought to participate in general acid-
base catalysis (orange).  
 
4.1.1.3 Lysostaphin as a zinc metalloprotein 
Lysostaphin is known to be a zinc metalloprotease, containing one zinc atom per protein 
molecule (Trayer and Buckley, 1979). Metalloproteins play important roles in biological 
systems and their function and stability is greatly influenced by the metal ion bound within 
the protein structure (Kaltashov et al., 2006).  The metal coordination sites within the protein 
structure can form catalytic, cocatalytic, structural or protein interface zinc binding sites 
(Auld, 2001). Although lysostaphin is widely regarded as a zinc-metalloprotease, the zinc-
binding region of the protein has not been fully elucidated.     
 
Following investigation into the elastolytic properties of lysostaphin, it was speculated that 
the zinc binding domain of lysostaphin could be conferred within or proximal to the Ala-Ala-
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Thr-His-Glu sequence of the protein, as indicated in Figure 4.6 (Park et al., 1995). This 
theory was further supported by the finding that exogenous addition of zinc could inhibit the 
elastolytic activity of lysostaphin. Although the exact mechanism of zinc inhibition is unclear, 
it was thought that the addition of exogenous zinc may have displaced the tightly bound 
endogenous zinc cation, detrimentally influencing the structure of the enzyme and interfering 
with catalytic activity. Furthermore staphylolytic and elastolytic activities are inhibited by zinc 
chelators indicating that the zinc-binding domain is of critical importance during catalytic 
activity (Park et al., 1995).  
 
However the sequence outlined by Park et al (1995) appears to differ from those outlined as 
zinc-binding domains in lysostaphin-type enzymes. Lysostaphin was originally classified as 
an M37 family metalloprotease, but like LytM can also be classified under the M23 peptidase 
family (Bardelang et al., 2009).  Considering the close homology between the sequence of 
lysostaphin and lysostaphin-type peptidases such as LytM, it could be possible that 
lysostaphin harbours the same or a similar series of conserved metal-chelating residues.  
Crystal structures of lysostaphin-type peptidases have therefore provided greater insight into 
the functional and structural domains, which may be responsible for the zinc binding and 
catalytic activity of lysostaphin.  
 
Lysostaphin-type peptidases and D-Ala-D-Ala metallopeptidases are known to possess 
similar active sites and a central zinc cation, which is tetra-coordinated by two histidine 
residues, an aspartate residue and asparagine residue or a water molecule.  These 
conserved ligands occur in the order: histidine, aspartate, histidine and the zinc cation is 
coordinated via the Nε, the Oδ and the Nδ respectively (Bochtler et al., 2004).  Due to the 
sequence homology between lysostaphin and LytM, it is possible that these zinc binding 
domain ligands may be conserved within the structure of lysostaphin.  
 
Should lysostaphin feature the same conserved zinc binding ligands as LytM, then it is likely 
that the zinc binding domain is critical for catalytic activity as postulated by Park et al (1995).   
Histidine, aspartate and glutamate residues bind strongly with zinc and provide coordination 
sites which are available to water or substrate complexes, providing catalytic function (Vallee 
and Auld, 1990). These residues also control local protein folding, structure and 
conformation and therefore influence the mode of action and specificity of catalytic action. 
The presence of a single zinc molecule indicates that the zinc-binding domain is not 
cocatalytic, as cocatalytic sites are composed of several coordinated metal ions (Auld, 2001) 
Structural zinc atoms are coordinated with four cysteine residues to provide high stability. As 
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lysostaphin is cysteine-less protein, the bound zinc is not exclusively responsible for 
structural conformation of the protein (Vallee and Auld, 1990).   
 
4.1.1.4 Activity of recombinant lysostaphin 
As discussed in Section 2.3.1, lysostaphin is inactive or exhibits reduced activity when 
expressed as an unprocessed prepro- or pro-enzyme, therefore it was imperative that 
recombinant lysostaphin was expressed in a mature, active form.  With the help of 
recombinant DNA technology, only the DNA sequence encoding mature lysostaphin was 
cloned and expressed, therefore it was extremely likely that recombinant lysostaphin would 
exhibit the expected staphylolytic activity. To confirm the presence of catalytic activity, an 
assay was developed which would allow fairly rapid identification of enzyme activity.   
 
The staphylolytic activity of lysostaphin has traditionally been assessed using a turbidometric 
assay in which the lysis of staphylococcal cells is monitored spectrophotometrically over a 
fixed time course (Schindler and Schuhardt, 1964). Variation upon this spectrophotometric 
method has led to the development of alternative dye release based monitoring to provide 
greater sensitivity and reproducibility (Zhou et al., 1988).  In recent years, more advanced 
assays have been developed whereby lysostaphin interactions could be examined kinetically 
and thermodynamically (Surovtsev et al., 2007). Furthermore, more sensitive assays in 
which hydrolysis of specific peptide substrates by lysostaphin which can be monitored by 
colorimetry or fluorescence spectrometry (Kline et al., 1994, Warfield et al., 2006).  
 
For the purposes of this work, a simple turbidometric assay was selected to confirm activity 
of recombinant lysostaphin. The assay was developed based on methods described by 
Iversen & Grov, (1973) and Kusuma & Kokai-Kun (2005) (Iversen and Grov, 1973, Kusuma 
and Kokai-Kun, 2005). Once optimised the assay was used to investigate the activity of 
recombinant lysostaphin and achieve a number of research objectives.  
 
Aims:  
 
 To establish a turbidometric assay that could be used to assess the staphylolytic 
activity of recombinant lysostaphin.  
 To assess whether recombinant lysostaphin constructs exhibited staphylolytic 
activity.  
 To evaluate whether staphylolytic activity was influenced by expression media, 
expression location or sample processing and purification.  
232 
 
 To perform turbidometric assay of charge variants separated during WCX analysis.  
 To perform bioinformatics analysis of lysostaphin amino acid sequences to establish 
the location of possible zinc binding residues.   
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4.1.2 Methods 
 
4.1.2.1 Media  
All media compositions are outlined in Appendix 7.292. 
 
4.1.2.2 Buffers 
All buffer compositions are outlined in Appendix 7.293. 
 
4.1.2.3 Bacterial strains  
Staphylococcus aureus subsp. aureus (NCIMB 12703) was grown for harvesting of cells for 
assay of lysostaphin activity.  Cultured S. aureus was stored in 50% (v/v) glycerol at -80C 
and as lenticules stored at -20C.   
 
4.1.2.4 Sample preparation 
Sample preparation is described in Appendix 7.294.  
 
4.1.2.5 Equipment 
All equipment used to assess the activity of recombinant lysostaphin is outlined in Appendix 
7.296. 
 
4.1.2.6 Homology-based identification of consensus zinc binding residues in the 
amino acid sequence of recombinant lysostaphin 
The amino acid sequence of glycyl-glycine endopeptidase LytM from Staphylococcus aureus 
(Q99WV0) was retrieved from the NCBI protein database (Appendix 7.323) and was 
subjected to ClustalW alignment against the mature sequence of recombinant lysostaphin 
without any fusion tags (Appendix 7.322).  ClustalW alignment was developed by the 
European Bioinformatics Institute and was made available at 
http://www.ebi.ac.uk/Tools/msa/clustalw2/.  
 
4.1.2.7 Lysostaphin assay  
S. aureus was cultured and harvested prior to assay, as described in Appendix 7.298 and 
Appendix 7.299 respectively. The protein concentrations of purified recombinant lysostaphin 
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preparations were established using UV spectrophotometry (Appendix 7.23).  Lysostaphin 
enzyme solutions of 2, 4, 6, 8 and 10 g/ml were prepared following dilution with assay 
buffer to give a total volume of 5 ml.  A blank solution (0 g/ml) was also prepared using 5 ml 
of assay buffer. The blank and test solutions were then incubated in a waterbath at 37C for 
at least 5 min prior to performing the assay to allow temperature equilibration. A S. aureus 
cell suspension was then prepared by defrosting harvested S. aureus cells, before diluting 
with assay buffer to give an OD620 nm of 1.3-1.5 when determined spectrophotometrically. 
The spectrometer was zeroed by reading the absorbance of a cuvette containing 1 ml of 
assay buffer at a wavelength of 620 nm.  The assay was performed using a 
spectrophotometer coupled to a waterbath, to ensure that absorbance readings were taken 
at 37C.  Following equilibration, 1 ml of S. aureus suspension was added to each of the 
blank and test solutions at 1 min intervals and mixed by swirling. The absorbance at 620 nm 
at 0 min (T0) was determined for each blank and test solution before incubating for 10 min at 
37C and determining the absorbance again after ten minutes (T10).  
 
4.1.2.8 Assay of recombinant lysostaphin  
Assays were primarily performed to assess the activity of N-terminally His-tagged 
recombinant lysostaphin (construct 1) as this was the most commonly analysed form of the 
protein (Appendix 7.300).  However assays were also performed to assess the influence of 
expression media (Appendix 7.301), expression location (Appendix 7.302), purification 
(Appendix 7.303) and lyophilisation (Appendix 7.304) upon the activity of recombinant 
lysostaphin. Charge variants were also assayed following routine WCX separation (Appendix 
7.305) and following WCX separation during culture analysis (Appendix 7.306).  
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4.1.3 Results  
 
4.1.3.1 Homology-based identification of consensus zinc binding residues in the 
amino acid sequence of recombinant lysostaphin 
According to published literature, the zinc binding domain of lysostaphin had not been fully 
elucidated; however zinc binding residues had been identified from the crystal structure of a 
lysostaphin-type peptidase called LytM (Figure 4.7).  
 
 
Figure 4.7: Amino acid sequence of glycyl-glycine endopeptidase LytM from 
Staphylococcus aureus (Q99WV0).  Consensus zinc binding residues were identified 
from the crystal structure of LytM by Firczuk et al (2005).  Metal chelating residues are 
indicated in red at histidine210, aspartate214 and histidine293.   
 
As the glycyl-glycine endopeptidase LytM shares sequence and functional homology with 
lysostaphin a bioinformatics experiment was performed to establish whether the sequence of 
recombinant lysostaphin harboured the consensus zinc binding residues which had been 
identified in the amino acid sequence of LytM and other lysostaphin-type peptidases.  The 
amino acid sequences of the glycyl-glycine endopeptidase LytM was obtained (Appendix 
7.323) and subjected to ClustalW alignment (Figure 4.8) against the amino acid sequence 
constituting the putative mature enzyme (Appendix 7.322).  
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Figure 4.8: Clustal W Alignment of lysostaphin and LytM (truncated) sequences. 
Consensus zinc binding residues are indicated in red. The alignment suggested that 
the sequences shared homology, with an alignment score of 411 being achieved 
during ClustalW analysis.   
 
Without obtaining the crystal structure of recombinant lysostaphin or performing mass 
spectrometric analysis of the zinc binding residues, it was not possible to provide conclusive 
confirmation that these residues acted as metal chelating residues in recombinant 
lysostaphin, However ClustalW alignment provided an insight into the potential residues 
which may dictate zinc binding within the tertiary structure of recombinant lysostaphin. 
 
4.1.3.2 Growth of S. aureus for turbidometric assay  
Prior to turbidometric assay of staphylolytic activity, S. aureus cells were cultured and 
harvested. To achieve greater cell density, S. aureus cells were harvested at the end of the 
exponential growth phase which was found to occur at an OD600 nm of 0.8 (Figure 4.9). 
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Figure 4.9: Growth of Staphylococcus aureus (NCIMB 12703) in liquid culture at 37°C. 
Bacterial growth in 1 L broth culture was monitored spectrophotometrically for over 
23 h. Acquired spectrophotometric readings are tabulated in Appendix 7.324 
 
4.1.3.3 Assay of staphylolytic activity of recombinant lysostaphin 
Turbidometric assays were performed periodically to assess whether the recombinant 
lysostaphin preparations exhibited the expected staphylolytic activity.  As recombinant 
lysostaphin preparations were primarily used to optimise or perform chromatographic 
separations, assays were not performed on every preparation that was produced.  
Nevertheless every recombinant lysostaphin preparation that was assayed at the correct 
protein concentrations, demonstrated a high level of staphylolytic activity.  Assays were 
primarily performed on recombinant lysostaphin constructs which had undergone intensive 
chromatographic analysis, such as N-terminally His-tagged recombinant lysostaphin 
(construct 1) or to assess other factors, such as expression media, expression location or 
sample processing upon the activity of recombinant lysostaphin preparations.  
 
 
 
 
 
238 
 
4.1.3.4 Assay of N-terminally His-tagged recombinant lysostaphin (construct 1)  
As N-terminally His-tagged recombinant lysostaphin (construct 1) was most commonly 
expressed and analysed during this research, several assays were performed on this form of 
recombinant lysostaphin. Repeated assay of N-terminally His-tagged recombinant 
lysostaphin revealed that the protein possessed staphylolytic activity in all preparations 
(Figure 4.10).  Activity levels in some of the preparations (4, 15 and 17) did however appear 
to be slightly lower than that exhibited by preparation 6 and preparations used in other assay 
experiments.  It was thought that the observed lower activity was due to slight differences in 
the state of staphylococcal cells harvested for the assay.   
 
Figure 4.10: Percentage lysis of S. aureus following turbidometric assay of the 
staphylolytic activity of N-terminally His-tagged recombinant lysostaphin preparations 
(construct 1).  Each recombinant lysostaphin preparation was expressed in E. coli 
BL21(DE3) cultured in AIM. UV spectrometric readings are tabulated in Appendix 
7.325, Appendix 7.326, Appendix 7.327 and Appendix 7.328.  
 
4.1.3.5 Influence of expression media upon the activity of recombinant lysostaphin 
Assays were performed on N-terminally His-tagged recombinant lysostaphin preparations 
(construct 1) which had been derived from E. coli BL21(DE3) which had been cultured in LB 
or AIM.  The choice of LB or AIM as expression media did not appear to have a significant 
influence upon the staphylolytic activity of the N-terminally His-tagged recombinant 
lysostaphin (Figure 4.11).  Both experiments were performed using the same batch of S. 
aureus substrate cells, which was found to maintain consistency between results.  
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Figure 4.11: Percentage lysis of S. aureus following turbidometric assay of the 
staphylolytic activity of N-terminally His-tagged recombinant lysostaphin (construct 1) 
expressed in E. coli BL21(DE3) cultured in LB or AIM.  A) Experiment 1. B) Experiment 
2. UV spectrometric readings are tabulated in Appendix 7.327, Appendix 7.328, 
Appendix 7.329 and Appendix 7.330.  
 
4.1.3.6 Influence of expression location upon the activity of recombinant lysostaphin 
All of the previous assays were performed on recombinant lysostaphin preparations which 
had been expressed in the cytoplasm of E. coli.  Periplasmically expressed C-terminally His-
tagged recombinant lysostaphin (construct 4) also exhibited a high level of staphylolytic 
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activity (Figure 4.12). This result demonstrated that recombinant lysostaphin which had been 
targeted to the periplasm was also active.  
 
 
Figure 4.12: Percentage lysis of S. aureus following turbidometric assay of the 
staphylolytic activity of C-terminally his-tagged recombinant lysostaphin (construct 
4). UV spectrometric readings are tabulated in Appendix 7.331. 
 
4.1.3.7 Influence of purification upon the activity of recombinant lysostaphin 
As described in Chapter 2.5, recombinant lysostaphin could be purified using a number of 
purification techniques.  IMAC and CXC provided fairly rapid purification of recombinant 
lysostaphin, whilst the application of a combination of purification techniques, such as HIC 
and GF took longer to achieve the desired level of purification, which was shown to result in 
sample degradation (Section 2.5.3.3).  It would therefore seem likely that lengthy purification 
of recombinant lysostaphin would lead to degradation and loss of catalytic activity.  However, 
as shown in Figure 4.13, recombinant lysostaphin (construct 3) demonstrated staphylolytic 
activity despite lengthy purification using HIC and GF.   
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Figure 4.13: Percentage lysis of S. aureus following turbidometric assay of the 
staphylolytic activity of C-terminally his-tagged recombinant lysostaphin (construct 
3).  Recombinant lysostaphin preparations were purified by IMAC or HIC and GF. UV 
spectrometric readings are tabulated in Appendix 7.325 and Appendix 7.332.  
 
These experiments also revealed that C-terminally His-tagged recombinant lysostaphin 
(construct 3) also displayed staphylolytic activity (Figure 4.13).  Therefore these results 
indicated that the presence of a C-terminal His-tag sequence did not interfere with catalytic 
activity, despite the sequence being located juxtaposed to the cell wall targeting domain 
sequence.   
 
4.1.3.8 Influence of lyophilisation upon the activity of recombinant lysostaphin  
During large-scale production of N-terminally His-tagged recombinant lysostaphin (construct 
1), IMAC purified protein was dialysed and lyophilised to concentrate the sample.  
Lyophilisation was found to detrimentally affect the solubility of the purified protein, however 
assay of the lyophilised product demonstrated that the protein retained staphylolytic activity 
(Figure 4.14).  
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Figure 4.14: Percentage lysis of S. aureus following turbidometric assay of the 
staphylolytic activity of lyophilised N-terminally His-tagged recombinant lysostaphin 
(construct 1). UV spectrometric readings are tabulated in Appendix 7.334. 
 
4.1.3.9 Assay of charge variants following WCX separation 
To assess whether the activity of recombinant lysostaphin was specific to particular charge 
variants, assays were performed to assess the activity of recombinant lysostaphin variants 
which had been separated by WCX.  Prior to WCX separation, recombinant lysostaphin 
(construct 1) was expressed and purified using IMAC.  Following IMAC, selected fractions 
were rapidly concentrated to permit assay and WCX separation of charge variants (Figure 
4.15). Cell lysates and IMAC fractions were analysed by SDS-PAGE (Appendix 7.319 and 
Appendix 7.321).  
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Figure 4.15: IMAC purification of N-terminally His-tagged recombinant lysostaphin 
(construct 1). Fractions 20-23 were assayed and subjected to WCX separation.  
 
Before WCX separation, the activity of the concentrated, purified recombinant lysostaphin 
was assessed first to ensure that the more complex preparation exhibited activity.  As shown 
in Figure 4.16, the activity of the recombinant lysostaphin preparation generally increased 
with the application of higher protein concentrations. 
 
Figure 4.16: Percentage lysis of S. aureus following turbidometric assay of the 
staphylolytic activity of N-terminally His-tagged recombinant lysostaphin (construct 
1).  
 
Concentrated recombinant lysostaphin was then separated by WCX, which revealed the 
presence of two major peaks (Figure 4.17).    
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Figure 4.17: WCX separation of 0.3 mg of purified N-terminally His-tagged 
recombinant lysostaphin (construct 1).  Fractions 21 and 29 were assayed for activity.  
 
A selected fraction from each of the peaks was desalted and assayed for activity.  Due to 
limited protein concentrations it was not possible to perform assays using the full range of 
recombinant lysostaphin concentrations.  However the performed assays demonstrated that 
the protein contained in both fractions exhibited staphylolytic activity (Figure 4.18).  
 
Figure 4.18: Percentage lysis of S. aureus following turbidometric assay of the 
staphylolytic activity of N-terminally His-tagged recombinant lysostaphin (construct 1) 
separated by WCX. UV spectrometric readings are tabulated in Appendix 7.336 and 
Appendix 7.337 
 
To provide further confirmation of these results, an additional WCX separation was 
performed after applying a higher concentration of recombinant lysostaphin to the column. 
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WCX separation resulted in separation of much higher quantities of charge variants (Figure 
4.19).   
 
 
Figure 4.19: WCX separation of 2.1 mg of purified N-terminally His-tagged 
recombinant lysostaphin (construct 1).  Fractions 19 and 26 were assayed for activity. 
 
Selected fractions were desalted and assayed over the full range of recombinant lysostaphin 
concentrations (Figure 4.20).  Assay of WCX separated protein peaks demonstrated that the 
charge variants that eluted within both peaks exhibited high levels of staphylolytic activity.  
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Figure 4.20: Percentage lysis of S. aureus following turbidometric assay of the 
staphylolytic activity of N-terminally His-tagged recombinant lysostaphin (construct 1) 
separated by WCX. UV spectrometric readings are tabulated in Appendix 7.338 and 
Appendix 7.339. 
 
4.1.3.10 Assay of charge variants following WCX separation during culture analysis 
Following extended culture analysis (Section 3.5.3.12) selected fractions were desalted, 
concentrated and assayed for activity.  In the majority of cases, the selected fractions only 
contained enough protein to allow assay of activity at low recombinant lysostaphin 
concentrations (0.4 µg/ml) and consequently activity was not noticeably observed (data not 
shown).  However noticeable activity could be observed in one of the fractions assayed 
following WCX separation of cell lysate harvested during culture analysis (Figure 4.21).    
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Figure 4.21: WCX separation of N-terminally His-tagged recombinant lysostaphin 
(construct 1) harvested at 15.0 h post-induction during extended culture analysis.  
Fraction 8 was assayed for activity. 
 
Low level staphylolytic activity was observed in the presence of a low concentration of 
recombinant lysostaphin (0.4 µg/ml) (Figure 4.22).  This result indicated that protein 
concentrations obtained during culture analysis were not sufficient enough to provide 
conclusive evidence of staphylolytic activity.  Confirmatory evidence of activity could only be 
obtained by increasing cell lysate concentrations during culture analysis, which was not 
feasible as the culture was being subjected to frequent sampling over an extended period of 
time.  
 
Figure 4.22: Percentage lysis of S. aureus following turbidometric assay of the 
staphylolytic activity of N-terminally His-tagged recombinant lysostaphin (construct 1) 
separated by WCX analysis. UV spectrometric readings are tabulated in Appendix 
7.340. 
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4.1.4 Discussion  
 
Bioinformatics comparison of the amino acid sequences composing recombinant lysostaphin 
and a lysostaphin-type peptidase, LytM, revealed that the amino acid sequence of 
recombinant lysostaphin contains the same amino acid residues that compose the zinc 
binding domain of LytM. ClustalW analysis identified these residues as being histidine210, 
aspartate214 and histidine293,
 which along with a water molecule, tetrahedrally coordinate with 
zinc (Figure 4.23).  This triad of amino acid residues indicates that the bound zinc is 
intended for catalytic rather than structural purposes. As zinc cannot participate in redox 
reactions, it can function as a Lewis acid-type catalyst,  therefore facilitates proteolytic action 
(Christianson and Alexander, 1989, McCall et al., 2000). Furthermore these residues 
modulate the nucleophilicity of the zinc bound water, whilst promoting zinc ion complexation 
(Christianson and Alexander, 1989).   
 
 
Figure 4.23: Tetrahedral coordination of zinc within the structure of recombinant 
lysostaphin. Histidine210, aspartate214 and histidine293and H2O are known to 
tetrahedrally coordinate with zinc.  Aspartate can form ligands with zinc in: A) 
monodentate mode or B) bidentate mode. Chemical structures drawn using 
ChemDraw Std 12. 
 
As zinc binding is highly involved in the staphylolytic and elastolytic activity of recombinant 
lysostaphin, the observed staphylolytic activity of the enzyme indicated that the protein 
structure did indeed feature the presence of a zinc cofactor (Park et al., 1995). To assess 
the enzymatic activity of recombinant lysostaphin, a turbidometric assay was developed to 
evaluate the staphylolytic activity of the protein. An appropriate strain of S. aureus was 
acquired and cultured to achieve substrate cells for the assay.  Lysostaphin is known to lyse 
staphylococcal cells regardless of their growth state, though S. aureus was harvested at the 
late exponential growth phase prior to turbidometric assay to provide high cell density and 
experimental consistency (Yang et al., 2007). Despite attempting to eliminate assay 
2+ 2+ 
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inconsistencies, slight variations in cellular growth state did appear to interfere with observed 
activity levels however.   
 
Assay of N-terminally His-tagged recombinant lysostaphin (construct 1) and C-terminally 
His-tagged recombinant lysostaphin (construct 3 and 4) verified that both forms of the 
protein possessed staphylolytic activity despite the addition of a fusion tag.  Staphylolytic 
activity of C-terminally His-tagged recombinant lysostaphin was particularly encouraging 
considering that the cell wall targeting domain of the protein was located adjacent to the C-
terminal His-tag sequence, and therefore the fusion tag sequence could have interfered with 
enzyme activity.  Furthermore, the activity of recombinant lysostaphin did not appear to be 
influenced by the choice of expression media or expression location, following targeting of 
the protein to the periplasm.  
 
Sample processing also did not appear to influence staphylolytic activity, with C-terminally 
His-tagged recombinant lysostaphin (construct 3) remaining active despite being purified by 
HIC and GF over an extended period of time.  Extended sample handling and purification 
was found to decrease the stability of the protein (Section 2.5.3.3), however the staphylolytic 
activity of the protein appeared to remain intact.  Lyophilisation of recombinant lysostaphin 
(construct 1) also did not appear to affect staphylolytic activity even though the solubility of 
the purified protein was adversely affected.  
  
The majority of assays were performed using recombinant lysostaphin preparations which 
had been purified but not separated and therefore were likely to be composed of a variety of 
charge isoforms. Turbidometric assays were therefore performed on protein which had been 
separated as distinct charge variants during WCX separation, to establish whether 
staphylolytic activity was exclusive to specific charge variants.  Due to differences in protein 
abundance and concentration, it was not possible to obtain comprehensive assay results 
initially, however once sample protein concentrations were increased prior to WCX 
separation; it was possible to obtain evidence that the eluted charge-distinct variants 
demonstrated staphylolytic activity. This finding confirmed that the absence or presence of 
zinc was unlikely to have led to the formation of the most predominant charge variants.  
 
Evidence of the staphylolytic activity of distinct charge variants suggested that post-
translational processing or modification of N-terminally His-tagged recombinant lysostaphin 
(construct 1) did not interfere with the activity of the protein isoforms.  It is therefore likely 
that any potential modifications or proteolytic events did not occur within regions of the 
recombinant lysostaphin amino acid sequence that encoded enzymatic activity.  However 
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high-resolution separation of charge variants using the ProPac® MAb SCX column (Section 
3.5.3.13) suggested that peaks resolved during WCX separation may be more 
heterogeneous than expected. Therefore assay of apparently homogeneous protein eluted 
during WCX separation may not have represented the activity of all protein isoforms present 
within the sample.   
 
Furthermore analysing the activity of charge variants which had been separated following 
IMAC purification may have not provided the complete representation of product 
heterogeneity. For instance, protein binding affinity during IMAC purification was questioned 
following unusual retention behaviour, as reported in Section 2.5.4.  Further investigation of 
N-terminal His-tag heterogeneity and retention behaviour was described in Section 4.2 and 
indicated that the charge heterogeneity of recombinant lysostaphin may lead to inefficient 
purification of particular charge isoforms and therefore the purified recombinant lysostaphin 
preparation may not have contained all of the expressed charge isoforms.  Certain charge 
isoforms may also not have been separated and assayed due to only pooling and 
concentrating a few of the peak fractions that eluted during IMAC purification.   
 
More reliable purification of charge isoforms could therefore be achieved using CXC 
separation, as was performed during culture analysis. Unfortunately evidence of staphylolytic 
activity of charge variants separated during culture analysis was not really possible due to 
the availability of limited protein concentrations. Staphylolytic activity could only be 
determined conclusively using higher protein concentrations (0.8-2.0 µg/ml), however such 
protein concentrations could not be achieved without increasing the concentration of cell 
lysate applied during WCX separation, which was not feasible due to the frequency of 
sampling during culture analysis. Furthermore differences in relative abundance of different 
protein isoforms over time also limited the availability of adequate protein concentrations of 
less abundant isoforms.  The implementation of a more sensitive assay technique would 
therefore be required to monitor enzyme activity during culture analysis.  
 
The use of a turbidometric assay provided convenient, economical and fairly rapid 
assessment of staphylolytic activity, however the application of more sophisticated assay 
techniques would have provided a greater insight into enzyme kinetics during activity.  A 
more sensitive assay was developed by Warfield et al, (2006) who synthesised internally 
quenched substrates which could be quantitated using fluorescence resonance energy 
transfer (FRET) assays, whereby substrate cleavage leads to an increase in detected 
fluorescence (Warfield et al., 2006, Bardelang et al., 2009).  In addition to providing more 
sensitive detection of staphylolytic activity, monitoring the cleavage of specific synthesised 
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substrates eliminates variability associated with the use of S. aureus cells, which may differ 
slightly in their growth phase physiology.  
 
Overall these experiments provided confirmation that recombinant lysostaphin exhibited the 
expected staphylolytic activity. Further assays of other recombinant lysostaphin constructs 
(constructs 2 and 5) would have been desirable to provide greater insight into the influence 
of protein structure upon enzyme activity.  Assay of separated charge variants also indicated 
that potential post-translational processing or modification of recombinant lysostaphin does 
not appear to adversely affect staphylolytic activity. However further investigation of the 
activity of charge variants separated using the higher resolution ProPac® MAb SCX column, 
using a more sensitive assay, would provide further insight into the influence of culture 
conditions upon the staphylolytic activity of recombinant lysostaphin.  Although the elastolytic 
activity of recombinant lysostaphin was not investigated in these experiments, evidence of 
elastolytic activity was observed during experiments performed during related work, following 
tryptic digestion of N-terminally His-tagged recombinant lysostaphin (construct 1) (Appendix 
7.341, associated data not shown). 
 
 
  
252 
 
4.2 IMAC analysis of recombinant lysostaphin 
 
4.2.1 Introduction  
IMAC is a highly selective purification technique, which can purify recombinant proteins to an 
extremely high degree. This selectivity is based upon specific metal affinity between 
immobilised metal ions and an oligohistidine affinity tag. Initial developments in metal affinity 
tag engineering involved attaching proteins to either very short tags, such as HisTrp or long 
extensions featuring up to 8 repeats of the peptide Ala-His-Gly-His-Arg-Pro (Gaberc-Porekar 
and Menart, 2001).  Hochuli et al then engineered recombinant proteins with oligohistidine 
His-tags consisting of five or six consecutive histidine residues, which were efficiently 
purified in combination with a nitriloacetic acid-nickel(II) (NTA-Ni(II)) matrix (Hochuli et al., 
1988). NTA-Ni(II) matrices selectively bind adjacent histidine residues, therefore this type of 
matrix is now commonly used for His-tag purification.  Penta-histidine and hexa-histidine 
tags provide high selectivity as the majority of natively expressed proteins do not harbour 
oligohistidine sequences and therefore the tags have become extremely popular (Knecht et 
al., 2009).    
The exact interaction mechanisms involved in binding of metal ions and oligohistidine His-
tags are not known at present.  Several reports suggest that protein binding involves a 
cooperative mechanism in which multipoint interactions between the proteins and the 
immobilised metal ions.  The work of Knecht et al, indicated that the histidine residues in an 
oligohistidine tag each offer varying contributions to the overall binding. It is thought that 
binding commences after a monovalent interaction is established.  Due to the vicinal 
presence of additional imidazole groups, a secondary ligand binds to the metal ion, creating 
multiple divalent interactions prior to elution (Figure 4.24).  More specifically, Knecht et al 
reported that the 1st and 3rd or the 1st and 6th histidine residues provide a greater 
contribution to divalent interactions than the 2nd, 4th and 6th residues do (Figure 4.25) (Knecht 
et al., 2009).     
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Figure 4.24: Representation of binding process involved in protein retention during 
IMAC purification using a Ni2+-NTA support, as proposed by Knecht et al (2008). The 
recombinant protein is applied to the column and the hexa-histidine tag sequence 
comes within proximity of the bound nickel ion (A). The His-tag sequence makes 
contact with the nickel via a monovalent interaction (B). Due to a high local ligand 
concentration, a second imidazole forms a divalent complex with the nickel (C). The 
His-tag sequence undergoes consecutive dissociation and reassociation of imidazole 
groups (D and E).  Upon the application of elution buffer, divalent interactions become 
monovalent (F) until the His-tag dissociates fully from the nickel ion (G).  Figure 
adapted from Knecht et al (2008). 
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Figure 4.25: Proposed divalent binding interactions between a His-tag sequence and 
immobilised nickel ions on an NTA matrix.  Knecht et al, (2008) reported that A) the 
first and third histidine residues and B) the first and sixth histidine residues provide a 
greater contribution to protein binding than the other histidine residues in the 
hexahistidine sequence.  Figure adapted from Knecht et al, (2008). 
 
The influence of His-tags upon catalytic activity may reflect altered protein folding kinetics.  
The presence of a His-tag sequence may affect the solubility, oligomerization or aggregation 
state of the protein and therefore alter active site conformation, which could detrimentally 
influence enzyme kinetics (Narmandakh and Bearne, 2010). Changes in protein 
conformation, due to the presence of His-tags may also adversely affect protein retention 
during IMAC.  For instance, the His-tag sequence may become inaccessible due to steric 
hindrance caused by inappropriate protein folding and therefore lead to poor retention during 
purification (Knecht et al., 2009).  Furthermore differences in protein folding may lead to 
variable metal affinities, depending on whether single or multiple histidyl residues are 
accessible on the protein surface or protein interior. Histidine residues are mildly 
hydrophobic therefore only a few histidine residues tend to be located on the surface of the 
protein (Gaberc-Porekar and Menart, 2001). Binding affinity is also influenced by the spatial 
distribution of the histidyl residues and how distant or vicinal to each other they are (Hemdan 
et al., 1989, Ueda et al., 2003).  
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If a His-tag is concealed at the N- or C-terminus of a protein, then altering the position of the 
His-tag to the opposite terminus of the protein may improve His-tag accessibility and restore 
correct folding and activity (Lee and Kim, 2009).  The position of the oligohistidine tag 
sequence can be important, as incorrect positioning of the tag may allow effective 
purification, but could prevent appropriate processing of the protein (Ueda et al., 2003).  For 
instance, the addition of a C-terminal His-tag to a recombinant β-lactamase altered the N-
terminal sequence due to interfering with the action of a signal peptidase (Ledent et al., 
1997).  Alternatively the presence of an N-terminal His-tag may interfere with protein 
synthesis, leading to premature termination and truncation of the expressed recombinant 
protein, increasing product heterogeneity.  Conversely the insertion of an N-terminal His-tag 
may stabilise the N-terminus of the protein and reduce the rate of protein turnover and 
heterogeneity (Ueda et al., 2003).  
 
Recombinant protein heterogeneity can also be increased by the presence of PTMs, which 
are known to occur within the His-tag region of the protein sequence (Table 4.1). To date 
numerous studies have demonstrated that the amino terminus of the protein can undergo α-
N-6 gluconoylation or α-N-6 phosphogluconoylation, following the addition of a gluconic acid 
or a phosphosphogluconic acid molecule (Du et al., 2005a, Yan et al., 1999a, Yan et al., 
1999b, Geoghegan et al., 1999, Kim et al., 2001, Du et al., 2005b).  Alternatively serine 
residues within the His-tag sequence can undergo phosphorylation (Du et al., 2005a, Du et 
al., 2005b, She et al., 2010).  Multiple phosphorylations may occur within the His-tag region, 
if the His-tag sequence features several serine residues.   
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Table 4.1: Modifications occurring at the N-terminal His-tag sequences of recombinant 
proteins. 
Protein Tag Sequence Modifications Observed  Reference 
FK506-binding 
protein (FKBP) 
GHHHHHHHHHHSSGHIEGR 1 α-N-6 gluconoylation Yan et al, 
1999(a) 
Spo0F GHHHHHHHHHHSSGHIEGR 1 α-N-6 gluconoylation  Yan et al, 
1999(a) 
FK506- binding 
protein (FKBP) 
GHHHHHHHHHHSGHIEGR 1 α-N-6 gluconoylation Yan et al, 
1999(b) 
G-protein-
coupled 
receptor kinase 
2 (GRK-2) 
GSSHHHHHHSSGLVPRGSHM 
 
1 α-N-6 gluconoylation  
1 α-N-6 phosphogluconoylation 
Geoghegan 
et al, 1999 
C-terminal SH2 
domain of p85α 
(C-p85) 
GSSHHHHHH 1 α-N-6 gluconoylation  
1 α-N-6 phosphogluconoylation  
Geoghegan 
et al, 1999 
C-terminal SH2 
domain of 
human ZAP-70  
(C-ZAP) 
GSSHHHHHHSSGLVPRGSHM 1 α-N-6 gluconoylation 
1 α-N-6 phosphogluconoylation  
Geoghegan 
et al, 1999 
Src tyrosine 
kinase (SH3 
domain) 
GSSHHHHHH 1 α-N-6  gluconoylation  Kim et al, 
2001 
Aurora 2 
catalytic domain 
GSSHHHHHHSSGLVPRGSHMK 1-5 phosphorylations on Ser Du et al, 
2005(a) 
Aurora A 
catalytic domain 
GSSHHHHHHSSGLVPRGSH 1-5 phosphorylations on Ser Du et al, 
2005(b) 
PAK1 catalytic 
domain  
GSSHHHHHHSSGLVPR 1-4 phosphorylations on Ser Du et al, 
2005(b) 
PAK7 catalytic 
domain 
GSSHHHHHHSSGLVPR 1-2 phosphorylations on Ser  
1 α-N-6 gluconoylation  
Du et al, 
2005(b) 
PKA catalytic 
subunit 
GSSHHHHHHSSGLVORGSH 1-5 phosphorylations on Ser Du et al, 
2005(b) 
NE2398 CBS 
domain 
GSSHHHHHHSSGRENLYFQGH 1 phosphorylation on Ser She et al, 
2010 
RPA3416 CBS 
domain 
GSSHHHHHHSSGRENLYFQG 1 phosphorylation on Ser She et al, 
2010 
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Table 4.1: Modifications occurring at the N-terminal His-tag sequences of recombinant 
proteins (continued) 
 
Protein Tag Sequence Modifications Observed  Reference 
PH0267 CBS 
domain 
GSSHHHHHHSSGRENLYFQG 1 phosphorylation on Ser She et al, 
2010 
Atu1752 CBS 
domain 
GSSHHHHHHSSGRENLYFQG 1 phosphorylation on Ser She et al, 
2010 
AF0847 CBS 
domain 
GSSHHHHHHSSGRENLYFQG 1 phosphorylation on Ser She et al, 
2010 
TV1335 CBS 
domain 
GSSHHHHHHSSGRENLYFQGH 1 phosphorylation on Ser She et al, 
2010 
MJ0653 CBS 
domain 
GSSHHHHHHSSGRENLYFQGH 1 phosphorylation on Ser She et al, 
2010 
SF0624 non-
CBS domain 
GSSHHHHHHSSGRENLYFQG None She et al, 
2010 
Altronate 
hydrolase SAF 
domain  
GSSHHHHHHSSGRENLYFQG None She et al, 
2010 
Transcriptional 
regulator 
GSSHHHHHHSSGRENLYFQG None She et al, 
2010 
 
Modifications of these charged groups should theoretically alter the thermodynamic and 
kinetic behaviour of the His-tag sequence and therefore also that of the recombinant protein. 
The addition of such a modification may lead to steric hindrance and protein misfolding, 
which could interfere with purification or enzyme activity. Most importantly the addition of 
phosphate groups on serine residues or gluconic acid at the N-terminus will interfere with the 
metal binding affinity of these ligands, but may also prevent adjacent histidine residues from 
participating in metal binding.  In view of all these complications, it is essential that the 
retention behaviour of each recombinant protein should be investigated to establish if there 
are any factors which could interfere with IMAC purification.  
 
4.2.1.1 Recombinant lysostaphin and N-terminal His-tag heterogeneity 
As described in Chapter 2.4, recombinant lysostaphin was expressed with either no His-tag 
sequence or with an N- or C-terminal His-tag.  The lysostaphin gene was cloned into pET 
expression system vectors, pET-28a and pET-22b vectors which encode particular fusion 
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tag sequences that can be engineered into a recombinant protein through careful selection 
of restriction enzymes during cloning.  The pET-28a vector encodes an N-terminal His-tag, 
whilst the pET-22b vector sequence encodes a C-terminal His-tag sequence (Sommer et al., 
2004). The N-terminal His-tag sequence is followed by a thrombin cleavage site, which 
facilitates enzymatic removal of the tag. Proteases can however be expensive and do not 
necessarily provide complete cleavage of the recombinant product.  
Fusion tags can also be unexpectedly cleaved by host-cell proteases following expression, 
which has the potential to interfere with subsequent purification (LaVallie and McCoy, 1995). 
Random cleavage of His-tag sequences by proteases can also increase the heterogeneity of 
a protein preparation, as well as altering protein charge and behaviour (Mohanty and 
Wiener, 2004).  In Section 2.5.3, recombinant lysostaphin was successfully purified from 
harvested cell lysate using either a Chelating Sepharose™ Fast Flow column or ProPac® 
IMAC-10 column. The successful purification of recombinant lysostaphin indicated that the 
His-tag sequences remained intact; therefore it was unlikely that the entire His-tag sequence 
had been lost through unexpected cleavage by host-cell proteases. 
Following purification, recombinant lysostaphin (constructs 1 and 3) were assayed for activity 
and both preparations were found to exhibit staphylolytic activity.  These results indicated 
that the presence of a N-or C-terminal His-tag did not appear to interfere with the activity of 
either preparation. Furthermore, the location of the His-tag sequence did not appear to 
interfere with expression yields and therefore reasonable amounts of recombinant 
lysostaphin could be purified during IMAC purification. The amount of protein that could be 
purified using IMAC, was largely dependent on expression media volume and column 
diameter.  Typically 5-20 mg of fusion protein is yielded per litre of LB culture and purity of 
over 90% can be obtained (Shih et al., 2002). 
ProPac® IMAC-10 columns were found to provide a higher degree of purification and more 
rapid separation of recombinant lysostaphin than Chelating Sepharose™ Fast Flow 
columns, however the capacity of the columns was initially unknown. Whilst testing the 
capacity of ProPac® IMAC-10 columns, it became apparent that some of the 
chromatographic peaks obtained during IMAC separation, were subject to severe retention 
time shifting.  Although retention time shifting may arise due variation in mobile phase pH or 
ionic strength, it was thought that the apparent shifting may have been explained by another 
reason, such as N-terminal His-tag heterogeneity or protein aggregation.  
To investigate this finding further, comparative IMAC purifications of N-terminally His-tagged 
recombinant lysostaphin (construct 1), recombinant lysostaphin without any His-tags 
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(construct 2) and C-terminally His-tagged recombinant lysostaphin (construct 3) were 
performed using a ProPac® IMAC-10 (4 x 250 mm) column. Even though construct 2 did not 
feature a His-tag sequence, cell lysate was subjected to IMAC purification to establish 
whether recombinant lysostaphin could demonstrate inherent metal affinity during IMAC.  It 
is known that the sequence of lysostaphin possesses metal affinity for zinc, which like nickel 
is an intermediate Lewis acid.  Therefore theoretically the expressed recombinant 
lysostaphin should bind zinc following expression, preventing the metal binding ligands from 
binding to stationary phase nickel ions. However it has been found that the bound zinc metal 
may become displaced by stationary phase nickel ions during IMAC, leading to a reduction 
in the activity of recombinant lysostaphin (Warfield, 2006).   
Evidently the presence of N- and C-terminal hexahistidine tags within the sequence of 
recombinant lysostaphin provides metal affinity permitting IMAC purification of the protein.  
Histidine residues exhibit the strongest interaction with immobilised metal ions, as electron 
donor groups within the imidazole ring act as electron donor groups and form coordination 
bonds with the transition metal (Terpe, 2003, Sundberg and Martin, 1974).  Even in the 
absence of His-tag sequences, the amino acid sequence of recombinant lysostaphin is not 
completely devoid of putative electron donor histidine residues. As shown in Figure 4.26, 
construct 2 features nine histidine residues, which will display an affinity for transition metal 
ions.  It is therefore likely that some of the histidine residues within the sequence of mature 
lysostaphin would be exposed on the surface of the molecule and therefore could contribute 
to the metal affinity of the molecule.  
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Figure 4.26: Comparison of amino acid sequences encoding 1) N-terminally His-
tagged recombinant lysostaphin (construct 1), 2) recombinant lysostaphin (construct 
2) and 3) C-terminally His-tagged recombinant lysostaphin (construct 3).  The amino 
acid sequence of construct 1 features 16 histidine residues, which encompass 6% of 
the entire amino sequence.  Construct 2 contains 9 histidine residues, whilst 
construct 3 has 15 residues, encompassing 3.6 and 5.9 % of the amino acid sequence 
respectively. His-tag residues are indicated in red, apart from histidine residues which 
are indicated in light blue. Serine residues present within the N-terminal His-tag of 
construct 1, which may be susceptible to phosphorylation are indicated in dark blue.  
Assuming that the N-terminal methionine residues are removed following expression, 
the N-terminal glycine residue of construct 1 or the N-terminal alanine residues of 
construct 2 and 3 may be susceptible to gluconoylation or phosphogluconoylation. 
These N-terminal residues are indicated in green. 
 
The presence of single histidine residues exhibiting metal affinity within the sequence of 
recombinant lysostaphin, may however not guarantee protein retention.  This is because 
bound nickel ions often require two or more adjacent histidine residues for retention, whilst 
copper ions can provide retention of single histidine residues (Gaberc-Porekar and Menart, 
2001, Hemdan et al., 1989). Protein retention may however be achieved when the histidine 
residues are adjacent to other amino acids displaying metal affinity, such as the thiol group 
of cysteine and other residues, which display some degree of metal affinity (Table 4.2).  
Recombinant lysostaphin does not contain any cysteine residues, however the histidine 
residues are vicinal to residues which may work in combination to provide mild protein 
retention during IMAC (Ueda et al., 2003).  
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Table 4.2: Ligands and functional groups involved in protein retention and their 
retention strengths. *Retention strength comparison based on work by Ueda et al 
(2003). 
Ligand Retention Strength* 
N-Terminus  ++ 
Arginine + 
Asparagine - 
Cysteine (reduced form) ++++ 
Glutamine - 
Histidine ++++ 
Lysine + 
Phenylalanine + 
Tryptophan + 
Tyrosine + 
 
The use of an N-terminal His-tag may also predispose recombinant lysostaphin to a PTM of 
the His-tag sequence.  For instance, the N-terminal His-tag sequence of construct 1 
possesses five serine residues, which could theoretically become phosphorylated (Figure 
4.26).  The C-terminal His-tag sequence of construct 3 does not have any serine residues 
therefore is unlikely to become phosphorylated.   
Recombinant lysostaphin could also become susceptible to gluconoylation or 
phosphogluconoylation of the N-terminus.  The incidence of this amino terminal modification, 
is however likely to be dependent on the N-terminal amino acid residue.  It is likely that the 
initiator methionine residue is removed by a methionine aminopeptidase following 
expression; therefore modification of the amino terminus is more likely to occur at the N-
terminal glycine residue in Construct 1 or the N-terminal alanine residue in Constructs 2 and 
3.  However it is possible that the N-terminal alanine residues may not exhibit reactivity for 
this type of modification as Geoghegan et al,(1999) proposed that this modification may be 
limited to sequences which are similar to Gly-Ser-Ser-[His]6- (Geoghegan et al., 1999).  
IMAC retention and purification of recombinant lysostaphin was therefore examined in 
further detail, to investigate the possibility of such modifications.  
Aims: 
 To assess whether N-terminally His-tagged recombinant lysostaphin (construct 1), 
recombinant lysostaphin without His-tags (construct 2) and C-terminally His-tagged 
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recombinant lysostaphin (construct 3) exhibit different degrees of charge 
heterogeneity using WCX separation.  
 To study the retention behaviour of N-terminally His-tagged recombinant lysostaphin 
(construct 1), through repeated purifications.  
 To compare the retention behaviour of N-terminally His-tagged recombinant 
lysostaphin against that of C-terminally His-tagged recombinant lysostaphin 
(construct 3). 
 To establish whether recombinant lysostaphin without any His-tags exhibits retention 
during IMAC purification. 
 To analyse protein eluted during IMAC purification using WCX analysis.  
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4.2.2 Methods  
 
4.2.2.1 Buffers  
All buffer compositions are outlined in Appendix 7.342. 
 
4.2.2.2 Equipment 
All equipment used during IMAC analysis of recombinant lysostaphin is outlined in Appendix 
7.343. 
 
4.2.2.3 Sample preparation 
Sample preparation is described in Appendix 7.345.  
 
4.2.2.4 WCX analysis of His-tag heterogeneity   
WCX separation was performed using a 0.5 ml/min flow rate and a ProPac® WCX-10 (4 x 
500 mm) column.  Cell lysate (500 µl) was loaded onto the column and the cellular debris 
was eluted whilst maintaining an isocratic gradient of 0% B for 10 min. Protein isoforms were 
separated by applying a linear gradient of 0-50% B over 70 min. The column was then 
washed using 90% B for 9 min and then the column was equilibrated at 0 % B for 15 min. 
UV data was acquired at 214 and 280 nm throughout the separation and fractions were 
collected by time, every 30 s between 30 and 65 min.  Following separation, fractions 
containing eluted protein were stored at 4°C until they could be analysed by SDS-PAGE 
(Appendix 7.15).  
 
4.2.2.5 WCX analysis of IMAC purified protein 
IMAC purification was performed as described in Appendix 7.346 and eluted fractions were 
concentrated as described in Appendix 7.347. WCX separation was performed using a 0.2 
ml/min flow rate and a ProPac® WCX-10 (2.0 x 500 mm) column.  Purified and concentrated 
protein samples were injected onto the column in 100 µl injection volumes.  Protein was 
separated by applying a linear gradient of 0-50% B over 20 min.  An isocratic gradient was 
maintained for a further 3 min, before washing the column using 90% B for 13 min. The 
column was then equilibrated at 0% B for 11 min.  UV data was acquired at 214 and 280 nm 
throughout the separation.  
  
264 
 
4.2.3 Results  
 
4.2.3.1 WCX analysis of His-tag heterogeneity   
Following optimisation of separation conditions, various recombinant lysostaphin constructs 
were subjected to WCX separation using a ProPac WCX-10 (4 x 500 mm) column.  Figure 
4.27 demonstrates that N-terminally His-tagged recombinant lysostaphin (construct 1) 
demonstrated greater heterogeneity than C-terminally His-tagged recombinant lysostaphin 
(construct 3) and recombinant lysostaphin with no His-tags (construct 2), which appeared to 
be composed of fewer charge isoforms.  Fractions were collected during each of the WCX 
separations and were subjected to PAGE analysis to confirm that the peaks being 
interpreted reflected protein with a molecular weight which corresponded to that of the 
recombinant lysostaphin construct being expressed (Appendix 7.348-Appendix 7.353). 
 
Figure 4.27: Comparison of WCX chromatograms obtained following separation of N-
terminally His-tagged recombinant lysostaphin (construct 1), C-terminally His-tagged 
recombinant lysostaphin (construct 3) and recombinant lysostaphin without any His-
tags (construct 3).  Each construct was expressed in E. coli BL21(DE3) which had 
been cultured in LB. Protein expression was induced at OD600 nm values of 1.010 
(construct 1), 0.821 (construct 2) and 0.852 (construct 3), before harvesting the 
cultures at 16.25 h post-induction. 
 
Assessment of this chromatogram would suggest a number of factors may be involved in the 
charge heterogeneity of recombinant lysostaphin preparations. As constructs 1, 2 and 3 all 
featured the same mature lysostaphin amino acid sequence it would be expected that the 
proteins would exhibit a similar charge during WCX analysis. However as constructs 1 and 3 
featured charged His-tag sequences, it would be expected that the charge of these fusion 
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proteins would differ slightly from that of the non-His-tagged recombinant lysostaphin.  N-
terminally His-tagged recombinant lysostaphin (construct 1) has a theoretical pI of 9.72 and 
therefore should have exhibited the greatest charge due to the extra charge provided by the 
N-terminal His-tag.  C-terminally His-tagged recombinant lysostaphin (construct 3) has a 
theoretical pI of 9.52, which was slightly less than that of recombinant lysostaphin without 
any His-tags (construct 2) at 9.59.   
These differences in theoretical pI values became evident during WCX separation of each of 
the recombinant lysostaphin preparations, through the resolution of a number of charge 
isoforms, which were designated A-D (Table 4.3 and Figure 4.28).  Surprisingly each WCX 
separation featured the resolution of acidic peaks A and B, indicating that the N-terminally 
His-tagged recombinant lysostaphin (construct 1) preparation also featured protein isoforms 
with the same or similar charge to that of C-terminally His-tagged recombinant lysostaphin 
(construct 3) and recombinant lysostaphin without any His-tags (construct 2). This result 
would suggest that a proportion of the protein molecules within the N-terminally His-tagged 
recombinant lysostaphin (construct 1) preparation may have lost charge through modification 
or truncation. Peaks C and D reflected the presence of more protein isoforms which would 
theoretically reflect the presence of protein isoforms with a more preserved or less 
processed or modified N-terminal His-tag sequence.   
 
Table 4.3: Retention time (min) values of identified peaks following WCX separation of 
recombinant lysostaphin with N-terminal, C-terminal or no His-tag sequences. Peaks 
which were not observed during WCX separation are represented by “X”. 
Construct Fusion Tag Theoretical pI Peak Retention Time (min) 
A B C D 
1 N-terminal His-tag 9.72 36.67 38.53 41.75 42.53 
2 None 9.59 36.64 38.23 X X 
3 C-terminal His-tag 9.52 36.53 38.28 X X 
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Figure 4.28: Comparison of WCX chromatograms obtained following separation of N-
terminally His-tagged recombinant lysostaphin (construct 1), C-terminally His-tagged 
recombinant lysostaphin (construct 3) and recombinant lysostaphin without any His-
tags (construct 2).  Multiple peaks were observed during WCX separation and were 
designated A-D as indicated.  
 
As WCX separation of C-terminally His-tagged recombinant lysostaphin (construct 3) and 
recombinant lysostaphin without any tags (construct 2) also featured peaks A and B, it was 
evident that both preparations also exhibited charge heterogeneity due to some form of post-
translational processing or modification.  It is interesting to note that the more basic protein 
isoforms (peaks C and D) were observed during this experiment, but also during culture 
analysis (Section 3.5) and therefore these variants appeared to be exclusive to N-terminally 
His-tagged recombinant lysostaphin (construct 1) preparations. These observations were 
however taken with caution given that certain conditions may have varied between cultures.  
Although expression media and incubation times were controlled in each culture, optical 
densities at the point of induction were not identical and therefore the presence and relative 
abundance of each peak would have been likely to vary over the course of culture.  
 
4.2.3.2 IMAC Purification of N-terminally His-tagged recombinant lysostaphin   
As N-terminally His-tagged recombinant lysostaphin (construct 1) preparations exhibited 
greater charge heterogeneity during WCX separation, it seemed likely that N-terminal His-
tag heterogeneity might interfere with the efficiency of IMAC purification.  Unusual protein 
binding efficiency was observed during the optimisation of IMAC purification using the 
ProPac® IMAC column (4 x 250 mm) column, as reported in Section 2.5.4 .  Experiments 
were performed to assess the capacity of the ProPac® IMAC column by applying various 
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volumes of cell lysate to the column. As shown in Figure 4.29, the peak height increased 
with increased volumes of CFE being applied to the column.    
 
Figure 4.29: Comparison of IMAC purifications following consecutive applications of 
0.25 L, 0.50 L and 1 L  
Peak fractions from the IMAC purification of CFE from 1 L of E. coli batch culture were 
pooled and concentrated so that the purification yield could be quantitated by UV 
spectrometry.  However UV spectrometry revealed that only 2.8 mg of N-terminally tagged 
recombinant lysostaphin (construct 1) was purified by the ProPac® IMAC-10 column, which 
was unexpectedly low considering the volume of E. coli culture that had been harvested.  In 
addition, the application of doubling quantities of cell lysate to the column did not result in 
proportionally increased peak heights. These unusual results suggested that the column 
may have had a poor binding capacity or that the N-terminally His-tagged form of 
recombinant lysostaphin demonstrated poor binding efficiency.  
In order to investigate further, another preparation of cell lysate containing N-terminally His-
tagged recombinant lysostaphin (construct 1) was produced and applied to the ProPac® 
IMAC-10 column.  The application of cell lysate resulted in the elution of a peak (peak A) 
representing purified recombinant lysostaphin (Figure 4.30).  
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Figure 4.30: IMAC purification of N-terminally His-tagged recombinant lysostaphin 
from cell lysate.  The purification yielded a single peak (A) representing purified 
recombinant lysostaphin.  The initial unbound cell lysate was collected manually, as 
indicated in the figure.    
 
The eluted column flow-through from the initial application of cell lysate was collected and 
re-applied to the column (Figure 4.31) to see whether more protein would bind to the 
column. Interestingly, re-application of unbound cell lysate (2) to the column resulted in two 
peaks (B and C).  Retention time comparison indicated that purified protein eluted in peak B 
demonstrated a weaker binding affinity than peak A, whilst the purified protein eluted in peak 
C demonstrated a stronger binding affinity than peak A did.  The peak height of peak C was 
approximately double the height of peak A indicating that a higher quantity of recombinant 
protein was purified from the cell lysate upon its second application to the column. This 
implied that the capacity of the column was greater than the initial purification of recombinant 
protein from cell lysate (1) had suggested.     
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Figure 4.31: Comparison of elution peaks following the application of cell-free lysate 
and re-application of unbound cell lysate (2) flow-through.  The re-application of 
unbound cell lysate (2) resulted in elution of two peaks (B and C) at retention times 
which were lower and higher than that of the elution of peak A after initial application 
of cell lysate (1). Unbound cell lysate (3) was again collected manually as indicated. 
 
Collected unbound cell lysate (3) was again collected and subsequently re-applied to the 
column to see if any more recombinant protein could be purified from cell lysate (Figure 
4.32).  By this third IMAC purification, it was evident that the amount of recombinant protein 
left in the cell lysate had been significantly reduced by the previous purifications, as 
evidenced by a reduction in amount of recombinant protein that had bound to the ProPac™ 
column.  The third IMAC purification resulted in the elution of peaks D and E, which have 
similar retention times to peaks B and C from the second IMAC purification. As the quantity 
of bound and unbound protein had reduced significantly by the third re-application of cell 
lysate, unbound cell lysate (4) was not re-applied to the column.  
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Figure 4.32: Comparison of elution peaks following the application of cell lysate (1), 
re-application of unbound cell lysate (2), followed by a re-application of secondary 
unbound cell lysate (3). Unbound cell lysate (4) was again collected manually as 
indicated and eluted peaks D and E are indicated alongside peaks A, B and C 
 
4.2.3.3 PAGE analysis of IMAC samples and fractions  
All of the applied and collected samples were analysed by PAGE to check for the presence 
of N-terminally His-tagged recombinant lysostaphin (Figure 4.33). PAGE analysis verified 
that the concentration of recombinant lysostaphin (construct 1) in the cell lysate reduced with 
each sequential IMAC purification and analysis of unbound cell lysate (4) suggests that 
recombinant lysostaphin had been largely removed from the applied cell extract by the third 
IMAC purification.   
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Figure 4.33: PAGE analysis of IMAC samples.  Lane 1: Sigma low molecular weight 
markers; Lane 2: Cell lysate (1); Lane 3: Unbound cell lysate (2); Lane 4: Sigma low 
molecular weight markers; Lane 5: Unbound cell lysate (3); Lane 6: Unbound cell 
lysate (4) 
 
To ensure that the hyper-expressed N-terminally His-tagged recombinant lysostaphin 
(construct 1) had been specifically purified from the E. coli cell lysate, resulting IMAC 
fractions were analysed by PAGE. Selected fractions from the elution of Peak A from IMAC 
purification of cell lysate (1) were therefore desalted, concentrated and analysed by PAGE 
(Figure 4.34 and Figure 4.35).  
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Figure 4.34: IMAC purification of N-terminally His-tagged recombinant lysostaphin 
(construct 1) from cell lysate (1). Fractions 19-39 were collected during the elution of 
peak A. The fractions were pooled, desalted and concentrated prior to PAGE analysis. 
 
 
Figure 4.35: PAGE analysis of peak A from IMAC purification of cell lysate (1). Lane 1: 
Sigma high molecular weight markers; Lane 2: purified recombinant lysostaphin 
(1:10); Lane 3: purified recombinant lysostaphin (1:100); Lane 4: Sigma low molecular 
weight markers.  
 
 
5  10  15  20  25  30  35  40  45  50  
273 
 
PAGE analysis of protein eluted within Peak A demonstrated that the IMAC purification 
specifically purified a recombinant protein with a molecular weight of around 29 kDa, which 
corresponded with the molecular weight of N-terminally His-tagged recombinant lysostaphin 
(construct 1).  Selected fractions resulting from the elution of Peak B and C from IMAC 
purification of unbound cell lysate (2), as indicated in Figure 4.36, were also analysed by 
PAGE (Figure 4.37). 
 
Figure 4.36: IMAC purification of N-terminally His-tagged recombinant lysostaphin 
(construct 1) from unbound cell lysate (2). Fractions 7, 10, 13 were desalted and 
concentrated prior to PAGE analysis of peak B, whilst fractions 32, 35 and 38 were 
desalted and concentrated prior to PAGE analysis of peak C. 
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Figure 4.37: PAGE analysis of peak B and C from IMAC purification of unbound cell 
lysate (2). Lane 1: Sigma high molecular weight markers; Lane 2: Fraction 7 (peak B); 
Lane 3: Fraction 10 (peak B); Lane 4: Fraction 13 (peak B); Lane 5: Fraction 32 (peak 
C); Lane 6: Fraction 35 (peak C); Lane 7: Fraction 38 (peak C); Lane 8: Sigma low 
molecular weight markers.  
 
Again PAGE analysis demonstrates that IMAC peaks B and C contained a purified protein 
with a molecular weight of 24-29 kDa which corresponded with the molecular weight of N-
terminally His-tagged recombinant lysostaphin (29.3 kDa). IMAC peak B was predominantly 
composed of recombinant lysostaphin, but also appears to have been contaminated with 
several proteins with higher molecular weights. It could be possible that these contaminating 
proteins interfered with the binding of recombinant lysostaphin, which resulted in the early 
elution of some of the recombinant lysostaphin.  Fractions collected during the elution of 
IMAC peak C did not appear to contain as many contaminating proteins, which may explain 
why the recombinant lysostaphin seemed to bind more strongly to the IMAC stationary 
phase.   
 
4.2.3.4 WCX analysis of IMAC purified protein  
The previous experiments demonstrated that N-terminally His-tagged recombinant 
lysostaphin (construct 1) was not entirely extracted from cell lysate upon initial purification 
attempts.  Subsequent IMAC purification of collected unbound cell lysate revealed that 
additional recombinant protein could be purified from cell lysate and that it bound to the 
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column with variable affinities.  It was possible that the observed variable binding affinities 
reflected the differential IMAC binding of different recombinant lysostaphin isoforms.  To 
assess this theory, selected fractions collected during the elution of peak A and E were 
pooled and concentrated (Figure 4.38).  The concentrated protein was then subjected to 
WCX analysis (Figure 4.39).  
 
 
Figure 4.38: IMAC purification of N-terminally His-tagged recombinant lysostaphin 
(construct 1) from unbound cell lysate (3).  Fractions 35 and 36 were desalted and 
concentrated prior to WCX analysis of peak E. 
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Figure 4.39: Comparison of WCX separations of IMAC purified N-terminally His-tagged 
recombinant lysostaphin (construct 1) from peaks A and E.  Both separations reveal 5 
distinct peaks (1-5 indicated by arrows)   
 
WCX analysis showed that both IMAC peaks reflect the presence of five distinct charge 
variants.  However the difference in IMAC retention times of peak A and peak E could be 
explained by clear differences in the relative abundances of WCX peaks 1 and 5. Basic 
WCX peak 5 appeared to be significantly more abundant in the protein collected during 
elution of IMAC peak A during the initial IMAC purification of cell lysate (1).  On the other 
hand, acidic WCX peak 1 is appreciably more abundant in the protein collected during 
elution of IMAC peak E during the third IMAC purification of unbound cell lysate (3).  These 
results suggest that stronger binding affinity, as exhibited by the retention of peak E, is 
associated with greater prevalence of more basic recombinant lysostaphin isoforms.  
 
4.2.3.5 IMAC purification of C-terminally His-tagged recombinant lysostaphin   
IMAC purification of N-terminally His-tagged recombinant lysostaphin provided interesting 
results which suggested that the relative quantities of different charge isoforms in a 
preparation may have affected the binding affinity between recombinant lysostaphin and the 
IMAC stationary phase.  These charge isoforms may differ due to post-translational 
processing or modification within the N-terminal His-tag region of the protein, which would 
alter the IMAC binding affinity of the protein.  As a consequence of these findings, C-
terminally His-tagged recombinant lysostaphin was prepared and purified using IMAC to 
establish whether this form of the protein exhibited unusual IMAC binding characteristics as 
well (Figure 4.40).  
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Figure 4.40: IMAC purification of C-terminally His-tagged recombinant lysostaphin 
from cell lysate (1).  The purification yielded a single peak (A) representing purified 
recombinant lysostaphin.  The initial unbound cell lysate was collected manually, as 
indicated in the figure.    
Figure 4.40 shows that a large quantity of C-terminally His tagged-lysostaphin (construct 3) 
was purified on the initial IMAC purification.  The quantity of purified protein was three times 
greater than that achieved during the initial IMAC purification of N-terminally His-tagged 
recombinant lysostaphin (construct 1), as shown in Figure 4.34.  However the shorter 
retention time of peak A, suggested that binding of C-terminally His-tagged recombinant 
lysostaphin to the IMAC stationary phase was not as strong as that of N-terminally His-
tagged recombinant lysostaphin (Figure 4.41).   
 
Figure 4.41: Comparison of initial IMAC purifications of N-terminally His-tagged 
recombinant lysostaphin (construct 1) and C-terminally His-tagged recombinant 
lysostaphin (construct 3) from cell lysate (1). The initial purification of C-terminally 
His-tagged recombinant lysostaphin purified a greater amount of protein than the 
initial purification of N-terminally His-tagged recombinant lysostaphin. 
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Unbound cell lysate (2) was collected manually and re-applied to the IMAC column to assess 
whether any more recombinant lysostaphin could be purified from the cell lysate (Figure 
4.42).  A very small quantity of recombinant protein bound to the column on the re-
application of cell lysate, indicating that the majority of recombinant protein had already been 
purified from the cell lysate in the previous purification.  This application resulted in elution of 
a peak (B) at a retention time which was slightly higher than that of the elution of peak A 
after initial application of cell lysate. Unbound cell lysate (3) was again collected manually as 
indicated. 
 
Figure 4.42: Comparison of elution peaks following the application of cell lysate (1) 
and re-application of unbound cell lysate (2) flow-through.  The re-application of 
unbound cell lysate resulted in the resolution of peak B as indicated.   
 
4.2.3.6 PAGE analysis of IMAC samples and fractions 
All of the applied and collected samples were analysed by PAGE to check for the presence 
of recombinant lysostaphin (Figure 4.43).  PAGE analysis verified that the concentration of 
recombinant lysostaphin in the cell lysate reduced with each sequential IMAC purification.  
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Figure 4.43: PAGE analysis of IMAC samples.  Lane 1: Sigma low molecular weight 
markers; Lane 2: Unbound cell lysate (3); Lane 3: Unbound cell lysate (2); Lane 4: Cell 
lysate (1) 
 
To ensure that the hyper-expressed recombinant lysostaphin had been specifically purified 
from the E. coli cell lysate, resulting IMAC fractions were also analysed by PAGE. Selected 
fractions from the elution of Peak A from IMAC purification of cell lysate (1) were selected as 
annotated in Figure 4.45 and analysed by PAGE (Figure 4.45). 
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Figure 4.44: IMAC purification of recombinant lysostaphin from cell lysate (1). 
Fractions 4, 7, 10, 13, 16, 19, 22 and 25 fractions represent fractions that were 
analysed by PAGE. 
 
 
Figure 4.45: PAGE analysis of peak A from IMAC purification of cell lysate (1). Lane 1: 
Sigma low molecular weight markers; Lane 2: Fraction 4; Lane 3: Fraction 7; Lane 4: 
Fraction 10; Lane 5: Fraction 13; Lane 6: Fraction 16; Lane 7: Fraction 19; Lane 8: 
Fraction 22; Lane 9: Fraction 25; Lane 10: Sigma high molecular weight markers.  
 
4.2.3.7 WCX analysis of IMAC purified protein  
IMAC purification of C-terminally His-tagged recombinant lysostaphin (construct 1) appeared 
to be more efficient, in that a much higher quantity of the expressed recombinant protein in 
the cell lysate could bind to the column on the first application.  IMAC peak B eluted after a 
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slighter longer retention time than IMAC peak A and therefore the protein collected during 
the elution of peaks A and B was subjected to WCX analysis.  A fraction was selected from 
IMAC peak A and was desalted and concentrated prior to WCX analysis (Figure 4.46).  
Multiple fractions from the elution of IMAC peak B were also desalted and concentrated for 
subsequent WCX separation (Figure 4.47)   
 
Figure 4.46: IMAC purification of C-terminally tagged recombinant lysostaphin 
(construct 3) from cell lysate (1). Fraction 17 was desalted and concentrated prior to 
WCX analysis of peak A. 
 
 
Figure 4.47: IMAC purification of C-terminally tagged recombinant lysostaphin 
(construct 3) from unbound cell lysate (2). Fractions 30-33 that were pooled, desalted 
and concentrated prior to WCX analysis of peak B. 
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WCX analysis showed that both IMAC peaks reflected the presence of one major distinct 
charge variant and around four minor more acidic charge variants (Figure 4.48).  The major 
peak has a higher peak height in the separation of IMAC peak A than that of peak B, 
however this is related to the presence of a much lower protein concentration. The only 
noticeable difference observed in Figure 4.48 concerns the retention time of the major peak, 
which is slightly shorter during WCX separation of Peak B. This may reflect the purification of 
a slightly more acidic protein isoform, which exhibits slightly enhanced binding during IMAC 
purification.  
 
Figure 4.48: Comparison of WCX separations of IMAC purified C-terminally His-tagged 
recombinant lysostaphin (construct 3) from peaks A and B.  Both separations reveal 
several minor peaks and one major distinct peak.     
 
4.2.3.8 IMAC purification of recombinant lysostaphin 
IMAC purification specifically binds His-tagged proteins, however in some cases non-His-
tagged proteins can bind to the IMAC stationary phase.  This form of unexpected binding 
may explain the variability of binding and differences in IMAC peak retention times observed 
during IMAC purification of C-terminally and N-terminally His-tagged proteins.  Therefore 
recombinant lysostaphin with no His-tag sequence (construct 2) was harvested and applied 
to the ProPac® IMAC-10 column to establish whether the protein could bind to the column 
(Figure 4.49).  
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Figure 4.49: IMAC purification of recombinant lysostaphin with no His-tag (construct 
2) from cell lysate.  The purification yielded peak A as indicated. The rising baseline 
represented an increasing imidazole concentration with progression of the elution 
gradient. Fractions 20-26 were collected and subjected to SDS-PAGE analysis.  
 
Protein eluted during the IMAC purification was collected and analysed by SDS-PAGE to 
ensure that the eluted protein possessed a molecular weight which corresponded with that of 
recombinant lysostaphin (construct 2), as demonstrated in Figure 4.50.  
 
Figure 4.50: PAGE analysis of IMAC fractions. Lane 1: Sigma low molecular weight 
markers; Lane 2: Fraction 20; Lane 3: Fraction 21; Lane 4: Fraction 22; Lane 5: 
Fraction 23; Lane 6: Fraction 24; Lane 7: Fraction 25; Lane 8: Fraction 26; Lane 9: 
Sigma high molecular weight markers.  
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This initial purification of recombinant lysostaphin (construct 2) demonstrated that the 
recombinant protein possessed a slight ability to bind to the IMAC stationary phase, as 
demonstrated by peak A in Figure 4.49.  The low concentration of purified protein suggests 
that the cell lysate may contain a small sub-population of recombinant lysostaphin, which 
can bind to an IMAC column.  This finding was not very surprising considering that 
recombinant lysostaphin is a zinc metalloprotein.  The protein which eluted in peak A may 
therefore have represented recombinant lysostaphin which did not harbour a zinc molecule 
and therefore the zinc binding domain of the protein was accessible for binding with the 
immobilised nickel bound to the IMAC stationary phase.  
As this purification indicated that only a small proportion of the recombinant lysostaphin 
preparation was available for nickel binding, IMAC purification was performed again 
following production of a greater amount of recombinant lysostaphin.  By applying an 
increased quantity of recombinant lysostaphin to the column, it should have been possible to 
purify larger concentrations of recombinant lysostaphin molecules which possessed IMAC 
binding affinity in the absence of a His-tag binding sequence.  As demonstrated in Figure 
4.51, IMAC purification of a more concentrated preparation of recombinant lysostaphin 
(construct 2) resulted in the elution of two peaks, A and B.  
 
Figure 4.51: IMAC purification of recombinant lysostaphin with no His-tags (construct 
2) from cell lysate. The cell lysate was harvested from 5 L of culture to achieve a 
higher protein concentration.  The purification yielded peaks A and B, as indicated 
and unbound cell lysate (1) was collected manually at the start of the separation. The 
rising baseline represented an increasing imidazole concentration with progression of 
the elution gradient.  
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4.2.3.9 PAGE analysis of IMAC samples and fractions 
All of the applied and collected samples were analysed by PAGE to check for the presence 
of recombinant lysostaphin (construct 2).  PAGE analysis demonstrated that the majority of 
the recombinant lysostaphin present in the cell lysate did not bind to the column (Figure 
4.52). 
 
 
Figure 4.52: PAGE analysis of IMAC samples. Lane 1: Sigma low molecular weight 
markers (poor resolution due to protein contamination from adjacent lane); Lane 2: 
Cell lysate (1); Lane 3: Unbound cell lysate (2); Lane 4: Sigma high molecular weight 
markers 
 
IMAC fractions were also analysed by PAGE to ensure that the IMAC peaks B and C 
reflected the presence of purified recombinant lysostaphin (construct 2).  Fractions selected 
for PAGE analysis are indicated in Figure 4.53 and PAGE demonstrated that IMAC peaks B 
and C were composed of a purified protein with a molecular weight which corresponded with 
the 27.0 kDa mass of recombinant lysostaphin without any His-tags (Figure 4.54). 
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Figure 4.53: IMAC purification of recombinant lysostaphin (construct 2) from cell 
lysate (1). Fractions 7, 9, 11, 13, 15, 17 and 19 were analysed by PAGE. 
 
 
Figure 4.54: PAGE analysis of IMAC fractions.  Lane 1: Sigma low molecular weight 
markers; Lane 2: Fraction 7 (peak A); Lane 3: Fraction 9 (peak A); Lane 4: Fraction 11 
(peak B); Lane 5: Fraction 13 (peak B); Lane 6: Fraction 15 (peak B); Lane 7: Fraction 
17 (peak B); Lane 8: Fraction 19 (peak B); Lane 9: Sigma high molecular weight 
markers 
 
Protein eluted during IMAC purification was collected and subjected to WCX analysis, 
however chromatographic issues resulted in the poor resolution of peaks (data not shown).  
These results do however indicate that the sequence of mature recombinant lysostaphin 
possesses IMAC binding affinity, which is likely to be associated with the inherent metal 
binding ability of the protein.  The results also indicate that a small proportion of recombinant 
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lysostaphin preparations may be composed of protein molecules, which do not possess zinc 
in their structure and therefore are available to participate during IMAC purification. 
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4.2.4 Discussion  
Overall this work has provided further insight into the heterogeneous nature of recombinant 
lysostaphin preparations and the implications that charge heterogeneity has upon protein 
purification using IMAC.  IMAC is a popular technique due to its ability to provide a very high 
degree of protein purity in an efficient manner.  Whilst IMAC has been shown to purify 
recombinant lysostaphin to a very high degree, the series of experiments performed in this 
work indicate that protein heterogeneity can interfere with the efficiency of IMAC purification.  
Therefore caution should be taken when performing IMAC purification of recombinant 
lysostaphin but also other recombinant proteins, which may possess unknown charge 
heterogeneity  
WCX separation of cell lysate containing recombinant lysostaphin expressed without or with 
C-terminal or N-terminal His-tags, revealed that each of the preparations demonstrated 
charge heterogeneity.  N-terminally His-tagged recombinant lysostaphin (construct 1) 
demonstrated the greatest charge heterogeneity during WCX separation, whilst C-terminally 
His-tagged recombinant lysostaphin (construct 3) and recombinant lysostaphin without any 
His-tags (construct 2) demonstrated a lesser yet similar degree of charge heterogeneity. 
PAGE analysis confirmed that the observed peaks reflected the elution of charge-distinct 
protein isoforms with a molecular weight which corresponded with the expected masses of 
recombinant lysostaphin (constructs 1-3). Furthermore all of the analysed preparations 
exhibited retention behaviour that correlated with their respective theoretical isoelectric 
points.  
Intriguingly WCX separation revealed that all of the recombinant lysostaphin preparations 
demonstrated the presence of the same or similarly charged acidic protein isoforms (peak A 
and B). This was a surprising finding considering that N-terminally His-tagged recombinant 
lysostaphin (construct 1) molecules were expected to possess a greater charge.  This result 
therefore indicated that a proportion of the protein molecules within the N-terminally His-
tagged recombinant lysostaphin (construct 1) preparation may have lost charge through 
modification or truncation.  WCX separation of N-terminally His-tagged recombinant 
lysostaphin (construct 1) also revealed the presence of more basic peaks (peaks C and D), 
which may have reflected the presence of protein isoforms with a more preserved or less 
processed or modified N-terminal His-tag sequence.  This experiment and previous WCX 
separations suggested that these more basic charge isoforms were exclusively formed 
within N-terminally His-tagged recombinant lysostaphin (construct 1) preparations.  
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Comparison of amino acid sequences in Section 4.2.1.1 indicated that the N-terminal His-tag 
sequence features serine residues which could be susceptible to phosphorylation.  
Phosphorylation of serine residues replaces neutral hydroxyl groups within the serine side 
chain with negatively charged phosphate groups (Rogakou et al., 1998).  Phosphorylation of 
serine groups within the N-terminal His-tag sequence may therefore lead to the formation of 
more acidic variants of N-terminally His-tagged recombinant lysostaphin (construct 1).  α-N-6 
gluconoylation of the N-terminus leads to loss of the positively charged free α-amino group 
at the N-terminal amino acidic residue.  This modification could also lead to the formation of 
acidic variants of N-terminally His-tagged recombinant lysostaphin.  Furthermore α-N-6 
phosphogluconoylation would introduce an additional negatively charged phosphate group 
to the protein, resulting in the production of even more acidic protein variants. These 
modifications can be sensitively detected using MS analysis as discussed in Chapter 5.  
Although N-terminally His-tagged recombinant lysostaphin (construct 1) exhibited the most 
charge heterogeneity, C-terminally His-tagged recombinant lysostaphin (construct 3) and 
recombinant lysostaphin without His-tags (construct 2) also demonstrated charge 
heterogeneity which was likely to have reflected some form of post-translational processing 
or modification.  Culture analysis of the expression of these forms of recombinant 
lysostaphin would be desirable to establish whether the charge heterogeneity of recombinant 
lysostaphin increased over time, as was found to be the case for N-terminally His-tagged 
recombinant lysostaphin (Sections 3.5.3.11 and 3.5.3.12).  Culture analysis would also 
provide more informative analysis of charge heterogeneity over time and would minimise 
concerns over culture conditions and batch-to-batch variability.  
 
His-tag sequences are commonly used to facilitate highly specific binding during IMAC 
purification; however these experiments suggest that the N-terminal His-tag sequence 
should be used with caution.  N-terminal His-tag sequences have already been found to 
undergo modification during expression in E. coli (Table 4.1) and these experiments would 
suggest the presence of an N-terminal His-tag is associated with such a modification or loss 
of charged N-terminal amino acids.  Removal of the N-terminal His-tag sequence may 
therefore be desirable and can be accomplished using a site-specific protease, which should 
not interfere with the activity of recombinant lysostaphin.  Cleavage is typically performed 
using a recombinant protease with an affinity tag which will permit subsequent removal by 
affinity purification (Terpe, 2006). However protease cleavage can be expensive and 
incomplete cleavage may increase preparation complexity further.  
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Alternatively the use of C-terminally His-tagged recombinant lysostaphin preparation 
(construct 3) may provide a less complex source of recombinant lysostaphin which can still 
be purified using IMAC.  C-terminally His-tagged recombinant lysostaphin (construct 3) was 
shown to possess staphylolytic activity and therefore, despite being positioned adjacent to 
the C-terminal cell wall targeting domain sequence, the presence of a C-terminal His-tag 
sequence does not interfere with protein activity (Section 4.1.3.7).  Furthermore as WCX 
analysis indicated that C-terminally His-tagged recombinant lysostaphin displays less charge 
heterogeneity than N-terminally His-tagged recombinant lysostaphin, it may be possible to 
create more homogeneous protein preparations by expressing these constructs using 
optimised culture conditions, as described in Section 3.4.3.12. Culture analysis during the 
expression of these constructs would provide a greater insight into how this could be 
achieved through optimisation of expression media, temperature and harvest points. 
In this work, IMAC provided purification of recombinant lysostaphin, but also an insight into 
the differential retention behaviour which occurred as a consequence of charge 
heterogeneity. Although purification is the primary application of IMAC, the technique has 
also been used for topographic purposes to assess the surface localisation, accessibility and 
frequency of histidine residues within a protein (Hemdan et al., 1989). As a consequence, 
IMAC has proven useful for the differentiation of modified recombinant protein variants, due 
to differences in the number of accessible histidine residues and therefore binding strength 
(Gaberc-Porekar and Menart, 2001, Ueda et al., 2003).    
As N-terminally His-tagged recombinant lysostaphin (construct 1) possessed considerable 
charge heterogeneity, it seemed likely that the charge-distinct protein isoforms would display 
different binding characteristics during IMAC purification.  This theory was confounded by 
unusual protein binding patterns observed whilst testing the capacity of the ProPac® IMAC 
column.  During these initial studies, the capacity of the column appeared poor and the 
application of increasing amounts of cell lysate did not result in proportionally increased peak 
heights.  These results therefore suggested that N-terminally His-tagged recombinant 
lysostaphin (construct 1) exhibited poor binding efficiency.  
To investigate this phenomenon further, a series of IMAC purifications were performed in 
which the column flow-through was reapplied to the column to see if further binding could be 
achieved.  Initial application of cell lysate resulted in a typical peak (peak A) which appeared 
to display moderate binding strength during elution.  Subsequent IMAC purification of 
unbound cell lysate resulted in the appearance of two peaks (peak B and C), which exhibited 
lesser and greater binding strength, when peak retention times were compared to that of 
protein eluted as peak A.  A third IMAC purification performed following reapplication of 
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unbound cell lysate resulted in the retention of two more peaks (peaks D and E). Protein 
eluted within peaks D and E also exhibited lesser and greater binding strength, than that 
exhibited by protein purified during the first IMAC purification.  
PAGE analysis of cell lysates provided confirmation that N-terminally His-tagged 
recombinant lysostaphin (construct 1) was not fully removed from the cell lysate until after 
three consecutive IMAC purifications had been performed.  PAGE analysis of IMAC fractions 
also provided confirmation that the peaks observed during purification contained a protein 
with a molecular weight, which corresponded to that of recombinant lysostaphin (construct 
1).  Overall these results indicated that the charge heterogeneity of recombinant lysostaphin 
isoforms lead to incomplete and sequential purification of different protein isoforms upon 
repeated applications of cell lysate to the column.  
The results also suggest that recombinant lysostaphin protein isoforms possess different 
binding strengths leading to different retention properties during IMAC purification. To 
establish whether retention time differences were attributable to different charge variants, 
WCX analysis was performed on protein eluted at different retention times (peak A and E).   
WCX indicated that the stronger binding affinity exhibited by protein eluted in peak E was 
associated with greater prevalence of more basic recombinant lysostaphin isoforms, whilst 
the moderate binding affinity exhibited by protein eluted in peak A was associated with the 
greater abundance of more acidic protein isoforms.   
As C-terminally His-tagged recombinant lysostaphin (construct 3) appeared to possess a 
lesser degree of charge heterogeneity, IMAC purifications were also performed using this 
form of the protein.  An initial purification resulted in the purification of a much larger quantity 
of protein, than was achieved during the initial purification of N-terminally His-tagged 
recombinant lysostaphin (construct 1).  Reapplication of unbound cell lysate resulted in the 
elution of a much smaller peak during the second IMAC purification, which indicated that the 
protein was efficiently purified during the first purification.  PAGE analysis confirmed that the 
observed peaks reflected the high-quality purification of a protein with a molecular weight 
which corresponded to that of C-terminally His-tagged recombinant lysostaphin (construct 3).  
Although the peaks resolved during repeated IMAC purification exhibited different retention 
times, WCX analysis did not suggest the retention time differences were attributable to 
differences in the abundance of particular charge variants.  
It is evident that the retention behaviour of fusion proteins during IMAC is not very easy to 
predict due to the complexity of protein adsorption.  During IMAC, protein adsorption is 
based upon multipoint interactions between specific groups on a protein structure and 
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individual binding sites distributed across the surface of the stationary phase. The strength of 
binding affinity is therefore largely dependent on the distribution of surface binding sites and 
the random, heterogeneous binding that occurs during multipoint interactions, resulting in a 
variety of binding energies (Johnson et al., 1996, Johnson and Arnold, 1995).  Greatest 
binding affinity is achieved when surface arrangements best match the distribution of 
functional groups within the protein structure, whilst less favourable arrangements result in 
lower affinity.   
Multipoint interactions leading to protein adsorption are hindered if the His-tag sequence is 
not accessible on the protein surface (Terpe, 2006, Du et al., 2008).  As recombinant 
lysostaphin (constructs 1 and 3) can be purified using IMAC, it is likely that the N-terminal 
and C-terminal His-tag sequences are sufficiently exposed during purification.  However the 
variable binding efficiency observed during purification of N-terminally His-tagged 
recombinant lysostaphin would suggest that some of the charge variants detected during 
WCX separation exhibit variable binding affinities.  Loss of several amino acids from the N-
terminus of the protein could contribute to reduced binding affinity if some of the histidine 
residues that compose the hexahistidine tag were lost through host proteolysis.  
PTM of residues within the His-tag sequence would also be likely to influence binding 
affinities during IMAC purification.  As the nucleophilic N-terminal amino groups possess 
metal binding affinity, neutralisation of this group by α-N-6 gluconoylation or α-N-6 
phosphogluconoylation would weaken binding affinity slightly (Geoghegan et al., 1999).  
Phosphorylation of serine residues within the His-tag sequence could have a more profound 
influence upon binding affinity due to the nature of the N-terminal His-tag sequence.  
Although serine residues do not participate in protein retention, the addition of negatively 
charged phosphate groups in close vicinity to the hexa-histidine residues may lead to steric 
hindrance of metal affinity, as demonstrated in Figure 4.55.  
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Figure 4.55: Sites of phosphorylation in N-terminal His-tag sequences and the 
influence upon binding affinity.  A) Phosphorylation of Ser3 or Ser12 would be more 
likely to interfere with binding affinity through steric hindrance of preferred multipoint 
interactions involving His5 and His10, as postulated by Knecht et al, (2009). B) 
Phosphorylation of Ser4, Ser11 or Ser19 would be less likely to interfere with binding 
affinity. 
 
Knecht et al, (2009) identified that the 1st and 3rd or the 1st and 6th histidine residues within 
the hexa-histidine sequence provide the greater contribution to divalent interactions than the 
2nd, 4th and 5th histidine residues do (Knecht et al., 2009). Therefore phosphorylation of the 
side group’s serine residues at the same axial rotation as the imidazole groups of the 1st and 
6th residues could potentially weaken binding affinity through steric hindrance.  As the N-
terminal His-tag sequence contains five serine residues, up to five phosphorylations could 
possibly occur.  Variation in the number and position of phosphorylation sites would 
therefore lead to varying binding affinities, such as those demonstrated by recombinant 
lysostaphin.  
Although modification or truncation of the N-terminus could explain the variability of binding 
affinity, it was not clear why the sequential application of cell lysate did not initially result in 
the binding of protein molecules with the greatest binding strength.  It is likely that this 
phenomenon was associated with heterogeneity of protein binding, high sample loading and 
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associated negative cooperative binding (Johnson et al., 1996).  Negative cooperative 
binding occurs when single-point binding of a ligand, decreases the affinity of the ligand for a 
second binding site.  This phenomenon is commonly observed when large amounts of 
protein are loaded onto column, as overpopulation of binding sites prevents the protein from 
achieving surface arrangements that best match the distribution of functional groups on the 
protein structure.  Net binding energy steadily decreases with increasing protein coverage, 
as less favourable binding sites become heavily populated (Johnson et al., 1996).    
These principles could explain the variability of binding affinity observed during IMAC 
purification, as postulated in Figure 4.56. Theoretically the presence of large amounts of 
protein would prevent stronger multipoint interactions from readily occurring as secondary 
binding sites would not necessarily be available due to overpopulation of binding sites.  
Therefore initial application of cell lysate would result in largely single-point, moderately 
strong interactions.  Following the initial purification, the protein concentration of the cell 
lysate would decrease and therefore re-application of the cell lysate to the column would 
allow more multi-point interactions to occur due to the availability of more favourable binding 
sites.  Weaker interactions would have also occurred at less favourable binding sites, as the 
stationary phase binding sites became more heavily populated at favourable sites.  
 
Figure 4.56: Model of variable binding interactions of during IMAC purification of 
recombinant lysostaphin (construct 1). A) Upon initial application of cell lysate, the 
ligand participated in single point interactions with the stationary phase, resulting in 
moderate interaction strength. Multipoint interactions may have been hindered by 
over-population of stationary phase binding sites or through modification or 
truncation of the His-tag sequence.  B) Upon reduction in protein concentration, 
reapplication of cell lysate allowed stronger multipoint interactions to occur due to 
the increased availability of favourable binding sites. Weak interactions could also 
occur with lesser binding strength due to the greater availability of less favourable 
binding sites.  
295 
 
WCX separation of IMAC purified protein would also suggest that particular charge variants 
influenced binding affinity by influencing whether single or multi-point interactions could 
occur.  Upon WCX separation, the eluted IMAC peaks were found to contain a number of 
charge variants, which could be explained by the heterogeneous nature of IMAC binding 
(Johnson and Arnold, 1995).  The greater prevalence of acidic variants was associated with 
more moderate binding, which could reflect steric hindrance of multi-point binding due to 
modifications or truncation of the His-tag sequence.  The presence of more basic 
recombinant lysostaphin isoforms was correlated with stronger binding affinity, which would 
support the theory that increased protein basicity was associated with protein variants with 
preserved His-tag sequences, which had not undergone modification or truncation. More 
comprehensive WCX analysis of protein eluted during these IMAC purification experiments 
would be desirable to support this retention behaviour model and provide additional 
confirmation of these findings.     
Although this model of retention behaviour was developed by examining retention behaviour 
observed during the purification of N-terminally His-tagged recombinant lysostaphin 
(construct 1), the same principles can be applied to retention behaviour observed during the 
IMAC purification of C-terminally His-tagged recombinant lysostaphin (construct 3). WCX 
separation of purified protein eluted following IMAC purification of C-terminally His-tagged 
recombinant lysostaphin (construct 3), did not reveal any associations between charge 
variants and retention behaviour.  However secondary application of cell lysate resulted in 
the elution of protein which displayed slightly greater binding affinity than protein eluted 
during the initial purification.  Once again this result can be explained by over-population of 
the stationary phase during the initial purification, which will have reduced the incidence of 
stronger multipoint interactions.  By the second purification, a greater number of favourable 
binding sites will have become available therefore permitting stronger multi-point 
interactions.  
To ensure that retention time differences were not caused by chromatographic conditions, 
stationary and mobile phase conditions were kept as constant as possible. For instance, the 
stationary phase was stripped and charged with nickel ions prior to purification to ensure that 
charging insufficiencies did not lead to binding variability between purifications.  Furthermore 
mobile phase conditions were kept constant to ensure that fluctuations in pH or imidazole 
concentrations did not lead to altered retention properties.  IMAC was performed at neutral 
pH, which would ensure that imidazole nitrogens of histidine residues were present in their 
non-protonated form and therefore available for complexation (Sundberg and Martin, 1974).  
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Mobile phase buffers were also of high ionic strength to minimise non-specific electrostatic 
interactions (Gaberc-Porekar and Menart, 2001).   
It was however less easy to control other factors, which may have occurred as a 
consequence of IMAC purification.  For example, IMAC purifications are typically performed 
under aerobic and mildly oxidative conditions, which may lead to undesirable protein 
oxidation.  Several amino acids are susceptible to metal-catalysed oxidation and therefore 
the presence of stationary phase metal ions can lead to destruction of amino acid side 
chains or result in cleavage of the protein backbone through metal-catalysed reactions within 
the internal column environment (Gaberc-Porekar and Menart, 2001).  Furthermore the use 
of imidazole buffers is known to result in protein aggregation, which was investigated in 
Section 4.3.  In light of these potential reactive factors, it could not be guaranteed that the 
structure of the zinc-binding domain or folding of recombinant lysostaphin had not been 
disrupted during the course of IMAC purification.    
Experiments were also performed to establish whether recombinant lysostaphin without His-
tags (construct 2) could bind to the column during IMAC purification.  As a zinc 
metalloprotease, it is known that lysostaphin possesses metal affinity which could interact 
during IMAC purification.  Whilst metal binding domains are only supposed to accept a 
specific metal ion, experiments by Warfield et al (2008) suggested that bound zinc molecules 
within the structure of recombinant lysostaphin can become substituted by nickel ions during 
IMAC purification (Warfield et al., 2006, Clark et al., 2009).  This result would suggest that 
unoccupied zinc binding domains of recombinant lysostaphin may be able to interact with the 
nickel stationary phase.  Alternatively IMAC is known to remove metal ions from 
metalloproteins, therefore bound nickel may have displaced bound zinc within the structure 
of recombinant lysostaphin (Terpe, 2003). 
Application of concentrated cell lysate revealed that a small proportion of a recombinant 
lysostaphin (construct 2) preparation could bind fairly weakly to the column. This indicated 
that a small proportion of recombinant lysostaphin preparations may not contain the bound 
zinc molecule that was required for catalytic activity. Furthermore apoprotein forms of 
recombinant lysostaphin may have been detected as low abundance charge variants during 
WCX separation.  Although WCX separation of the bound recombinant lysostaphin could not 
be achieved, PAGE analysis revealed that the peaks resolved during IMAC purification did 
contain a protein with a molecular weight that corresponded with that of recombinant 
lysostaphin (construct 2). Comparative WCX and IMAC purification of recombinant 
lysostaphin within a single cell lysate would have provided an insight into whether IMAC 
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purification perturbed the structure of recombinant lysostaphin through removal or 
replacement of metal ions or through oxidative damage.  
Overall these experiments demonstrated that the charge heterogeneity of a recombinant 
preparation can complicate and interfere with the efficiency of IMAC purification.  Whilst the 
presence of a C-terminal His-tag does not appear to interfere with IMAC purification of 
recombinant lysostaphin, the addition of an N-terminal His-tag leads to increased charge 
heterogeneity and inefficient IMAC purification due to the charge variants exhibiting variable 
binding affinities.  To achieve improved product heterogeneity, removal of the N-terminal 
His-tag sequence or the use of a C-terminal His-tag sequence would be advisable. 
Alternatively a high degree of purification of recombinant lysostaphin could be achieved 
using CXC in the absence of His-tag sequences. As recombinant lysostaphin without His-tag 
sequences also exhibits charge heterogeneity, optimisation of culture and harvest conditions 
would be required to produce the protein in a more homogeneous state.  
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4.3 GF analysis of recombinant lysostaphin 
 
4.3.1 Introduction 
 
4.3.1.1 Aggregation during recombinant protein expression  
Recombinant protein production in E. coli can be compromised by protein mis-folding and 
aggregation, which lead to poor yields and formation of insoluble inclusion bodies (Ghosh 
Moulick et al., 2007). As recombinant protein expression puts excessive demands on cellular 
metabolism and translational apparatus, the host environment undergoes cellular stress. 
Should levels of denatured protein accumulate, then inclusion bodies form, often adversely 
affecting enzyme activity and potentially downstream processing (Sorensen and Mortensen, 
2005, Cserjan-Puschmann et al., 2006).  Inclusion body formation is most likely to occur 
when the rate of heterologous expression dramatically exceeds that of host protein 
expression. This may also be due to protein folding regimes being overwhelmed, 
inappropriate translational speeds, expression location and culture conditions, such as 
temperature.   
Eukaryotic proteins expressed heterologously in E. coli are more susceptible to misfolding 
and protein aggregation, due to differences between prokaryotic and eukaryotic chaperones 
(Haacke et al., 2009). Molecular chaperones minimise protein aggregation by shielding 
exposed hydrophobic regions of non-native proteins and assisting the folding of newly 
synthesised and partially folded proteins into their native states (Haacke et al., 2009, 
Derlinden et al., 2008).  The eukaryotic cytosol contains chaperones which are highly 
capable of cotranslational folding protein polypeptides as they leave the ribosome.  
Chaperones present in the bacterial cytosol may be incompatible with eukaryotic folding 
regimes, therefore simultaneous co-expression of molecular chaperones has been employed 
to try and improve the yield and quality of recombinant products derived from eukaryotic 
genes.     
In addition to differences in molecular chaperones, differences in translational speeds can 
lead to protein aggregation.  Prokaryotic translation rates are faster than eukaryotic 
translation rates, leading to greater conformational possibilities.  During slow growth in E. 
coli, polypeptide elongation occurs at a rate of around 1 amino acid per second (aa/s), whilst 
during fast growth, elongation rates can increase to around 20 aa/s.  Eukaryotic polypeptide 
elongation rates are thought to remain fairly constant and at a considerably slower rate of 3-
8 aa/s (Siller et al., 2010). The speed of recombinant protein translation can be further 
influenced by codon bias, as the translation of rare codons can lead to ribosomal pausing 
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and therefore a reduced protein synthesis rate.  Slow translational speeds may restrict 
incorrect folding, whilst faster translational speeds may expose the emerging nascent 
polypeptide to a greater number of conformational influences.    
In addition to increasing the rate of protein translation, the increased incubation 
temperatures required for recombinant protein expression support aggregate formation by 
encouraging hydrophobic interactions.  As hydrophobic interactions are temperature 
dependent, reducing culture temperature can minimise hydrophobic interactions and also 
reduce the incidence of protein misfolding by decreasing translation rates.  Induction 
temperatures as low as 18°C can be used, however misfolded proteins may still result as the  
reduced temperature can also adversely affect the biochemical activities of molecular 
chaperones and intrinsic folding rates (Siller et al., 2010). 
The location of protein expression also influences the likelihood of protein aggregation.  
When expressed intracellularly, proteins may exist in a reduced form, however upon cell 
lysis the proteins become exposed to an oxidizing environment which encourages disulfide 
bond formation (Hale et al., 2004).  When cysteine residues form disulphide bonds, covalent 
cross-linking creates protein aggregation and affects overall protein conformation.  
Furthermore the incidence of PTMs, such as deamidation, glycation and oxidation, can also 
lead to intramolecular cross-linking and therefore protein aggregates (Nagaraj et al., 1996, 
Manning et al., 2010, Cromwell et al., 2006).  
 
4.3.1.2 Aggregation during protein purification  
It is evident that several factors lead to incorrect folding and aggregation of a recombinant 
protein during protein expression.  However the recombinant protein preparation also 
remains susceptible to conformational changes during protein purification procedures.  It is 
therefore important that the recombinant protein is processed quickly and considerately to 
ensure that product stability is not jeopardised during purification. Environmental 
temperature changes may of course influence protein stability; however the sample is 
unlikely to undergo heat denaturation during purification, as temperatures are generally 
conserved or controlled at cool or ambient temperatures.  
The ionic strength and pH of buffer solutions used during protein purification therefore has a 
greater influence upon protein folding during purification. Fortunately the ionic strength and 
pH of buffers is typically selected to ensure that the structural and functional integrity of the 
protein is not unnecessarily perturbed during purification (Gadgil et al., 2007).  However in 
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some instances acidic buffers may be required to achieve elution during chromatography, 
which would increase the incidence of aggregation (Cromwell et al., 2006).  Sometimes 
elution buffers are supplemented with non-ionic surfactants, which minimise undesirable 
adsorption and aggregation during purification, though may result in oxidation (Manning et 
al., 2010). Following purification, the protein may also encounter aggregation during 
ultrafiltration. During ultrafiltration, the protein concentration at the membrane surface can be 
much greater than that of the sample solution, leading to membrane fouling through 
aggregation formation within the membrane region (Cromwell et al., 2006). 
 
4.3.1.3 Aggregation during storage and formulation 
Following purification, a recombinant product is stored until required for its intended 
application.  Storage temperature is the most critical factor determining preservation of 
protein structure and prevention of protein aggregation.  As mentioned previously high-
temperatures lead to thermal denaturation, protein unfolding and aggregation. Likewise 
proteins can also become susceptible to cold denaturation, as proteins can retain mobility at 
-10°C. A storage temperature of below -30°C is therefore required to prevent cold 
denaturation (Manning et al., 2010).  However freezing temperatures also induce stress 
upon the protein structure by altering the pH and ionic strength, which influences the 
conformational and colloidal stability (Kueltzo et al., 2008). 
Ionic strength and pH can be altered during freezing, through crystallization of buffer salts 
leading to changes in protein conformation (Manning et al., 2010).  Furthermore the warming 
and cooling rates associated with the freeze-thaw process influence freeze concentration 
and the surface area of the ice water interface.  When frozen, a sample undergoes freeze 
concentration as water is lost from the sample, leading to concentration of the solute, which 
increases protein interactions and therefore increases the likelihood of protein aggregation 
(Manning et al., 1989).  Freeze concentration tends to be more problematic with larger 
volumes and concentrations of a protein.  Conversely increased sample protein 
concentrations decrease the amount of protein which is exposed to the ice-water interface 
(Kueltzo et al., 2008).  This is problematic as when surface-labile proteins are exposed to the 
ice-water interface, they can undergo surface induced denaturation (Manning et al., 1989).   
Due to the stress that the freeze-thaw process imposes upon protein structure, repeated 
freeze-thaw cycles are avoided as much as possible.  A purified recombinant protein sample 
may however undergo freeze-drying to produce a dried solid state, which remains stable 
over the long-term.  Although the removal of water by freeze-drying should theoretically 
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minimise protein degradation, the freeze-dry process can put stress upon protein structure.  
A protein may unfold during lyophilisation and aggregate during rehydration, producing 
protein dimers and high-molecular mass multimers (HMM) (Dalmora et al., 1997).  As a 
result, sucrose is a frequently used as an excipient during protein formulation, as it can act 
as a stabilising agent in liquid and lyophilised protein formulations (Allison et al., 1996).  
Protein stability is enhanced as the sucrose increases the thermal transition temperature of 
proteins, inhibiting unfolding and therefore irreversible aggregation.  Although the addition of 
sucrose may increase the recovery of folded protein molecules, its presence may lead to 
glycation of the recombinant product (Gadgil et al., 2007).  
 
4.3.1.4 Protein structure and aggregation  
The susceptibility to protein aggregation is also determined by protein structure.  For 
instance, some proteins interact strongly or weakly in vivo to form oligomers or protein 
complexes.  In addition, multimeric protein assemblies often interact with other biomolecules 
and participate in signal transduction and substrate binding (Heck and van den Heuvel, 
2004). Protein oligomerisation is thought to improve protein stability, minimising the risk of 
proteolysis and thermal denaturation. The addition of a non-covalent cofactor can also 
induce subunit association which further enhances resistance towards chemical and thermal 
denaturation.  Metal cofactors reduce conformational heterogeneity and encourage transition 
to the folded state (Kaltashov et al., 2006).  The incidence of aggregation and insolubility of 
recombinant proteins may also be reduced by the presence of fusion tags, such as GST and 
MBP, which were developed to enhance the solubility of the expressed protein (Cheng and 
Lee, 2010).  
 
4.3.1.5 Aggregation of recombinant lysostaphin  
As recombinant lysostaphin demonstrated charge heterogeneity, recombinant protein 
preparations were analysed for signs of protein aggregation.  It is important to assess 
whether a recombinant protein preparation is affected by aggregation, as protein aggregates 
and particulates may elicit an immune response if clinically administered (Rosenberg, 2006, 
Cromwell et al., 2006). As protein cross-linking and aggregation can influence the charge of 
a protein, it was therefore possible that the protein isoforms detected during CXC separation 
reflected the presence of dimeric or larger HMMs (Cromwell et al., 2006). Furthermore, in 
Section 2.4.3.2, SDS-PAGE analysis of N-terminally His-tagged recombinant lysostaphin 
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(construct 1) suggested that hyper-expression may result in the production of soluble and 
insoluble fractions.  
Unlike the expression of eukaryotic genes in E. coli, the expression of recombinant 
lysostaphin is advantaged by the fact that the gene is derived from a prokaryotic origin, S. 
staphylolyticus. Therefore it is less likely that protein folding will be detrimentally affected by 
the absence of suitable prokaryotic chaperones.  In addition, the prokaryotic origin of 
lysostaphin will mean that native lysostaphin and recombinant lysostaphin are translated at a 
similar elongation rates in S. staphylolyticus and E. coli respectively. Expression of 
recombinant lysostaphin was performed under standard expression temperatures of 30°C or 
20°C. If expression was performed at 37°C, the optimal growth temperature for E. coli, 
aggregate formation would have been encouraged. As expression was performed at 30°C or 
20°C, these temperatures would make the expressed recombinant lysostaphin less 
susceptible to protein misfolding.   
As the amino acid sequence of recombinant lysostaphin does not contain any cysteine 
residues, the structure of the protein will not contain any disulphide bonds and therefore the 
protein should not be susceptible to this form of covalent aggregation. Covalent aggregation 
could however occur through oxidation and cross-linking of tyrosine residues, forming 
bityrosine (Cromwell et al., 2006).  The amino acid sequence of N-terminally His-tagged 
recombinant lysostaphin (construct 1) contains sixteen tyrosine residues which have the 
potential become cross-linked in such a manner. Reversible protein aggregation can also 
occur following relatively weak, non-covalent protein interactions. The reversibility of the 
interactions often result from alterations in pH or protein concentration (Cromwell et al., 
2006).  
N-terminally His-tagged recombinant lysostaphin is regarded as a stable protein in vitro 
following calculation of the proteins instability index by ProParam analysis (Appendix 7.82).  
In Section 4.1, recombinant lysostaphin was found to exhibit the expected staphylolytic 
activity, which indicated that the protein was unlikely to be mis-folded or aggregated to a 
state that interfered with activity. Furthermore, the presence of a bound zinc ion should also 
theoretically minimise the incidence of protein aggregation, through the strength of zinc 
metal coordination.  The zinc binding domain of recombinant lysostaphin is known to be a 
catalytic zinc site, which is distinct from a structural zinc site and therefore should not act to 
stabilize the tertiary structure of recombinant lysostaphin (McCall et al., 2000). However as 
recombinant lysostaphin is devoid of cysteine residues it seems logical that the bound zinc 
molecule will influence the stability and conformation of the protein.  
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During the purification of recombinant lysostaphin, it became apparent that certain conditions 
could affect the solubility of the protein (Sections 2.5.3.3 and 2.5.3.8).  For instance, purified 
protein preparations could not be concentrated by ASF without protein precipitation. In some 
instances it was possible to regain solubility by adding salts to the resuspension, however 
this solution was not compatible with subsequent CXC analysis. As ASF could not be used, 
protein concentration and buffer exchange was achieved through ultrafiltration.  During 
ultrafiltration, recombinant lysostaphin was exchanged into water and whilst visible 
aggregation was rarely observed, it was possible that non-visible aggregated particles may 
have been present within the concentrated sample.  The development of a rapid analysis 
strategy therefore minimised the incidence of protein aggregation by eliminating the 
requirement for ultrafiltration (Section 3.5).  
Following the expression of recombinant lysostaphin, the temperature of the protein was 
maintained at around 4°C during storage or 22°C whilst handling.  Freezing of samples was 
avoided where possible to minimise stress upon the protein structure.  However purified 
recombinant lysostaphin was frozen following large-scale IMAC purification and dialysis, 
prior to lyophilisation.  Although lyophilisation provided long-term stability of recombinant 
lysostaphin, it was not possible to completely resuspend the lyophilised protein prior to CXC 
separation. The macroscopic particulates could be removed by brief centrifugation, however 
this interfered with subsequent IMAC and CXC analysis through poor peak resolution and 
height. 
During the development of a rapid analysis strategy, harvested cells and cell lysates were 
frozen to try and maximise sample throughput (Section 3.5.3.7). However it was found that 
the freeze-thaw process interfered with the charge of recombinant lysostaphin isoforms, 
possibly through freeze concentration or cold denaturation.  Following separation of 
recombinant lysostaphin isoforms, eluted fractions were stored at 4°C as frozen storage 
would not have been suitable considering that the samples were within sodium phosphate 
buffers.  Sodium phosphate is known to crystallise out during freezing, which would therefore 
alter the pH and ionic strength of the samples, potentially leading to protein interactions and 
potentially aggregation (Kueltzo et al., 2008).   
In this work, gel filtration was used to assess whether protein aggregation occurred during 
the recombinant expression of lysostaphin.  Protein aggregation of recombinant protein 
preparations is almost exclusively analysed using gel filtration (Rosenberg, 2006). In Section 
2.5.3.3, preparative GF was used to provide secondary purification of recombinant 
lysostaphin. However preparative GF provides poor resolution of protein aggregates due to 
larger amounts of protein being loaded, therefore an analytical GF column was used to 
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provide enhanced resolution of smaller amounts of protein.  GF can typically resolve protein 
species that demonstrate approximately 25% difference in their hydrodynamic radii, and 
resolution is further reduced if dilute samples are being analysed (Cromwell et al., 2006). 
Resolution is inversely related to the dynamic range over which molecular masses can be 
separated, therefore GF typically has a limited dynamic range (Arakawa et al., 2010).  It is 
therefore important that a GF resin is selected, which provides a good compromise between 
dynamic range and resolution. 
Analysis of potential aggregation of recombinant lysostaphin was performed with an 
analytical GF column, which could provide enhanced resolution.  The Agilent Zorbax® GF-
250 (4.6 x 250 mm) column is a surface-stabilised, hydrophilic column commonly designed 
for the separation of proteins. This column has a dynamic range of between 4 and 400 kDa, 
however provides linear separation between 10 and 250 kDa, therefore should provide good 
separation of recombinant lysostaphin (27.0-29.3 kDa) and any aggregated species.  The 
stationary phase is composed of 4 µm spherical silica particles, providing efficient and high 
resolution separation.  In addition the separation can be performed at 1.0 ml/min which 
permits fairly rapid separation.  This column was therefore used to analyse recombinant 
lysostaphin preparations to assess for presence of mass distinct protein species, with a 
number of aims: 
Aims:  
 To assess the stability of recombinant lysostaphin preparations during storage and 
formulation.  
 To establish whether recombinant lysostaphin becomes aggregated following 
purification using gel filtration.  
 To evaluate whether protein isoforms separated using CXC exhibited aggregation 
using gel filtration. 
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4.3.2 Methods  
 
4.3.2.1 Buffers  
All buffer compositions are outlined in Appendix 7.354.  
 
4.3.2.2 Equipment 
All equipment used during GF analysis of recombinant lysostaphin is outlined in Appendix 
7.355. 
 
4.3.2.3 Sample preparation 
Sample preparation is described in Appendix 7.357.  
 
4.3.2.4 PAGE analysis of protein stability after prolonged storage 
Purified and concentrated recombinant lysostaphin preparations were stored in solution at 
4°C until required for analysis. During analysis the preparations were transferred to ice to 
ensure that the protein was stored at cool temperatures as much as possible. Following 
prolonged storage, a selection of recombinant lysostaphin preparations (preparations 3, 4, 6, 
13 and 19) were subjected to 12% (w/v) SDS-PAGE analysis (Appendix 7.15) to establish 
whether the protein remained stable and retained its expected molecular weight during 
storage.  
 
4.3.2.5 GF Analysis  
GF analysis was performed on fractions which had eluted following IMAC purification of 
recombinant lysostaphin under non-denaturing (Appendix 7.359) and denaturing conditions 
(Appendix 7.360).  GF analysis was also performed on fractions eluted following WCX 
separation of recombinant lysostaphin isoforms (Appendix 7.361).  
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4.3.3 Results  
 
4.3.3.1 PAGE analysis of protein stability after prolonged storage 
Following purification, several recombinant lysostaphin preparations were stored in solution 
at 4°C for prolonged periods of time. The samples were removed from storage occasionally 
to obtain an aliquot for chromatographic separation or assay.  Whilst removed, the samples 
were stored on ice and swiftly returned to 4°C to ensure that the protein was not subjected to 
fluctuations in temperature.  To assess whether the recombinant lysostaphin preparations 
remained stable during storage, the samples were analysed by SDS-PAGE.  As shown in 
Figure 4.57, the majority of the samples remained remarkably stable despite prolonged 
storage at 4°C.  
Figure 4.57: PAGE analysis of recombinant lysostaphin preparations following 
storage at 4°C.  Lane 1: Sigma low molecular weight markers; Lane 2: N-terminally 
His-tagged recombinant lysostaphin (construct 1; preparation 19) at 311 days post-
expression; Lane 3: C-terminally His-tagged recombinant lysostaphin (construct 3, 
preparation 4) at 140 days post-expression; Lane 4: C-terminally His-tagged 
recombinant lysostaphin (construct 3, preparation 3) at 260 days post-expression; 
Lane 5: C-terminally His-tagged recombinant lysostaphin (construct 3. Preparation 13) 
at 225 days post-expression; Lane 6: N-terminally His-tagged recombinant 
lysostaphin (construct 1, preparation 6) at 90 days post-expression; Lane 7: Sigma 
high molecular weight markers.  
 
Some preparations of recombinant lysostaphin (construct 3) seemed to retain their expected 
molecular weights upon analysis at 140 to 260 days, which suggested that the protein 
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remained stable in solution, whilst stored at 4°C. Intriguingly one preparation of recombinant 
lysostaphin (construct 1) appeared to maintain its expected molecular weight for up to 311 
days, whilst another preparation appeared to have undergone degradation after only 90 
days storage.  The latter sample was analysed more frequently during the optimisation of 
protein separation, therefore it is likely that this protein was subjected to mild temperature 
fluctuations on a more regular basis than the other samples were.  
 
4.3.3.2 Influence of lyophilisation on the solubility of recombinant lysostaphin 
As described in Section 3.4.3.3, lyophilised recombinant lysostaphin did not resuspend very 
well after freeze-drying, which complicated downstream processing.  Figure 4.58 
demonstrates how protein adsorption was dramatically reduced following application of N-
terminally His-tagged recombinant lysostaphin (construct 1) which could only be partially 
solubilised following lyophilisation.  Poor peak heights were observed following application of 
between 100 and 1000 µg of re-suspended lyophilised recombinant lysostaphin. However 
the application of liquid preparations of between 8 and 40 µg of recombinant lysostaphin 
demonstrated significantly greater adsorption, which could typically be observed during 
IMAC purification.  
 
Figure 4.58: Comparison of protein binding concentrations following IMAC 
purification of fresh recombinant lysostaphin (construct 1) and re-suspended 
lyophilised recombinant lysostaphin (construct 1).  IMAC purification revealed 
apparent inconsistencies between protein concentration and protein binding with 
fresh and lyophilised samples.   
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It was thought that this apparent lack of binding occurred as a result of the lyophilised 
recombinant protein not fully solubilising in water. Precipitation of the recombinant 
lysostaphin would have led to heterogeneous distribution of the protein within the sample, 
which would have compromised injection of the correct concentrations of protein within the 
sample, due to precipitation. 
 
4.3.3.3 GF of fractions eluted following IMAC purification 
Recombinant lysostaphin (construct 1) was purified by IMAC, as demonstrated in Figure 
4.59. IMAC resulted in the elution of a very broad peak, from which fractions were collected 
and a single fraction was taken and subjected to GF 
Figure 4.59: IMAC purification of N-terminally His-tagged recombinant lysostaphin 
(construct 1).  Fraction 13 was selected for GF separation. 
 
GF separation resulted in the elution of two major peaks and the resolution of multiple minor 
peaks, which indicated that a number of different molecular weight species were present 
within the eluted IMAC fraction (Figure 4.60).  This result was rather unexpected and it was 
unclear whether the difference in molecular weight could be attributable to aggregation, 
which may have occurred following expression, during purification or during storage, as GF 
was performed 24 h after IMAC purification.  
5  10  15  20  25  30  35  40  45  50  
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Figure 4.60: Gel filtration of IMAC fraction 13.  Multiple peaks were resolved during GF 
demonstrating that the fraction was composed of different molecular weight species.  
Fractions 13-17 were subjected to PAGE analysis.  
 
To assess whether differences in molecular weight species could be detected during PAGE 
analysis, selected fractions were subjected to PAGE analysis (Figure 4.61).  PAGE analysis 
indicated that the GF peaks reflected a protein with a molecular weight of just over 26 kDa, 
which corresponded with the mass of recombinant lysostaphin (29.3 kDa). The bands did not 
reveal any difference in the molecular weights of protein eluted during GF, despite resolution 
of distinct molecular weight species.  However the denaturing conditions applied during 
SDS-PAGE will have disrupted aggregated species.  
5  10  15  
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Figure 4.61: PAGE analysis of selected GF fractions.  Lane 1: Fraction 13; Lane 2: 
Fraction 14; Lane 3: Fraction 15; Lane 4: Fraction 16; Lane 5: Fraction 17; Lane 6: NEB 
broad molecular weight markers.  
 
4.3.3.4 GF of fractions eluted following IMAC purification under denaturing 
conditions 
To establish whether different molecular weight species formed through aggregation 
following expression or during IMAC purification, IMAC was performed under denaturing 
conditions by supplementing the chromatographic buffers with urea.  IMAC purification 
resulted in a broad peak from which eluted protein was collected and selected fractions were 
subjected to GF analysis (Figure 4.62).  
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Figure 4.62: IMAC purification of N-terminally His-tagged recombinant lysostaphin 
(construct 1) under denaturing conditions.  Fractions 12, 24, 32 and 36 were subjected 
to GF separation. 
 
Theoretically if the multiple peaks observed previously resulted from aggregated species, 
then the supplementation of IMAC buffers with high concentrations of urea, should have 
dissociated the pre-formed aggregated species.  In addition, by supplementing the buffers 
during IMAC, the risk of aggregation during purification and storage was reduced and 
therefore GF analysis should have revealed fewer peaks.  This however was not the case 
with the elution of multiple peaks during GF (Figure 4.63).  This result indicated that the 
major peak eluting at 12.3 min may have reflected native recombinant lysostaphin, whilst 
peaks eluting after 13 min reflected smaller molecular weight species, which may have 
resulted from protein truncation or degradation.  
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Figure 4.63: Gel filtration of IMAC fractions.  Multiple peaks were resolved during GF 
demonstrating that each fraction was composed of different molecular weight 
species.   
 
Interestingly GF separation of fraction 12 resulted in greater abundance of smaller protein 
species, which in conjunction with the previous experiment, suggest that smaller protein 
isoforms are more poorly retained during IMAC.  IMAC binding of recombinant lysostaphin 
was investigated further in Section 4.2.  The apparent molecular mass heterogeneity 
observed during GF analysis of each IMAC fraction may have also been attributable to the 
charge heterogeneity of recombinant lysostaphin, which may have increased the complexity 
of peaks eluted during GF separation.  
 
4.3.3.5 GF of fractions eluted following WCX separation of recombinant lysostaphin 
isoforms  
In order to minimise sample heterogeneity and to assess whether charge distinct WCX 
peaks occur as a consequence of protein aggregation, WCX fractions from a selected WCX 
separation were subjected to GF analysis.  WCX separation of E. coli cell lysate harvested at 
10.5 h post-induction during culture analysis yielded four distinct peaks representing different 
charge isomers (Figure 4.64).    
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Figure 4.64: WCX separation of N-terminally His-tagged recombinant lysostaphin 
(construct 1) from E. coli cell lysate harvested at 10.5 h post-induction.  WCX peaks of 
interest are indicated by arrows (1-4). The charge isoforms are labelled in order of 
development during culture analysis. Fractions 6, 7 and 8 were selected for SDS-
PAGE analysis. 
 
Despite differences in charge, SDS-PAGE analysis of the major peaks eluted during WCX 
separation did not indicate that the peaks contained different molecular weight protein 
isoforms (Figure 4.65).  
 
Figure 4.65: PAGE analysis of selected WCX fractions.  Lane 1: Sigma low molecular 
weight markers; Lane 2: Fraction 6; Lane 3: Fraction 7; Lane 4: Sigma low molecular 
weight markers; Lane 5: Fraction 8.  
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Although PAGE analysis did not reveal any evidence of molecular weight heterogeneity, the 
charge-distinct protein isoforms were subjected to GF analysis. Comparison of GF results 
suggested that in addition to differences in charge, each GF separation indicated that each 
WCX peak contained protein isoforms which had subtle differences in molecular weight as 
well (Figure 4.66).    
 
Figure 4.66: Comparison of chromatograms following gel filtration of WCX fractions.  
GF results suggest that each WCX peak was composed of protein isoforms of 
relatively similar molecular weights, however in some of the peaks there were 
additionally resolved molecular weight-distinct species. 
  
Interpretation of the GF chromatograms revealed the presence of at least seven size-
variable peaks or peak-shoulders (A-G), which are detailed in Table 4.4.   
 
Table 4.4: Retention time (min) values of identified peaks or peak-shoulders (A-G) 
following gel filtration analysis of fractionated WCX peaks. Peaks which are absent in 
the GF separation are represented by “X”. 
Analysed 
WCX 
peak 
Retention time (min) of Identified GF Peaks 
A B C D E F G 
1 11.960 12.540 13.100 X X X 14.814 
2 11.967 12.607 13.067 X X X 14.747 
3 11.880 X 13.020 X X X 14.980 
4 11.907 X X 13.230 13.787 14.667 X 
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Individual examination of each gel filtration chromatogram shows that there were slight 
differences in protein molecular weights that could not be sufficiently separated, but could be 
resolved using the selected gel filtration resin and chromatographic conditions. GF analysis 
of peak 1, the peak which was found to be observed earliest during culture analysis, 
revealed the resolution of four peaks (Figure 4.67).   
 
Figure 4.67: GF separation of WCX peak 1. All four isoform peaks were identified and 
annotated as A, B, C and G.  
 
The same peaks were also resolved after gel filtration of WCX peak 2 (Figure 4.68).  Peak A 
was slightly more evident, whilst peak G appeared to represent an increasingly abundant 
isoform.  Peak B and C eluted at very similar retention times, whilst peak C also gained 
greater peak height.  
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Figure 4.68: GF separation of WCX peak 2.  Two major peaks were resolved with four 
different molecular weight isoforms (annotated as A, B, C and G and indicated by 
arrows).  
 
Gel filtration of WCX peak 3 demonstrated the separation of two distinct peaks, C and G 
(Figure 4.69). The longer retention time of peak G indicated that the peak represents a 
protein isoform with a significantly lower mass than that of the protein isoform represented 
by peak C.  Peak A also appeared more evident; however this was due to the absence of 
peak B. The loss of peak B indicated that peak 3 contained a greater proportion of protein 
isoforms with a slightly decreased molecular mass.  
 
 
Figure 4.69: GF separation of WCX peak 3.  Two distinct peaks were resolved (C and 
G) with shoulder peak A also remaining apparent. Size isoforms have been annotated 
A, C and G and are indicated by arrows. 
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Gel filtration of WCX peak 4 demonstrated a single peak, which was composed of at least 
four protein isoforms, which had not been separated but had slight differences in molecular 
weight (Figure 4.70).  These isoforms presented as peak shoulders which were identified in 
Figure 4.70.  Isoform D and E appeared to be the most abundant isoforms in WCX peak 4, 
whilst peak A represented the largest molecular weight isoform and peak F the smallest 
molecular weight isoform.   
 
Figure 4.70: GF separation of WCX peak 4.  A single peak is present, however this 
peak is composed of at least four unresolvable protein isoforms which are likely to 
differ slightly in molecular weight (size isoforms have been annotated (A, D, E and F) 
and indicated by arrows). 
 
Overall these results indicate that WCX peaks 3 and 4, which became apparent later in the 
course of culture analysis, were predominantly composed of protein isoforms with a slightly 
smaller molecular weight. These differences in molecular weight would alter the charge of 
the protein, leading to the observed resolution of increasingly acidic protein isoforms during 
WCX separation.  To establish whether these findings could be observed from protein which 
was obtained later in culture analysis, GF analysis was also performed on charge-distinct 
protein isoforms which had been separated during other WCX separations, such as those 
harvested at 21.0 and 24.0 h post-induction of protein expression (Figure 4.71 and Figure 
4.72 respectively).    
 
 
 
  G 
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Figure 4.71: WCX separation of N-terminally His-tagged recombinant lysostaphin 
(construct 1) from E. coli cell lysate harvested at 21.0 hours post-induction.  WCX 
peaks are indicated by arrows (1-4).  Fractions 6, 7 and 8 were subjected to gel 
filtration analysis. 
 
 
Figure 4.72: WCX separation of N-terminally His-tagged recombinant lysostaphin 
(construct 1) from E. coli cell lysate harvested at 24.0 hours post-induction.  WCX 
peaks are indicated by arrows (1-4). Fractions 6 and 8 were subjected to gel filtration 
analysis.  
 
Once again, fractions containing the most prominent peaks were analysed by SDS-PAGE 
(Figure 4.73). However in both instances, PAGE analysis indicated that peaks 2 and 3 
demonstrated molecular weight heterogeneity, which could be resolved by 12% SDS-PAGE. 
This was an unexpected result, which was also observed following PAGE analysis of peaks 
resolved during some other WCX separations performed during culture analysis.   
5 10 15 
5 10 15 
319 
 
 
Figure 4.73: PAGE analysis of WCX fractions prior to gel filtration analysis. A) 
Fractions eluted during WCX separation of cell lysate harvested at 21 h post-
induction. Lane 1: Sigma low molecular weight markers; Lane 2: Peak 2/3; Lane 3: 
Peak 3, Lane 4: Peak 4. B) Fractions eluted during WCX separation of cell lysate 
harvested at 24 h post-induction. Lane 1: Sigma high molecular weight markers; Lane 
2: Peak 2/3; Lane 3: Peak 4.  
 
As PAGE analysis clearly showed variance in the molecular weight of a sub-population of 
protein eluted in certain WCX peaks, gel filtration was performed on selected fractions from 
WCX separations of N-terminally His-tagged recombinant lysostaphin (construct 1) analysed 
at 21 h and 24 h post-induction (Figure 4.74 and Figure 4.75).  Surprisingly GF analysis did 
not indicate the presence of an additional peak reflecting the presence of a higher molecular 
weight isoform.  Instead the resolved peaks all exhibited retention times which corresponded 
with peaks observed during GF analysis of WCX fractions eluted following separation of cell 
lysate harvested at 10.5 h post-induction.  However the most abundant peak demonstrated a 
retention time which was between those observed for peak B and C, therefore could not be 
definitely assigned as being of the same molecular weight species.  
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Figure 4.74:  Comparison of chromatograms following GF separation of WCX 
fractions resulting from WCX analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) harvested at 21 h post-induction.  GF analysis results 
suggested that the analysed WCX fractions were composed of protein isoforms of 
very similar molecular weights.  Identified peaks were annotated A, B, C and G as 
indicated by arrows. 
 
Figure 4.75: Comparison of chromatograms following GF separation of WCX fractions 
resulting from WCX analysis of N-terminally His-tagged recombinant lysostaphin 
(construct 1) harvested at 24 hr post-induction.  Gel filtration results suggest that the 
analysed WCX fractions were composed of protein isoforms of very similar molecular 
weights. Identified peaks were annotated A, B, C and G as indicated by arrows. 
 
Comparison of all the GF separations performed on fractions collected during WCX 
separations of cell lysates harvested at 10.5, 21.0 and 24.0 h post-induction demonstrated 
that all WCX peaks were composed of several protein isoforms which differed slightly in their 
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molecular weights. Seven peaks or peak shoulders were identified and the retention times of 
these were collated and compared in Table 4.5.  
 
Table 4.5: Retention time (min) values of identified peaks or peak-shoulders (A-G) 
following GF analysis of fractionated WCX peaks. Peaks which were absent during GF 
separation are represented by “X”. 
Sample WCX 
peak 
Retention time (min) of identified GF Peaks 
A B C D E F G 
10.5 h post-
induction 
1 11.960 12.540 13.100 X X X 14.814 
2 11.967 12.607 13.067 X X X 14.747 
3 11.880 X 13.020 X X X 14.980 
4 11.907 X X 13.230 13.787 14.667 X 
21.0 h post-
induction 
1 11.920 12.860 X X X 14.734 
2/3 11.793 12.873 X X X 14.747 
24.0 h post-
induction 
1 11.774 12.880 X X X 14.814 
2/3 11.887 12.900 X X X 14.740 
 
Table 4.5 demonstrates that the largest molecular weight isoform (Peak A) was present in all 
samples analysed by gel filtration, with very close retention times achieved in all samples. 
Closer examination of the GF chromatograms suggested that peak A may have in fact 
reflected the presence of the additional faint increased molecular weight band observed 
during PAGE analysis (Figure 4.73).  For instance, the peak height of peak A was 
considerably higher during GF separation of fractions, which had demonstrated the presence 
of a higher molecular weight band during PAGE analysis. It therefore could be possible that 
this higher molecular weight protein isoform was present in all of the WCX peaks, however 
was not always detectable by PAGE analysis due to low abundance.  
Further examination of PAGE analysis may even suggest that the higher molecular weight 
band may represent the “native” N-terminally His-tagged recombinant lysostaphin (construct 
1), as the observed molecular weight was nearer to the 29 kDa size marker than the 
stronger protein band was.  Peaks B-G may have therefore reflected truncated or degraded 
forms of recombinant lysostaphin.  Peaks B and C appeared to occur in the majority of 
samples, however peak retention times tended to deviate anywhere between 12.5 and 13.1 
min, which complicated identification of distinct isoforms. Peaks D, E and F were only 
distinguishable after gel filtration of WCX peak 4, which was separated from cell lysate 
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harvested at 10.5 h post-induction.  Due to the isolated observation of these peaks, it 
seemed likely that these peaks had occurred transiently, possibly during the formation of the 
lowest mass protein isoform (peak G).   
Through interpretation of these results it became apparent that peaks containing charge 
isoforms that were separated by WCX analysis, also demonstrated considerable mass 
heterogeneity.  This was an unusual finding as it seemed unlikely that protein which could 
demonstrate the same apparent charge, would also differ in mass.  Fortunately as the cell 
lysates separated by the ProPac® WCX (2 x 500 mm) column were also separated by using 
a higher resolution ProPac® MAb SCX (4 x 500 mm) column, it became apparent that 
recombinant lysostaphin isoforms could demonstrate both macro- and micro-heterogeneity 
with regard to protein charge (Figure 4.76).   
 
Figure 4.76: Comparison of chromatograms following SCX separation of N-terminally 
His-tagged recombinant lysostaphin (construct 1) from cell lysate harvested at 10.5, 
21.0 and 24.0 h post-induction during culture analysis.  SCX separation using the 
ProPac® MAb SCX (4 x 500 mm) column demonstrated that greater charge 
heterogeneity could be observed within the harvested recombinant lysostaphin 
preparations.  
 
Closer examination of SCX separations during culture analysis revealed that peaks that 
would have appeared homogeneous during WCX separation, were in fact heterogeneous 
(Figure 4.77).  The ProPac® MAb SCX (4 x 500 mm) resolved at least three protein isoforms 
within the peaks that reflected more acidic or basic forms of recombinant lysostaphin when 
separated by the ProPac® WCX (2 x 500 mm).  Due to slight differences in charge, these 
minor protein isoforms were likely to reflect the detection of the molecular weight species 
that were observed during GF separation of WCX fractions.  
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Figure 4.77: Comparison of chromatograms following SCX separation of cell lysate 
harvested at 10.5, 21.0 and 24.0 h post-induction during culture analysis.  Closer 
examination of peaks separated using the ProPac® MAb SCX (4 x 500 mm) column 
suggested that the peaks observed during WCX separation were likely to be 
composed of multiple protein isoforms, which differed slightly in charge.  
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4.3.4 Discussion 
Through repeated expression, purification and separation of recombinant lysostaphin 
preparations, it was possible to gain an insight into the stability of the protein. If maintained 
in a soluble state, recombinant lysostaphin (constructs 1 and 3) were found to remain stable 
in liquid formulation for prolonged periods of time, provided that it was stored at 4°C and not 
subjected to repeated fluctuations in temperature during usage. However lyophilised 
recombinant lysostaphin preparations were not found to respond well to solubilisation and 
protein precipitation was found to interfere with sample loading concentrations during 
chromatographic analysis.  Due to the insolubility of lyophilised recombinant lysostaphin, 
subsequent chromatographic analysis was performed using only freshly prepared liquid 
preparations or cell lysates, which ensured better solubility and ease of preparation. 
GF analysis following protein purification via IMAC also provided an insight into molecular 
mass heterogeneity of the purified recombinant product.  GF separation of a single fraction 
eluted during IMAC, resulted in the elution of two major and a number of minor peaks. SDS-
PAGE analysis confirmed that the eluted peaks contained a protein with a molecular mass 
which corresponded to that of N-terminally His-tagged recombinant lysostaphin (29.3 kDa).  
However PAGE analysis did not give an indication of any significant differences in molecular 
mass due to the denaturing conditions used during analysis, which would prevent detection 
of non-covalent interactions (Price and Nairn, 2009).  More appropriate estimation of native 
masses and oligomerisation states would have been achievable using clear-native PAGE 
(CN-PAGE) or higher resolution blue-native PAGE (BN-PAGE)  (Wittig and Schägger, 2005, 
Wittig et al., 2006).  
In order to establish whether aggregated species contributed to the observation of mass 
distinct species during GF analysis, IMAC purification was performed under denaturing 
conditions to dissociate molecules which may have aggregated during expression or during 
purification. In addition, elution using buffers containing urea also minimised the risk of 
aggregation during storage prior to GF analysis. Given the denaturing conditions, it would be 
expected that GF separation would resolve fewer peaks, particularly those with shorter 
retention times, reflecting the presence of larger dimeric or oligomeric species.  However this 
was not the case as the largest molecular weight major peak remained present, whilst there 
was a reduction in the abundance of smaller molecular species instead.  This finding was 
likely to have reflected minor differences in culture conditions, which would lead to 
differences in product heterogeneity.  
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These initial GF experiments indicated that purified recombinant lysostaphin preparations 
could demonstrate molecular mass heterogeneity. However it was also evident that the 
charge heterogeneity of the recombinant lysostaphin purified during IMAC increased the 
complexity of peaks eluted during GF and therefore it would be more appropriate if GF 
analysis was performed on protein which had undergone prior WCX separation.  GF analysis 
of peaks eluted during WCX separation of cell lysates harvested during culture analysis also 
demonstrated the resolution of a number of molecular mass species.  Although GF 
separation did not result in separation of distinct molecular mass species, seven distinct 
peaks or peak shoulders were resolved within the samples. Further examination of the 
peaks resolved during GF analysis, indicated that although the peaks resolved during WCX 
separation contained charge-distinct protein isoforms, they also contained protein isoforms 
which differed slightly in mass.  
The mass heterogeneity observed within peaks which eluted during WCX separation was a 
much unexpected finding as the recombinant lysostaphin preparation had already been 
separated into fairly distinct charge isoforms. It would seem rational that proteins that 
differed in molecular mass would also differ in charge and vice-versa.  Furthermore it was 
unclear as to why multiple molecular mass species could be observed within all of the 
analysed samples, regardless of the charge that the protein exhibited during WCX 
separation.  However as culture analysis of cell lysates was performed using both the 
ProPac® WCX (2 x 500 mm) and higher-resolution ProPac® MAb SCX (4 x 500 mm) it 
became clear that recombinant lysostaphin could demonstrate both macro- and micro-
heterogeneity with regard to charge. The observed micro-heterogeneity detected during 
ProPac® MAb SCX separation therefore explained why molecular weight species of a similar 
charge could be detected.  
The apparent differences in mass were compounded by SDS-PAGE analysis which 
indicated that some of the peaks resolved during WCX separation could also contain mass-
distinct protein isoforms that were resolvable by PAGE analysis.  This finding had not been 
noticeably observed until SDS-PAGE analysis was performed on a substantial number of 
fractions, which had been generated from WCX separations performed during culture 
analysis.  Although SDS-PAGE is not a high-resolution technique, SDS-PAGE and 
Coomassie blue staining are known to provide resolution to within 1-2% of a 50 kDa protein, 
which would equate to a difference of 4.5-9 amino acids (Price and Nairn, 2009).  The 
technique could therefore be used to detect post-translational processing or proteolysis, 
which resulted in the loss of 4 or more amino acids. Recombinant lysostaphin may therefore 
be susceptible to truncation through proteolytic action.   
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Intriguingly the presence of the increased molecular mass protein isoform resolved during 
SDS-PAGE, was also not noticeably apparent following GF separation.  The most 
reasonable explanation for this finding was that this protein may have actually been detected 
in all of the samples, as peak A, the highest molecular weight protein resolved during GF 
analysis. However due to being of a low protein concentration, this high-molecular weight 
protein may have been present but not always necessarily detectable during PAGE or GF 
analysis. In addition the greater abundance of slightly smaller molecular weight species, 
reflected by resolution of peaks B and C often hindered the resolution of peak A during GF 
analysis.  
Furthermore SDS-PAGE analysis suggested that this protein may possess molecular weight 
which more correctly corresponded with the 29.3 kDa mass of N-terminally His-tagged 
recombinant lysostaphin (construct 1). This minor protein may therefore reflect the presence 
of native, unmodified recombinant lysostaphin, which contradicted theories involving “native” 
protein expression that were developed following culture analysis in Section 3.6.  
Alternatively this minor, higher-molecular mass protein species may have represented a 
post-translationally modified form of the protein, which could explain the increased mass yet 
apparent decreased charge of the protein.   
As SDS-PAGE is a low-resolution technique it was not possible to make any definite 
conclusions about the cause of this finding.  To gain a better indication of the degree of 
mass difference between the observed peaks, comparison could have been made with 
standard proteins.  In addition, the application of some protein standards could have been 
used to confirm that the mobile phase conditions did not promote protein adsorption, whilst 
in the presence of high phosphate concentrations.  However estimation of protein mass 
using standards has been known to lead to overestimation of protein mass, particularly of 
those bearing modifications  (Arakawa et al., 2010). Mass spectrometric analysis would 
therefore provide greater, more sensitive determination of protein mass, as described in 
Section 4.4.  
Overall these experiments indicated that the Agilent Zorbax® GF-250 column could be used 
to provide separation of protein isoforms with significant differences in mass, however could 
only provide resolution of protein variants with only minor differences in molecular weight.  
The Agilent Zorbax® GF-250 column is more commonly used to separate a mixture of 
proteins with different molecular weights or oligomeric proteins, which would display a much 
more dramatic difference in molecular weight.  GF analysis using this column indicated that 
charge variants observed during WCX separation of recombinant lysostaphin were unlikely 
to reflect aggregated, oligomeric species. However GF analysis of protein eluted during 
327 
 
WCX separation indicated that recombinant lysostaphin preparations may display 
considerable charge and mass heterogeneity, which could be attributable to protein 
truncation, through proteolysis or post-translational processing.  As resolution is inversely 
related to the dynamic range of a GF resin, the selection of a GF column with a decreased 
dynamic range would hopefully provide increased resolution of these closely related 
molecular mass isoforms.  
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4.4 LC-MS analysis of recombinant lysostaphin 
 
4.4.1 Introduction 
 
In this work, intact recombinant lysostaphin was analysed using LC-MS analysis. Intact mass 
measurements were acquired using a MaXis Ultra-high resolution (UHR) quad-TOF mass 
spectrometer.  The MaXis system was introduced in 2008 and can achieve mass accuracy 
to within less than 1 ppm and mass resolution of over 40,000 kDa.  Given the accuracy and 
resolution of the instrument, intact mass measurements could provide a valuable insight into 
the how PTMs or sequence variation contributed to the heterogeneity of recombinant 
lysostaphin.  
 
Aims:  
 
 To establish accurate intact mass measurements for recombinant lysostaphin 
variants.  
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4.4.2 Methods  
 
4.4.2.1 Buffers  
All buffer compositions are outlined in Appendix 7.363  
 
4.4.2.2 Equipment 
All equipment used during LC-MS analysis of recombinant lysostaphin is outlined in 
Appendix 7.364. 
 
4.4.2.3 Sample preparation 
Sample preparation is described in Appendix 7.366. 
 
4.4.2.4 Intact LC-MS analysis  
Recombinant lysostaphin isoforms were separated by WCX (Appendix 7.368) and selected 
eluted fractions were concentrated prior to LC-MS analysis (Appendix 7.369). Online LC 
separation of intact protein was performed using a 2.5 µl/min flow rate and a PepSwift® PS-
DVB column.  Following concentration, the protein samples were diluted 1:1 with RP Buffer 
A and 1 µl of the diluted sample was injected onto the column.  An isocratic gradient of 4% B 
was applied for 3 min at the start of separation following injection of the sample. Protein 
separation was achieved by applying a linear gradient of 4-90% B over 9 min. The column 
was then washed using 90% B for 8 min and then the column was equilibrated at 4% B for 
6.5 min.  
 
Separated proteins were delivered to the MaXis UHR-TOF via an ESI source.  The MaXis 
was operated in positive mode under the following conditions: capillary voltage: 4500 V; 
nebuliser gas flow: 1.0 bar; drying gas: 4.0 L/min; drying temperature: 180°C; spectra rate: 
1.0 Hz. The acquired MS spectrum was analysed using Data Analysis Version 4.0 SP1 (253) 
(Bruker Daltonics, UK) and were subjected to Maximum Entropy (MaxEnt) deconvolution 
using the following conditions: low mass: 10000; high mass: 35000; data point spacing: 5 
and instrument resolving power: 200002. Acquired intact mass measurements were 
                                               
2
 Intact MS/MS analysis was performed at the North East Proteome Analysis Facility (NEPAF) with 
assistance from Mr David Blinco 
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compared against theoretical intact protein mass values determined using ProtParam 
prediction (Section 2.4.2.6). 
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4.4.3 Results 
 
4.4.3.1 Intact MS analysis of recombinant lysostaphin 
Prior to intact MS analysis, a purified recombinant lysostaphin preparation was subjected to 
WCX separation (Figure 4.78).  As previous experiments demonstrated that less abundant 
isoforms were not well resolved if low concentrations of protein were applied to the column 
(Section 3.4.3.2), the WCX separation was performed following injection of 31 mg of protein 
to ensure that less abundant protein isoforms could also be resolved.  The injection of a high 
amount of protein resulted in the resolution of several peaks with high absorbance readings 
and significant peak broadening due to column or detector overloading.  
 
 
Figure 4.78: WCX separation of 31 mg of N-terminally His-tagged recombinant 
lysostaphin (construct 1) using a ProPac® WCX-10 (4 x 500 mm) column.  Fractions 14 
and 25 were subjected to intact MS analysis 
 
The separation did however resolve at least three peaks which contained charge distinct 
protein isoforms, which could be subjected to intact MS analysis.  Fractions were collected 
during the separation and selected fractions were therefore analysed to determine intact 
mass measurements. Intact MS analysis generated a mass spectrum which revealed the 
presence of a charge envelope reflecting the presence of intact protein with an estimated 
mass of approximately 29049.7 Da (Figure 4.79). Figure 4.79 also demonstrated that the 
MaXis UHR-TOF instrument could provide extremely high-resolution and high-accuracy 
mass data.   
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Figure 4.79: Acquired mass spectrum following LC-MS of intact protein eluted within 
WCX fraction 14.  
 
Closer examination of a peak within the charge envelope (m/z 938.1, 31+) indicated isotopic 
resolution of less abundant species of the same charge state (Figure 4.80). This finding 
indicated that even though charge isoforms had been separated by WCX separation, the 
eluted protein still demonstrated micro-heterogeneity, which could be clearly resolved by the 
maXis. 
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Figure 4.80: Enlarged base peak region (m/z 938.1, 31+) within charge state envelope 
of protein eluted within Fraction 14. Several less abundant peaks could be observed 
at the same charge state, indicating microheterogeneity within the sample. 
 
The acquired mass spectrum was subjected to MaxEnt deconvolution to provide accurate 
masses of proteins detected within the resolved peaks (Figure 4.81).  Deconvolution 
revealed that Fraction 14 was composed of a number of protein variants with a molecular 
weight similar to that of N-terminally His-tagged recombinant lysostaphin (construct 1) at 
29337.8 Da. The mass associated with the most abundant peak, indicated that Fraction 14 
was predominantly composed of a protein isoform with a mass of 29050.5 Da.  The mass of 
this protein isoform reflected the loss of 287.3 Da from the overall expected molecular weight 
of N-terminally His-tagged recombinant lysostaphin (construct 1) in its apoprotein state.  
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Figure 4.81: Deconvoluted mass spectrum following LC-MS of intact protein eluted 
within WCX fraction 14. MaxEnt deconvolution revealed that Fraction 14 contained 
multiple protein species with a molecular weight similar to that of N-terminally His-
tagged recombinant lysostaphin (construct 1).  
 
Intact MS analysis of protein eluted in WCX fraction 25 also produced a high-resolution 
mass spectrum, which contained a charge envelope reflecting the presence of intact protein 
with an estimated mass of approximately 29106.8 Da (Figure 4.82). 
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Figure 4.82: Acquired mass spectrum following LC-MS of intact protein eluted within 
WCX fraction 25.  
 
Closer examination of a peak within the charge envelope (m/z 939.9, 31+) indicated isotopic 
resolution of less abundant species of the same charge state (Figure 4.83).  Once again the 
complexity of the charge envelope indicated that the protein eluted within WCX fraction 25 
displayed micro-heterogeneity despite prior separation of charge isoforms by WCX.  The 
fraction appeared to be slightly less heterogeneous than protein contained within Fraction 14 
however.   
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Figure 4.83: Enlarged base peak region (m/z 939.3, 31+) within charge state envelope 
of protein eluted within Fraction 25. Several less abundant peaks could be observed 
at the same charge state, indicating microheterogeneity within the sample.  
 
The acquired mass spectrum was subjected to MaxEnt deconvolution to provide accurate 
masses of proteins detected within the resolved peaks (Figure 4.84).  Deconvolution 
revealed that Fraction 25 was predominantly composed of a protein variant with a molecular 
weight of 29107.7 Da.  Once again this mass was similar to the molecular weight of N-
terminally His-tagged recombinant lysostaphin (construct 1), which had a predicted 
molecular weight of 29337.8 Da.  This result would indicate that the most abundant protein 
isoform present within Fraction 25 had a mass which was 230.1 Da less than the predicted 
mass of N-terminally His-tagged recombinant lysostaphin (construct 1) in its apoprotein 
state.    
 
Deconvolution of the mass spectrum also revealed lesser abundance of protein species with 
higher molecular weights ranging between 29150.7 and 29630.0 Da, which may have 
reflected less processed or modified forms of recombinant lysostaphin. Furthermore a 
protein species with a molecular weight of 29336.9 Da could be observed at low abundance 
337 
 
within the deconvoluted mass spectrum, reflecting a protein species with a mass that was 
extremely close to the expected 29337.8 Da mass of N-terminally His-tagged recombinant 
lysostaphin (construct 1) in its apoprotein state.  
 
 
Figure 4.84: Deconvoluted mass spectrum following LC-MS of intact protein eluted 
within WCX fraction 25. MaxEnt deconvolution revealed that Fraction 25 contained 
multiple protein species with a molecular weight similar to that of recombinant 
lysostaphin (construct 1).  The arrow indicates the presence of a low abundance 
protein species with a molecular weight which was very close to that of N-terminally 
His-tagged recombinant lysostaphin (construct 1), which had a mass of 29337.8 Da in 
its apoprotein state. 
 
Intact mass measurements indicated that protein eluted in WCX Fractions 14 and 25 was 
predominantly composed of protein isoforms with molecular weights that were at least 230.1 
and 287.3 Da less than the expected mass of N-terminally His-tagged recombinant 
lysostaphin (construct 1) in its apoprotein state, respectively.  This would suggest loss of 
amino acids from either the N- or C-terminus of the protein.  
 
338 
 
Unfortunately due to instrumental issues, MS/MS analysis could not be performed on the 
precursor ions detected during these experiments to provide sequence data.  Therefore the 
acquired intact mass measurements were compared with the theoretical masses of N-
terminally His-tagged recombinant lysostaphin (construct 1) with loss of amino acids from 
the N- or C-terminus (Figure 4.85 and Figure 4.86). Theoretical mass values of N-terminally 
His-tagged recombinant lysostaphin (construct 1) with loss of N-terminal residues, loss of C-
terminal residues and loss of both N- and C-terminal residues were established using 
ProParam analysis and are presented in Table 4.6, Table 4.7 and Table 4.8 respectively. 
 
Table 4.6: Theoretical masses and pI of recombinant lysostaphin (construct 1) 
sequence variants following sequential loss of N-terminal amino acid residues. 
ProtParam results are presented in Appendix 7.370-Appendix 7.375.  
 
Sequence variant Apoprotein 
mass (Da) 
Number of 
Amino Acids 
Theoretical 
pI 
Intact protein sequence 29337.8 267 9.72 
ΔM1 29206.7 266 9.72 
ΔM1-G2 29149.6 265 9.72 
ΔM1-S3 29062.5 264 9.72 
ΔM1-S4 28975.4 263 9.72 
ΔM1-H5 28838.3 262 9.72 
ΔM1-H6 28701.2 261 9.72 
 
Table 4.7: Mass and theoretical pI of recombinant lysostaphin sequence variants 
following sequential loss of C-terminal amino acid residues. ProtParam results are 
presented in Appendix 7.376-Appendix 7.381.  
 
Sequence variant Apoprotein 
mass (Da) 
Number of 
Amino Acids 
Theoretical 
pI 
Intact protein sequence 29337.8 267 9.72 
ΔK267 29209.7 266 9.68 
ΔI266-K267 29096.5 265 9.68 
ΔT265-K267 28995.4 264 9.68 
ΔG264-K267 28938.4 263 9.68 
ΔW263-K267 28752.1 262 9.68 
ΔL262-K267 28639.0 261 9.68 
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Table 4.8: Mass and theoretical pI of recombinant lysostaphin sequence variants 
following loss of N-terminal and C-terminal amino acid residues. ProtParam results 
are presented in Appendix 7.382-Appendix 7.392.  
 
Sequence variant Apoprotein 
mass (Da) 
Number of 
amino acids 
Theoretical 
pI  
Intact protein sequence 29337.8 267 9.72 
ΔM1+ΔK267 29078.5 265 9.68 
ΔM1+ΔI266-K267 28965.3 264 9.68 
ΔM1+ΔT265-K267 28864.2 263 9.68 
ΔM1+ ΔG264-K267 28807.2 262 9.68 
ΔM1-G2+ΔK267 29021.4 264 9.68 
ΔM1-G2+ΔI266-K267 28908.3 263 9.68 
ΔM1-G2+ΔT265-K267 28807.2 262 9.68 
ΔM1-S3+ΔK267  28934.4 263 9.68 
ΔM1-S3+ ΔI266-K267 28821.2 262 9.68 
ΔM1-S4+ΔK267 28847.3 262 9.68 
ΔM1-S4+ΔI266-K267 28734.1 261 9.68 
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Figure 4.85: Deconvoluted mass spectrum following LC-MS analysis of intact protein 
eluted within WCX fraction 14.  Selected detected masses correlated (within 5 Da) to 
the theoretical masses of truncated recombinant lysostaphin (construct 1) variants in 
an apoprotein state.  
341 
 
Comparison of intact mass measurements obtained during LC-MS analysis of protein eluted 
in Fraction 14 during WCX separation and theoretical masses of full-length and truncated 
forms of N-terminally His-tagged recombinant lysostaphin (Appendix 7.393-Appendix 7.395) 
indicated that the most predominant mass was not directly associated with the loss of 
particular N- or C- terminal amino acids (Figure 4.85). Other less abundant protein species 
may have been attributable to the loss of N-terminal glycine2 or C-terminal isoleucine266 from 
recombinant lysostaphin (construct 1). Mass associations were made allowing a variation of 
up to 5 Da between theoretical and acquired mass values, therefore all of these mass 
comparisons may not have reflected the true composition of protein species detected during 
LC-MS analysis, given the mass accuracy of the MaXis UHR-TOF instrument.   
 
Comparison of intact mass measurements obtained during LC-MS of protein eluted in 
Fraction 25 during WCX separation and theoretical masses of full-length and truncated 
forms of N-terminally His-tagged recombinant lysostaphin (Appendix 7.396-Appendix 7.398) 
did not suggest that the most predominant mass was specifically attributable to the loss of 
particular residues (Figure 4.86).  However one of the detected low abundance mass 
species, presented with a mass within 0.9 Da of the theoretical mass of full-length 
recombinant lysostaphin (construct 1) in its apoprotein state.  Other less abundant protein 
species may have also been attributable to the loss of N-terminal glycine2 or both N-terminal 
glycine2
 and C-terminal isoleucine266. Once again mass associations were made allowing a 
variation of up to 5 Da between theoretical and acquired mass values, therefore all of these 
mass comparisons may not have reflected the true composition of protein species detected 
during LC-MS analysis. 
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Figure 4.86: Deconvoluted mass spectrum following LC-MS analysis of intact protein 
eluted within WCX fraction 25. Selected detected masses correlated (within 5 Da) to 
the theoretical masses of truncated recombinant lysostaphin (construct 1) variants in 
an apoprotein state. 
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4.4.4 Discussion  
 
LC-MS analysis of intact protein separated by WCX proved successful and informative. The 
high resolving power and mass accuracy of the MaXis UHR-TOF mass spectrometer 
provided high resolution mass spectra from which accurate intact protein mass 
measurements could be determined. The acquired mass spectra revealed that both WCX 
fractions contained a heterogeneous mixture of protein, despite prior separation of charge 
isoforms by WCX.  This finding was not especially surprising considering that additional 
heterogeneity was also resolved during SCX separation (Section 3.5.3.13) and GF 
separation (Section 4.3.3.5).  Furthermore column over-loading during WCX separation led 
to band broadening, which decreased the ability of the column to efficiently separate distinct 
charge variants prior to intact LC-MS analysis.  
 
Fortunately the MaXis UHR-TOF could resolve the heterogeneous mixture of proteins 
present within WCX fractions 14 and 25.  LC-MS analysis of intact protein present within 
WCX fraction 14 indicated that the most predominant protein isoform had a mass of 29050.5 
Da, reflecting loss of 287.3 Da from the expected mass of N-terminally His-tagged 
recombinant lysostaphin (construct 1) in an apoprotein state. This loss could have reflected 
the loss of several amino acids from either the N- or C-terminus of the protein, or possibly 
both termini.  Loss of C-terminal lysine267 seemed rational, as the loss of a charged lysine 
residue from the C-terminus would decrease the pI of the protein isoform, leading to 
separation of a more acidic protein isoform, as was known to have eluted into WCX fraction 
14.  
 
LC-MS analysis of intact protein present within WCX fraction 25 also indicated that the most 
predominant protein isoform had a mass of 29107.7 Da, reflecting loss of 230.1 Da from the 
expected mass of N-terminally His-tagged recombinant lysostaphin (construct 1) in an 
apoprotein state.  These losses would also reflect the loss of several amino acids from either 
the N- or C-terminus of the protein, or possibly both termini.  Given that the average mass of 
an amino acid is 110 Da, such a mass decrement would signify the loss of two or three 
amino acids from the sequence of N-terminally His-tagged recombinant lysostaphin 
(construct 1).  As fraction 25 predominantly contained more basic protein isoforms, it 
seemed logical that loss of amino acids would have occurred at the N-terminus of 
recombinant lysostaphin, which features neutral or hydrophobic amino acid residues.   
 
Comparison of deconvoluted intact protein masses and theoretical masses for full-length and 
truncated forms of recombinant lysostaphin (construct 1) did not provide a clear identification 
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of detected mass species. However during LC-MS analysis of protein eluted into Fraction 25, 
a protein species with a mass within 0.9 Da of the theoretical mass of full-length recombinant 
lysostaphin (construct 1) was observed. This finding supported the theory that the intact 
recombinant lysostaphin was present within the protein preparation, but only at low 
abundance. Unfortunately the most predominant protein species masses detected in 
Fraction 14 and Fraction 25 were not directly associated with the masses of truncated 
protein variants.  However evaluation of mass associations identified in Figure 4.85 and 
Figure 4.86 would suggest that the some of the detected protein species could be 
associated with the loss of N-, C- or N- and C-terminal residues.  
 
Identification of detected protein species was complicated further by slight differences 
between the theoretical and detected masses. Given the high mass accuracy of the MaXis 
UHR-TOF, it seemed unlikely that mass errors as great as 5 Da would occur. Data analysis 
would have been complicated further if mass comparisons were based on average 
metalloprotein masses, due to variance in zinc isotopic masses and uncertainty over 
retention of the water molecule within the coordination sphere of the zinc binding domain.  
However as mobile phase conditions used during RP separation were acidic, it is very likely 
that recombinant lysostaphin became denatured during separation, leading to dissociation of 
the bound zinc molecule (Hann et al., 2006). For this reason, detected masses were only 
compared against theoretical average apoprotein masses, rather than theoretical 
metalloprotein masses.  
 
Overall LC-MS analysis indicated that the separated recombinant lysostaphin variants were 
predominantly composed of protein species with a mass that was significantly less than 
theoretical values of full-length recombinant lysostaphin (construct 1) in an apoprotein state. 
Due to the extent of mass loss, it seemed probable that the most predominant variants 
detected in Fraction 14 and 25 represented truncated forms of N-terminally His-tagged 
recombinant lysostaphin (construct 1). Both deconvoluted mass spectra also revealed the 
presence of a number of peaks reflecting the presence of intact proteins with a mass greater 
than the theoretical masses of recombinant lysostaphin (construct 1).  These augmented 
masses may have reflected the presence of protein contaminants with a similar mass to that 
of recombinant lysostaphin or may have reflected post-translationally modified forms of the 
recombinant lysostaphin (construct 1).  
 
To identify PTMs which could explain the heterogeneity of recombinant lysostaphin, the 
acquisition of supporting sequence data was required. Unfortunately it was not possible to 
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perform MS/MS analysis of intact protein using the MaXis UHR-TOF due to instrumental 
issues during these experiments.  However subsequent LC-MS/MS analysis could be used 
to localise and quantify PTMs, which may further increment or decrement the mass of 
truncated forms of recombinant lysostaphin (construct 1). 
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4.5 Discussion  
 
Chromatographic analysis of recombinant lysostaphin produced some interesting findings 
which provided further insight into the nature of the expressed protein.  Turbidometric assay 
of the staphylolytic activity of recombinant lysostaphin demonstrated that enzyme 
preparations were active despite their charge heterogeneity. As lysostaphin is a zinc 
metalloprotease and is dependent on zinc for staphylolytic and elastolytic activity, the 
observed activity suggested that the bound zinc cofactor was indeed present (Park et al., 
1995). Bioinformatic comparison of the sequence of recombinant lysostaphin with LytM, a 
lysostaphin type endopeptidase, revealed that the amino acid sequence of recombinant 
lysostaphin contains the same amino acid residues that compose the zinc binding domain of 
LytM. This finding provided further knowledge about the structure and mass of recombinant 
lysostaphin in its metalloprotein state.   
 
Enzyme activity was studied using a simple turbidometric assay in which the lysis of S. 
aureus was monitored over a fixed time course.  The presence of an N- or C-terminal His-tag 
was not found to interfere with the activity of recombinant lysostaphin, which was 
encouraging considering that the cell wall targeting domain of the protein is located 
juxtaposed to the C-terminal His-tag sequence. Furthermore, the activity of recombinant 
lysostaphin did not appear to be influenced by the choice of expression media or expression 
location, with recombinant lysostaphin found to be active following translocation to the 
periplasm.  Recombinant lysostaphin even retained its expression following lengthy 
purification and lyophilisation, which was surprising considering that prolonged storage, 
purification and lyophilisation were found to interfere with the stability of the protein.  
 
Initial assays were performed on recombinant lysostaphin preparations, which had been 
purified by IMAC, which in retrospect was less reliable given that a proportion of the 
expressed recombinant lysostaphin may not have bound to the IMAC column and therefore 
may have not been available for assay. Furthermore assay of whole preparations may not 
have reflected the activity of individual charge variants; therefore additional experiments 
were performed to establish whether staphylolytic activity was restricted to particular 
variants. The assays revealed that charge variants separated during WCX analysis did 
demonstrate staphylolytic activity, which suggested that post-translational processing or 
modification of N-terminally His-tagged recombinant lysostaphin (construct 1) did not 
interfere with staphylolytic activity. Conversely, this result would suggest that any potential 
modifications or proteolytic events did not occur within the regions of the protein sequence 
that encoded catalytic activity.  
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However these experiments may not have accounted for the activity of all charge variants, 
as the assays were performed on apparently homogeneous protein variants separated by 
the ProPac® WCX (2 x 500 mm) column, which were found to be more heterogeneous when 
separated by the higher resolution ProPac® MAb SCX column (4 x 500 mm) (Section 
3.5.3.13). As recombinant lysostaphin preparations were found to exhibit macro- and micro-
heterogeneity, which could be resolved but not necessarily separated, it may not be possible 
to analyse the activity of every charge variant, especially when present at low 
concentrations. The application of a more sophisticated assay, such as a FRET assay would 
provide more sensitive assessment of staphylolytic activity and enzyme kinetics displayed by 
separated charge variants, even at low concentrations (Warfield et al., 2006). In addition to 
providing more sensitive detection of staphylolytic activity, monitoring the cleavage of 
specific, synthesised substrates would eliminate variability associated with the use of S. 
aureus cells, which can differ in their growth phase physiology and interfere with the 
reproducibility of turbidometric assays. 
 
Using chromatographic separations and LC-MS analysis, the retention behaviour, stability 
and mass of recombinant lysostaphin was investigated. The retention behaviour of 
recombinant lysostaphin was investigated following the observation of poor binding 
efficiency whilst testing the capacity of a ProPac® IMAC-10 column. Further IMAC 
purifications demonstrated that the charge heterogeneity of recombinant lysostaphin 
(construct 1) could interfere with the efficiency of IMAC purification. It is therefore imperative 
that caution is taken when using IMAC to purify recombinant proteins expressed in E. coli, 
particularly if the homogeneity of the preparation is not known.  
 
WCX separation demonstrated that N-terminally His-tagged recombinant lysostaphin 
(construct 1) was found to demonstrate greater charge heterogeneity, whilst C-terminally 
His-tagged recombinant lysostaphin (construct 3) and recombinant lysostaphin without His-
tags (construct 2) both demonstrated a lesser, yet similar degree of charge heterogeneity.  
The peaks eluted during WCX separation corresponded with the theoretical pI of each of 
form of recombinant lysostaphin, however it was interesting to observe that the N-terminally 
His-tagged recombinant lysostaphin (construct 1) preparation contained variants with the 
same charge as observed during separation of recombinant lysostaphin (constructs 2 and 
3).  This result indicated that a high proportion of the N-terminally His-tagged recombinant 
lysostaphin preparation may have undergone truncation. Alternatively the formation of more 
acidic variants may be attributable to phosphorylation, gluconoylation or 
phosphogluconoylation of the N-terminal His-tag sequence (Du et al., 2005a, Du et al., 
2005b, She et al., 2010).  
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Further IMAC purifications suggested that the charge heterogeneity of N-terminally His-
tagged recombinant lysostaphin (construct 1) was associated with unusual retention 
behaviour, in which sequential application of cell lysate resulted in the retention of protein 
which displayed differential binding affinities.  WCX analysis of the purified protein indicated 
that strongest retention was associated with the greater abundance of more basic protein 
isoforms, whilst moderate retention was associated with greater abundance of more acidic 
isoforms. IMAC purification of C-terminally His-tagged recombinant lysostaphin (construct 3) 
was associated with more normal retention behaviour permitting more efficient purification of 
recombinant lysostaphin (construct 3). Variable binding affinity was also observed during the 
purification of C-terminally His-tagged recombinant lysostaphin (construct 1), however WCX 
separation of purified protein suggested that this was likely to be attributable to high column 
loading rather than C-terminal His-tag heterogeneity. 
 
Overall it was thought that the observed variable binding affinities could be attributable to 
negative cooperative binding during application of larger amounts of protein, whereby protein 
molecules with a stronger binding affinity cannot achieve multipoint adsorption due to a lack 
of favourable binding sites. The strength of binding affinity could be influenced by PTMs 
within the His-tag sequence, such as phosphorylation of serine residues, which, depending 
on location could interfere with multipoint binding interactions during IMAC.  Application of 
large amounts of recombinant lysostaphin without a His-tag (construct 2) indicated that a 
small proportion of the preparation could bind to the IMAC column in the absence of a His-
tag. This finding may have indicated that a small proportion of the preparation did not contain 
a bound zinc molecule and therefore could bind to the nickel ions on the stationary phase. 
Alternatively IMAC purification may have perturbed the structure of recombinant lysostaphin 
through removal or replacement of metal ions or through oxidative damage (Warfield et al., 
2006).   
 
These experiments indicated that caution must be taken during IMAC purification to ensure 
that charge heterogeneity and protein structure does not interfere with the ability to purify a 
His-tagged recombinant protein in an efficient manner. The additional charge heterogeneity 
associated with the N-terminal His-tag sequence of recombinant lysostaphin would suggest 
that removal of the N-terminal His-tag sequence or use of alternative forms of recombinant 
lysostaphin (construct 2 and 3) would be advisable. Both C-terminally His-tagged 
recombinant lysostaphin (construct 3) and recombinant lysostaphin without His-tags 
(construct 2) are active and are likely to be less heterogeneous than the N-terminally His-
tagged form of the protein. Both forms of the protein could be purified by CXC which would 
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be the preferred option, or using IMAC in the case of C-terminally His-tagged recombinant 
lysostaphin (construct 3). 
 
Further chromatographic studies revealed that recombinant lysostaphin preparations 
remained stable for long periods of time whilst in liquid formulation and stored at 4°C. 
Lyophilised recombinant lysostaphin also possessed long-term stability however lost 
solubility following resuspension which interfered with peak resolution during WCX analysis 
and contraindicated its usage. SDS-PAGE of recombinant lysostaphin preparations indicated 
that the purified protein was homogeneous, however the use of denaturing conditions during 
SDS-PAGE prevented the detection of larger dimeric or oligomeric species. GF was 
therefore performed on recombinant lysostaphin (construct 1) which had been purified by 
IMAC under non-denaturing and denaturing conditions; to detect and dissociate potentially 
aggregated species. GF analysis resulted in the elution of a number of peaks, which did not 
seem to indicate aggregated species but rather more subtle mass heterogeneity within the 
purified recombinant lysostaphin preparation.  
 
As it was thought that the molecular weight heterogeneity observed during GF analysis was 
attributable to the charge heterogeneity of the purified recombinant lysostaphin preparation, 
further GF separations were performed on protein variants which had been separated by 
WCX during culture analysis.  However molecular weight heterogeneity was also resolved 
during GF analysis of charge distinct protein variants which had been separated by WCX.  
This was an unexpected finding considering that the complexity of the preparation had been 
reduced by WCX and it would be expected that differences in mass may also be associated 
with differences in charge. The macro- and micro-heterogeneity resolved by ProPac® MAb 
SCX separations did however provide an explanation for the presence of different molecular 
weight species with a similar charge.  
 
Molecular weight heterogeneity was also observed during culture analysis following SDS-
PAGE analysis, which was quite surprising considering that the detected protein appeared to 
possess a molecular weight which corresponded more closely with the molecular weight of 
recombinant lysostaphin (construct 1). This finding provided the first indication that the bulk 
of the recombinant lysostaphin (construct 1) preparation may have undergone truncation, 
through loss of N-terminal or C-terminal amino acid residues. It was initially expected that 
the mass differences observed during SDS-PAGE analysis would be evident during GF 
separation, however this was found not to be the case. Closer examination of the GF 
chromatograms suggested that the higher molecular weight species may have in fact been 
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detected as a low abundance peak observed in all of the samples, however low 
concentrations may have interfered with prior detection by SDS-PAGE.    
 
Overall GF analysis indicated that recombinant lysostaphin (construct 1) preparations could 
demonstrate molecular weight heterogeneity as well as charge heterogeneity. Associated 
SDS-PAGE analysis also suggested that the bulk of the recombinant lysostaphin may 
actually be composed of a truncated form of the protein rather than the full length “native” 
recombinant lysostaphin that was initially expected to be expressed. GF separations 
performed using the Zorbax® GF-250 column were therefore informative, however greater 
resolution of molecular weight species could have been achieved using a GF column with a 
smaller dynamic range or through LC-MS analysis.  
 
LC-MS analysis using the MaXis UHR-TOF system provided high resolution and high 
accuracy mass spectra from which accurate intact protein mass measurements could be 
achieved. LC-MS analysis of charge distinct protein isoforms indicated that that eluted 
protein was heterogeneous despite prior WCX separation. This finding was not surprising 
considering that the column was overloaded with sample and that greater heterogeneity had 
already been observed during SCX and GF separations performed using ProPac® MAb SCX 
and Zorbax® GF-250 columns. The obtained mass spectra indicated that protein eluted 
during WCX separation was largely composed of protein with a mass below the expected 
mass of N-terminally His-tagged recombinant lysostaphin (construct 1).  
 
LC-MS analysis of more acidic protein variants eluted within WCX fraction 14 indicated that 
the most predominant variant has a mass of 29050.5 Da, reflecting loss of 287.3 Da from the 
expected mass of recombinant lysostaphin (construct 1) in an apoprotein state. The most 
predominant protein species detected in Fraction 14 could be more definitively associated 
with loss of both N- and C-terminal residues. Loss of C-terminal lysine267
 would provide a 
logical explanation for the observed acidity of the protein during WCX analysis.   
 
LC-MS analysis of more basic protein variants eluted within WCX fraction 25 indicated that 
the most predominant variant has a mass of 29107.7 Da, reflecting loss of 230.1 Da from the 
expected mass of recombinant lysostaphin (construct 1) in an apoprotein state.  However 
the most predominant protein species was less definitively associated with loss of C-terminal 
residues and therefore loss of N-terminal residues seemed more probable.  As fraction 25 
contained more basic protein isoforms, it seemed logical that truncation could have occurred 
at the N-terminus of recombinant lysostaphin, which features neutral or hydrophobic amino 
acid residues.   
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Comparison of deconvoluted intact protein masses and theoretical masses for full-length and 
truncated forms of recombinant lysostaphin (construct 1) resulted in the identification of a 
few closely related masses. For instance, LC-MS analysis of WCX fraction 25 demonstrated 
the presence of a low abundance protein with a mass of 29336.9 Da which may have 
reflected the presence of unmodified and unprocessed recombinant lysostaphin (construct 1) 
in an apoprotein state. This finding supported previous theories that the intact recombinant 
lysostaphin was present within the protein preparation, but only at low abundance.  
 
Associations between theoretical truncated masses and the determined masses of less 
abundant protein species provided further indication that recombinant lysostaphin (construct 
1) may have become truncated at the N- and C-termini during expression.  However as 
theoretical and detected protein masses differed slightly, these identifications could not be 
confirmed as such a mass error would not occur given the high mass accuracy of the MaXis 
UHR-TOF. It therefore seemed likely that the separated charge variants may have 
undergone loss of N-terminal or C-terminal residues, in conjunction with mass increments or 
decrements associated with the addition of PTMs. 
 
LC-MS analysis of N-terminally His-tagged recombinant lysostaphin (construct 1) would 
provide further knowledge about the truncation events and PTMs. Unfortunately it was not 
possible to perform MS/MS and MSn analysis using the MaXis UHR-TOF due to 
instrumental issues. However following rectification of these issues, it is likely that sensitive 
MS/MS and MSn analysis could be performed using the MaXis UHR-TOF system as 
recombinant lysostaphin has a fairly low mass, therefore high sequence coverage and 
characterisation of sequence modifications could be achievable.  However PTMs which 
result in minimal mass shifting, such as deamidation (+0.98 Da) would probably not be 
detectable by intact protein analysis and would therefore analysis of fragmented protein 
would be more sensitive (Xie et al., 2009). Ideally a combination of both analyses would be 
applied to achieve maximal MS/MS sequence coverage and characterise the protein 
structure fully.  The application of de novo sequencing or MALDI-MS would also provide 
sensitive analysis of N-terminal and C-terminal sequences (Bruni et al., 2005, Yamaguchi et 
al., 2004).   
 
Overall these studies provided greater insight into the influence of heterogeneity upon the 
activity, behaviour, stability and mass of recombinant lysostaphin. Product heterogeneity did 
not appear to affect the staphylolytic activity of recombinant lysostaphin, however interfered 
with the ability to efficiently purify N-terminally His-tagged recombinant lysostaphin (construct 
1).  N-terminally His-tagged recombinant lysostaphin (construct 1) was also shown to 
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demonstrate mass heterogeneity during GF and intact protein LC-MS analysis, which was 
thought to be largely attributable to protein truncation. The implications of which are 
discussed further in Chapter 5. 
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5 Discussion  
 
5.1 Cloning, expression and purification of recombinant lysostaphin  
 
During this research recombinant lysostaphin was analysed extensively using 
chromatographic techniques.  However prior to chromatographic analysis, the mature 
lysostaphin domain from S. staphylolyticus was amplified and cloned in E. coli using a 
combination of PCR and gene cloning techniques.  Cloning of the mature lysostaphin 
domain was uneventful and lead to the production of five pET vector constructs, which could 
be used to express recombinant lysostaphin with or without N- or C-terminal His-tags, within 
the cytoplasm or the periplasm of E. coli BL21(DE3). However sequencing of the pET vector 
constructs 1, 2 and 3 lead to the elucidation of two nucleotide mis-matches within the 
lysostaphin gene sequence published by Heinrich et al, (1987).  These nucleotide mis-
matches were confirmed by the work of Gargis et al (2010), who sequenced the pACK1 
plasmid of S. staphylolyticus, which encodes the lysostaphin gene (Gargis et al., 2010, 
Heinrich et al., 1987).  
Whilst the mis-identification of cytosine at position 456 was not found to alter the translation 
of proline152, mis-identification of cytosine at position 96, was found to result in the 
translation of methionine32 rather than isoleucine32.  The presence of a guanine rather than 
cytosine at position 96 was unlikely to have significantly altered the physicochemical 
properties of recombinant lysostaphin, however increased the predicted mass of the protein 
by 18 Da.  This mass increment was not particularly significant; however knowledge of this 
amino acid difference would be useful during characterisation of recombinant lysostaphin, in 
which the correct amino acid sequence would be required for accurate peptide identification 
during LC-MS/MS analysis. Given that the sequence of the pACK1 plasmid was only 
published in 2010, it is unlikely that many past characterisation studies will have been 
performed with knowledge of these amino acid mis-identifications. 
Once transformed into E. coli BL21(DE3), all five pET vector constructs were found to 
express a recombinant protein with a molecular weight that corresponded with the expected 
weight of cloned recombinant lysostaphin (with or without N- or C-terminal His-tag 
sequences). Expression of pET constructs 4 and 5, which featured pelB leader sequences, 
was also found to lead to effective translocation of recombinant lysostaphin to the 
periplasmic space. In the majority of experiments recombinant lysostaphin was hyper-
expressed in a largely soluble form, even when E. coli BL21(DE3) was cultured in a variety 
of expression media and at a several different incubation temperatures. Time-course 
experiments suggested that recombinant lysostaphin expression persisted for between 24 
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and 85 h after the induction of protein expression and was largely determined by bacterial 
growth rates.  Expression of recombinant lysostaphin was also observed following induction 
of protein expression at OD600 nm values above and below the recommended range (0.6-1.0).  
Following expression, it was found that recombinant lysostaphin could be efficiently purified 
using IMAC or CXC to achieve a high level of purity. Single-stage purification was essential 
to ensure that purified recombinant lysostaphin could be obtained rapidly so as to prevent 
sample degradation or modification during purification or storage.  N-terminally His-tagged 
recombinant lysostaphin (construct 1) was most commonly expressed and was purified 
using IMAC due to the high purity that the technique could provide. However this technique 
was used with caution as several publications reported that the N-terminally His-tagged 
sequences could become modified by phosphorylation, gluconoylation and 
phosphogluconoylation (She et al., 2010, Du et al., 2005a, Du et al., 2005b). These 
concerns were confounded by the observation of unusual retention behaviour, whilst testing 
the capacity of an analytical ProPac® IMAC-10 column, which suggested that recombinant 
lysostaphin may exhibit N-terminal His-tag heterogeneity.  
5.2 Separation of recombinant lysostaphin 
 
The ability of CXC to bind recombinant lysostaphin was an unusual finding considering that 
the majority of cellular proteins are anionic and therefore would bind during AXC. 
Nonetheless, the basicity of recombinant lysostaphin proved extremely useful during the 
purification and separation of recombinant lysostaphin isoforms. Greater resolution and 
separation of protein isoforms could be achieved using pellicular rather than monolithic 
stationary phase resins, and therefore ProPac™ IEX were selected in preference over 
ProSwift® IEX columns.  The most superior resolution of protein isoforms could be achieved 
using the ProPac® MAb SCX columns, however as this column was only released in the later 
stages of this research, high-resolution, reproducible separation was achieved using 
ProPac® WCX-10 columns.  
Optimisation of protein separation was primarily achieved using Ultimate™ 3000 HPLC 
systems which provided flexibility to perform one-dimensional or two-dimensional separation 
using various column formats and fraction collection settings. Two-dimensional separation 
could be easily achieved and provided further confirmation that recombinant lysostaphin 
variants could be selectively separated from purified and crude preparations.  Second 
dimensional RP separations also indicated that recombinant lysostaphin preparations 
contained protein variants which differed in their hydrophobicity as well as charge.  Greater 
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resolution of product heterogeneity was achieved using ProPac® MAb SCX separations or 
through intact protein LC-MS however.  
Enhanced resolution and separation of protein isoforms was achieved through optimisation 
of mobile and stationary phase conditions.  Adjustment of mobile phase pH from 7.0 to 8.0 
and extension of gradient duration to 70 min was found to provide the most efficient 
separation using the ProPac® WCX-10 (4 x 250 mm) column. The use of an extended 
ProPac® WCX-10 (4 x 500 mm) column or a narrower bore ProPac® WCX-10 (2 x 500 mm) 
was found to provide enhanced separation.  Column dimensions were ultimately selected 
according to amount of protein available for analysis and the speed at which analysis 
needed to be performed.  
Sample preparation was of paramount importance during this research due to the unknown 
origins of charge heterogeneity, which may have arisen during expression, purification or 
storage. Whilst purified preparations of recombinant lysostaphin provided material which 
could be used to steadily optimise mobile and stationary phase conditions, reliable 
assessment of charge heterogeneity could not be achieved due to retention time variability 
and differences in expression and harvest conditions. In addition, lyophilised preparations 
could not be reliably separated, despite demonstrating staphylolytic activity and providing 
long-term stability.  The ability to efficiently and selectively separate recombinant lysostaphin 
charge variants, directly from cell lysate therefore provided a convenient and reliable source 
of recombinant lysostaphin for analysis.  
Separation of protein isoforms present within purified recombinant lysostaphin or cell lysate 
derived from large shake-flask cultures, was readily achieved using the ProPac® WCX-10 
(4.0 x 500 mm) column and demonstrated that recombinant lysostaphin preparation can 
demonstrate considerable charge heterogeneity. Greater charge heterogeneity was 
associated with higher incubation temperatures or induction of protein expression at higher 
optical densities. Knowledge of these contributing factors lead to a series of experiments that 
demonstrated that expression at 16°C and earlier protein harvesting was associated in a 
more homogeneous protein preparation.  It was therefore evident that like product yield, 
product heterogeneity must be manipulated and monitored during recombinant protein 
expression, to yield a homogeneous product.  
WCX analysis of other cationic recombinant protein preparations, including recombinant 
oxidoreductase and recombinant NADPH-dependent 1-acyl dihydroxyacetone phosphate 
reductase (Ayr1p) demonstrated that charge heterogeneity was not restricted to recombinant 
lysostaphin. Post-translational processing or modification of recombinant proteins expressed 
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in E. coli is not uncommon, as evidenced by publications cited in Section 1.2.1. However it 
was surprising that two other basic recombinant proteins, which do not share functional or 
sequence homology with recombinant lysostaphin, could also demonstrate charge 
heterogeneity upon WCX separation.  These findings indicate that charge heterogeneity, 
post-translational processing and modification of recombinant proteins could be a 
widespread phenomenon, which must be acknowledged during the industrial and 
biopharmaceutical production of recombinant proteins within E. coli.  
The influence of time and optical density at the point of induction upon the charge 
heterogeneity of recombinant lysostaphin only became apparent through rapid analysis of 
protein isoforms present within cell lysate using the ProPac® WCX-10 (2.0 x 500 mm) 
column and ProPac® MAb SCX-10 (4.0 x 500 mm) columns.  Rapid analysis of N-terminally 
His-tagged recombinant lysostaphin (construct 1) revealed a time-dependent pattern of 
charge heterogeneity, in which particular acidic charge variants emerged over time.  
Extended culture analysis of a second culture demonstrated the same pattern of variant 
formation, providing secondary confirmation of this finding. Protein variant formation did 
however occur at a slower rate which corresponded with the slower bacterial growth rate of 
the culture. Rapid analysis therefore provided comprehensive evaluation of the time-
dependent nature of charge variant formation during the course of expression.  
The time-dependent pattern of charge variant formation provided an explanatory mechanism 
for the emergence of acidic and basic protein isoforms during the expression of recombinant 
lysostaphin and explained the variable nature of charge heterogeneity observed when 
cultures were induced at various optical densities. With a knowledge of how charge variant 
formation occurs and factors affecting the degree of charge heterogeneity, it would be 
possible to adjust expression and harvesting conditions to produce a more homogeneous 
product. For instance, reduced optical densities at the point of induction (> 1.0 AU), reduced 
expression temperatures (16°C) and early harvest of the recombinant product (>3h post-
induction) would provide a more homogeneous product.  The use of AIM should be avoided 
on the grounds that the time and optical density at auto-induction could not be monitored 
precisely, unlike IPTG induction.  
This research also demonstrated the power of existing IEX column chemistries to resolve 
charge heterogeneity within recombinant protein preparations.  Using various column 
formats, ProPac® WCX and SCX columns provided separation and resolution of charge 
variants to provide an insight into heterogeneity of recombinant lysostaphin. In addition, 
rapid analysis also provided a robust and efficient method that could be used to provide 
rapid, real-time analysis of recombinant protein production. The greatest separation and 
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resolution was demonstrated using the ProPac® MAb SCX column in the later stages of 
research. The resolution of this column provided explanations for many questions 
encountered during the characterisation of recombinant lysostaphin.  Therefore it is hoped 
that further developments of ProPac® MAb SCX column format and chemistries will provide 
even greater resolution and separation of charge variants in the near future.   
5.3 Activity of recombinant lysostaphin 
 
Functional analysis of recombinant lysostaphin demonstrated that purified and lyophilised 
preparations demonstrated staphylolytic activity. Staphylolytic activity was not affected by 
the presence of N- or C-terminal His-tags, the choice of expression media or translocation to 
the periplasmic space.  Furthermore turbidometric assay of charge variants which had been 
separated by WCX, revealed that putative post-translational processing or modification of 
recombinant lysostaphin did not interfere with staphylolytic activity.  Confirmed staphylolytic 
activity of all assayed samples indicated that the expressed protein structure contained zinc, 
which is essential for the catalytic activity of lysostaphin and suggested that protein 
truncation or the presence of fusion tags or PTMs does not interfere with enzyme activity. 
Bioinformatic analysis also suggested that the zinc cofactor may have bound at conserved 
zinc binding domain residues which are common to lysostaphin-type enzymes, such as LytM 
(Bochtler et al., 2004).  
Although separated charge variants demonstrated staphylolytic activity, it could not be 
guaranteed that every charge variant present within the micro-heterogeneity of recombinant 
lysostaphin preparations possessed staphylolytic activity.  Product micro-heterogeneity could 
be resolved during ProPac® MAb SCX separation, however separation of distinct charge 
variants at sufficient concentrations to enable assay would be difficult to achieve, particularly 
using a turbidometric assay.  The implementation of a more sensitive assay, which could 
assess enzyme kinetics, at a low concentration of recombinant lysostaphin, would therefore 
be desirable to achieve greater functional characterisation of recombinant lysostaphin. For 
the purposes of this research, a simple turbidometric assay sufficed and demonstrated the 
potent anti-staphylococcal activity of recombinant lysostaphin.  
5.4 IMAC analysis of recombinant lysostaphin 
 
Recombinant lysostaphin was analysed during a number of chromatographic studies in 
which the retention behaviour, stability and mass were investigated.  Retention behaviour 
was investigated after poor binding efficiency was observed during IMAC purification. 
Sequential IMAC purifications demonstrated that the charge heterogeneity of N-terminally 
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His-tagged recombinant lysostaphin (construct 1) interfered with binding efficiency during 
IMAC and therefore to achieve full purification, cell lysate had to be applied to the column 
several times, leading to the observation of unusual retention behaviour. WCX analysis of 
purified protein indicated that a greater abundance of more basic variants was associated 
with stronger binding affinity, whilst more moderate binding affinity was associated with a 
greater abundance of more acidic variants.  
C-terminally His-tagged recombinant lysostaphin (construct 3) exhibited much greater 
binding efficiency during IMAC purification. Although some unusual retention behaviour was 
observed during IMAC purification, WCX separation did not suggest that protein binding 
affinity was associated with charge heterogeneity, but rather high sample loading. It was 
thought that unusual retention behaviour observed during IMAC purification could be 
attributed to high sample loading and the principles of negative cooperative binding, whereby 
protein molecules with a stronger binding affinity cannot achieve multipoint adsorption due to 
a lack of favourable binding sites. Furthermore, it was thought that truncation or modification 
of N-terminal His-tag residues may compromise the strength of binding affinity. 
WCX separation of N-terminally His-tagged recombinant lysostaphin (construct 1) revealed 
that the protein preparations demonstrated greater charge heterogeneity than C-terminally 
His-tagged recombinant lysostaphin (construct 3) and recombinant lysostaphin without His-
tags (construct 2) which both exhibited a lesser, yet similar degree of charge heterogeneity. 
The observed charge variants appeared to reflect the respective theoretical pIs of the 
proteins, however it was interesting to note that the N-terminally His-tagged recombinant 
lysostaphin (construct 1) preparation contained variants with the same charge as observed 
during separation of recombinant lysostaphin (constructs 2 and 3). This result suggested that 
N-terminally His-tagged recombinant lysostaphin preparations may have undergone 
truncation. Alternatively the formation of more acidic variants may be attributable to 
phosphorylation, gluconoylation or phosphogluconoylation of the N-terminal His-tag 
sequence (She et al., 2010, Du et al., 2005a, Du et al., 2005b).  
Overall these results indicated that great care must be taken when using IMAC to purify a 
recombinant protein expressed in E. coli, particularly if the homogeneity of the product is 
uncertain. N-terminally His-tagged recombinant lysostaphin (construct 1) was associated 
with inefficient IMAC purification, therefore removal of the N-terminal His-tag sequence 
would be advisable. Alternatively expression and purification of C-terminally His-tagged 
recombinant lysostaphin (construct 3) or recombinant lysostaphin without His-tags (construct 
2) using IMAC or preferably CXC would be advisable to improve the efficiency of purification 
and minimise the heterogeneity of the recombinant protein preparation.  
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5.5 GF analysis of recombinant lysostaphin 
 
Recombinant lysostaphin was found to display long-term stability in liquid formulation when 
stored at 4°C which was extremely useful during the optimisation of protein separation.  
Lyophilised preparations also provided long-term stability, however issues with protein 
insolubility interfered with the capacity to analyse the resuspended recombinant lysostaphin. 
GF analysis of recombinant lysostaphin which had been purified by IMAC under non-
denaturing and denaturing conditions indicated that the protein was unlikely to be 
aggregated.  GF separation of protein which had been separated by WCX during culture 
analysis also did not suggest the presence of aggregated species, however did indicate that 
protein eluted within peaks separated during WCX analysis demonstrated subtle mass 
heterogeneity.  The observed heterogeneity was thought to be attributable to micro-
heterogeneity which could only be observed following separation using the ProPac® MAb 
SCX column. 
Mass heterogeneity was also detected during SDS-PAGE performed following culture 
analysis, which revealed the presence of a low abundance protein with a molecular weight 
corresponding more closely to that of recombinant lysostaphin (construct 1).  This finding 
indicated that the bulk of recombinant lysostaphin preparations may in fact be composed of 
a truncated form of the protein. Closer examination of GF chromatograms provided further 
evidence that full-length “native” lysostaphin may be present in the majority of samples 
however was often undetectable during SDS-PAGE due to being present at such low 
concentrations. Whilst GF analysis proved to be very informative, high resolution analysis of 
mass heterogeneity could not be achieved using the Zorbax® GF-250 column.  
5.6 LC-MS analysis of recombinant lysostaphin 
 
High resolution analysis of mass heterogeneity could be obtained through LC-MS analysis of 
intact recombinant lysostaphin (construct 1) using a MaXis UHR-TOF system.  LC-MS 
analysis revealed that the intact protein samples were heterogeneous despite prior 
separation by WCX. This finding was not surprising considering that previous SCX and GF 
separations performed using the ProPac® MAb SCX and Zorbax® GF-250 columns had 
demonstrated additional charge and mass heterogeneity.  The obtained mass spectra 
indicated that protein eluted during WCX separation was largely composed of protein with a 
mass below the expected mass of N-terminally His-tagged recombinant lysostaphin 
(construct 1), suggesting that the protein had undergone truncation.  
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LC-MS analysis of more acidic protein variants eluted within WCX fraction 14 demonstrated 
that the most predominant variant has a mass of 29050.5 Da, reflecting loss of 287.3 Da 
from the expected mass of recombinant lysostaphin (construct 1) in an apoprotein state. 
Such a loss may have reflected the loss of several amino acids from either the N- or C-
terminus of the protein, or possibly both termini. Loss of C-terminal lysine267
 would provide a 
logical explanation for the observed acidity of the protein during WCX analysis. 
LC-MS analysis of more basic protein variants eluted within WCX fraction 25 indicated that 
the most predominant variant has a mass of 29107.7 Da, reflecting loss of 230.1 Da from the 
expected mass of N-terminally His-tagged recombinant lysostaphin (construct 1) in an 
apoprotein state. Once again this loss may have indicated the loss of several amino acids 
from either the N- or C-terminus of the protein, or possibly both termini. As fraction 25 
contained more basic protein isoforms, it seemed logical that truncation could have occurred 
at the N-terminus of recombinant lysostaphin, which features neutral or hydrophobic amino 
acid residues.   
The acquired intact mass measurements were found to correlate with some of the theoretical 
mass measurements of full-length and truncated forms recombinant lysostaphin (construct 
1) in an apoprotein state. For instance, during LC-MS analysis of WCX fraction 25, a low 
abundance protein was detected with a mass of 29336.9 Da which was extremely close to 
the mass of full-length recombinant lysostaphin (construct 1). This finding supported the 
theory that the intact recombinant lysostaphin was present within the protein preparations, 
but only at low abundance. Due to the high mass accuracy provided by the MaXis UHR-
TOF-system and slight differences between theoretical and acquired masses it was evident 
that nature of resolved protein variants could not be elucidated without confirmatory 
sequence data acquired by LC-MS/MS.   
Nonetheless the acquired mass measurements indicated that the majority of the N-terminally 
His-tagged recombinant lysostaphin (construct 1) preparation had undergone truncation of 
N- C- or N- and C-terminal residues. It also seemed likely that the intact mass 
measurements reflected protein truncation, in conjunction with mass increments or 
decrements associated with the addition of PTMs. These findings would provide an 
explanation for the micro- and macro-heterogeneity observed during chromatographic 
separation of recombinant lysostaphin preparations.  Further confirmation of these theories 
could be achieved by performing MS/MS analysis of intact protein or digested peptides in 
combination with MSn analysis, 100% sequence coverage should be obtainable, permitting 
full characterisation of sequence variants and PTMs.  N-and C-terminal sequences could 
also be investigated by MALDI-MS or by using MS/MS data to perform de novo sequencing.  
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5.7 Heterogeneity of recombinant lysostaphin  
 
This research has demonstrated that recombinant lysostaphin displays considerable 
heterogeneity when expressed in E. coli.  Charge heterogeneity within recombinant 
lysostaphin preparations became evident whilst optimising CXC separation following cloning, 
expression and purification of recombinant lysostaphin (construct 1, 2, 3 and 4). 
Recombinant lysostaphin was expressed within the cytoplasm of E. coli or was translocated 
to the periplasmic space, however charge heterogeneity was still observed upon CXC 
separation of periplasmically expressed C-terminally His-tagged recombinant lysostaphin 
(construct 4).  The charge heterogeneity of recombinant lysostaphin (construct 5), which had 
been successfully translocated to the periplasm in a soluble form, was not investigated 
however, as the other forms of recombinant lysostaphin were more convenient to harvest 
and purify during initial studies. 
Through continued expression, purification and separation of recombinant lysostaphin it 
became apparent that the charge heterogeneity of recombinant lysostaphin could be 
extremely variable and therefore could be attributable to a number of factors, including 
amino acid sequence and expression conditions, such as temperature, location and media.  
To minimise variables, analysis was primarily focused on N-terminally His-tagged 
recombinant lysostaphin (construct 1), which could be conveniently harvested from the 
cytoplasm of E. coli and purified efficiently using IMAC or CXC.  Repeated CXC separation 
of N-terminally His-tagged recombinant lysostaphin (construct 1) demonstrated that most 
preparations were associated with the presence of a number of acidic and basic protein 
variants. It also became apparent that the abundance of such variants was dependent upon 
time and optical density at the point of induction of protein expression.  
Rapid analysis of shake-flask cultures which were incubated for between 30 and 85.5 h post-
induction, demonstrated a time-dependent pattern of charge variant formation (Sections 
3.5.3.11 and 3.5.3.12).  In this pattern, recombinant protein expression was marked by the 
presence of more basic charge variants, which appeared to undergo conversion to produce 
a more acid charge variant.  A conversion mechanism was proposed as the initial increase in 
abundance of basic variants was followed by a steady increase in acidic variants, which 
appeared to occur in proportion to a steady decrease in the abundance of basic variants. 
The expression level of the basic variant was not found to decrease completely, which 
supported the theory that this variant reflected the ‘native’ state in which E. coli translated 
recombinant lysostaphin (construct 1) during the course of expression.  
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The term ‘native’ state could only be used tentatively, as it was not clear whether E. coli 
translated N-terminally His-tagged recombinant lysostaphin exactly as encoded by the pET 
vector construct (construct 1). This could only be confirmed by performing a series of 
characterisation experiments to assess the mass of N-terminally His-tagged recombinant 
lysostaphin.  The mass of N-terminally His-tagged recombinant lysostaphin was investigated 
through SDS-PAGE, GF separation and LC-MS analysis, which provided an increasing 
degree of mass resolution. SDS-PAGE generally indicated that recombinant lysostaphin 
preparations were homogeneous, however SDS-PAGE analysis of recombinant lysostaphin 
harvested during culture analysis indicated that a small proportion of the preparation actually 
had a mass which appeared closer to the expected mass of recombinant lysostaphin 
(construct 1) (Section 3.5.3.11). This was an unexpected finding, as the mass determination 
by SDS-PAGE was assumed to be fairly inaccurate considering the fairly low resolution of 
the technique. In addition it seemed unusual that the majority of the protein preparation 
appeared to be of a lesser mass. This finding therefore provided the first indication that N-
terminally His-tagged recombinant lysostaphin (construct 1) may become truncated upon 
expression in E. coli.  
GF analysis provided further confirmation of mass heterogeneity within recombinant 
lysostaphin (construct 1) preparations, which seemed unlikely to be attributable to 
aggregated species. Correlation of SDS-PAGE and GF results suggested that most 
recombinant lysostaphin preparations contained a low abundance protein with a mass closer 
to the expected mass of recombinant lysostaphin.  The greater abundance of lower 
molecular weight species further supported the theory that recombinant lysostaphin 
(construct 1) may have undergone truncation.  Mass heterogeneity was even observed 
following WCX separation of charge variants, which was a little surprising, however 
correlated with separations performed using the ProPac® MAb SCX column in which macro- 
and micro-heterogeneity was clearly observed.   
High-resolution analysis of mass could be achieved through LC-MS analysis of intact 
recombinant lysostaphin. LC-MS analysis revealed that protein which had been separated 
by WCX still displayed mass heterogeneity and that the most predominant protein isoforms 
possessed masses which were 287.3 Da and 230.1 Da less than the expected mass of N-
terminally His-tagged recombinant lysostaphin (construct 1), which had a mass of 29337.8 
Da. As the more acidic protein variant was associated with loss of 287.3 Da it was 
postulated that this loss may be associated with cleavage of the C-terminal lysine267 residue 
and additional uncharged residues from the N- or C-terminus. The more basic protein variant 
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was therefore only thought to be associated with loss of uncharged amino acids from the N-
terminus of the protein.   
LC-MS, GF and SDS-PAGE analysis all indicated that recombinant lysostaphin preparations 
may have contained a low abundance protein variant with a molecular weight close to the 
theoretical mass of N-terminally His-tagged recombinant lysostaphin (construct 1).  These 
results therefore indicated that the ‘native’ protein that was predicted to be expressed during 
culture was in fact a truncated form of the protein. On the grounds of LC-MS data, it seemed 
likely however that the ‘native’ protein detected during culture analysis had a very similar 
charge to that of full-length recombinant lysostaphin, possibly due to loss of uncharged N-
terminal residues. Further explanation of the charge and mass heterogeneity of N-terminally 
His-tagged recombinant lysostaphin (construct 1) is provided in Figure 5.1.  
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Figure 5.1:  Explanation of observed charge and mass heterogeneity within N-
terminally His-tagged recombinant lysostaphin (construct 1) preparations. 
Comparison of results obtained during CXC separation (A), LC-MS analysis (B), GF 
analysis and SDS-PAGE (C) provided the proposed explanations. Macro-and micro-
heterogeneity observed during separation of recombinant lysostaphin using the 
ProPac® MAb SCX column (A) revealed a number of acidic and basic peaks upon 
which these explanations are based. LC-MS analysis (B) revealed that acidic and 
basic peaks were likely to be associated with loss of amino acids from the N- or C-
terminus, but also PTMs resulting in mass decrements or increments. LC-MS analysis 
(B), GF analysis and SDS-PAGE (C) suggested that full-length recombinant 
lysostaphin may be present as a low abundance basic variant and a low abundance 
variant with PTMs which reduce protein charge.  
 
Further confirmation of these explanations is required and could be achieved through 
MS/MS analysis of intact and digested recombinant lysostaphin. Additional validation of 
these results is also essential considering that these concepts have been derived from data 
which was obtained following analysis of N-terminally His-tagged recombinant lysostaphin 
(construct 1), which had been expressed in different shake-flask cultures.  Correlation 
between LC-MS, CXC, GF and SDS-PAGE analysis results does however favour these 
explanations.  
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5.8 Truncation of recombinant lysostaphin 
 
The theoretical mass of N-terminally His-tagged recombinant lysostaphin was calculated on 
the basis that the N-terminal methionine residue was retained.  The N-terminal methionine 
residue is not always retained as methionine aminopeptidases (MetAPs) co-translationally 
process the removal of the N-terminal methionine as the nascent polypeptide emerges from 
the ribosome.  In a few instances, the N-terminal methionine residue has found to not be 
removed during recombinant production (Table 1.6); therefore the theoretical mass of N-
terminally His-tagged recombinant lysostaphin was calculated based on the maximum 
number of amino acids which could be translated within the polypeptide. The intact protein 
masses obtained during LC-MS analysis suggested that the N-terminal methionine was likely 
to have been co-translationally removed during expression, in additional to post-translational 
removal of additional N- or C-terminal residues.  
Truncation of N-terminally His-tagged recombinant lysostaphin (construct 1) may have 
arisen as a consequence of cloning and expressing only the mature lysostaphin encoding 
domain, rather than the gene encoding preprolysostaphin. In S. staphylolyticus lysostaphin is 
expressed extracellularly as a catalytically active 27 kDa mature enzyme, following 
conversion from prolysostaphin by a cell wall-associated cysteine protease (Grundling and 
Schneewind, 2006). Prolysostaphin is itself derived from signal peptidase cleavage of the N-
terminal signal peptide of 42 kDa preprolysostaphin upon signal peptide-mediated 
translocation from the cytoplasm to the periplasm. The presence of the N-terminal signal 
peptide region of preprolysostaphin and the prepropeptide of prolyostaphin therefore shields 
the N-terminal residues of mature lysostaphin from proteolytic cleavage, as the 
preproenzyme translocates from the cytoplasm to periplasm and to extracellular space.   
An alternative explanation for the truncation of N-terminally His-tagged recombinant 
lysostaphin may be dependent on the elastolytic activity of lysostaphin. Although 
recombinant lysostaphin is produced to take advantage of its potent staphylolytic activity, the 
elastolytic activity of the enzyme is often disregarded. As the amino acid sequence of elastin 
is glycine rich, it is likely that lysostaphin’s elastolytic activity is attributable to the enzymes 
preference for glycine-rich sequences (Park et al., 1995).  Elastolytic activity of lysostaphin 
proceeds under slow kinetics, however could theoretically auto-catalyse cleavage of peptide 
bonds associated with hydrophobic or aromatic amino acids which are accessible within the 
structure of recombinant lysostaphin (Park et al., 1995, Mecham et al., 1997). Evidence of 
such an interaction was observed in related work following peptide identification of tryptically 
digested N-terminally His-tagged recombinant lysostaphin (construct 1) (Appendix 7.341, 
associated data not shown).  
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As explained in Section 4.1.1.2, elastolytic activity is dependent on the presence of zinc and 
a distinct catalytic binding domain, featuring an Ala-Ala-Thr-His-Glu sequence in the N-
terminal portion of mature lysostaphin (Figure 5.2).  The tertiary conformation of recombinant 
lysostaphin is likely to be primarily dictated by the zinc binding domain residues within the 
protein, however in the absence of the crystal structure of lysostaphin it is hard to predict 
how the protein will fold.  It does however seem feasible that the elastolytic catalytic domain 
could interact with the C-terminal residues if they became proximal. If auto-elastolytic activity 
was responsible for proteolysis of cleavage of peptide bonds within the sequence of 
recombinant lysostaphin, then expression of recombinant prolysostaphin may help to reduce 
elastolytic activity, as prolysostaphin is known to be 4.5 fold less active than mature 
lysostaphin (Thumm and Götz, 1997).   
 
Figure 5.2: Amino acid sequence of N-terminally His-tagged recombinant lysostaphin 
(construct 1) indicating the N-terminal His-tag sequence (red), proposed catalytic site 
for elastolytic activity (green) and zinc binding domain residues (blue) as determined 
by ClustalW analysis performed in Section 4.1.3.1. 
 
Protein truncation can also result during expression due to a number of reasons, such as 
codon bias or proteolytic processing. As lysostaphin is derived from a prokaryotic source, 
extreme codon bias would not be expected during the expression of recombinant lysostaphin 
in E. coli. S. staphylolyticus has a GC content of 35%, whilst E. coli BL21(DE3) has a slightly 
higher GC content of 50.8% and therefore codon bias is unlikely to exert a significant 
influence on protein expression (Sloan et al., 1982). If codon bias did occur, then premature 
termination of protein translation would occur, yielding an abnormal protein, which would be 
rapidly recognised and degraded by host cell proteases.  
The cytoplasm of E. coli does however possess a number of proteases which can degrade 
abnormal or foreign proteins.  Cellular proteasomes survey the cellular environment to detect 
incomplete proteins, mis-sense proteins, post-synthetically damaged proteins, denatured 
proteins, mis-folded proteins or genetically-engineered proteins (Goldberg, 2003). In 
prokaryotes, such as E. coli, degradation involves a number of ATP-dependent proteases, 
such as Lon (La), HflB (FtsH), ClpAP, ClpXP and ClpYQ (Hs1UV), which have distinct 
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substrate specificities (Gottesman et al., 1998). Although peptide bond hydrolysis does not 
require ATP hydrolysis, the ATP dependence is thought to be required to permit substrate 
unfolding to facilitate degradation (Starkova et al., 1998). The proteases are co-ordinately 
induced along with molecular chaperones, as part of a heat-shock response, which is 
initiated when large amounts of unfolded or foreign proteins are expressed (Goldberg, 2003).  
Protein unfolding is a critical factor in proteolysis and therefore chaperones enhance the 
process of protein degradation.  Proteolysis therefore occurs in a progressive manner in 
which the substrate is unravelled from a ‘degradation signal’ which is present somewhere in 
the amino acid sequence of the protein.  The selectivity of intracellular proteolysis depends 
on the ability of the enzyme to detect a specific ‘degradation signal’ which is typically 
determined by C- or N-terminal sequences or chemical damage such as oxidation, glycation 
or deamidation (Goldberg, 2003, Keiler and Sauer, 1996).  The level of degradation by the 
proteases is then determined by protein stability, which is weaker if a protein has been mis-
folded or has an absent co-factor (Prakash et al., 2004, Goldberg, 2003).  
GF analysis suggested that N-terminally His-tagged recombinant lysostaphin (construct 1) 
was unlikely to be aggregated and therefore it was less likely that the protein was mis-folded 
following expression.  Zinc is known to bind tightly within the structure of metalloproteins and 
therefore the structure of recombinant lysostaphin would be preserved by the presence of 
the zinc cofactor.  However as demonstrated by Figure 5.2, the genetically engineered N-
terminal His-tag sequence or C-terminal residues may have been accessible to proteases 
and therefore may provide a degradation signal, which leads to progressive degradation of 
recombinant lysostaphin, which was believed to be observed during the later stages of 
culture analysis (Section 3.5.3.11).  The speed and consistency at which acidic charge 
variants developed would also suggest that an enzymatic mechanism of conversion was 
involved.  Proteolytic activity would also be enhanced by increased temperatures or richness 
of expression media, which would explain why charge heterogeneity was increased at higher 
temperatures or within complex media such as AIM or LB (Swamy and Goldberg, 1982).  
5.9 PTM of recombinant lysostaphin 
 
LC-MS analysis of N-terminally His-tagged recombinant lysostaphin (construct 1) revealed 
that intact mass measurements could not be exclusively attributable to the loss of specific N- 
or C-terminal residues and therefore it was thought that PTM of recombinant lysostaphin 
variants could provide an explanation for additional mass increments or decrements.  This 
theory was supported by the additional mass and charge micro-heterogeneity, which was 
observed during GF and SCX analysis, performed using the ProPac® MAb SCX and Zorbax® 
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GF-250 columns.  Whilst mass heterogeneity could be attributable to PTM of any amino acid 
residue, charge heterogeneity would only be caused by modification of charged amino acid 
residues. As discussed in Section 3.6, there are multiple charged residues within the 
sequence of recombinant lysostaphin which may have become modified by enzymatic or 
chemical modifications.  
WCX analysis revealed that N-terminally His-tagged recombinant lysostaphin (construct 1) 
exhibited greater heterogeneity than C-terminally His-tagged or non-tagged forms of 
recombinant lysostaphin, which would suggest that the N-terminal His-tag sequence may 
have undergone modification. Furthermore, N-terminally His-tagged recombinant lysostaphin 
(construct 1) exhibited unusual retention behaviour and poor binding capacity during IMAC 
purification, indicating N-terminal His-tag heterogeneity.  N-terminal His-tag heterogeneity is 
not unknown, as reported in Table 4.1 and therefore it was possible that the N-terminal His-
tag sequence may have undergone phosphorylation of serine residues or modification of the 
α-amino acid, in the form of gluconoylation or phosphogluconoylation.  
 
Phosphorylation of serine residues and gluconoylation or phosphogluconoylation of the α-
amino acid would lead to the development of acidic recombinant lysostaphin variants, 
through the introduction of negative charges or neutralisation of the positively charged α-
amino terminus.  Given that α-N-6 gluconoylation and α-N-6  phosphogluconoylation result in 
mass increments of 178 Da and 258 Da respectively, such modifications would have to have 
occurred in conjunction with loss of several N-terminal or C-terminal residues.  The 
occurrence of such α-N-terminal modifications could trigger N-terminal proteolysis or 
conversely N-terminal proteolysis may minimise the occurrence of such modifications. 
Phosphorylation of serine residues would seem more logical considering that the addition of 
single or multiple negatively charged phosphate groups could interfere with the binding 
affinity of the N-terminal His-tag sequence during IMAC purification.  
Other N-terminal modifications may have led to the development of more acidic recombinant 
lysostaphin variants, such as the retention of N-formylmethionine or addition of N-acetyl or 
N-methyl groups.  The retention of N-formylmethionine is unlikely considering the loss of 
mass detected during LC-MS analysis, however N-acetylation of N-terminal residues may 
feasibly occur to stabilise the structure of recombinant lysostaphin following removal of N-
terminal methionine or glycine residues (Charbaut et al., 2002). Chemical modification of 
amino acid side chain groups, such as oxidation, deamidation or glycation could also 
produce acidic variants, and if present at N- or C-terminal sequences, could act as a 
degradation signal for proteolysis. Given the chemical nature of these modifications, it is 
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however unclear whether more complex multi-stage modifications such as glycation could 
lead to the formation of acidic recombinant lysostaphin variants, as readily and consistently 
as was observed during culture analysis.  Smaller, less complex chemical modifications such 
as oxidation or deamidation would therefore seem more likely.  
Enzyme-catalysed side chain modification would be able to occur readily and in a more 
consistent manner, therefore would have led to the formation of acidic recombinant 
lysostaphin variants. Phosphorylation and acetylation are known to increase the net charge 
of a protein, whilst methylation can either neutralise ε-amino charges upon the addition of 
mono- or di-methyl groups, or introduce a positively charged tri-methyl group (Gooley and 
Packer, 1997). The majority of these modifications would have decreased the charge of N-
terminally His-tagged recombinant lysostaphin (construct 1), but would have also increased 
the mass of the protein (Table 5.1).  These modifications would therefore have had to occur 
along with truncation events, which reduced the mass of the protein.  
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Table 5.1: N-terminal and side chain modifications and their monoisotopic mass 
increments 
 
Modification location Modification Mass increment (Da) 
N-terminal Formylation 27.99 
Acetylation 42.01 
Gluconoylation 178.05 
Phosphogluconoylation 258.02 
Side chain  Phosphorylation  79.97 
Acetylation  42. 01 
Methylation  
- Dimethylation 
- Trimethylation 
14.02 
28.04 
43.06 
Glycation 162.05 
Deamidation 0.98 
Oxidation 15.99 
 
Elucidation and confirmation of PTMs and sequence variation contributing the observed 
charge and mass heterogeneity could be achieved by MS/MS analysis of intact and digested 
recombinant lysostaphin.  It is possible that recombinant lysostaphin, like other recombinant 
proteins, may be only partially modified at a particular site or affected by several kinds of 
PTM, which complicates identification (Hepner et al., 2005, Lahnstein et al., 1993). The 
presence of multiple modifications would however help to explain the charge and mass 
heterogeneity of recombinant lysostaphin.  
5.10 Consequences of product heterogeneity  
 
Even though this research has raised a number of concerns over the heterogeneity of 
recombinant lysostaphin, it does not necessarily mean that E. coli usage should be 
discontinued during the production of recombinant lysostaphin for industrial, research or 
even potential therapeutic purposes. For instance, recombinant lysostaphin was shown to 
exhibit potent staphylolytic activity during activity assays, which demonstrated that the 
enzyme is of importance for research or diagnostic purposes where the heterogeneity of the 
protein mixture is not of concern or importance. IMAC purification of N-terminally His-tagged 
forms of recombinant lysostaphin would however have to be performed with caution, to 
ensure complete purification of the protein. 
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In terms of therapeutic efficacy, recombinant lysostaphin was shown to provide potent 
staphylolytic activity, which shows great promise for the treatment of blood-borne and 
biofilm-associated staphylococcal infections. Furthermore, the loss of N- or C-terminal amino 
acids would be unlikely to initiate an immunogenic response upon therapeutic administration 
of recombinant lysostaphin. However without performing immunological studies, it is unclear 
whether potential PTMs of recombinant lysostaphin would contravene its use as a 
therapeutic agent. The identification of PTMs affecting the structure of recombinant 
lysostaphin would however be extremely desirable so that their presence could be prevented 
or eliminated.  Prevention or elimination of PTMs is largely dependent on the nature of the 
modification which may be reversible or irreversible, necessitating removal of the modified 
amino acid. 
Overall E. coli has been shown to produce large amounts of recombinant lysostaphin in an 
economical manner; however the observed heterogeneity would contravene drug quality 
standards. Further investigation of the heterogeneity is therefore essential to establish 
whether a more homogeneous recombinant lysostaphin preparation can be produced, 
without resorting to the use of less well characterised expression hosts, such as L. lactis or 
Bacillus sphaericus (Mierau et al., 2005a, Climo et al., 2001).  
Charge heterogeneity observed during CXC separation of other basic recombinant proteins, 
recombinant oxidoreductase and recombinant NADPH-dependent 1-acyl dihydroxyacetone 
phosphate reductase (Ayr1p) is however more concerning as it indicates that product 
heterogeneity may be a widespread phenomenon that affects many recombinant proteins 
which are expressed in E. coli.  Further more stringent characterisation of biologically 
important recombinant proteins is therefore required to assess whether the origins of 
heterogeneity follow the same or different mechanisms. Such information would then permit 
optimisation of expression and harvesting conditions or the development of additional 
genetically and metabolically engineered expression strains (Aon et al., 2008). 
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5.11 Detection and remediation of product heterogeneity  
 
As product heterogeneity was believed to arise as a consequence of His-tag heterogeneity, 
proteolysis of N- and C-terminal sequences, PTMs and culture duration, remediation would 
be focused on these key areas. As the N-terminal His-tag sequence was associated with 
greater charge heterogeneity and unusual retention behaviour, chemical or enzymatic 
removal of this His-tag sequence or use of a C-terminal His-tag would be the simplest way to 
reduce product heterogeneity (Ueda et al., 2003).  Alternatively if N-terminal His-tag 
heterogeneity was found to be attributable to phosphorylation of serine residues within the 
His-tag sequence then a modified vector sequence, devoid of serine residues could be used 
during cloning and expression instead (Lomas-Lopez et al., 2008).  
The detection of proteolytic action could be monitored through combined AXC and CXC 
separation of cell lysate, in which cellular proteases would be likely to bind to an anion 
exchange resin, whilst recombinant lysostaphin would bind to the cation exchange resin. If 
cell lysate was rapidly analysed from the start of culture analysis, it would be likely that the 
induction of heat-shock response proteins could be detected by AXC, concomitant to the 
induction of recombinant lysostaphin expression, detected by CXC.  Fractionated peaks 
which corresponded with up-regulated proteases could then be subjected to LC-MS based 
protein identification to elucidate the origins of proteolysis.  Upon detection of a specific 
protease which could contribute to truncation of N-terminally His-tagged recombinant 
lysostaphin (construct 1), expression conditions could be adjusted by the use of protease 
inhibitors or an expression strain which is deficient in that particular protease (Strauch and 
Beckwith, 1988) 
To protect the N-terminal residues of mature lysostaphin from proteolytic action, recombinant 
prolysostaphin could be expressed in E. coli and purified prior to in vitro conversion to 
mature lysostaphin by addition of a cysteine protease (Wandersman, 1989). The protein 
would have to be expressed as prolysostaphin rather than preprolysostaphin, as the signal 
peptide sequence of preprolysostaphin is specific to translocation of the inner membrane of 
S. staphylolyticus rather than E. coli. Even though prokaryotic signal peptides share a 
canonical design, signal peptides expressed within Gram-positive bacteria tend to be longer 
than those expressed within Gram-negative bacteria therefore it is unknown whether the 
signal peptide of preprolysostaphin can translocate the cell wall of E. coli (von Heijne, 1990, 
Chan, 1996). Given the basicity of recombinant mature lysostaphin, it would be hoped that 
the cleaved mature enzyme could be efficiently separated and purified from any uncleaved 
prolysostaphin, which would be acidic on the grounds of the high number of negatively 
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charged glutamate residues within the repetitive sequences that encode the propeptide 
region.  
Alternatively targeted expression of recombinant lysostaphin within the periplasm may 
protect the N-terminal residues of the protein, due to the addition of an N-terminal PelB 
leader sequence. Recombinant lysostaphin (constructs 4 and 5) were cloned and expressed 
within the periplasm of E. coli, however these forms of the protein were not investigated fully.  
The presence of a PelB leader sequence would theoretically protect N-terminal residues until 
the leader sequence was cleaved by signal peptidases upon translocation through the inner 
membrane. However it is not clear whether the action of cytoplasmic proteases may cleave 
PelB leader sequence leading to ineffective translocation.  Recombinant lysostaphin may 
also become susceptible to the action of proteases within the periplasm.  
Following LC-MS/MS identification and localisation of PTMs affecting the structure of 
recombinant lysostaphin, product heterogeneity could be remediated through prevention or 
removal of the modifications.  PTM prevention can be achieved through site-directed 
mutagenesis of known modification sites to prevent a particular PTM forming at a specific 
amino acid residue (Lu et al., 1999).  Alternatively enzyme-mediated side chain modification, 
such methylation, acetylation and phosphorylation could be removed by treating the enzyme 
with demethylases, deacetylases and dephosphorylases respectively (Walsh and Jefferis, 
2006, Paik et al., 2007). This approach would however require additional purification and 
characterisation of recombinant lysostaphin, to ensure that the contaminating enzyme had 
been removed and that the modification had been successfully removed.  
Chemical modifications are however often more insidious and may involve several stages of 
development.  For instance, during deamidation the primary modification mechanism results 
in the irreversible formation of a metastable, five-membered succinimide ring intermediate, 
which ultimately yields aspartic acid (Reissner and Aswad, 2003). Whilst deamidation may 
not elicit immunogenicity, it can interfere with the stability of a protein therefore is 
undesirable.  The occurrence of advanced glycation can result in the irreversible addition of 
a glucose moiety at lysine or arginine residues, which may elicit an immune response 
(Wilton et al., 2006). The removal of chemical modifications may therefore be more difficult 
unless a specific enzyme is available, such as an amadoriase, which can deglycate proteins 
(Capuano et al., 2007) .   
As charge heterogeneity increases over the course of culture, product heterogeneity can be 
minimised by harvesting the protein shortly after induction of protein expression.  The micro-
heterogeneity of recombinant lysostaphin may be reduced further by utilising different E. coli 
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expression strains, such as E. coli Tuner or E. coli Tuner pLysS, which have been 
engineered to achieve homogeneous distribution of IPTG or tighter control of the lac 
promoter.  By using such strains, induction of protein expression may occur in a more 
synchronised manner within the heterogeneous microbial cell population (Zhang et al., 2007, 
Strauss et al., 2001). The addition of pLysS also minimises leaky expression, which would 
prevent the premature expression and potential early modification of recombinant protein 
prior to induction of protein expression (Vincentelli et al., 2003).  
5.12 Recombinant lysostaphin as a zinc glycyl-glycine endopeptidase 
 
During this research, the consequences of the presence of zinc within the structure of 
recombinant lysostaphin were largely unknown. It is known that lysostaphin is a zinc 
metalloprotease, in which the zinc molecule is essential for catalytic activity, but is also likely 
to help modulate protein structure in the absence of cysteine residues.  As recombinant 
lysostaphin was found to exhibit staphylolytic activity, the bound zinc molecule will have 
been present in the majority of the protein population.  This knowledge was extremely useful 
as it suggested that charge variants observed during CXC separation were less likely to be 
attributable to the presence of apo- and metalloprotein forms of recombinant lysostaphin.  
This finding was partially supported by IMAC purification of recombinant lysostaphin 
(construct 2) which suggested that only a small proportion of the recombinant protein 
preparation possessed metal affinity. Whilst many amino acids can act as metal ion ligands, 
the inherent metal affinity of the zinc binding domain of recombinant lysostaphin would be 
most likely to participate in retention during IMAC.  This theory was supported by the work of 
Warfield et al, (2006), who found that lysostaphin could bind nickel ions.  However nickel 
binding was also thought to occur as a consequence of zinc displacement during the course 
of IMAC purification, therefore the incidence of metal affinity during IMAC may have been 
more attributable to zinc displacement (Warfield et al., 2006). 
Through functional analysis of recombinant lysostaphin, it was possible to gain further insight 
into structural conformation of the zinc binding domain of recombinant lysostaphin. ClustalW 
comparison of the amino acid sequences encoding recombinant lysostaphin and a 
lysostaphin-type peptidase, LytM, revealed that the zinc binding domain of recombinant 
lysostaphin was likely to involve histidine33, aspartate37 and histidine116, which along with
 a 
water molecule, tetrahedrally coordinate with zinc. Knowledge about this zinc binding 
domain enhanced knowledge about the activity of recombinant lysostaphin as a zinc 
metalloprotease but also provided an insight into protein structure.    
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5.13 Conclusions 
 
In summary this research has shown that when recombinant lysostaphin is expressed in E. 
coli, the resulting active protein can demonstrate considerable charge heterogeneity. Using a 
variety of chromatographic modes, including IEX, GF, IMAC, HIC and RP, several variants of 
recombinant lysostaphin were resolved indicating differences in charge, mass and 
hydrophobicity. The degree of charge heterogeneity observed was influenced by a number 
of factors, including expression temperature, amino acid sequence, optical density at point of 
induction and duration of culture.  Rapid analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) demonstrated that charge variant formation occurred in a time-
dependent manner whereby basic protein variants become steadily converted to more acidic 
variants.  
LC-MS analysis of intact N-terminally His-tagged recombinant lysostaphin (construct 1) 
indicated that the protein was likely to have become truncated during expression. 
Comparison of WCX and LC-MS analysis suggest that amino acids were lost from the N-
terminus to produce basic variants, whilst loss of C-terminal lysine267 may have explained 
the detection of more acidic variants.  As intact mass measurements acquired during LC-MS 
analysis of intact recombinant lysostaphin (construct 1) did not match exactly with theoretical 
intact protein masses, it was thought that the protein variants were also subject to enzymatic 
or chemical PTMs. These conclusions were made, using supporting evidence that was 
acquired during GF, SDS-PAGE and CXC analysis. Additional LC-MS/MS analysis would be 
desirable to confirm these findings.  
Overall these findings are of concern during the production of recombinant lysostaphin and 
other recombinant proteins which are expressed in E. coli.  However this research 
suggested that chromatography can be used to sensitively detect and monitor of product 
heterogeneity, so that a more homogeneous product could be produced by careful 
adjustment of expression, harvest and formulation conditions. 
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5.14 Further work  
 
To extend this research further, a variety of experiments could be performed to gain further 
insight into protein variant formation and the origins of truncation events and PTMs.  As rapid 
analysis of cell lysate during the course of expression provided the most comprehensive 
evaluation of charge variant formation, further rapid analysis experiments should be 
performed upon forms of recombinant lysostaphin (constructs 1, 2 and 3) expressed within 
the cytoplasm of E. coli. Optimisation of periplasmic lysate expression conditions would also 
permit rapid analysis of recombinant lysostaphin (constructs 4 and 5) which have been 
translocated to the periplasm. This would permit assessment of the influence of cellular 
location upon the charge heterogeneity of recombinant lysostaphin, but would also allow 
further assessment of the lesser charge heterogeneity of C-terminally His-tagged and non-
tagged forms of recombinant lysostaphin.    
 
Further rapid analysis of cell lysate harvested from cultures grown using different expression 
media, temperatures and E. coli strains, such as E. coli Tuner or E. coli Tuner pLysS, may 
permit more regulated and homogeneous production of recombinant lysostaphin.  Rapid 
analysis of cell lysate harvested during the expression of other basic recombinant proteins, 
such as recombinant oxidoreductase and recombinant NADPH-dependent 1-acyl 
dihydroxyacetone phosphate reductase (Ayr1p) would also be desirable to establish whether 
charge variant formation follows a similar pattern to that of recombinant lysostaphin 
(construct 1).  
 
To provide the most sensitive detection of charge variants, rapid analysis should be 
performed using the ProPac® MAb SCX column, whilst applying more optimised fraction 
collection settings to ensure that charge variants are most appropriately fractionated.  
Most importantly, LC-MS/MS analysis of separated charge variants would be essential to 
establish whether amino acids are being lost from the N-and C-termini of recombinant 
lysostaphin (construct 1). In addition LC-MS/MS analysis would permit elucidation of the 
type, location and abundance of PTMs affecting the structure of recombinant lysostaphin. 
The MaXis UHR-TOF demonstrated excellent resolution of protein species; therefore 
analysis using this instrument should provide high sequence coverage following MS/MS of 
intact proteins.  LC-MS/MS analysis of digested peptides would complement top-down 
analysis and provide confirmation of sequence data. The use of targeted MSn should also 
increase sequence coverage, whilst de novo sequencing would facilitate elucidation of N- or 
C-terminal sequences.  
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Identification of PTMs and sequence variation could ultimately facilitate remediation of 
charge and mass heterogeneity. Cloning and expression of prolysostaphin may protect the 
N-terminal His-tag sequence from potential proteolysis or PTM. Whilst IEX separation of cell 
lysate harvested during the early stages of culture could lead to the detection of up-
regulation of cellular proteases during the heat-shock response.  LC-MS based protein 
identification could then be used to identify specific proteases responsible for the truncation 
of recombinant lysostaphin, which could advocate the use of protease inhibitors or a 
protease-deficient expression strain.  
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7 Appendix 
 
7.1 Cloning, Expression and Purification of Recombinant Lysostaphin  
 
Appendix 7.1: Bacterial strains used during cloning, expression and characterisation 
of recombinant lysostaphin 
 
Bacteria Strain Source 
Escherichia coli TOP10 Invitrogen, UK 
Escherichia coli XL-1 Blue Agilent, UK  
Escherichia coli BL21(DE3) Merck4Biosciences, UK 
Staphylococcus simulans  b.v staphylolyticus DSMZ, Germany 
Staphylococcus aureus b.v aureus DSMZ, Germany 
 
Appendix 7.2: Preparation of media  
 
All media were prepared using 18.2 M/cm H2O (unless specified otherwise) and sterilised 
by autoclaving. Any solutions which could not be autoclaved were sterilised by filtration.  To 
achieve the correct stated pH, the pH of solutions was adjusted using HCl or NaOH and a 
pH meter. Solid media was stored at 4C, whilst liquid media was stored at room 
temperature.    
 
Appendix 7.3: Storage of bacterial strains  
 
Glycerol stocks of bacterial strains were prepared by mixing 0.5 ml of bacterial culture broth 
with 0.5 ml of 50 % (v/v) glycerol.  E. coli Top 10, E. coli XL1-Blue and Staphylococcus 
aureus were stored in 50 % (v/v) glycerol at -80C.  Staphylococcus staphylolyticus was 
stored in 50 % (v/v) glycerol at -80C.  
 
Appendix 7.4: Growth of bacteria on agar plates    
 
The bacteria were streaked or plated onto agar plates and incubated overnight at 37C.  
Bacterial colonies were then picked using a sterile wire loop and inoculated into liquid 
cultures.  
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Appendix 7.5: Streaking of bacterial strains  
 
Before streaking, agar plates were surface dried at 65C for 10 min by placing them open 
and face down in an oven.  Using a sterile wire loop, a loop-full of bacterial glycerol stock 
was streaked onto the agar plate.  The agar plate was then inverted and incubated at 37C 
overnight.  
 
Appendix 7.6: Plating of bacterial suspensions 
 
Before plating, agar plates were surface dried at 65C for 10 min by placing them open and 
face down in an oven.  A sterile glass spreader was used to spread bacterial suspension 
evenly on the surface of the agar.  The glass spreader was immersed in 70% (v/v) ethanol 
and passed through a blue Bunsen flame to remove the excess ethanol and ensure 
sterilisation of the glass spreader.  Once the bacterial suspension had fully absorbed into the 
agar, the agar plate was inverted and incubated overnight at 37C.  
 
Appendix 7.7: Measurement of bacterial growth 
 
Bacterial growth in liquid culture was measured at 600 nm using a Visible light 
spectrophotometer. Prior to each measurement, 1 ml of sterile culture media was added to a 
cuvette and used to blank the spectrophotometer, before measuring the absorbance of 1 ml 
of the culture in a fresh cuvette.  
 
Appendix 7.8: Preparation of chemical solutions and buffers  
 
All solutions were prepared using 18.2 M/cm H2O which had been purified by a Milli-Q 
water purification system and stored at room temperature, unless specified otherwise.   
Following preparation, all solutions were autoclaved at 121 C.  Alternatively when solutions 
could not be autoclaved, solutions were sterilised by filtration using 0.2 m filters (Sartorius 
Stedim Biotech, Germany).  To achieve the correct stated pH, the pH of solutions was 
adjusted using HCl or NaOH and a pH meter.  
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Appendix 7.9: Chemicals and media  
 
Acros    Disodium phosphate 
Iron chloride 
Lactose 
Monosodium phosphate 
Potassium dihydrogen orthophosphate 
Sodium molybdate 
N,N,N′,N′-Tetramethylethylenediamine (TEMED) 
 
BDH    Bacto-peptone 
Beef extract 
Bromophenol blue 
Nickel (II) chloride 
Trypticase soy yeast extract 
 
Fisher BioReagents  Acrylamide/Bisacrylamide (37.5:1, 40 % solution) 
Coomassie Blue R-250 
Methanol 
Phenol 
 
Fisher Chemicals  Acetic acid, glacial 
Acetone 
Acetonitrile(LC-MS grade) 
Ammonium chloride 
Ammonium sulphate 
Calcium carbonate 
Ethanol 
Glycerol 
2-(N-morpholino)ethanesulfonic acid (MES) 
Sodium sulphate 
Trifluoroacetic acid 
 
Fluka     Ammonium bicarbonate 
 
Melford Laboratories Ltd Agarose (High gel strength) 
    Ampicillin 
Dithiothreitol 
Ethylene diamine tetraacetic acid (EDTA) 
Glycine 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
Kanamycin 
Sodium chloride 
Sodium dodecylsulphate (SDS) 
Sodium phosphate dibasic 
Tris (Hydroxymethyl) aminomethane (Tris-HCl) 
Tryptone 
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Yeast extract 
 
Oxoid    Agar biological no. 1 
 
Riedel-deHaen  Hydrochloric acid 
 
Sigma    Ammonium dihydrogen phosphate 
Ammonium sulphate 
Ammonium persulphate (APS) 
Bovine serum albumin, Fraction V (BSA) 
Bradford’s reagent 
Bromophenol blue 
Calcium chloride anhydrous 
Cobalt chloride 
Cupric chloride 
Dipotassium phosphate 
Ethidium bromide 
Ferrous sulphate 
Glucose 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
Hydrogen borate 
Imidazole 
Isopropanol (2-propanol) 
Manganous sulphate 
Magnesium chloride 
Nickel sulphate 
β-mercaptoethanol 
Potassium chloride 
Potassium phosphate monobasic 
Potassium sulphate 
Sodium acetate 
Sodium hydroxide 
Sodium phosphate monobasic 
Sodium sulphite 
Sodium selenite 
Sucrose 
Urea 
Zinc sulphate 
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Appendix 7.10: Equipment used during this research  
 
Purpose Equipment  Manufacturer 
General Milli-Q water purification system Millipore Corporation, USA 
Chemi doc XRS gel documentation system BioRad, UK 
Prestige
®
 Medical 2100 Classic autoclave Prestige Medical, UK 
Priorclave front loading autoclave Priorclave, UK 
UV-visible Heλios α spectrophotometer. Spectronic Unicam, UK 
UV-visible Pharmacia Ultrospec 2000 Pharmacia, UK 
Cecil 2000 Series Visible Spectrophotometer Cecil Instruments,UK 
Jenway Ion Meter 3340 Jenway, UK 
Cloning  
/Expression 
Techne TC-512 thermal cycler Jencons Plc, UK 
Gene Pulser Xcell™ Electroporation System BioRad, UK 
Static incubator Weiss Gallenkamp, UK  
Orbital shaking incubator Weiss Gallenkamp, UK 
Bench top micro-centrifuge (1-15) Sigma-Aldrich, UK 
Refrigerated bench top centrifuge (3K18C) Sigma-Aldrich, UK 
Sorvall
®
RC5B Plus ThermoScientific, UK 
MSE Soniprep 150-ultrasonicator MSE, UK 
Mini-sub cell electrophoresis kit Bio-Rad, UK 
Mini-protean 3 cell electrophoresis kit Bio-Rad, UK 
Centrifugal evaporator RVC 2-18 Martin Christ, Germany 
Purification ӒKTA™ Prime Plus System GE Healthcare, UK 
Microtube peristaltic pump (MP3) Eyela, China 
Ultimate™ 3000 LC system Dionex, UK 
Christ
®
 Alpha 1-2 freeze drier. Martin Christ, Germany 
Separation Ultimate™ Titanium system Dionex, UK 
Chromatography Ultimate™ 3000 Titanium system Dionex, UK 
Ultimate™ 3000 LC system Dionex, UK 
ISCO Foxy
®
 Jr fraction collector Teledyne ISCO, USA 
LC-MS MaXis Hybrid Quad TOF Bruker Daltonics, UK 
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Appendix 7.11: Chromatographic columns used during this research
Application Separation Column Mode  Stationary 
Phase 
Dimension  
(mm) 
Manufacturer 
Protein  
Purification 
IMAC Chelating Sepharose™ Fast Flow, XK 16/20  Preparative  Porous 16.0 x 50.0 GE Healthcare, UK 
IMAC Chelating Sepharose™ Fast Flow, XK 50/20 Preparative Porous 50.0 x 12.0 GE Healthcare, UK 
IMAC ProPac
®
 IMAC-10 Analytical Pellicular 2.0 x 250  Dionex, UK 
IMAC ProPac
®
 IMAC-10 Analytical  Pellicular 4.0 x 250   Dionex, UK 
HIC Phenyl Sepharose™ High Performance, XK 
16/20 
Preparative Porous 16.0 x 45.0 GE Healthcare, UK 
GF HiLoad 16/60 Superdex 200 prep grade Preparative Porous 16.0 x 600.0 GE Healthcare, UK 
AXC Source™ 30Q media XK 16/20 Preparative Porous  16.0 x 40.0 GE Healthcare, UK 
CXC Source™ 30S media, XK 16/20 Preparative Porous 16.0 x 32.0 GE Healthcare, UK 
Protein  
Separation 
WCX ProPac
®
 WCX-10 Analytical Pellicular 2.0 x 250  Dionex, UK 
WCX ProPac
®
 WCX-10 Analytical Pellicular 4.0 x 250 Dionex, UK 
WCX ProSwift
®
 WCX-1S  Analytical Monolithic 2.0 x 50  Dionex, UK 
SAX ProPac
®
 SAX-10 Analytical Pellicular 2.0 x 250  Dionex, UK 
SCX ProPac
®
 SCX-10 Analytical Pellicular 2.0 x 250 Dionex, UK 
SCX ProPac
® 
SCX-10 Analytical Pellicular 4.0 x 250 Dionex, UK 
SCX ProSwift
®
 SCX-1S   Analytical Monolithic 4.6 x 50  Dionex, UK  
SCX ProPac
®
 MAb SCX Analytical Pellicular 4.0 x 250  Dionex, UK 
RP ProSwift
®
 RP-4H Analytical Monolithic 1.0 x 250  Dionex, UK 
Protein 
Characterisation 
GF Zorbax
®
 GF-250 Analytical Porous 4.6 x 250 Agilent, UK 
Protein  
Separation 
RP PepSwift
®
 PS-DVB Analytical Monolithic 0.2 x 50 Dionex, UK 
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Appendix 7.12: Buffers and solutions 
 
50 x TAE buffer (1L) 
Tris-base     242.0 g 
Glacial acetic acid    57.1 ml  
EDTA (5 mM)     100.0 ml  
The pH was adjusted to pH 8.0 and the solution was stored at 4°C. 
EDTA (1L) 
EDTA (500 mM)    186.1 g  
To dissolve the EDTA, the pH of the solution was adjusted to pH 8.0.  
6 x Bromophenol blue loading buffer (10 ml) 
Bromophenol blue (0.25% w/v) 0.025 g 
Glycerol (30% w/v)   3.000 g 
The solution was stored at 4°C. 
6 x Xylene cyanol loading buffer (10 ml) 
Xylene cyanol  (0.25% w/v)  0.025 g  
Glycerol (30 % w/v)   3.000 g  
The solution was stored at 4°C. 
Ethidium bromide solution (100 ml) 
Ethidium bromide (10 mg/ml)   100 µl  
The solution was protected from light.  
SDS-PAGE Buffer B (200 ml) 
Tris-HCl (2M)    150 ml  
SDS (10 %)    8 ml   
18.2 /cm H2O   42 ml  
The pH of the buffer was adjusted to pH 8.8 prior to the addition of SDS.  The solution was 
stored at 4°C. 
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SDS-PAGE Buffer C (200 ml) 
Tris-HCl (1M)     100 ml  
SDS (10%)     8 ml 
18.2 /cm H2O    92 ml  
The pH of the buffer was adjusted to pH 6.8 prior to the addition of SDS.  The solution was 
stored at 4°C. 
SDS-PAGE loading buffer (10 ml) 
Tris-HCl, pH 6.8 (1M)     0.6 ml  
50% (w/v) glycerol     5.0 ml  
10% (w/v) sodium dodecyl sulphate (SDS)   2.0 ml 
-mercaptoethanol (14.4 mM)   0.5 ml 
18.2 /cm H2O     0.9 ml  
1% (w/v) bromophenol blue (BPB)      1.0 ml 
The pH of the buffer was adjusted to pH 6.8 prior to the addition of SDS.  The solution was 
stored as aliquots at -20°C.  
SDS-PAGE solubilising cracking buffer (10 ml) 
SDS-PAGE loading buffer    7.6 ml   
Urea      2.4 g       
The solution was stored at 4°C.  
10 x SDS-PAGE running buffer (1 L) 
Tris-HCl, pH 8.0   30.2 g 
Glycine   144.0 g 
SDS     10.0 g 
The pH of the buffer was adjusted to pH 8.0 prior to the addition of SDS.  The solution was 
stored at room temperature and diluted 1:10 with 18.2 /cm H2O during SDS-PAGE.  
SDS-PAGE stain  
Methanol    450.0 ml  
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Glacial acetic acid  100.0 ml   
Coomassie Blue (R250) 1.0 g  
The SDS-PAGE stain was stored at room temperature. The stain could be filtered through 
filter paper and re-used. 
SDS-PAGE de-stain 
Methanol   100 ml 
Glacial acetic acid   100 ml 
18.2 /cm H2O  800 ml 
De-stain was stored at room temperature. Polyacrylamide gels were placed in de-stain 
overnight or until protein bands could be clearly resolved.  
 
Appendix 7.13: Analytical agarose gel electrophoresis 
 
A 1 % agarose gel was prepared by dissolving 0.3 g agarose in 30 ml of 1 x TAE buffer 
under heat using a Bunsen burner.  Once dissolved and allowed to cool for a short period of 
time, the agarose was poured in a continuous movement into a sealed mini-gel casting tray 
containing an 8-well comb, on a level work surface.  Diluted 1x TAE buffer was poured into 
the reservoirs of the electrophoresis tank and over the gel and casting tray which was placed 
onto the back plate of the tank.  After allowing the gel to soak, the 8-well comb was carefully 
removed from the gel and DNA samples were loaded using a Gilson pipette.  Samples were 
loaded by combining 5 l of DNA with 1 l of bromophenol blue or xylene cyanol loading 
buffer.  Loading buffers were selected based on the molecular weight of the DNA being 
analysed to prevent co-migration of DNA and dye molecules. The samples were run 
alongside a 1 kb size standard (Appendix 7.17).   
 
Electrophoresis was performed at 100 V and 1.20 mA for 45 min.  The gel was removed 
from the tank, stained with ethidium bromide solution for 10 min and washed with distilled 
H2O.  The DNA bands were visualised by transferring the gel to a Chemi doc XRS UV gel 
documentation system with Quantity One™ software. Hard copies of the gel images were 
obtained from a linked Mitsubishi Video Copy Processor printer.  
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Appendix 7.14: Preparative agarose gel electrophoresis 
 
Agarose gel electrophoresis was performed as described in Appendix 7.13; however the 
gels were stained only using freshly prepared ethidium bromide solution to avoid DNA 
contamination.  The gel was visualised using white UV-light and the DNA band of interest 
was excised from the gel using a scalpel.  DNA was then extracted from the gel by gel 
extraction (Appendix 7.44). 
Appendix 7.15: SDS-PAGE 
 
SDS-PAGE was performed using 12 % (w/v) polyacrylamide gels which were prepared 
following polymerisation of a resolving gel and a stacking gel.  The resolving gel was 
prepared by combining 3.0 ml of acrylamide (40%), 4.5 ml of 18.2 /cm H2O, 2.5 ml of SDS-
PAGE Buffer B, 50 l of 10 % (w/v) ammonium persulphate (APS) and 10 l of 
tetramethylethylenediamine (TEMED) before casting the mixture between two glass plates. 
Once cast the resolving gel was overlaid with 18.2 /cm H2O and allowed to set for 20 min.  
A stacking gel was then prepared containing 0.5 ml of acrylamide (30%), 2.5 ml of 18.2 
/cm H2O, 1.0 ml of SDS-PAGE Buffer C, 30 l of APS (10%), 10 l of TEMED and a few 
drops of 1% bromophenol blue. The stacking gel was used to overlay the resolving gel, after 
blotting away residual 18.2 M H2O, and a 10-well comb was added to the gel.  The gel was 
allowed to set for 20 min and once polymerised, the comb was removed and the wells were 
washed with distilled water to remove any polyacrylamide gel debris.  
 
The gel was loaded into the PAGE tank and 1 L of 1 x SDS-PAGE running buffer was added 
to the tank.  Loading buffer (5 µl) was added to 20 µl of protein sample and electrophoresed 
against a protein size standard.  A number of protein size standards were used during this 
research based on their availability and were prepared as described in Appendix 7.16.  
 
During protein expression experiments, the solubility of protein samples could be tested by 
resuspending insoluble cellular protein in solubilising cracking buffer (described further in 
Appendix 7.77). Prior to SDS-PAGE, protein samples and standards were transferred to a 
boiling water bath and heated for 3 min prior to loading onto the SDS-PAGE gel using a 25 
µl Hamilton syringe.  Electrophoresis was performed at 200 V and 60 mA for 60 min. The 
gels were then stained with SDS-PAGE stain for 10-15 min and then de-stained using SDS-
PAGE de-stain overnight. Protein bands were visualised and photographed using a Chemi 
doc XRS UV gel documentation system with a GS 800 densitometer.  Hard copies of the gel 
images were obtained from a linked Mitsubishi Video Copy Processor printer.  
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Appendix 7.16: Protein size standards used during SDS-PAGE analysis 
 
Size standard Loading composition Reference Supplier 
Sigma low range 8 µl standard   
4 µl loading buffer 
Appendix 7.18 Sigma-Aldrich, UK 
Sigma high range 8 µl standard  
4 µl loading buffer 
Appendix 7.18 Sigma-Aldrich, UK 
NZY broad range 5 µl standard  
5 µl loading buffer 
Appendix 7.19 
Appendix 7.20 
NZYtech, Portugal 
NEB pre-stained broad range 15 µl standard Appendix 7.21 
Appendix 7.22 
NE Biolabs, USA 
 
Appendix 7.17: Size standards for agarose gel electrophoresis. The DNA standards 
composing Hyperladder I (Bioline Ltd) range between 200 and 10,000 bp. 
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Appendix 7.18: Sigma low- and high-range size standards for SDS-PAGE (Sigma-
Aldrich, UK). Low and high molecular standards were composed of a number of 
protein standards.  
 
Proteins Source Molecular 
Weight (Da) 
High 
Range 
Low 
Range 
Myosin  Rabbit 
muscle 
200,000 X  
β-galactosidase  E. coli 116,000 X  
Phosphorylase b  Rabbit 
muscle 
97,000 X  
Albumin Bovine serum 66,000 X X 
Glutamic dehydrogenase  Bovine liver 55,000 X  
Ovalbumin  Chicken egg 45,000 X X 
Glyceraldehyde-3-phosphate dehydrogenase  Rabbit 
muscle 
36,000 X X 
Carbonic anhydrase  Bovine 
erythrocytes 
29,000  X 
Trypsinogen  Bovine 
pancrease 
24,000  X 
Trypsin inhibitor  soybean 20,000  X 
α-Lactoalbumin  Bovine milk 14,200  X 
Aprotinin  Bovine lung 6,500  X 
  
Appendix 7.19: Visual representation of NZY broad-range size standard for SDS-PAGE 
(NZYtech, Portugal). The molecular weights of the size standard ranged between 18.5 
and 96 kDa.  
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Appendix 7.20: NZY broad-range size standard for SDS-PAGE (NZYtech, Portugal). 
The molecular weights of size standard ranged between 18.5 and 96 kDa.  
 
Protein Source Molecular 
Weight (Da) 
Xylanase U4 Clostridium Thermocellum 96000 
Albumin Bovine serum 66000 
Phosphomanose isomerase Cellvibrio mixtus 48000 
Cellulase 5A Cellvibrio mixtus 40000 
Cellulase M9 Clostridium Thermocellum 32000 
Family 4 Carbohydrate esterase Clostridium Thermocellum 26000 
Xyloglucan-binding domain M6 Clostridium Thermocellum 18500 
 
Appendix 7.21: Visual representation of NEB pre-stained broad-range protein 
standard for SDS-PAGE (NE Biolabs, USA). The molecular weights of size standard 
ranged between 7 and 175 kDa.  
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Appendix 7.22: NEB pre-stained broad-range protein standard for SDS-PAGE (NE 
Biolabs, USA). The molecular weights of size standard ranged between 7 and 175 kDa.  
 
Proteins Source Molecular 
Weight (Da) 
MBP-ß-galactosidase E. coli 175000 
MBP-paramyosin E. coli 80000 
MBP-CBD E. coli 58000 
CBD-Mxe Intein-2CD  E. coli 46000 
CBD-Mxe Intein  E. coli 30000 
CBD-BmFKBP13 E. coli 25000 
Lysozyme Chicken egg white 17000 
Aprotonin Bovine lung 7000 
 
Appendix 7.23: UV spectrophotometric quantification of DNA and protein 
concentrations  
 
DNA and protein concentrations were accurately quantified using a UV-visible Heλios α 
Spectronic Unicam spectrophotometer, which was programmed to scan between 200 and 
350 nm.  The spectrophotometer was zeroed with 18.2 M/cm H2O prior to use.  For DNA 
samples, a 1:14 dilution of the sample was prepared to a minimum volume of 70 µl, whilst 
protein samples were diluted to 1:10, 1:100 or 1:1000 (by serial dilution) with a minimum 
volume of 70 µl.  The samples were then transferred to a 50 μl quartz cuvette and scanned 
in the spectrophotometer.  The absorbance reading at 260 nm was used to quantitate 
double-stranded DNA concentrations using the following formula: 
 
[dsDNA] μg/μl = (A260) x 50 x dilution / 1000 
The absorbance reading at 280 nm was used to quantitate protein concentrations using the 
following formula:  
[protein] μg/μl = ((A280) x dilution) / molecular extinction coefficient) x molecular weight 
If absorbance readings exceeded 1.0, the samples were diluted ten-fold to ensure that the 
absorbance reading was between 0 and 1.0 to ensure accurate quantitation.  
When sample concentrations were limited, sample concentration was determined using a 
UV vis spectrophotometer and plastic cuvettes, so that the sample could be used for 
subsequent applications. 
 
408 
 
Appendix 7.24: Detection of protein using Bradford’s reagent  
 
To test for the presence of protein, 20 µl of sample was mixed with 200 µl of Bradford’s 
reagent within a 96-well microtitre plate. A transition in colour from brown to blue denoted 
the presence of protein.  
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7.1.1 Cloning of the gene encoding lysostaphin 
 
Appendix 7.25: Media  
 
Luria-Bertani (LB) Broth (1 L) 
 
Tryptone   10.0 g 
Yeast extract     5.0 g 
NaCl   10.0 g  
 
The pH was adjusted to pH 7.0 using NaOH, before autoclaving the media and storing it at 
room temperature.  
 
LB agar (100 ml) 
 
LB broth      100 ml  
Agar (bacteriological agar no. 1)       2.0 g  
 
The media was autoclaved to make the agar soluble and allowed to cool to less than 50C, 
before pouring into petri dishes and leaving to set for ~ 20 min.  
 
Luria-Bertani (LB) low salt media (1L) 
 
Tryptone   10.0 g  
Yeast extract    5.0 g 
Sodium chloride   5.0 g  
 
The pH of the media was adjusted to pH 7.0 using NaOH, prior to autoclaving.  
 
Trypticase soy yeast extract medium (1L) 
 
Trypticase soy broth  30.0 g  
Yeast extract    3.0 g  
 
The pH of the media was adjusted to be within the range of pH 7.0-7.2 before autoclaving.  
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Trypticase soy yeast extract agar (100 ml) 
 
Trypticase soy yeast extract medium  100 ml 
Agar (bacteriological agar no. 1)      1.5 g        
 
The media was autoclaved to make the agar soluble and allowed to cool to less than 50C, 
before pouring into petri dishes and leaving to set for ~ 20 min. 
 
SOC medium   
 
SOB media (100 ml):  
 
Tryptone   2.0 g  
Yeast extract   0.5 g 
NaCl (5M)  0.20 ml  
KCl (1M)  0.25 ml 
 
Each chemical was dissolved sequentially in 90 ml of 18.2 M/cm H2O. The pH of the media 
was adjusted to pH 7.0 using NaOH, before bringing the volume to 100 ml using 18.2 
M/cm H2O. The SOB media was divided into 10 ml aliquots and autoclaved. Following 
sterilisation, SOB media was stored at room temperature.  
 
The following chemicals were aseptically added to each 10 ml aliquot of SOB media to give 
SOC medium:   
 
MgCl2 (1M)    0.1 ml  
MgSO4 (1M)     0.1 ml  
Filter sterilised glucose (1 M)  0.2 ml 
 
Appendix 7.26: Enzyme and buffer composition  
 
During gene cloning, a number of enzymes and their associated reaction buffers were 
employed, as described in Appendix 7.27 and Appendix 7.28.  
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Appendix 7.27: Enzymes used during gene cloning 
 
Enzyme Enzyme Units per µl Supplier 
KOD Hot Start Polymerase 1 Merck4Biosciences, UK 
T4 DNA ligase  4 New England Biolabs, UK 
EcoRI  10 New England Biolabs, UK 
NdeI 20 New England Biolabs, UK 
NcoI 10 New England Biolabs, UK 
XhoI 20 New England Biolabs, UK  
 
Appendix 7.28: Reaction buffers and compositions 
 
Buffer Composition Supplier 
10 x KOD Hot Start Polymerase 
buffer 
20 mM Tris-HCl 
8 mM MgCl2 
7.5 mM DTT (≡50 µg/ml) 
Merck4Biosciences, UK 
10 x Ligation buffer 60 mM Tris-HCl, pH 7.5 
60 mM MgCl2 
50 mM NaCl 
1 mg/ml BSA  
70 mM β-mercaptoethanol  
1 mM ATP 
20 mM dithiothreitol  
10 mM spermidine 
New England Biolabs, UK 
10 x Buffer 4  50 mM potassium acetate 
20 mM Tris-acetate 
10 mM magnesium acetate 
1 mM dithiothreitol, pH 7.9   
New England Biolabs, UK 
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Appendix 7.29: pCR-Blunt vector map (Invitrogen, 2010) 
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Appendix 7.30: pET-22b cloning/ expression region and vector map 
(Merck4Biosciences, 2010b) 
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Appendix 7.31: pET-28a cloning/ expression region and vector map 
(Merck4Biosciences, 2010a) 
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Appendix 7.32: Composition of Qiagen® kit buffer solutions 
 
Qiagen kits:  DNeasy® Mini Spin Kit  
QIAprep® Spin Miniprep Kit   
  QIAquick® Gel Extraction Kit  
  Qiagen® Plasmid Maxi Kit  
 
Qiagen® kit buffer Function Buffer composition 
Enzymatic lysis buffer Lysis 20 mM Tris-HCl, pH 8.0 
2 mM sodium EDTA 
1.2% Triton X100 
20 mg/ml lysozyme  
AL Lysis Concentrated solution containing guanidinium 
chloride 
200 µl ethanol (96-100%) 
Full composition not provided by manufacturer 
AW1 Neutralisation Concentrated solution containing guanidinium 
chloride 
30 ml ethanol (96-100%) 
Full composition not provided by manufacturer 
AW2 Wash 30 ml ethanol (96-100%) 
Full composition not provided by manufacturer 
P1 Resuspension 50 mM Tris-HCl, pH 8.0  
10 mM EDTA,  
100 µg/ml RNase A 
P2 Lysis 200 mM NaOH 
1 % SDS (w/v) 
P3 Neutralization 3 M potassium acetate, pH 5.0 
N3 Neutralization 25-50 % guanidinium chloride  
10-25 % acetic acid  
Full composition not provided by manufacturer 
EB Elution Full composition not provided by manufacturer 
PE Wash Full composition not provided by manufacturer 
QG Agarose gel 
solubilisation 
50-100 % guanidinium chloride  
Full composition not provided by manufacturer 
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Appendix 7.32: Composition of Qiagen® kit buffer solutions (continued) 
 
Qiagen® kit buffer Function Buffer composition 
PB Wash 25-50 % guanidinium chloride 
25-50 % isopropanol 
Full composition not provided by manufacturer 
QBT Equilibration 750 mM NaCl 
50 mM MOPS, pH 7.0  
15 % isopropanol (v/v)  
0.15 % Triton® X-100 (v/v) 
QC Wash 1 M NaCl 
50 mM MOPS, pH 7.0 
15 % isopropanol (v/v) 
QF Elution 1.25 M NaCl 
50 mM Tris-HCl, pH 8.5  
15 % isopropanol (v/v) 
 
Appendix 7.33: Growth of S. staphylolyticus for isolation of genomic DNA 
 
An ampoule of dried culture of S. staphylolyticus was rehydrated with trypticase soy yeast 
extract media and streaked onto trypticase soy yeast extract agar plates and grown 
overnight at 37°C. A single colony of S. staphylolyticus was then inoculated from the agar 
plate into 50 ml of trypticase soy yeast extract medium using a sterile wire loop. The culture 
was incubated overnight at 37°C with orbital shaking at 200 rpm. Cells were harvested after 
16 h and genomic DNA was purified using DNeasy mini spin kit. 
  
Appendix 7.34: Purification of genomic DNA from S. staphylolyticus using a DNeasy 
Mini Spin kit 
 
Cells (0.5 ml) were harvested in a microcentrifuge tube by centrifugation at 5000 x g and the 
supernatant was discarded.  The bacterial cell pellet was resuspended in 180 µl of 
enzymatic lysis buffer, before incubation at 37°C for at least 30 min. Following incubation, 25 
µl of proteinase K and 200 µl of buffer AL were added to the microcentrifuge tube and mixed 
by vortexing. The tube was then incubated for 30 min at 70°C, before adding 200 µl of 
ethanol (96-100%, v/v) and mixing thoroughly by vortexing to produce a homogeneous 
solution. A DNeasy® mini spin column was placed in a 2 ml collection tube and the mixture 
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was pipetted into the column and centrifuged at 6000 x g for 1 min, before discarding the 
flow-through and collection tube. The DNeasy® mini spin column was placed into a fresh 2 
ml collection tube and 500 µl of buffer AW1 was added to the column before recentrifuging 
for 1 min at 6,000 x g. The flow-through and collection tube were discarded and the column 
was placed in a fresh 2 ml collection tube, before adding 500 µl of buffer AW2 and 
centrifuging for 3 min at 20,000 x g to dry the DNeasy® membrane.  The flow-through and 
collection tube were discarded, prior to placing the DNeasy® spin column into a clean 1.5 ml 
microcentrifuge tube. Sterile 18.2 M/cm H2O (200 µl) was added directly to the DNeasy 
membrane, before incubating at room temperature for 1 min and then centrifuging for 1 min 
at ≥ 6,000 x g. The eluant was retained and a second elution was acquired in a fresh 
microcentrifuge tube, by applying a further 200 µl of sterile 18.2 M/cm H2O to the DNeasy
® 
membrane and centrifuging for 1 min at ≥ 6,000 x g. The purified genomic DNA was 
analysed by agarose gel electrophoresis (Appendix 7.13).. 
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Appendix 7.35: Lysostaphin gene from Staphylococcus staphylolyticus (X06121).  The 
15 tandem repeats in the prolysostaphin sequence are hi-lighted, with the initial 14 
identical repeats (encoding A-E-V-E-T-S-K-A-P-V-E-N-T) hi-lighted in green, whilst the 
15th repeat (encoding A-E-V-E-T-S-K-A-L-V-Q-N-R) is hi-lighted in red. The mature 
lysostaphin gene sequence is indicated in blue. 
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Appendix 7.36: PCR amplification of lysostaphin gene 
 
The lysostaphin gene was amplified by PCR from template S. staphylolyticus genomic DNA 
under the conditions described in Appendix 7.37. Each 50 l PCR reaction contained 5 l of 
10 x KOD Hot Start Polymerase buffer, 1 l of template genomic DNA from S. 
staphylolyticus, 3 l of MgSO4 (25 mM), 1 l of KOD Hot Start DNA polymerase (1U/l), 5 l 
of dNTPs (2 mM each), 1.5 l of sense 5’ primer (LSNdeIFP or LS NcoIFP) or 1.5 l of 
antisense 3’ primer (LSXhoISRP or LSXhoINSRP) and 32 l of PCR grade H2O.  PCR 
amplification was performed using a Techne TC-512 thermal cycler.  Agarose gel 
electrophoresis was performed to determine the molecular weight of the PCR products 
(Appendix 7.13).  The concentration of the PCR products was determined from the agarose 
gel bands using the analysis tool of the Bio-Rad Gel Doc 2000 Quantity One™ software prior 
to ligation. 
 
Appendix 7.37: PCR conditions used for the amplification of the lysostaphin gene 
 
Cycles Temperature (°C) Time (min:sec) 
Initial Denaturation 95 02:00 
5 95 00.20 
 54 00:10 
 70 00:30 
14 95 00:20 
 69.6 ≤ 2°C (decreasing 
by 0.5
o
C every cycle) 
00:10 
 70 00:30 
20 95 00:20 
 62.6 ≤ 2°C 00:10 
 70 00:30 
Final Extension 70 10:00 
Final Hold 10 Hold 
 
Appendix 7.38: Ligation of PCR product and pCR-Blunt vector 
 
Ligation reactions were prepared containing 1 l of pCR-Blunt (25 ng), 5 l of PCR product, 
1 l of 10 x ligation buffer, 2 l of 18.2 MΩ/cm H2O and 1l of T4 DNA ligase (4U/l). The 
reaction was incubated at 16C for 16 h in a thermal cycler.  Following incubation, the 
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recombinant plasmid was transformed into electrocompetent E. coli using electroporation on 
a Gene Pulser X-cell electroporator.  
 
Appendix 7.39: Growth of E. coli TOP10/ XL1-BLUE for preparation of 
electrocompetent cells  
 
E. coli TOP10 was streaked onto LB agar and E. coli XL1-Blue was streaked onto LB agar 
supplemented with 125 g/ ml tetracycline, and the plates were incubated at 37C overnight.  
A single colony of E. coli TOP10/ XL1-Blue was inoculated from an agar plate into 50 ml of 
pre-warmed low-salt LB broth, using a sterile wire loop. The culture was incubated at 37C 
with orbital shaking at 200 rpm and the growth was monitored spectrophotometrically by 
measuring the optical density (OD) of the cells at 600 nm. Cells were harvested during 
exponential phase at an OD600 nm in the range of 0.5-0.6.  In order to obtain the correct OD600 
nm, 1 ml of the culture was transferred into a cuvette and the OD was determined using a 
visible-light spectrophotometer set at a wavelength of 600 nm. The spectrophotometer had 
previously been zeroed using a cuvette of sterile LB media. 
 
Appendix 7.40: Preparation of electrocompetent cells 
 
Once an OD600 nm of 0.5-0.6 had been obtained, the E. coli XL1-Blue/ TOP10 were 
harvested. The cells were placed on ice for 20 min and then centrifuged at 4000 x g for 15 
min at 4C. Following centrifugation the supernatent was discarded and the pellet was 
resuspended in 25 ml of ice cold 18.2 M/cm H2O.  The resuspension was then centrifuged 
at 4000 x g for 15 min at 4C and the pellet was resuspended in 12.5 ml of ice cold 18.2 
M/cm H2O.  The resuspension was centrifuged at 4000 x g for 15 min at 4C and the pellet 
was resuspended in 5 ml of ice cold 18.2 M/cm H2O.  The resuspension was centrifuged 
again at 4000 x g for 15 min at 4C and the pellet was finally resuspended in 200 l of ice 
cold 18.2 M/cm H2O. The cells were separated into 40 l aliquots and transformed by 
electroporation.   
 
Appendix 7.41: Transformation of electrocompetent cells   
 
To perform electroporation, 2 l of ligation reaction was added to 40 l of electrocompetent 
cells and the mixture was transferred to an ice cold sterile 2 mm electroporation cuvette 
(BioRad, UK). The cells were gently tapped down to the bottom of the cuvette and the 
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cuvette was dried before being enclosed in a BioRad ShockPod of a Gene Pulser Xcell™ 
Electroporation System.  The cells were electroporated with 2500 volts at a pulse time 
constant of 4.8-4.9 msec.  Following electroporation, 200 l of SOC medium was aseptically 
added to recover the cells. The cells were then incubated for 1 h at 37C then spread on LB 
agar plates supplemented with 50 g/ml kanamycin and incubated overnight at 37C.  After 
overnight incubation, transformed E.coli colonies were inoculated into 5 ml LB media 
supplemented with 50 g/ml kanamycin and incubated overnight at 37C and 200 rpm prior 
to plasmid DNA extraction using a QIAprep® spin miniprep kit.  
 
Appendix 7.42: Extraction of plasmid DNA using QIAprep spin miniprep kit  
 
Following overnight culture of transformed E. coli colonies, the cells were pelleted by 
centrifugation at 4000 x g in microcentrifuge tubes.  The pelleted cells were resuspended in 
250 l of buffer P1, before adding 250 l of buffer P2 and mixing thoroughly by inverting the 
tube 4-6 times.  After mixing, 350 l of Buffer N3 was added and mixed thoroughly by 
inverting the tube 4-6 times.  The sample was centrifuged at 17,900 x g for 10 min before 
decanting the supernatant into a QIAprep® spin column. The column was then centrifuged at 
17,900 x g for 60 s and the flow-through was discarded. The sample was washed by 
applying 0.5 ml of buffer PB to the column, prior to centrifuging at 17,900 x g for 60 s.  The 
flow-through was discarded and 0.75 ml of buffer PE was added to the column before 
centrifuging at 17,900 x g for 60 s and then discarding the flow-through. To remove any 
residual wash buffer, the column was centrifuged at 17,900 x g for a further 60 s and the 
column was transferred to a clean microcentrifuge tube. The DNA was eluted by adding 50 
l of 18.2 M/cm H2O to the column, leaving it to stand for 1 min and then centrifuging at 
17,900 x g for 1 min.  The eluted DNA was analysed by agarose gel electrophoresis to 
ensure that purification was successful and then the plasmid DNA was restriction digested to 
check for the presence of the insert DNA.  
 
Appendix 7.43: Restriction digestion of plasmid DNA 
 
Restriction digestions were performed in accordance with instructions provided by the 
enzyme manufacturers.  Prior to digestion, the amount of DNA was determined by UV 
spectrometry and for each µg of DNA, 5 units of enzyme were used for the digestion 
performed at 37°C for 2 h.  Enzyme unit values are described in Appendix 7.27.  All 
digestions were performed using 10 x Buffer 4 and the reactions were supplemented with 
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BSA (0.1 mg/ml) when using XhoI.  As the enzymes used were stored in glycerol, it was 
ensured that the glycerol concentration of the reaction did not exceed 10% (v/v).  When 
required, the restriction enzymes were inactivated by heating the samples at 65°C for 10 
min.  
 
A number of restriction digestions were performed during gene cloning. To establish whether 
extracted DNA from pCR-Blunt clones contained the appropriate insert DNA fragment, a 
restriction digestion with EcoRI was performed. Samples which were found to contain the 
insert DNA were subjected to a second, confirmatory restriction digest using both NdeI and 
XhoI or NcoI and XhoI, depending on the gene construct being analysed. To assess the 
orientation of insert ligation within pCR-Blunt, single XhoI restriction digests were also 
performed.  Digested samples were then subjected to analytical or preparative agarose gel 
electrophoresis.  
 
Appendix 7.44: Gel extraction of DNA 
 
Following excision of gel containing the DNA of interest, the gel was weighed so that 3 
volumes of Buffer QG could be added to 1 volume of gel.  The sample was incubated at 
50°C for 10 min or until the gel had dissolved completely.  To aid solubility, the sample was 
mixed by vortexing every 2-3 min during the incubation.  Once dissolved, 1 gel volume of 
isopropanol was added to the sample and mixed.  A QIAquick® spin column was placed into 
a 2 ml collection tube and the sample was applied to the QIAquick® column to bind the DNA, 
before centrifuging at 17,900 x g for 1 min.  The flow-through was discarded and the 
QIAquick® column was placed back into the collection tube.  To remove traces of agarose, 
0.5 ml of buffer QG was added to the column and centrifuged for 1 min.  To wash the DNA, 
0.75 ml of Buffer PE was added to the column and centrifuged for 1 min, before discarding 
the flow-through and centrifuging at 17,900 x g for an additional 1 min.  The column was 
transferred to a clean microcentrifuge tube and the DNA was eluted by adding 50 µl of 18.2 
M/cm H2O. The eluted DNA was analysed by agarose gel electrophoresis.  
 
Appendix 7.45: Growth of E. coli pET vector transformants for preparation of pET 
vector DNA  
 
A glycerol stock of E. coli which had been previously transformed with pET-22b was streak 
plated onto LB agar supplemented with 100 µg/ml ampicillin, and incubated at 37C 
overnight.  A glycerol stock of E. coli which had been previously transformed with pET-28a 
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was streak plated onto LB agar supplemented with 50 µg/ml kanamycin, and incubated at 
37C overnight.  Following incubation, a single colony was extracted from each of the agar 
plates and inoculated into separate conical flasks containing 50 ml of LB supplemented with 
either 50 µg/ml kanamycin or 100 µg/ml ampicillin, depending on the pET-vector being used.  
The LB cultures were incubated at 37C and 200 rpm overnight in preparation for extraction 
of plasmid DNA.    
Appendix 7.46: Preparation of pET vector DNA 
 
Following culture of E. coli transformed with pET vector DNA, 5 ml of cells were removed 
from the culture and pelleted by centrifugation at 4000 x g.  Plasmid DNA was extracted 
using the QIAprep® spin miniprep kit (Appendix 7.42) or using a Plasmid Maxi Kit.    
 
When using the Plasmid Maxi Kit, 5 ml starter cultures of E. coli transformed with pET vector 
DNA were inoculated and incubated overnight at 37°C and shaken vigorously at 250 rpm.  
The starter culture was diluted 1/1000 into 100 ml of LB supplemented with an appropriate 
antibiotic and cultured at 37°C and 250 rpm for 12-16 hours. The cells were harvested by 
centrifugation at 6000 x g for 15 min at 4°C and then the supernatant was discarded.  The 
bacterial pellet was resuspended in 10 ml of buffer P1 and then 10 ml of Buffer P2 was 
added to the resuspension before mixing by inversion 4-6 times and incubating at room  
temperature for 5 min.  Buffer P3 was chilled and then 10 ml of the buffer was added to the 
sample and mixed immediately but in a gentle manner by inversion 4-6 times, before 
incubating on ice for 20 min.  The sample was centrifuged at ≥20000 x g for 30 min at  °C 
and the supernatant containing the plasmid DNA was removed promptly. The supernatant 
was centrifuged again at ≥ 20000 x g for 15 min at  °C and once again the supernatant that 
contained the plasmid DNA was removed swiftly.   
 
A Qiagen®-tip 500 was equilibrated by applying 10 ml of Buffer QBT, before allowing the 
column to empty by gravity flow.  The supernatant was applied to the Qiagen®-tip and was 
allowed to enter the resin by gravity flow.  The Qiagen®-tip was washed twice with 30 ml of 
Buffer QC and then the DNA was eluted through the application of 15 ml of Buffer QF. The 
DNA was precipitated by adding 10.5 ml of room temperature isopropanol to the eluted DNA, 
before mixing and centrifuging immediately at ≥ 15000 x g for 30 min at  °C.  The 
supernatant was carefully decanted and the DNA pellet was washed with 5 ml of room 
temperature 70% (v/v) ethanol and centrifuged at ≥ 15000 x g for 10 min.  Without disturbing 
the pellet, the resulting supernatant was decanted and the pellet was air-dried for 5-10 min 
and the DNA was dissolved in a suitable volume of 18.2 M/cm H2O. The eluted plasmid 
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DNA was analysed by agarose gel electrophoresis to check the success of extraction and 
DNA purity (Appendix 7.13).  The pET vector DNA was restriction digested (Appendix 7.43) 
and gel extracted (Appendix 7.44), prior to ligation (Appendix 7.47).   
 
Appendix 7.47: Ligation of insert and pET vector DNA  
 
The ligation reaction contained 50 ng of pET-vector DNA, 1.0 µl T4 DNA ligase buffer (10X), 
20 ng of insert DNA, 0.5 µl of T4 DNA ligase (4 U/µl) and 18.2 M/cm H2O to bring the total 
volume of the reaction to 10 µl.  The reaction was incubated at 16C for 16 h in a thermal 
cycler.  Following incubation, the recombinant plasmid was transformed into 
electrocompetent E. coli using electroporation and plated on agar plates supplemented with 
either 50 µg/ml kanamycin or 100 µg/ml ampicillin depending on the antibiotic resistance of 
the pET-vector being used.  Following culture of transformant colonies, plasmid DNA was 
extracted (Appendix 7.42).  Extracted plasmid DNA was restriction digested to establish if 
the plasmid DNA harboured the gene insert (Appendix 7.43).   
 
Appendix 7.48: Preparation of plasmid DNA for sequencing  
 
Prior to sequencing, plasmid DNA was extracted from 8 ml of cultured transformed E. coli 
(Appendix 7.42).  Plasmid DNA was eluted in 50 µl of 18.2 M/cm H2O.  The concentration 
of the plasmid DNA was established by UV spectrometry (Appendix 7.23) and 30 µl of 
plasmid DNA, at a concentration of 30-100 ng/µg, was sent for single read sequencing at 
GATC Biotech (UK).  The resulting data was examined and the expected and observed DNA 
sequences were aligned using ClustalW. ClustalW alignment was developed by the 
European Bioinformatics Institute and was made available at 
http://www.ebi.ac.uk/Tools/msa/clustalw2/.  To assess the influence of nucleotide 
substitutions upon the translated amino acid sequence of the mature lysostaphin domain, 
original and substituted DNA sequences were translated in silico by Translate tool (Expasy 
Proteomics Server, Swiss Institute of Bioinformatics), available at 
http://expasy.org/tools/dna.html.  The resulting amino acids sequences were then compared 
using ClustalW alignment.  
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Appendix 7.49: Chromatographic representation of sequence data for recombinant 
pET-28a DNA encoding N-terminally His-tagged recombinant lysostaphin (construct 1)  
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Appendix 7.49: Chromatographic representation of sequence data for recombinant 
pET-28a DNA encoding N-terminally His-tagged recombinant lysostaphin (continued) 
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Appendix 7.50: Chromatographic representation of sequence data for recombinant 
pET-22b DNA encoding recombinant lysostaphin (construct 2) 
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Appendix 7.50: Chromatographic representation of sequence data for recombinant 
pET-22b DNA encoding recombinant lysostaphin (construct 2) (continued). 
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Appendix 7.50: Chromatographic representation of sequence data for recombinant 
pET-22b DNA encoding recombinant lysostaphin (construct 2) (continued). 
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Appendix 7.51: Chromatographic representation of sequence data for recombinant 
pET-22b DNA encoding C-terminally His-tagged recombinant lysostaphin (construct 
3) 
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Appendix 7.51: Chromatographic representation of sequence data for recombinant 
pET-22b DNA encoding C-terminally His-tagged recombinant lysostaphin (construct 
3) (continued). 
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Appendix 7.52: The known mature lysostaphin domain encoding sequence 
incorporating the N-terminal His-tag encoding sequence in red (construct 1).  
 
 
Appendix 7.53: Sequence data acquired following sequencing of plasmid DNA 
containing the gene sequence encoding the N-terminally His-tagged mature 
lysostaphin domain (construct 1). The N-terminal His-tag encoding sequences are 
denoted in red, whilst the mature lysostaphin domain encoding sequence is denoted 
in blue. 
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Appendix 7.54: DNA sequence encoding recombinant lysostaphin (construct 2). 
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Appendix 7.55: Sequence data acquired following sequencing of plasmid DNA 
containing the gene sequence encoding recombinant lysostaphin (construct 2). The 
recombinant lysostaphin gene sequence is denoted in blue 
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Appendix 7.56: DNA sequence encoding C-terminally His-tagged recombinant 
lysostaphin (construct 3). The C-terminal His-tag sequence is denoted in red. 
 
 
Appendix 7.57: Sequence data acquired following sequencing of plasmid DNA 
containing the gene sequence encoding C-terminally His-tagged recombinant 
lysostaphin (construct 3). The C-terminal His-tag sequences are denoted in red, whilst 
the recombinant lysostaphin gene sequence is denoted in blue. 
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Appendix 7.58: ClustalW alignment of the known mature lysostaphin domain 
encoding sequence (with no His-tag encoding sequence added) and the acquired DNA 
sequence from pET construct 2. The known mature lysostaphin domain encoding 
sequence (with no His-tag encoding sequence added) is presented in Appendix 7.54. 
The sequence acquired from construct 2 is presented in Appendix 7.55. 
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Appendix 7.59: Mis-indentification of nucleotides during sequencing of pET construct 
2. Mis-identified bases are indicated with the expected nucleotide,  
 
 
 
Appendix 7.60: Sequence data supporting base differences supported by ClustalW.  
The positions of substituted nucleotides are marked by an asterisk. 
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Appendix 7.61: ClustalW alignment of the known mature lysostaphin domain 
encoding sequence (with C-terminal His-tag encoding sequence added) and the 
acquired DNA sequence from pET construct 3. The known mature lysostaphin domain 
encoding sequence (with C-terminal His-tag encoding sequence added) is presented 
in Appendix 7.56. The sequence acquired from construct 3 is presented in Appendix 
7.57  
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Appendix 7.62: Mis-identification of nucleotides during sequencing of pET construct 
3.  Mis-identified bases are indicated 
 
 
 
Appendix 7.63: Sequence data supporting base differences supported by ClustalW.  
The positions of substituted bases are marked by an asterisk. 
 
 
 
 
 
440 
 
Appendix 7.64: ClustalW alignment of the mature lysostaphin gene sequence from 
Staphylococcus staphylolyticus (X06121) and the complete sequence of the PACK1 
plasmid from Staphylococcus simulans bv. Staphylolyticus 
(gi│291246341│ref│NC_013944.1) 
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Appendix 7.65: DNA sequence encoding the mature lysostaphin domain.  Substituted 
guanine bases are indicated in blue (position 96 and 456). 
 
 
 
Appendix 7.66: Amino acid sequence encoding the mature lysostaphin domain with 
mis-identified amino acids (indicated in red) 
 
Appendix 7.67: Amino acid sequence encoding the mature lysostaphin domain with 
substituted amino acids (indicated in red) 
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7.1.2 Expression of recombinant lysostaphin  
 
Appendix 7.68: Media 
 
Luria-Bertani (LB) Broth (1L)   (as described in Section 2.3.2.1/Appendix 7.25) 
LB agar (100 ml)     (as described in Section 2.3.2.1/Appendix 7.25) 
SOC media     (as described in Section 2.3.2.1/Appendix 7.25) 
MDG starter media (10 ml) 
Sterile 18.2 M/cm H2O 9.55 ml 
MgSO4 (1M)   20.00 µl 
1000 x metals¶  2.00 µl 
Glucose (40%, w/v)  125.00 µl 
Aspartate (25%, w/v)  100.00 µl 
50 x M+   200.00 µl 
Antibiotic    100.00 µg/ml 
The chemicals were aseptically added to a sterile universal tube to create starter cultures. 
¶1000 x metals (100 ml) was prepared by sequentially dissolving the following chemicals in 
deionized 18.2 M H2O to achieve a final volume of 1 litre: 
Sterile 18.2 M/cm H2O 36.0 ml 
FeCl3-6H2O
†   50.0 ml 
CaCl2 (1M) anhydrous 2.0 ml 
MnCl2-4H2O (1M)  1.0 ml 
Zn-SO4-7H2O (1 M)  1.0 ml 
CoCl2-6H2O (0.2 M)   1.0 ml 
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CuCl2-2H2O (0.1M)  2.0 ml 
NiCl2-6H2O (0.2 M)  1.0 ml 
Na2MoO4-5H2O (0.1 M) 2.0 ml 
Na2SeO3-5H2O (0.1M) 2.0 ml 
H3BO3 (0.1 M) anhydrous 2.0 ml 
†FeCl3-6H2O was dissolved in a 100-fold dilution of HCl (~0.12 M HCl) before filter 
sterilisation using a 0.2 µm filter.  
Each of the other solutions was autoclaved separately and aseptically combined to formulate 
1000 x metals.    
+50 x M (100 ml) was prepared by sequentially dissolving the following chemicals in 
deionized 18.2 M H2O to achieve a final volume of 100ml: 
Na2SO4 anhydrous   3.6 g  
NH4Cl anhydrous  13.4 g  
KH2PO4 anhydrous  17.0 g 
Na2HPO4 anhydrous  17.7 g 
The solution was autoclaved before and between use.    
ZYM-5052 auto-induction media (AIM) (500 ml) 
ZY‡    478.5 ml  
MgSO4 (1M)   1.0 ml 
1000 x metals¶  0.5 ml 
50 x M+   1.0 ml 
Antibiotic    100.0 µg/ml 
50 x 5052*   1.0 ml 
The chemicals were aseptically added to a 2 L baffled flask.   
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‡ZY (1 L) was prepared by sequentially dissolving the following compounds in deionized 18.2 
M H2O to achieve a final volume of 1 litre:  
Tryptone    10 g  
Yeast extract   5 g  
The pH of the solution was adjusted to pH 7.0, prior to autoclaving.  
*50 x 5052 (100 ml) was prepared by sequentially dissolving the following chemicals in 
deionized 18.2 M H2O to achieve a final volume of 100 ml:  
Glycerol    25.0 g 
Glucose   2.5 g 
α-lactose   10.0 g  
The chemicals were dissolved sequentially in 18.2 M/cm H2O prior to autoclaving.  
M9 minimal media (MM) (1 L) 
To 750 ml of sterile 18.2 /cm H2O (cooled to 50˚C or less) the following chemicals were 
added:  
5 x M9 salts†   200.0 ml 
1 M MgSO4    2.0 ml  
20% (w/v) glucose  20.0 ml 
1 M CaCl2    0.1 ml  
The volume was made up to 980 ml with sterile 18.2 M/cm H2O.  
†5 x M9 salts were prepared by dissolving the following salts in deionized 18.2 M H2O to 
achieve a final volume of 1 litre:  
Na2HPO4-7H2O  64.0 g 
KH2PO4   15.0 g 
NaCl     2.5 g 
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NH4Cl    5.0 g 
The salt solution was divided into 200 ml aliquots, which were sterilized by autoclaving.  
The MgSO4 and CaCl2 solutions were prepared separately, sterilized by autoclaving and 
were aseptically combined with the solutions after diluting the 5 x M9 salts to 980 ml with 
sterile H2O.  The glucose was sterilised by passing it through a 0.22 µm filter before being 
added to the diluted M9 salts. 
Terrific broth (TB) (1 L) 
To 900 ml of 18.2 M/cm H2O, the following chemicals were added:  
Tryptone   12 g 
Yeast extract   24 g 
Glycerol   4 ml  
The solutes were shaken until they had dissolved, before autoclaving the media for 20 min at 
15 psi on liquid cycle.  The solution was allowed to cool to 60 ˚C or less and before adding 
100 ml of a sterile solution of 0.17 M KH2PO4/0.72 M K2HPO4 (made by dissolving 2.31 g of 
KH2PO4 and 12.54 g of K2HPO4 in 90 ml of deionized H2O, before autoclaving the solution 
for 20 minutes at 15 psi).   
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Appendix 7.69: Chemicals 
 
MgSO4 (100 ml) 
MgSO4    26.65 g  
The MgSO4 was dissolved in 18.2 M/cm H2O and then autoclaved before and between 
use.  
Glucose (20 ml) 
Glucose (40%, w/v)   8.0 g   
The glucose was sterilised by filter sterilisation using a 0.2 µm filter (Sartorius, Germany), 
prior to use.   
Aspartate (20 ml) 
Aspartate (25% w/v)  5.0 g 
The pH was adjusted to 7.0 using NaOH, prior to autoclaving.   
CaCl2 (100 ml)  
CaCl2 (1M)    14.7 g 
The CaCl2 was dissolved in 18.2 M/cm H2O and then autoclaved before and between use.  
MgCl2-CaCl2 (200 ml) 
MgCl2 (80 mM)  3.25 g 
CaCl2 (0.02 M)  0.59 g 
The chemicals were dissolved sequentially in 18.2 M/cm H2O and then autoclaved before 
and between use.  
CaCl2 (200 ml) 
CaCl2 (0.1 M)   2.9 g 
The CaCl2 was dissolved in 18.2 M/cm H2O and then autoclaved before and between use.  
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EDTA (50 ml) 
EDTA, pH 8.0 (0.5 M)  9.3 g 
The EDTA was dissolved in 18.2 M/cm H2O and the pH was adjusted to 8.0. The solution 
was autoclaved before and between use.  
Appendix 7.70: Buffers  
De-salting buffer (50 ml) 
Tris-HCl, pH 8.0 (25 mM)  0.15 g    
The tris-base was dissolved in 18.2 M/cm H2O and the pH of the buffer was adjusted to pH 
8.0, using HCl, prior to autoclaving.  
Osmotic-shock buffer (100 ml) 
 
Tris-HCl, pH 8.0 (10 mM)  0.12 g 
Sucrose (20%, w/v)    20.00 g  
The chemicals were dissolved sequentially in 18.2 M/cm H2O prior to autoclaving.  
Resuspension buffers  
 
During cytoplasmic protein extraction, harvested E. coli was resuspended in a buffer that 
was compatible with the subsequent protein purification by various modes of 
chromatography. The appropriate buffers are indicated in Appendix 7.71.  
 
  
448 
 
Appendix 7.71: Resuspension buffers used to resuspend E. coli during cytoplasmic 
protein extraction prior to protein purification 
Type of 
chromatography 
Column Buffer 
IMAC Chelating Sepharose Fast Flow IMAC IMAC buffer A (Appendix 7.105) 
ProPac
® 
IMAC-10 IMAC buffer A (Appendix 7.105) 
HIC Phenyl Sepharose HP  HIC buffer A (Appendix 7.105) 
AXC Source™ 30Q  AXC buffer A (Appendix 7.105) 
ProPac
®  
SAX IEX buffer A (Appendix 7.105) 
CXC Source™ 30S  CXC buffer A (Appendix 7.105) 
ProPac
® 
 WCX/SCX IEX buffer A (Appendix 7.136) 
WCX buffer A (Appendix 7.136) 
SCX buffer A (Appendix 7.136) 
ProPac
® 
 MAb SCX MAb SCX buffer A (Appendix 7.136) 
 
Appendix 7.72: Preparation of chemically competent E. coli BL21 
 
To produce competent cells for transformation, a bacterial colony was transferred into a 100 
ml LB broth in a 1 L conical flask and grown until an OD600 nm of 0.35-0.4 was reached.  The 
cells were transferred to two cold, sterile universal tubes and stored on ice for 10 min.  The 
universal tubes were centrifuged at  000 x g for 10 min at  ˚C, and following centrifugation 
the supernatent discarded into a Virkon solution, as viable cells may have been present. The 
supernatent was discarded to leave a dry pellet, which was re-suspended in 15 ml of ice-
cold MgCl2 -CaCl2 by gently swirling.  The cells were recovered by centrifugation at 4000 x g 
for 10 min at  ˚C, before the supernatent was discarded into Virkon and the pellet 
resuspended by swirling in 1 ml of ice cold 0.1 M CaCl2. The competent cells were aliquoted 
into 50 µl volumes and used directly for transformation.  To any remaining cells, sterile 
glycerol was added to 15% (v/v) and the cells then stored at -80°C until required for 
subsequent transformations.     
Appendix 7.73: Transformation of chemically competent E. coli BL21 
 
Competent cells were mixed with 2.5 µl of ligation and incubated on ice for 30 min. The cells 
were then transferred to a water bath at 42°C for 90 sec, before incubating on ice for at least 
2 min. The cells were recovered through aseptic addition of 200 µl of SOC medium and then 
incubated at 37°C for 45 min. The recovered cells were aseptically plated onto LB media, 
supplemented with an appropriate antibiotic, and incubated overnight at 37°C to allow 
growth of transformed bacterial colonies.  
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Appendix 7.74: Preparation of media for shake flask cultures 
 
In order to minimise batch-to-batch variability during culture, the expression media was 
prepared, ensuring that chemical constituents were weighed as accurately as possible. The 
pH of the media was verified prior to sterilisation of the media. Small-scale cultures were 
performed using between 50 and 100 ml of expression media. To provide sufficient aeration 
to the cultures, small-scale batch cultures were performed in suitable Erlenmeyer flasks, 
ensuring that the expression media volume did not exceed more than 20% of the volumetric 
capacity of the flask. Large-scale batch cultures containing 1L of expression media were 
performed in 2 L baffled Erlenmeyer flasks to provide increased aeration.  Where multiple 1L 
batch cultures were used in a single experiment, expression media was prepared as a single 
large volume to ensure consistency of media formulation between cultures.  
Appendix 7.75: Recombinant protein expression following auto-induction 
 
Transformed E. coli BL21 colonies or glycerol stocks were used to inoculate MDG starter 
cultures, which were incubated overnight at 37°C and 200 rpm.  A 1% (v/v) inoculum of the 
MDG starter culture was aseptically transferred into an appropriate volume of ZYM-5052 
autoinduction media. The culture was incubated at 37°C and 200 rpm, whilst being 
monitored spectrophotometrically until an OD600 nm of 0.6-1.0 had been obtained. At the 
appropriate OD600 nm, the incubation conditions were adjusted to 30°C and 100 rpm shaking 
overnight, before the cell-free extract was extracted by cytoplasmic or periplasmic extraction 
methods, depending on the location of protein expression. The cell-free extract was then 
analysed by SDS-PAGE (Appendix 7.15) to establish whether the target protein had been 
overexpressed in a soluble form.  
 
Appendix 7.76: Recombinant protein expression following IPTG induction 
 
IPTG-induced protein expression was performed using LB, TB or MM. Transformed E. coli 
BL21(DE3) colonies or glycerol stocks were used to inoculate starter cultures containing 10 
ml of the chosen expression media, supplemented with an appropriate antibiotic. The starter 
cultures were incubated overnight at 37°C and 200 rpm, before aseptic transfer of a 1% (v/v) 
inoculum into an appropriate volume of expression media, supplemented with an antibiotic. 
The culture was incubated at 37°C and 200 rpm, whilst the optical density of the culture was 
monitored by spectrometry during growth. Once an OD600 nm of 0.6-1.0 was obtained, IPTG 
to a concentration of 240 µg/ml was added to the culture to induce protein expression.  At 
the appropriate OD600 nm, the culture was incubated at 30°C and 100 rpm overnight. A cell-
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free extract was then extracted by cytoplasmic or periplasmic extraction methods, depending 
on the location of protein expression.    
Appendix 7.77: Cytoplasmic protein extraction  
 
Following culture, the E. coli BL21(DE3) were harvested by centrifugation at 4000 x g for 15 
min at 4°C to pellet the cells.  The bacterial cell pellet was resuspended in an appropriate 
resuspension buffer. The resuspension buffer was selected to facilitate subsequent 
purification of the recombinant protein by chromatography, as indicated in Appendix 7.71. 
The resuspended cells were lysed by sonication at amplitude of 15 microns amplitude at 10 
sec intervals for 2 min, whilst on ice.  After sonication, the cells were centrifuged at 24000 x 
g for 20 min at 4°C and the resulting supernatant (cell-free extract, CFE) was decanted from 
the pellet and retained.  The residual cell pellet was mixed with 300 µl of solubilising 
(cracking) buffer to provide an initial indication of protein solubility during protein expression. 
The solubilised samples and neat and diluted CFE samples were boiled for 3 min and then 
analysed by PAGE to establish whether the target protein had been overexpressed in a 
soluble form.      
Appendix 7.78: Periplasmic protein extraction  
 
Following culture, the E. coli BL21(DE3) were placed on ice for 10 min, before being 
centrifuged at 4000 x g for 10 min to pellet the cells.  The bacterial cell pellet was gently 
resuspended in 5 ml of 10 mM Tris-HCl, pH 8.0 containing 20 % (w/v) sucrose. After re-
suspension, 0.25 ml of 0.5 M EDTA, pH 8.0 was added to the mixture and incubated on ice 
for 30 min. After incubation, the suspension was transferred to a 50 ml centrifuge tube and 
centrifuged for 10 min at 4000 x g.  The resulting bacterial pellet was resuspended by gentle 
vortexing in 4 ml of ice cold 18.2 M/cm H2O and incubated on ice for 30 min.  Following 
incubation the mixture was centrifuged at 30000 x g at 4 C for 10 min. The sucrose and 
salts were then removed from the supernatent by gel filtration using PD10 columns 
(Appendix 7.79).   
Appendix 7.79: Desalting of cell-free extract using gel filtration (PD10 columns) 
 
A PD10 gel filtration column was prepared by resuspending 2 g of Sephadex™ G-25 
(medium gel filtration matrix) in 15 ml of de-salting buffer in a 20 ml plastic universal tube.  A 
plastic PD-10 column was prepared by cutting off the bottom of the column and inserting a 
filter at the bottom to prevent loss of resin during filtration. The contents were transferred to 
the PD-10 column, homogenised, then allowed to settle.  After adding the resin, a 10 ml 
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syringe plunger was used to encourage the excess buffer to leave the column. Another filter 
was then placed on top of the resin and caps were placed on the top and bottom of the 
column to prevent dehydration prior to use.   
Extracted CFE (2.5 ml) was then applied to the column and allowed to flow through the 
column by gravity, without collecting the flow-through.  The desalted recombinant protein 
was eluted by applying 3.5 ml of desalting buffer to the column, whilst retaining the eluate.  
To remove sucrose and salts from the column, 6.0 ml of desalting buffer was then applied to 
the column, without collecting the flow-through. This process was repeated until all of the 
extracted CFE had been desalted and collected. Neat and diluted cell-free extract was then 
analysed by PAGE to establish whether the target protein had been overexpressed in a 
soluble form.     
Appendix 7.80: Nucleotide sequence of N-terminally His-tagged recombinant 
lysostaphin (construct 1). The N-terminal His-tag region is presented in red.  
 
 
Appendix 7.81: Predicted amino acid sequence of N-terminally His-tagged 
recombinant lysostaphin (construct 1).   
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Appendix 7.82: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with a retained N-terminal methionine residue 
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Appendix 7.82: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with a retained N-terminal methionine residue (continued). 
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Appendix 7.83: Nucleotide sequence of recombinant lysostaphin (construct 2)   
 
 
Appendix 7.84: Predicted amino acid sequence of recombinant lysostaphin (construct 
2) 
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Appendix 7.85: ProtParam analysis of recombinant lysostaphin (construct 2) with a 
retained N-terminal methionine residue 
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Appendix 7.85: ProtParam analysis of recombinant lysostaphin (construct 2) with a 
retained N-terminal methionine residue (continued). 
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Appendix 7.86: Nucleotide sequence of C-terminally His-tagged recombinant 
lysostaphin (construct 3). The C-terminal His-tag region is presented in green.  
 
 
Appendix 7.87: Predicted amino acid sequence of C-terminally His-tagged 
recombinant lysostaphin (construct 3) 
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Appendix 7.88: ProtParam analysis of C-terminally His-tagged recombinant 
lysostaphin (construct 3) with a retained N-terminal methionine residue 
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Appendix 7.88: ProtParam analysis of C-terminally His-tagged recombinant 
lysostaphin (construct 3) with a retained N-terminal methionine residue (continued). 
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Appendix 7.89: Nucleotide sequence of C-terminally His-tagged recombinant 
lysostaphin (construct 4). The C-terminal His-tag region is presented in green. 
 
 
Appendix 7.90: Predicted amino acid sequence of C-terminally His-tagged 
recombinant lysostaphin (construct 4) 
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Appendix 7.91: ProtParam analysis of C-terminally His-tagged recombinant 
lysostaphin (construct 4) with a retained N-terminal methionine residue 
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Appendix 7.91: Prot Param analysis of C-terminally His-tagged recombinant 
lysostaphin (construct 4) with a retained N-terminal methionine residue (continued). 
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Appendix 7.92: Nucleotide sequence of recombinant lysostaphin (construct 5)   
 
 
Appendix 7.93: Predicted amino acid sequence of recombinant lysostaphin (construct 
5) 
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Appendix 7.94: ProtParam analysis of recombinant lysostaphin (construct 5) with a 
retained N-terminal methionine residue 
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Appendix 7.94: ProtParam analysis of recombinant lysostaphin (construct 5) with a 
retained N-terminal methionine residue (continued). 
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Appendix 7.95: Cytoplasmic expression of recombinant lysostaphin (construct 2) by 
E. coli BL21(DE3) cultured in AIM. Lane 1: Sigma low molecular weight markers; Lane 
2: CFE (1:100); Lane 3: CFE (neat); Lane 4: CFE (1:10); Lane 5: CFE in solubilising 
buffer; Lane 6: Sigma high molecular weight markers.   
 
 
Appendix 7.96: Cytoplasmic expression of C-terminally His-tagged recombinant 
lysostaphin in E.coli BL21(DE3) cultured in AIM. Lane 1: Sigma low molecular weight 
markers; Lane 2: CFE (neat); Lane 3: CFE (1:10); Lane 4: CFE (1:100); Lane 5: CFE in 
solubilising buffer; Lane 6: Sigma high molecular weight markers.   
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Appendix 7.97: Periplasmic expression of C-terminally His-tagged recombinant 
lysostaphin (construct 4) in E. coli BL21 (DE3) cultured in AIM. Lane 1: Sigma low 
molecular weight markers; Lane 2: periplasmic lysate in solubilising buffer sample; 
Lane 3: periplasmic lysate (neat); Lane 4: periplasmic lysate (1:10); Lane 5: Sigma 
high molecular weight markers.   
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Appendix 7.98: Periplasmic expression of C-terminally His-tagged recombinant 
lysostaphin (construct 4).  E. coli BL21(DE3) harbouring plasmid DNA encoding 
construct 4 was cultured and the expressed C-terminally recombinant lysostaphin 
was harvested from periplasm on several separate occasions (A-D).  In each instance, 
a hyper-expressed protein was observed with a molecular weight of around 28 kDa, 
which was likely to represent recombinant lysostaphin. The harvested cell lysates 
also showed evidence of larger proteins with molecular weights of around 36 kDa and 
45 kDa, which were especially prevalent in the harvested periplasmic lysate. A) Lane 
1: NZY broad range size marker; Lane 2: periplasmic lysate (neat). B) Lane 1: NZY 
broad range size marker; Lane 2: periplasmic lysate (neat). C) Lane 1: Sigma low 
molecular weight markers; Lane 2: periplasmic lysate (neat).  D) Lane 1: Sigma low 
molecular weight markers; Lane 2: periplasmic lysate (neat). 
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Appendix 7.99: Periplasmic expression of recombinant lysostaphin (construct 5) by E. 
coli BL21(DE3) cultured in AIM. Lane 1: Sigma low molecular weight markers; Lane 2: 
periplasmic cell lysate in solubilising buffer; Lane 3: periplasmic lysate (neat); Lane 4: 
periplasmic lysate (1:10); Lane 5: Sigma high molecular weight markers.   
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Appendix 7.100: Periplasmic expression of recombinant lysostaphin (construct 5) in 
E. coli BL21(DE3) cultured in AIM media.  Recombinant lysostaphin was harvested 
from periplasm on several separate occasions (A-D).  In each instance, a hyper-
expressed protein was observed with a molecular weight of around 27 kDa, which was 
likely to represent recombinant lysostaphin.  The harvested cell lysates also showed 
evidence of larger proteins with molecular weights of around 36 kDa and 45 kDa, 
which were especially prevalent in the harvested periplasmic lysate. A) Lane 1: NZY 
broad range size marker; Lane 2: periplasmic lysate (neat). B) Lane 1: NZY broad 
range size marker; Lane 2: periplasmic lysate (neat). C) Lane 1: Sigma low molecular 
weight markers; Lane 2: periplasmic lysate (neat). D) Lane 1: Sigma low molecular 
weight markers; Lane 2: periplasmic lysate (neat). 
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Appendix 7.101: Expression of N-terminally His-tagged recombinant lysostaphin 
(construct 1) using different expression media. In each instance, over-expression of 
protein with a molecular weight of around 29 kDa, was observed indicating the 
presence of N-terminally His-tagged recombinant lysostaphin.  A) Recombinant 
protein expression in AIM; Lane 1: Sigma low molecular weight markers; Lane 2: CFE 
(1:10); Lane 3: CFE in solubilising buffer, Lane 4: Sigma high molecular weight 
markers. B) Recombinant protein expression in LB. Lane 1: Sigma low molecular 
weight markers; Lane 2: CFE (neat); Lane 3: CFE (1:10); Lane 4: CFE in solubilising 
buffer; Lane 5: Sigma high molecular weight markers. C) Recombinant protein 
expression in TB; Lane 1: Sigma low molecular weight markers; Lane 2: CFE in 
solubilising buffer, Lane 3: CFE (neat), Lane 4: CFE (1:10), Lane 5: CFE (1:100);  
Recombinant protein expression in MM;  Lane 6: CFE in solubilising buffer, Lane 7: 
CFE (neat), Lane 8: CFE (1:10), Lane 9: CFE (1:100); Lane 10: Sigma high molecular 
weight markers.   
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Appendix 7.102: Cytoplasmic expression of N-terminally His-tagged recombinant 
lysostaphin (construct 1) in E. coli BL21(DE3) in AIM or LB. CFE was analysed by 
SDS-PAGE. A) Expression of construct 1 in AIM. Lane 1: Sigma low molecular weight 
markers; Lane 2: CFE (neat); Lane 3: CFE (1:10); Lane 4: CFE (1:100); Lane 5: CFE in 
solubilising buffer; Lane 6: Sigma high molecular weight markers. B) Expression of 
construct 1 in AIM.  Lane 1: NZY broad range size markers; Lane 2: CFE (neat); Lane 
3: CFE (1:10); Lane 4: CFE (1:100); Lane 5: CFE in solubilising buffer; Lane 6: NZY 
broad range size markers; C) Expression of construct 1 in LB. Lane 1: NZY broad 
range size markers; Lane 2: CFE (1:10); Lane 3: CFE (1:100); Lane 4: CFE in 
solubilising buffer; Lane 5: NZY broad range size markers.  D) Expression of 
construct 1 in LB. Lane 1: Sigma low molecular size markers; Lane 2: CFE in 
solubilising buffer; Lane 3: CFE (neat); Lane 4: CFE (1:10); Lane 5: Sigma high 
molecular weight size markers.     
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Appendix 7.103: Expression of recombinant lysostaphin (construct 2) using different 
expression media.  In each instance, over-expression of protein with a molecular 
weight of around 28 kDa, was observed indicating the presence of recombinant 
lysostaphin.  A) Recombinant protein expression in AIM; Lane 1: Sigma low molecular 
weight markers; Lane 2: CFE (neat); Lane 3: CFE (1:10), B) Recombinant protein 
expression in LB. Lane 1: CFE (neat); Lane 2: CFE (1:10); Lane 3: Sigma low 
molecular weight markers.  
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Appendix 7.104: Expression of C-terminally His-tagged recombinant lysostaphin 
(construct 3) in E. coli BL21(DE3) using different expression media.  In each instance, 
over-expression of protein with a molecular weight of around 28 kDa, was observed 
indicating the presence of C-terminally His-tagged recombinant lysostaphin.  A) 
Recombinant protein expression in AIM; Lane 1: Sigma low molecular weight 
markers; Lane 2: CFE (neat); Lane 3: CFE (1:10), B) Recombinant protein expression 
in LB. Lane 1: Sigma low molecular weight markers; Lane 2: CFE (neat); Lane 3: CFE 
(1:10); Lane 4: CFE (1:100).  
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7.1.3 Purification of recombinant lysostaphin 
 
Appendix 7.105: Buffers  
Resuspension buffer (1 L) 
Tris-HCl, pH 8.0 (10 mM)  1.21 g 
Tris-base was dissolved in 18.2 M/cm H2O and the pH of the buffer was adjusted to pH 8.0 
using HCl. The buffer was autoclaved prior to use. 
HIC buffer A (1L)  
Tris-HCl, pH 8.0 (10 mM)  1.21 g 
(NH4)2SO4 (1.5 M)   198.21 g  
Tris-base and ammonium sulphate were dissolved in 18.2 M/cm H2O and the pH of the 
buffer was adjusted to pH 8.0 using HCl. The buffer was autoclaved prior to use.  
HIC buffer B (1 L) 
Tris-HCl, pH 8.0 (10 mM)  1.21 g 
Tris-base was dissolved in 18.2 M/cm H2O and the pH of the buffer was adjusted to pH 8.0 
using HCl. The buffer was autoclaved prior to use. 
Column storage buffer (1 L) 
EtOH (20%, v/v)   200 ml 
EtOH was added to 800 ml of 18.2 M/cm H2O. 
GF buffer (1L) 
Tris-HCl, pH 8.0 (25 mM)  3.03 g 
NaCl (200 mM)   11.68 g  
Tris-base and NaCl were dissolved in 18.2M/cm H2O and the pH of the buffer was 
adjusted to pH 8.0 using HCl. The buffer was autoclaved prior to use.  
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AXC buffer A (1 L)  
Tris-HCl, pH 8.0 (25 mM)  3.03 g 
Tris-base was dissolved in 18.2M/cm H2O and the pH of the buffer was adjusted to pH 8.0 
using HCl. The buffer was autoclaved prior to use.  
AXC buffer B (1 L)  
Tris-HCl, pH 8.0 (25 mM)  3.03 g 
NaCl (1 M)    58.44 g  
Tris-base and NaCl were dissolved in 18.2 M/cm H2O and the pH of the buffer was 
adjusted to pH 8.0 using HCl. The buffer was autoclaved prior to use.  
CXC buffer A (1 L) 
HEPES (50 mM)    11.9 g 
HEPES was dissolved in 18.2 M/cm H2O and the pH of the buffer was adjusted to pH 8.0 
using NaOH. The buffer was autoclaved prior to use. 
CXC buffer B (1L) 
HEPES (50 mM)   11.90 g 
NaCl (1.0 M)    58.44 g 
HEPES and NaCl were dissolved in 18.2 M/cm H2O and the pH of the buffer was adjusted 
to pH 8.0 using NaOH. The buffer was autoclaved prior to use. 
 
CXC storage buffer (1L) 
EtOH (20%)    200.0 ml 
NaC2H3O2 (0.2 M)    16.4 g 
EtOH and sodium acetate were added to an appropriate volume of 18.2 M/cm H2O.  
IMAC buffer A (1 L)  
Sodium phosphate (20 mM)  100 ml of 200 mM stock solution  
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Imidazole (10 mM)   0.68 g 
NaCl (500 mM)   29.20 g 
Sodium phosphate stock solution, imidazole and NaCl were combined and dissolved in 18.2 
M/cm H2O, before the pH of the buffer was adjusted to pH 7.4 using NaOH. The buffer was 
autoclaved prior to use. 
IMAC buffer B (1L)  
Sodium phosphate (20 mM)  100 ml of 200 mM stock solution  
Imidazole (500 mM)   34.04 g 
NaCl (500 mM)   29.20 g 
Sodium phosphate stock solution, imidazole and NaCl were combined and dissolved in 18.2 
M/cm H2O, before the pH of the buffer was adjusted to pH 7.4 using NaOH. The buffer was 
autoclaved prior to use. 
 
Appendix 7.106: Chemicals  
EDTA (1 L) 
EDTA (100 mM)   37.22 g  
EDTA was dissolved in 18.2 M/cm H2O and the pH of the buffer was adjusted to pH 8.0 
using NaOH. The solution was autoclaved prior to use. 
NaH2PO4 stock solution (1 L) 
NaH2PO4 H2O (200 mM)  27.6 g  
Na2HPO4.H2O (200 mM)   28.4 g 
NaH2PO4.H2O and Na2HPO4.H2O were dissolved in 18.2 M/cm H2O to create two separate 
solutions. Appropriate volumes of each solution were combined to create buffers with 
appropriate pH and molarity. The stock solution was autoclaved prior to use.  
NiSO4 (1 L) 
NiSO4 (100 mM)  
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NiSO4 was dissolved in 18.2 M/cm H2O. 
 
Appendix 7.107: Equipment 
 
Protein purifications were performed using an ӒKTA™ prime plus purification system, a 
FPLC system, a peristaltic pump or an Ultimate™ 3000 Titanium system.  
 
The ÄKTA™ prime plus purification system consisted of a gradient pump, buffer selection 
valves, a UV and conductivity detector and a fraction collector.  The system was fitted with a 
100 µl injection loop. Data collection and analysis was performed using PrimeView™ 5.0 
evaluation software.   
 
The FPLC system consisted of a Pharmacia LKB pump P-500, a Pharmacia LKB controller 
LCC-501 plus, buffer selection valves, a Unicord VW 2251 detector and a Pharmacia LKB 
Frac-100 fraction collector.  Data collection and analysis was performed using FPLC 
director™ version 1.03 software.   
 
Large-scale IMAC purifications were performed using an Eyela microtube peristaltic pump 
(MP3).  Chromatographic flow was manually adjusted to provide flow rates of 0-10 ml/min. 
Protein elution was monitored by Bradford’s assay during each step elution (Appendix 7.24).  
 
The Ultimate™ 3000 Titanium system consisted of an analytical titanium pump, a thermal 
compartment with two column change valves, a VWD detector and a WPS-3000 
Biocompatible autosampler.  The autosampler was fitted with 250 µl syringe and a 1 ml 
injection loop.  Although the autosampler could accommodate fractionation, fractionation 
was performed using an ISCO Foxy® Jr Fraction collector in this instance. Data collection 
and analysis was performed using a Chromeleon® Chromatography Data System software 
with fractionation license.   
 
Chromatographic separations were performed using a number of separation modes and 
columns, as described in Appendix 7.108.  
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Appendix 7.108: Chromatography columns used during purification of recombinant 
lysostaphin 
 
Separation 
Mode 
Column Chromatography 
System 
Dimension 
(mm) 
IMAC 
 
Chelating Sepharose™ Fast Flow, XK 16/20  ÄKTA™ prime plus 16.0 x 50 
Chelating Sepharose™ Fast Flow, XK 50/20 Peristaltic pump 50.0 x 12 
ProPac
®
 IMAC-10 Ultimate™ 3000  2.0 x 250  
ProPac
®
 IMAC-10 Ultimate™ 3000  4.0 x 250   
HIC Phenyl Sepharose™ High Performance, XK 16/20 ÄKTA™ prime plus 16.0 x 55 
GF HiLoad™ 16/60 Superdex 200prep grade FPLC  16.0 x 600  
CXC Source™ 30S media, XK 16/20 ÄKTA™ prime plus 16.0 x 32 
AXC Source™ 30Q media XK 16/20 ÄKTA™ prime plus  16.0 x 40 
 
Appendix 7.109: Ammonium sulphate fractionation 
 
Extracted cell lysate was mixed with 20% (w/v) ammonium sulphate at 4°C until dissolved.  
The solution was centrifuged at 4000 x g and 4°C for 5 min before retaining the supernatant 
and re-suspending the resulting pellet in 10 ml of resuspension buffer.  The ammonium 
sulphate concentration of the supernatant was increased to 30% (w/v) and the solution was 
mixed at 4°C until the ammonium sulphate had dissolved. The solution was centrifuged at 
4000 x g for 5 min before retaining the supernatant and re-suspending the resulting pellet in 
10 ml of resuspension buffer. This process was repeated whilst steadily increasing the 
saturation of ammonium sulphate from 30% to 40% and then 60% (w/v). The resuspended 
pellets from each stage of fractionation and the remaining supernatant were analysed by 
SDS-PAGE to establish the ammonium sulphate concentration at which recombinant 
lysostaphin became insoluble.  
To concentrate a sample during protein purification, recombinant lysostaphin was 
precipitated through the addition of 50 or 60% (w/v) ammonium sulphate, before mixing at 
4°C until dissolved. Once dissolved, the precipitation was centrifuged at 4000 x g for 5 min.  
The pellet was resuspended in a buffer which was compatible with the subsequent 
chromatographic purification method.    
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Appendix 7.110: HIC using Phenyl Sepharose™ High Performance media and an 
ӒKTA™ purification system 
 
An XK 16/20 column was packed with Phenyl Sepharose™ High Performance media and 
incorporated into an ӒKTA™ purification system. The column was packed to a bed height of 
approximately 5.5 cm and had previously been equilibrated with 100 ml of HIC buffer A at a 
flow rate of 5.0 ml/min.  CFE was loaded onto the column at a flow rate of 2.0 ml/min via 
buffer line C.  Following application, 100% of HIC buffer A was applied to the column for 10 
min at flow rate of 2.0 ml/min using the same buffer line, to ensure that the CFE had been 
fully loaded onto to column. The target protein was eluted by applying a linear gradient from 
0-100% of HIC buffer B over 50 min at 5.0 ml/min.  Absorbance at 280 nm was monitored 
throughout the separation and the data was acquired using PrimeView™ software. The 
column eluate was collected as fractions in 5 ml volumes and using the chromatogram 
produced, fractions were selected and analysed by SDS-PAGE (Appendix 7.15). After use, 
the column was stored in EtOH after flowing 100 ml of column storage buffer through the 
column at 5.0 ml/min.   
 
Appendix 7.111: GF using HiLoad 16/60 Superdex 200 media and a FPLC system 
 
A gel filtration column packed with HiLoad 16/60 Superdex 200 prep grade was equilibrated 
with GF buffer at a flow rate of 1 ml/ min using an FPLC system. Following HIC purification 
and ultrafiltration, concentrated protein (0.5 ml) was manually loaded on to the gel filtration 
column by injection. The target protein was eluted over 120 min using an isocratic flow rate 
of 1 ml/ min. Absorbance at 280 nm was monitored throughout the separation and the data 
was acquired using FPLCdirector™ software. Fractions were collected in 5 ml volumes and 
fractions thought to contain the target protein were analysed by SDS-PAGE (Appendix 7.15). 
The column was stored in 20% (v/v) EtOH.  
 
Appendix 7.112: AXC using Source™ 30Q media and an ӒKTA™ purification system  
 
An XK 16/20 column was packed with Source™ 30Q media and incorporated into an 
ӒKTA™ purification system. The column was packed to a bed height of approximately 4.0 
cm and had previously been equilibrated with 100 ml of AXC buffer A at a flow rate of 5.0 
ml/min.  CFE was loaded onto the column at a flow rate of 2.0 ml/min via buffer line C.  
Following application, 100% of AXC buffer A was applied to the column for 10 min at flow 
rate of 2.0 ml/min using the same buffer line, to ensure that the CFE had been fully loaded 
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onto to column. The target protein was eluted by applying a linear gradient from 0-100% of 
AXC buffer B over 50 min at 5.0 ml/min.  Absorbance at 280 nm was monitored throughout 
the separation and the data was acquired using PrimeView™ software. The column eluate 
was collected as fractions in 5 ml volumes.  The purification process was monitored using 
PrimeView™ software.  Using the chromatogram produced, fractions were selected and 
analysed by SDS-PAGE (Appendix 7.15). After use, the column was stored in EtOH after 
flowing 100 ml of column storage buffer through the column at 5.0 ml/min.  
 
Appendix 7.113: CXC using Source™ 30S media and an ӒKTA™ purification system  
 
An XK 16/20 column was packed with Source™ 30S media and incorporated into an 
ӒKTA™ purification system. The column was packed to a bed height of approximately 3.2 
cm and had previously been equilibrated with 100 ml of CXC buffer A at a flow rate of 5.0 
ml/min.  CFE was loaded onto the column at a flow rate of 2.0 ml/min via buffer line C.  
Following application, 100% of CXC buffer B was applied to the column for 10 min at a flow 
rate of 2.0 ml/min using the same buffer line, to ensure that the CFE had been fully loaded 
onto the column. The target protein was eluted by applying a linear gradient from 0-100% of 
CXC buffer B over 50 min at 5.0 ml/min. Absorbance at 280 nm was monitored throughout 
the separation and the data was acquired using PrimeView™ software. The column eluate 
was collected as fractions in 5 ml volumes.  The purification process was monitored using 
PrimeView™ software.  Using the chromatogram produced, fractions were selected and 
analysed by SDS-PAGE (Appendix 7.15). After use, the column was stored in EtOH and 
sodium acetate, after flowing 100 ml of CXC storage buffer through the column at 5.0 
ml/min.   
 
Appendix 7.114: IMAC using Chelating Sepharose™ Fast Flow media and an ӒKTA™ 
purification system 
 
An XK 16/20 column was packed with Chelating Sepharose™ Fast Flow media and 
incorporated into an ӒKTA™ purification system.  Prior to sample loading, the nickel column 
had been stripped and charged by sequentially applying 30 ml of 18.2 M/cm H2O, 30 ml 
EDTA (100mM), 30 ml of 18.2 M/cm H2O and 30 ml NiSO4 (0.1M) at a rate of 5.0 ml/min. 
The column was then equilibrated with 100 ml of IMAC buffer A at 5.0 ml/min.  CFE was 
loaded onto the column (via buffer line C) at a flow rate of 2.0 ml/min. Following application, 
100% of IMAC buffer A was applied to the column for 10 min at a flow rate of 2.0 ml/min 
using the same buffer line, to ensure that the CFE had been fully loaded onto to column. The 
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target protein was eluted by applying a linear gradient from 0-100% of IMAC buffer B over 50 
min at 5.0 ml/min. Absorbance at 280 nm was monitored throughout the separation and the 
data was acquired using PrimeView™ software. The column eluate was collected as 
fractions in 5 ml volumes and fractions thought to contain the target protein were analysed 
by SDS-PAGE. After use, the column was stored in EtOH after flowing 100 ml of column 
storage buffer through the column at 5.0 ml/min.   
 
Appendix 7.115: IMAC using Chelating Sepharose™ Fast Flow media and a peristaltic 
pump 
 
An XK 50/20 column packed with 250 ml of Chelating Sepharose™ Fast Flow media was 
prepared and used to perform IMAC purification, with the assistance of a peristaltic pump.  
The nickel column was stripped and charged by sequentially applying 300 ml of 18.2 M/cm 
H2O, 300 ml EDTA (100mM), 300 ml of 18.2 M/cm H2O and 300 ml NiSO4 (0.1M) at a rate 
of 5-10 ml/min. The column was then equilibrated with 1000 ml of IMAC buffer A at 5-10 
ml/min.  CFE was loaded onto the column and the target protein was eluted by applying a 
step gradient featuring elution buffers containing 50 mM, 100 mM, 200 mM, 300 mM, 400 
mM and 500 mM imidazole.  At each stage of the step gradient, protein elution was 
monitored using Bradford’s reagent (Appendix 7.24) and the concentration of the imidazole 
gradient was only increased when Bradford’s reagent confirmed that protein elution had 
ceased. The column eluate at each stage of the step elution was collected and precipitated 
with ammonium sulphate or dialysed (Appendix 7.109 or Appendix 7.118) and lyophilised to 
concentrate the eluted protein (Appendix 7.119). The purified protein was analysed by SDS-
PAGE. After use, the column was stored in 20% (v/v) EtOH.  
 
Appendix 7.116: IMAC using a ProPac® IMAC-10 column (2 x 250 mm) and an 
Ultimate™ 3000 system  
 
Prior to purification, the ProPac® IMAC-10 column was stripped and charged through manual 
injection of 500 µl of EDTA (100 mM) and 1000 µl of NiSO4 (100 mM).  Purified recombinant 
lysostaphin (preparation 9) was loaded onto the column through automated injection of 8 µg 
and then 40 µg.  During the first 10 min, IMAC buffer A was applied to the column at a flow 
rate of 0.25 ml/min, to remove non-binding proteins and cellular contaminants.  The bound 
protein was eluted by applying a linear gradient from 0-100% of IMAC buffer B over 20 min 
at a flow rate of 0.25 ml/min.  Fractions were collected by time, every 60 s during this linear 
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gradient.  The column was re-equilibrated for 10 min with 100% of IMAC buffer A at a flow 
rate of 0.25 ml/ min.  UV absorbance was recorded at 214 and 280 nm throughout the 
purification and the acquired data was analysed using Chromeleon software.  The column 
eluate was collected as fractions in 0.25 ml volumes and fractions thought to contain the 
target protein were analysed by SDS-PAGE.  
 
Appendix 7.117: IMAC using a ProPac® IMAC-10 column (4 x 250 mm) and an 
Ultimate™ 3000 system  
 
Prior to purification, the ProPac® IMAC-10 column was stripped and charged through manual 
injection of 500 µl of EDTA (100 mM) and 1000 µl of NiSO4 (100 mM),  CFE (66 ml) was 
loaded onto the column (via buffer line C) at a flow rate of 1.0 ml/min. Following application 
of the cell lysate, 100% of IMAC buffer A was applied to the column for 20 min at a flow rate 
of 1.0 ml/min, to remove non-binding proteins and cellular contaminants. The target protein 
was eluted by applying a linear gradient from 0-100% of IMAC buffer B over 50 min at 0.5 
ml/min.  The column was re-equilibrated for 25 min with 100% of IMAC buffer A at a flow rate 
of 1.0 ml/ min.  UV absorbance was recorded at 214 and 280 nm throughout the purification 
and the acquired data was analysed using Chromeleon™ software.  The column eluate was 
collected as fractions in 0.25 ml volumes and fractions thought to contain the target protein 
were analysed by SDS-PAGE (Appendix 7.15).  
 
Appendix 7.118: Dialysis 
 
Dialysis tubing (Sigma Aldrich, USA) was cut into 30 cm strips and boiled for 20 min in 18.2 
M/cm H2O over a Bunsen burner. The boiled dialysis tubing was then rinsed internally and 
externally four times with 18.2 M/cm H2O to remove residual surface contaminants, such 
as glycerol and sodium azide.  The washed tubing was used for dialysis immediately or 
stored in 18.2 M/cm H2O at 4°C until required.   
The prepared dialysis tubing was filled with the eluate following elution with an IMAC elution 
buffer containing 200 mM imidazole and sealed to prevent leakage.  The sealed dialysis 
tubing was placed into beakers containing 3 L of 18.2 M/cm H2O and stirred at 4°C for 1 h.  
It was ensured that the volume of dialysed protein solution did not exceed 1/200 of the 
volume of the 18.2 M/cm H2O. After 1 h, the dialysate was replaced with fresh 18.2 M/cm 
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H2O and the samples were dialysed for a further 2 h, before exchanging the dialysate and 
continuing dialysis for a further 3 h. Following 6 h of dialysis, the dialysate was replaced 
again and dialysis was continued overnight.  Following dialysis, the desalted protein solution 
was lyophilised to concentrate the purified recombinant lysostaphin.   
 
Appendix 7.119: Lyophilisation  
 
Following dialysis, 25 ml aliquots of the protein solution were transferred to Petri dishes, 
sealed with adhesive tape and frozen at -20°C.  The frozen samples were then transferred to 
a freeze-drier until they had reached complete lyophilisation. 
 
Appendix 7.120: Ultrafiltration  
 
Following purification, chromatographic fractions were analysed by SDS-PAGE to establish 
which fractions contained the target protein.  The fractions containing the target protein were 
pooled and concentrated using Vivaspin 20 ml ultrafiltration columns with a 10 kDa 
membrane to remove salts and other contaminating micromolecules (Sartorius Stedim, 
Germany).  After adding the pooled fractions to the column, the column was centrifuged at 
4000 x g and 4C until the volume had been reduced from 20 ml to 0.5 ml.  The flow-through 
was retained and Bradford’s reagent was used to confirm that protein had not passed 
through the ultrafiltration membrane.  Once the protein volume had been reduced to 0.5 ml, 
the protein was washed three times with 20 ml of 18.2 M/cm H2O by continuing to 
centrifuge at 4000 x g and 4C.  After the third wash with 18.2 M/cm H2O, the protein was 
stored as a 0.5 ml volume at 4C.  
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Appendix 7.121: Expression of recombinant lysostaphin (construct 2) in E. coli 
BL21(DE3) cultured in AIM.  Over-expression of protein with a molecular weight of 
around 27 kDa was observed indicating the presence of recombinant lysostaphin. 
Lane 1: Sigma low molecular weight markers; Lane 2: CFE (neat); Lane 3: CFE (1:10); 
Lane 4: CFE (1:100); Lane 5: CFE in solubilising cracking buffer; Lane 6: Sigma high 
molecular weight markers. 
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Appendix 7.122: Purification of C-terminally His-tagged recombinant lysostaphin 
(construct 4) using AXC.  Cell lysate extracted from recombinant E. coli BL21(DE3) 
cultured in AIM was applied to the Source™ 30Q column.  Bound protein was eluted 
by applying an increasing NaCl concentration (0-1.0 M).  
 
 
 
Appendix 7.123: SDS-PAGE analysis of fractions eluted during AXC of cell-lysate 
containing C-terminally His-tagged recombinant lysostaphin (construct 4).  Lane 1: 
Sigma low molecular weight markers; Lane 2: dialysed lysate (neat); Lane 3: Fraction 
26; Lane 4: Fraction 28; Lane 5: Fraction 30; Lane 6: Fraction 32; Lane 7: Fraction 34; 
Lane 8: Fraction 36; Lane 9: Fraction 38; Lane 10: Sigma high molecular weight 
markers; Lane 11: Fraction 40; Lane 12: Fraction 42; Lane 13: Fraction 54; Lane 14: 
Fraction 44; Lane 15: Fraction 46; Lane 16: Sigma low molecular weight markers. 
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Appendix 7.124: Purification of recombinant lysostaphin (construct 5) using AXC.  
Cell lysate extracted from recombinant E. coli BL21(DE3) cultured in AIM was applied 
to the Source™ 30Q column.  Bound protein was eluted by applying an increasing 
NaCl concentration (0-1.0 M). 
 
 
Appendix 7.125: SDS-PAGE analysis of fractions eluted during AXC of cell-lysate 
containing recombinant lysostaphin (construct 5).  Lane 1: Sigma low molecular 
weight markers; Lane 2: dialysed lysate (neat); Lane 3: Fraction 29; Lane 4: Fraction 
31; Lane 5: Fraction 33; Lane 6: Fraction 35; Lane 7: Fraction 37; Lane 8: Fraction 39; 
Lane 9: Fraction 41; Lane 10: Sigma high molecular weight markers; Lane 11: Fraction 
43; Lane 12: Fraction 45; Lane 13: Fraction 47; Lane 14: fraction 49; Lane 15: Sigma 
low molecular weight markers.   
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Appendix 7.126: Expression of C-terminally His-tagged recombinant lysostaphin 
(construct 3) in E. coli BL21(DE3) cultured in AIM.  Over-expression of protein with a 
molecular weight of around 28 kDa was observed indicating the presence of C-
terminally His-tagged recombinant lysostaphin. Lane 1: Sigma high molecular weight 
markers; Lane 2: CFE (neat); Lane 3: CFE (1:10). 
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Appendix 7.127: Purification of N-terminally His-tagged recombinant lysostaphin 
(construct 1) using CXC.  Cell lysate extracted from recombinant E. coli BL21(DE3) 
cultured in TB was applied to the Source™ 30s column.  Bound protein was eluted by 
applying an increasing NaCl concentration (0-1.0 M).  
 
Appendix 7.128: SDS-PAGE analysis of CXC fractions following purification of N-
terminally His-tagged recombinant lysostaphin (construct 1) derived from E.coli 
BL21(DE3) cultured in TB. Lane 1: Sigma low molecular weight markers; Lane 2: 
Fraction 20; Lane 3: Fraction 22: Lane 4: Fraction 24; Lane 5:Fraction 26; Lane 6: 
Sigma low molecular weight markers; Lane 7: Column flow through; Lane 8: Fraction 
28; Lane 9: Fraction 30; Lane 10: Fraction 32; Lane 11: Fraction 34; Lane 12: Fraction 
36; Lane 13: Fraction 38; Lane 14; Fraction 40; Lane 15: Sigma high molecular weight 
markers.   
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Appendix 7.129: Purification of N-terminally His-tagged recombinant lysostaphin 
(construct 1) using CXC.  Cell lysate extracted from recombinant E. coli BL21(DE3) 
cultured in MM was applied to the Source™ 30s column.  Bound protein was eluted by 
applying an increasing NaCl concentration (0-1.0 M).  
 
Appendix 7.130: SDS-PAGE analysis of CXC fractions following purification of N-
terminally His-tagged recombinant lysostaphin (construct 1) derived from E.coli 
BL21(DE3) cultured in MM. Lane 1: Sigma low molecular weight markers; Lane 2: 
Fraction 29; Lane 3: Fraction 31: Lane 4: Fraction 33; Lane 5: Fraction 35; Lane 6: 
Sigma low molecular weight markers; Lane 7: Fraction 37; Lane 8: Fraction 39; Lane 
9: Fraction 41. 
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Appendix 7.131: Purification of N-terminally His-tagged recombinant lysostaphin 
(construct 1; preparation 19) using IMAC.  Cell lysate extracted from recombinant E. 
coli BL21(DE3) cultured in AIM was applied to the Chelating Sepharose™ Fast Flow 
media column.  Bound protein was eluted by applying an increasing imidazole 
concentration (20-500 mM).  
 
 
Appendix 7.132: SDS-PAGE analysis of fractions following IMAC purification of N-
terminally His-tagged recombinant lysostaphin (construct 1; preparation 19) derived 
from E.coli BL21(DE3) cultured in AIM. Lane 1: Sigma low molecular weight markers; 
Lane 2: Fraction 46; Lane 3: Fraction 48: Lane 4: Fraction 50; Lane 5: Fraction 52; 
Lane 6: Fraction 54; Lane 7: Fraction 56; Lane 8: Fraction 58; Lane 9: Fraction 60; 
Lane 10: Sigma high molecular weight markers.   
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Appendix 7.133: Purification of C-terminally His-tagged recombinant lysostaphin 
(construct 4) using IMAC.  Cell lysate extracted from recombinant E. coli BL21(DE3) 
was applied to the Chelating Sepharose™ Fast Flow media column.  Bound protein 
was eluted by applying an increasing imidazole concentration (20-500 mM).  
 
Appendix 7.134: SDS-PAGE analysis of GF fractions following IMAC purification of C-
terminally His-tagged recombinant lysostaphin (construct 4) derived from E. coli 
BL21(DE3) cultured in AIM. Lane 1: Sigma low molecular weight markers; Lane 2: 
Fraction 45; Lane 3: Fraction 47: Lane 4: Fraction 49; Lane 5: Fraction 51; Lane 6: 
Fraction 53; Lane 7: Fraction 55; Lane 8: Fraction 57; Lane 9: Fraction 59; Lane 10: 
Sigma high molecular weight markers.   
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Appendix 7.135: Dionex Customer Application Note entitled “Rapid His-tag 
purification of recombinant proteins using Dionex ProPac IMAC columns”.  Available 
at http://www.dionex.com/en-us/webdocs/86266-CAN107-LC-Recombinant-Proteins 
15April2010-LPN2495.pdf. 
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Appendix 7.135: Dionex Customer Application Note entitled “Rapid His-tag 
purification of recombinant proteins using Dionex ProPac IMAC columns”.  Available 
at http://www.dionex.com/en-us/webdocs/86266-CAN107-LC-Recombinant-Proteins 
15April2010-LPN2495.pdf (continued). 
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Appendix 7.135: Dionex Customer Application Note entitled “Rapid His-tag 
purification of recombinant proteins using Dionex ProPac IMAC columns”.  Available 
at http://www.dionex.com/en-us/webdocs/86266-CAN107-LC-Recombinant-Proteins 
15April2010-LPN2495.pdf (continued). 
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7.2 Separation of Recombinant Lysostaphin Isoforms 
 
Appendix 7.136: Buffers  
 
IEX buffer A (1 L) 
 
Sodium phosphate (20 mM)   100 ml of 200 mM stock solution 
 
The stock solution was mixed with 900 ml of 18.2 M/cm H2O and the pH of the buffer was  
adjusted to pH 7.0 using NaOH. The buffer was autoclaved prior to use. 
 
IEX buffer B (1L) 
 
Sodium phosphate (20 mM)   100 ml of 200 mM stock solution 
NaCl (1.0 M)    58.44 g 
 
The stock solution and NaCl were added to 18.2 M/cm H2O to achieve a total volume of 1 
L. The pH of the buffer was adjusted to pH 7.0 using NaOH. The buffer was autoclaved prior 
to use. 
 
MAb SCX buffer A (1 L) 
 
MES (20 mM)    3.9 g  
 
MES was dissolved in 18.2 M/cm H2O and the pH of the buffer was adjusted to pH 6.4 
using NaOH. The buffer was autoclaved prior to use. 
 
MAb SCX buffer B (1 L) 
 
MES (20 mM)    3.90 g 
NaCl (1.0 M)    58.44 g 
 
MES and NaCl were dissolved in 18.2 M/cm H2O and the pH of the buffer was adjusted to 
pH 6.4 using NaOH. The buffer was autoclaved prior to use. 
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WCX buffer A (1 L) 
 
Sodium phosphate (20 mM)   100 ml of 200 mM stock solution 
 
The stock solution was mixed with 900 ml of 18.2 M/cm H2O and the pH of the buffer was 
adjusted to pH 7.0 using NaOH. The buffer was autoclaved prior to use. 
 
WCX buffer B (1 L)  
 
Sodium phosphate (20 mM)   100 ml of 200 mM stock solution 
NaCl (1.0 M)    58.44 g 
 
The stock solution and NaCl were added to 18.2 M/cm H2O to achieve a total volume of 
1L. The pH of the buffer was adjusted to pH 7.0 using NaOH. The buffer was autoclaved 
prior to use. 
 
SCX buffer A (1 L) 
 
Sodium phosphate (20 mM)   100 ml of 200 mM stock solution 
 
The stock solution was mixed with 900 ml of 18.2 M/cm H2O and the pH of the buffer was 
adjusted to pH 8.0 using NaOH. The buffer was autoclaved prior to use. 
 
SCX buffer B (1 L) 
 
Sodium phosphate (20 mM)   100 ml of 200 mM stock solution 
NaCl (1.0 M)    58.44 g 
 
The stock solution and NaCl were added to 18.2 M/cm H2O to achieve a total volume of 
1L. The pH of the buffer was adjusted to pH 7.0 using NaOH. The buffer was autoclaved 
prior to use. 
 
RP buffer A (1 L) 
 
Acetonitrile (LC/MS grade) (2.0%, v/v)  20.0 ml 
Trifluoracetic acid (TFA) (0.1%, v/v)   1.0 ml 
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The volume was made up to 1 L with LC/MS grade H2O 
 
RP buffer B (1 L) 
 
Acetonitrile (LC/MS grade) (90%, v/v)  900.0 ml 
Trifluoracetic acid (TFA) (0.09%, v/v)  1.0 ml 
 
The volume was made up to 1 L with LC/MS grade H2O 
 
Appendix 7.137: Equipment  
 
Initial ion exchange separations were performed using a Dionex DX500 HPLC system 
consisting of a GP40 Gradient Pump, an AD25 variable wavelength absorbance detector, an 
LC20 Chromatography Enclosure.  Fractions were collected using a Foxy Jr fraction 
collector.  The system was operated using a Dionex PeakNet Chromatography Workstation 
and acquired data was collected using PeakNet Version 5.01.  UV data was acquired at 280 
nm throughout each separation. 
 
Subsequent separations were performed using one of two Ultimate™ 3000 Titanium 
systems. Both systems consisted of a dual gradient titanium pump, a thermal compartment 
with two column change valves, a VWD detector and a WPS-3000 Biocompatible 
autosampler.  The thermal compartment was maintained at 25°C, unless specified 
otherwise. The system was fitted with a PEEK fluidic pathway and the autosampler was 
fitted with a 250 µl syringe and a 1 ml injection loop.  Although both autosamplers could 
accommodate fractionation, fractionation was performed using an ISCO Foxy® Jr Fraction 
collector when using one of the systems, due to the use of higher flow rates (0.5-1.0 ml). 
Data collection and analysis was performed using Chromeleon® Chromatography Data 
system software with fractionation license. UV data was acquired at 214 and 280 nm 
throughout each separation. 
 
Chromatographic separations were performed using a number of analytical columns, as 
described in Appendix 7.138.  
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Appendix 7.138: Analytical columns and mobile phase compositions used during 
separation of recombinant lysostaphin isoforms 
Column IEX 
mode 
Dimensions Mobile Phase 
ProPac
®
 WCX-10 WCX 2.0 x 250 WCX buffer A and B  
ProPac
®
 WCX-10 WCX 4.0 x 250 IEX buffer A and B or  
WCX buffer A and B 
ProSwift
®
 WCX-1S   WCX 2.0 x 50 IEX buffer A and B 
ProPac
®
 SAX-10 SAX 2.0 x 250 IEX buffer A and B 
ProPac
®
 SCX-10 SCX 2.0 x 250 IEX buffer A and B or 
SCX buffer A and B 
ProSwift
®
 SCX-1S  SCX 4.6 x 50 IEX buffer A and B 
ProPac
®
SCX-10 SCX 4.0 x 250 IEX buffer A and B 
ProPac
®
 MAb SCX SCX 4.0 x 250 MAb SCX Buffer A and B  
ProSwift
®
 RP-4H RP 1.0 x 250 RP buffer A and B 
 
Appendix 7.139: Sample preparation  
 
Recombinant lysostaphin was harvested from E. coli BL21(DE3) cultured in either LB or AIM 
and purified using either IMAC or HIC and GF.  Following purification, the purified protein 
was concentrated using ultrafiltration. Further details about preparation of recombinant 
lysostaphin is provided in Appendix 7.140.  
 
The ProPac® WCX-10 column was validated using a Cytochrome C standard (LC Packings, 
UK). Prior to use the lyophilised cytochrome C was resuspended in 200 µl of LC/MS grade 
H2O and stored at -20˚C between use.  
 
The ProPac® MAb SCX column was validated using a standard protein mix composed of a 
mixture of Lysozyme (0.25 mg/ml), Ribonuclease A (1.0 mg/ml) and Cytochrome C (0.20 
mg/ml).  The lyophilized standard was provided by Dionex, UK for beta-testing purposes. 
Prior to use, the standard protein mix was resuspended in 200 µl of LC/MS grade H2O and 
10 µl of standard was injected onto the column during each standard separation. Following 
resuspension the standard samples was refridgerated at 2-8˚C. 
 
 
  
500 
 
Appendix 7.140: Purified recombinant lysostaphin preparations  
 
Preparation 
ID 
Construct Expression 
media 
Mode of 
purification 
Protein 
concentration 
(µg/µl) 
Related results 
1 4 AIM IMAC 55.42 Appendix 7.97 
Appendix 7.133 
Appendix 7.134 
2 3 AIM IMAC 8.67 Appendix 7.141 
Figure 2.26 
Figure 2.27 
3 3 AIM HIC, GF 1.46 Appendix 7.142 
Figure 2.17 
Figure 2.18 
Figure 2.19 
Figure 2.20 
Figure 2.21 
4 1 AIM IMAC 37.80 Appendix 7.143 
Appendix 7.144 
Appendix 7.145 
5 3 LB IMAC 16.34 Appendix 7.146 
Figure 2.37 
Figure 2.39 
6 1 AIM IMAC 157.85 Appendix 7.147 
Appendix 7.148 
Appendix 7.149 
7 1 AIM IMAC 55.35 Appendix 7.150 
Appendix 7.151 
Appendix 7.152 
8 1 AIM IMAC 140.12 Appendix 7.153 
Appendix 7.154 
Appendix 7.155 
9 1 AIM IMAC 91.68 Appendix 7.156 
Appendix 7.157 
Appendix 7.158 
10 1 LB IMAC 16.69 Appendix 7.159 
Appendix 7.160 
Appendix 7.161 
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Appendix 7.140: Purified recombinant lysostaphin preparations (continued)  
 
Preparation 
ID 
Construct Expression 
media 
Mode of 
purification 
Protein 
concentration 
(µg/µl) 
Related results 
11 1 LB IMAC 39.35 Appendix 7.162 
Appendix 7.163 
Appendix 7.164 
12 1 LB IMAC 5.71 Appendix 7.165 
Appendix 7.166 
Figure 4.29 
13 3 AIM IMAC/GF 19.08 Appendix 7.167 
Figure 2.26 
Figure 2.27 
Figure 2.28 
Figure 2.29 
 
 
Appendix 7.141: SDS-PAGE analysis of cell lysate containing C-terminally His-tagged 
recombinant lysostaphin (construct 3, preparation 2) expressed in E.coli BL21(DE3) 
cultured in AIM. Lane 1: Sigma low molecular weight markers; Lane 2: CFE (neat); 
Lane 3: CFE (1:10 dilution), Lane 4: CFE (1:100 dilution). 
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Appendix 7.142: SDS-PAGE analysis of cell lysate containing C-terminally His-tagged 
recombinant lysostaphin (construct 3, preparation 3) expressed in E.coli BL21(DE3) 
cultured in AIM. Lane 1: Sigma low molecular weight markers; Lane 2: CFE (neat); 
Lane 3: CFE (1:10 dilution), Lane 4: CFE (1:100 dilution); Lane 5: CFE in solubilising 
cracking buffer; Lane 6: Sigma high molecular weight markers 
 
Appendix 7.143: SDS-PAGE analysis of cell lysate containing N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 4) expressed in E.coli BL21(DE3) 
cultured in AIM. Lane 1: Sigma low molecular weight markers; Lane 2: CFE (1:10); 
Lane 3: CFE (neat), Lane 4: Sigma high molecular weight markers 
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Appendix 7.144: IMAC purification of N-terminally His-tagged recombinant 
lysostaphin (construct 1, preparation 4) using a Chelating Sepharose™ Fast Flow 
media column and ӒKTA™ prime plus system. Bound protein was eluted by applying 
an increasing imidazole concentration (20-500 mM).  Fractions were collected every 60 
s throughout the separation. Fractions 38-48 were pooled and concentrated.   
 
 
 
Appendix 7.145: SDS-PAGE analysis of fractions eluted during IMAC of cell-lysate 
containing N-terminally His-tagged recombinant lysostaphin (construct 1, preparation 
4).  Lane 1: Sigma low molecular weight markers; Lane 2: Fraction 38; Lane 3: 
Fraction 40; Lane 4: Fraction 42; Lane 5: Fraction 44; Lane 6: Fraction 46; Lane 7: 
Fraction 48; Lane 8: Sigma high molecular weight markers. 
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Appendix 7.146: SDS-PAGE analysis of cell lysate containing C-terminally His-tagged 
recombinant lysostaphin (construct 3, preparation 5) expressed in E.coli BL21(DE3) 
cultured in AIM. Lane 1: Sigma low molecular weight markers; Lane 2: CFE (neat); 
Lane 3: CFE (1:10 dilution), Lane 4: CFE (1: 100 dilution). 
 
Appendix 7.147: SDS-PAGE analysis of cell lysate containing N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 6) expressed in E.coli BL21(DE3) 
cultured in AIM. Lane 1: Sigma low molecular weight markers; Lane 2: CFE (neat); 
Lane 3: CFE (1:10 dilution), Lane 4: CFE (1:100 dilution). 
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Appendix 7.148: IMAC purification of recombinant lysostaphin (construct 1, 
preparation 6) using a Chelating Sepharose™ Fast Flow media column and ӒKTA™ 
prime plus system. Cell lysate was applied to the column on two consecutive 
occasions (A and B). Bound protein was eluted by applying an increasing imidazole 
concentration (20-500 mM). Fractions were collected every 60 s throughout the 
separations.  Fractions 48-63 collected during the first purification (A) and fractions 
40-52 collected during the second purification (B) were pooled and concentrated.   
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Appendix 7.149: SDS-PAGE analysis of purified, concentrated N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 6). Lane 1: Sigma low molecular 
weight markers; Lane 2: concentrated protein (neat). 
 
Appendix 7.150: SDS-PAGE analysis of cell lysate containing N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 7) expressed in E.coli BL21(DE3) 
cultured in AIM. Lane 1: Sigma low molecular weight markers; Lane 2: CFE (neat); 
Lane 3: CFE (1:10).   
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Appendix 7.151: IMAC purification of recombinant lysostaphin (construct 1, 
preparation 7) using a Chelating Sepharose™ Fast Flow media column and ӒKTA™ 
prime plus system. Bound protein was eluted by applying an increasing imidazole 
concentration (20-500 mM).  Fractions were collected every 60 s throughout the 
separation. Fractions 58-70 were pooled and concentrated.   
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Appendix 7.152: SDS-PAGE analysis of purified, concentrated N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 7). Lane 1: Sigma low molecular 
weight markers; Lane 2: concentrated protein (1:2); Lane 3: concentrated protein 
(1:10), Lane 4: concentrated protein (1:100); Lane 5: Sigma high molecular weight 
markers.   
 
Appendix 7.153: SDS-PAGE analysis of cell lysate containing N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 8) expressed in E.coli BL21(DE3) 
cultured in AIM. Lane 1: Sigma low molecular weight markers; Lane 2: CFE (neat); 
Lane 3: CFE (1:10), Lane 4: Sigma high molecular weight markers.  
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Appendix 7.154: IMAC purification of recombinant lysostaphin (construct 1, 
preparation 8) using a Chelating Sepharose™ Fast Flow media column and ӒKTA™ 
prime plus system. Fractions were collected every 60 s throughout the separations. 
Cell lysate was applied to the column on two consecutive occasions (A and B). Bound 
protein was eluted by applying an increasing imidazole concentration (20-500 mM).  
Fractions 52-62 collected during purifications A and B were pooled and concentrated.   
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Appendix 7.155: SDS-PAGE analysis of purified, concentrated N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 8). Lane 1: Sigma low molecular 
weight markers; Lane 2: concentrated protein (1:10).  
 
Appendix 7.156: SDS-PAGE analysis of cell lysate containing N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 9) expressed in E.coli BL21(DE3) 
cultured in AIM. Lane 1: Sigma low molecular weight markers; Lane 2: CFE (neat). 
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Appendix 7.157: IMAC purification of recombinant lysostaphin (construct 1, 
preparation 9) using a Chelating Sepharose™ Fast Flow media column and ӒKTA™ 
prime plus system. Bound protein was eluted by applying an increasing imidazole 
concentration (20-500 mM).  Fractions were collected every 60 s throughout the 
separation. Fractions 56-70 were pooled and concentrated.   
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Appendix 7.158: SDS-PAGE analysis of purified, concentrated N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 9). Lane 1: Sigma low molecular 
weight markers; Lane 2: concentrated protein (neat); Lane 3: concentrated protein 
(1:10); Lane 4: concentrated protein (1:100); Lane 5: Sigma high molecular weight 
markers  
 
Appendix 7.159: SDS-PAGE analysis of cell lysate containing N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 10) expressed in E.coli BL21(DE3) 
cultured in 14 x 1 L LB. Lane 1: Sigma low molecular weight markers; Lane 2: CFE 
(neat); Lane 3: CFE (1:10), Lane 4: CFE (1:100); Lane 5: CFE (1:1000); Lane 6: CFE in 
solubilising buffer; Lane 7: Sigma high molecular weight markers 
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Appendix 7.160: SDS-PAGE analysis of purified N-terminally His-tagged recombinant 
lysostaphin (construct 1, preparation 10) following large-scale IMAC purification. Lane 
1: Sigma low molecular weight markers; Lane 2: 200 mM imidazole (elution A); Lane 3: 
200 mM imidazole (elution B), Lane 4: 300 mM imidazole; Lane 5: 400 mM imidazole; 
Lane 6: 500 mM imidazole; Lane 7: Sigma high molecular weight markers. 
 
.  
Appendix 7.161: SDS-PAGE analysis of purified freeze-dried recombinant lysostaphin 
(construct 1, preparation 10). Lane 1: Sigma low molecular weight markers; Lane 2: 
lysostaphin expressed in LB media (neat); Lane 3: lysostaphin expressed in LB media 
(1/10), Lane 4: lysostaphin expressed in LB (1/100); Lane 5: Sigma low molecular 
weight markers; Lane 6: lysostaphin expressed in AIM media (neat); Lane 7: 
lysostaphin expressed in AIM media (1/10); Lane 8: lysostaphin expressed in AIM 
media (1/100).  
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Appendix 7.162: SDS-PAGE analysis of cell lysate containing N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 11) expressed in E.coli BL21(DE3) 
cultured in LB. Lane 1: NZY broad size markers; Lane 2: CFE (1:10); Lane 3: CFE 
(1:100). 
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Appendix 7.163: IMAC purification of recombinant lysostaphin (construct 1, 
preparation 11) using a Chelating Sepharose™ Fast Flow media column and ӒKTA™ 
prime plus system. Bound protein was eluted by applying an increasing imidazole 
concentration (20-500 mM).  Fractions were collected every 60 s throughout the 
separation. Fractions 44-60 were pooled and concentrated.   
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Appendix 7.164: SDS-PAGE analysis of purified, concentrated N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 11). Lane 1: NZY broad range size 
markers; Lane 2: concentrated protein (1:10); Lane 3: concentrated protein (1:100); 
Lane 4: concentrated protein (1:1000). 
 
 
 
Appendix 7.165: SDS-PAGE analysis of cell lysate containing N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 12) expressed in E.coli BL21(DE3) 
cultured in LB. Lane 1: CFE (neat); Lane 2: Sigma low molecular weight markers.  
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Appendix 7.166: SDS-PAGE analysis of purified, concentrated N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 12). Lane 1:concentrated protein 
(1:10); Lane 2: concentrated protein (1:100); Lane 3: Sigma low molecular weight 
markers 
 
 
 
Appendix 7.167: SDS-PAGE analysis of purified, concentrated N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 13). Lane 1: Sigma low molecular 
weight markers; Lane 2: concentrated protein (neat). 
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7.2.1 Column selection 
 
Appendix 7.168: Protein separation using ProPac® SAX-10, SCX-10 and WCX-10 
columns and DX500 chromatography system 
 
Initial ion exchange separations were performed using a 0.5 ml/ min flow rate and linear 
gradient from 0-50% IEX buffer B in 60 min.  The ion exchange column was washed at 90% 
B for 10 min and then the column was equilibrated at 0% B for 10 min.  Mobile phase buffers 
were degassed for 15 min prior to system equilibration.  Manual injections of 100 µl of 
recombinant lysostaphin (construct 4, preparation 1 or construct 3, preparations 2 or 3) were 
delivered to the system.  Fractions were collected using a Foxy Jr fraction collector and 
fraction collection was initiated manually upon peak elution.    
 
Appendix 7.169: Protein separation using ProPac® WCX-10 column and Ultimate™ 
3000 chromatography system 
 
WCX separation was performed using a 0.5 ml/ min flow rate and linear gradient from 0-50% 
IEX buffer B in 30 min. The WCX column was washed at 90% B for 2 min and then the 
column was equilibrated at 0 % B for 4 min. A 5 µl injection of a 1:2 dilution of purified 
recombinant lysostaphin (construct 1, preparation 4) was applied to the system.  Fractions 
were collected by time, every 60 s between 6 and 36 min.  Following separation, fractions 
containing eluted protein were analysed by SDS-PAGE.  
 
Appendix 7.170: Validation of ProPac® WCX-10 column 
 
Multiple WCX separations were performed to validate a ProPac® WCX-10 column (4.0 x 250 
mm).  The separations were performed using a 0.5 ml/ min flow rate and linear gradient from 
0-50% B over 70 min. The WCX column was washed at 90% B for 4 min and then the 
column was equilibrated at 0% B for 20 min. A 50 µl injection of cytochrome C standard was 
injected onto the system.   
 
Appendix 7.171: Protein separation using ProSwift® SCX-1S column and an Ultimate™ 
3000 system 
 
SCX separation was performed using a 0.5 ml/ min flow rate and linear gradient from 0-50% 
IEX buffer B in 30 min. The ProSwift® SCX-1S column was washed at 90% B for 2 min and 
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then the column was equilibrated with 0 % B for 4 min. A 5 µl of injection of purified 
concentrated recombinant lysostaphin (construct 1, preparation 4) was delivered onto the 
system.  Fractions were collected by time, every 60 s between 6 and 28 min.   
 
Appendix 7.172: Protein separation using ProSwift® WCX-1S column and an 
Ultimate™ 3000 system 
 
WCX separation was performed using an 80 µl/ min flow rate and linear gradient from 5-50% 
IEX buffer B in 20 min. The ProSwift® WCX-1S column was washed at 90% B for 2 min and 
then the column was equilibrated at 5 % B for 8 min. A 30 µl injection of a 1:10 dilution of 
purified recombinant lysostaphin (construct 1, preparation 4) was applied to the system. 
Fractions were collected by time, every 60 s between 2 and 22 min.   
 
Appendix 7.173: Validation of ProPac® MAb SCX beta test column 
 
The ProPac® MAb SCX-1S column was validated according to a beta-test protocol provided 
by Dionex, UK.  During each separation,10 µl of standard protein mix was injected onto the 
column. Each separation was performed using a flow rate of 1.0 ml/min. The column was 
equilibrated for 10 min using 100% MAb SCX buffer A, before applying a linear gradient of 0-
48% MAb SCX buffer B in 20.3 min.  The column was then washed for 5 min using 100% 
MAb SCX buffer B.  
 
Appendix 7.174: Protein separation using the ProPac® MAb SCX beta test column  
 
Purified recombinant lysostaphin was separated using the beta-test protocol (Appendix 
7.173).  During the separation, 10 µl of a 1:10 dilution of purified recombinant lysostaphin 
(construct 3, preparation 5) was applied to the column.  
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7.2.2 Optimisation of protein isoform separation 
 
Appendix 7.175: Optimisation of sample loading conditions 
 
Separations were performed using ProPac® WCX-10 column (4 x 250 mm) or ProPac® 
WCX-10 column (4 x 500 mm) column at a flow rate of 0.5 ml/min.  Separation was achieved 
by applying a linear gradient from 0-50% WCX Buffer B in 70 min. The column was washed 
at 90% B for 4 min before being equilibrated with 0% B for 10 min. Manual 100 µl injections 
of recombinant lysostaphin (construct 1, preparation 8 or 9) were delivered to the Dionex 
DX500 HPLC system. Fractions were collected using a Foxy Jr fraction collector every 30 s 
between 15 and 55 min.  
 
Appendix 7.176: Optimisation of sample preparation 
 
Separations were performed using a ProPac® WCX-10 column (4 x 500 mm) column at a 
flow rate of 1.0 ml/min.  Separation was achieved by applying a linear gradient from 0-50% B 
in 15 min. The column was washed at 90% IEX Buffer B for 2 min before being equilibrated 
with 0% B for 8 min. Automated injections of 270, 300 or 350 µl of recombinant lysostaphin 
(construct 1, preparation 10) were delivered to the system.  
 
Appendix 7.177: Optimisation of gradient conditions  
 
Gradient duration experiments were performed using a ProPac® WCX-10 column (4 x 250 
mm) at a flow rate of 0.5 ml/min.  Separation was achieved by applying a linear gradient 
from 0-50% IEX buffer B for either 60, 70, 90, 120 or 240 min. The column was washed at 
90% B for 3 min before being equilibrated with 0% B for 9 min. Automated 5 µl injections of 
recombinant lysostaphin (construct 1, preparation 4) were delivered to the system.  
 
Gradient steepness experiments were performed using ProPac® WCX-10 column (4 x 250 
mm) at a flow rate of 0.5 ml/min. Separation was achieved by applying a linear gradient from 
0-50% or 0-90% IEX buffer B for 70 min. The column was washed at 90% B for 10 min 
before being equilibrated with 0% B for 20 min. Manual 20 µl injections of a 1:10 dilution of 
recombinant lysostaphin (construct 1, preparation 7) were delivered to the Dionex DX500 
HPLC system. 
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Appendix 7.178: Optimisation of mobile phase conditions 
 
Separation was performed as described in Appendix 7.176 with injection of 260 µl of 
recombinant lysostaphin (construct 1, preparation 4). 
 
Appendix 7.179: Optimisation of column length  
 
Separations were performed as described in Appendix 7.175 following manual injection of 
100 µl of recombinant lysostaphin (construct 1, preparation 8). 
  
Appendix 7.180: Optimisation of column diameter 
 
First dimensional SCX separation of purified recombinant lysostaphin was performed using a 
ProPac® SCX-10 column (2 x 250 mm) at a flow rate of 0.2 ml/min.  Separation was 
achieved by applying a linear gradient from 0-50% SCX Buffer B in 20 min. The column was 
washed at 90% B for 13 min before being equilibrated with 0% B for 11 min. An automated 
200 µl injection of recombinant lysostaphin (construct 1, preparation 11) was delivered to the 
system. Fractions were collected using a Foxy Jr fraction collector every 60 s between 5 and 
35 min. The thermal compartment was maintained at 40°C.  
 
Second dimensional RP separations were performed using a ProSwift® RP-4H (1 x 250 mm) 
column at a flow rate of 0.3 ml/min.  Separation was achieved by applying a linear gradient 
from 13-65% RP Buffer B in 20 min. The column was washed at 90% B for 3 min before 
being equilibrated with 13% B for 6 min. An automated 60 µl injection of each SCX fraction 
was then delivered to the system  
 
First dimensional SCX separations of cell lysate were performed using a ProPac® SCX-10 
column (2 x 250 mm) at a flow rate of 0.2 ml/min. Cell lysate was prepared as described in 
Appendix 7.233.  Separation was achieved by applying a linear gradient from 0-50% SCX 
Buffer B in 20 min. An isocratic gradient was maintained at 50% B for 1 min before washing 
the column at 90% B for 3 min. The column was then equilibrated with 0% B for 11 min. An 
automated 100 µl injection of cell lysate containing recombinant lysostaphin (construct 1) 
was delivered to the system.  Cell lysate harvested at 4 h post-induction was prepared as 
described in Appendix 7.233. Fractions were collected using a Foxy Jr fraction collector 
every 60 s between 12 and 35 min. Second dimensional separation was performed as 
described above.  
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WCX separation of purified recombinant lysostaphin was performed using the ProPac® 
WCX-10 column (2 x 250 mm) column at a flow rate of 0.2 ml/min.  Separation was achieved 
by applying a linear gradient from 0-50% WCX Buffer B in 20 min. An isocratic gradient was 
maintained at 50% B for 2.9 min before washing the column at 90% B for 13 min. The 
column was then equilibrated with 0% B for 11 min. An automated 50 µl injection of 
recombinant lysostaphin (construct 1, preparation 12) was delivered to the system. WCX 
separation of cell lysate was performed as described in Appendix 7.224.  
 
Appendix 7.181: Optimisation of fraction collection by time 
 
Separation of recombinant lysostaphin (construct 1, preparation 9) was performed using a 
ProPac® WCX-10 column (4 x 250 mm) column, whilst separation of recombinant 
lysoststaphin (construct 1, preparation 10) was achieved using ProPac® WCX-10 column (4 
x 500 mm) column. Separation was performed as described in Appendix 7.175, however 100 
µl of a 1:3 dilution of preparation 9 or 150 µl of preparation 10 were delivered to the Dionex 
DX500 HPLC system. During the separation of preparation 9, fractions were collected every 
30 s between 15 and 55 min, whilst fractions were collected every 30 s between 20 and 55 
min during separation of preparation 10. 
 
Appendix 7.182: Optimisation of fraction collection by peak recognition  
 
Initial separations of recombinant lysostaphin was performed using a ProPac® WCX-10 
column (2 x 250 mm) at a flow rate of 150 µl/min. Automated 20 µl injections of recombinant 
lysostaphin (construct 3, preparation 13) were delivered to the system. Separation was 
achieved by applying a linear gradient from 0-50% IEX buffer B over 70 min. The column 
was washed at 90% B for 3 min before being equilibrated with 0% B for 9 min. Fraction 
collection was performed by peak recognition between 3 and 50 min using default settings. 
Fractions were not collected outside of peaks and collection was based upon UV 
absorbance at 214 nm or 280 nm. During the next separation, peak recognition settings 
were modified from default values, with peak start threshold decreased from 10 to 5 mAU, 
peak start/end true times increased from 1 s to 3 s and threshold no peak end increased 
from 100 mAU to 2000 mAU.  
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Appendix 7.183: Analysis of recombinant lysostaphin using optimised conditions 
 
Separation was performed as described in Appendix 7.175 using a ProPac® WCX-10 (4 x 
250 mm) column however 20 µl of purified recombinant lysostaphin (construct 3, preparation 
13) was delivered to the Dionex DX500 HPLC system. Fraction 25 collected during WCX 
separation was re-applied to the column and separated using the same conditions.  
 
Appendix 7.184: Influence of culture temperature upon charge heterogeneity of 
recombinant lysostaphin  
 
To assess the influence of temperature upon the charge heterogeneity of recombinant 
lysostaphin a number of cultures were setup and incubated at 16, 20 or 30°C (Appendix 
7.185).  Recombinant protein expression was performed in LB as described in Appendix 
7.232.  Some of the cultures were aseptically split at the point of induction to ensure the cells 
cultured at different temperatures were induced at the same optical density. The duration of 
expression was adjusted according to the results obtained. Cell lysate was harvested as 
described in Appendix 7.77 and applied directly to the ProPac® WCX (4 x 500 mm) column.  
 
Separation of cell lysate was performed using a ProPac® WCX-10 column (4 x 500 mm) 
column at flow rate of 0.5 ml/min.  Following sample injection, an isocratic gradient of 0% 
WCX buffer B was applied before separating protein isoforms by applying a linear gradient 
from 0-50% WCX Buffer B in 70 min. The column was washed at 90% B for 9 min and then 
equilibrated with 0% B for 15 min. An automated 500 µl injection of cell lysate containing 
recombinant lysostaphin (construct 1) was delivered to the system 
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Appendix 7.185: Culture conditions 
Culture Construct Temperature 
(°C) 
Induction optical 
density (OD600 nm) 
Duration of 
Expression (h) 
1 1 20 0.847 16.0 
1 30 
2 1 20 0689 16.0 
1 30 
3 1 20 1.080 16.0 
1 30 
4 2 16 0.718 17.5 
20 
5 2 16 0.704 17.5 
20 
6 2 16 1.112 14.0 
7 2 16 0.723 14.0 
 
Appendix 7.186: Separation of alternative recombinant protein preparations 
 
The genes encoding recombinant oxidoreductase from Clostridium acetobutylicum 
(gi:15004706) and recombinant NADPH-dependent 1-acyl dihydroxyacetone phosphate 
reductase (Ayr1p) from Saccharomyces cerevisiae (gi:6322067), were synthesised or 
amplified and cloned into pET-YSBLIC using ligation-independent cloning and E. coli 
TOP103. The recombinant pET-YSBLIC was transformed into E. coli BL21(DE3) and the 
recombinant proteins were expressed in LB and AIM, as described in Appendix 7.76 and 
Appendix 7.75 respectively.  E. coli cultures grown in LB were induced at OD600 nm values of 
0.788 and 0.747 for recombinant oxidoreductase and recombinant Ayr1p respectively and 
cell lysate was harvested 19.5 h post-induction. E. coli cultures grown in AIM were induced 
at OD600 nm values of 1.228 and 0.912 for recombinant oxidoreductase and recombinant 
Ayr1p respectively and cell lysate was harvested 16.0 h post-induction. 
 
Harvested cell lysate was directly applied to the ProPac® WCX (4 x 500 mm) column and the 
protein preparation was separated as described in Appendix 7.184.  ProtParam analysis was 
performed on the amino acid sequences of both recombinant proteins (Appendix 7.206 and 
Appendix 7.207) to ensure that the expected charge of the expressed protein would permit 
                                               
3
 These basic recombinant proteins were cloned and transformed in to E. coli BL21(DE3) by Dr Meng 
Zhang at Northumbria University.  
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binding during WCX. ClustalW analysis was also performed to establish whether the 
selected proteins shared sequence homology, as described in Appendix 7.48.  
 
Appendix 7.187: Optimisation of sample loading conditions  
 
Separation was performed as described in Appendix 7.173 using the ProPac® MAb SCX 
beta test (4 x 250 mm) column. During each separation, 10, 100 or 200 µl of recombinant 
lysostaphin (construct 3, preparation 5) was injected onto the column.  
 
Appendix 7.188: Optimisation of chromatographic gradient conditions  
 
The first separation was performed as described in Appendix 7.173 using the ProPac® MAb 
SCX beta test (4 x 250 mm) column. During each separation 200 µl of a 1:10 dilution of 
recombinant lysostaphin (construct 3, preparation 5) was injected onto the column.  
 
The second separation was performed using a ProPac® WCX-10 column (2 x 250 mm) at a 
flow rate of 500 µl/min. Following injection of 200 µl of a 1:10 dilution of recombinant 
lysostaphin (construct 3, preparation 5), an isocratic gradient was maintained for 3 min at 0% 
B. Separation was achieved by applying a linear gradient of 0-50% MAb SCX buffer B over 
20 min. The column was washed at 90% B for 4 min before being equilibrated with 0% B for 
8 min.  
 
Appendix 7.189: Optimisation of mobile phase conditions 
 
Separation was performed as described in Appendix 7.173 using the ProPac® MAb SCX 
beta test (4 x 250 mm) column. However two separations were performed using MAb SCX 
buffer A and B and two separations were performed using WCX buffer A and B. During each 
separation, 20 µl of recombinant lysostaphin (construct 3, preparation 5) was injected onto 
the column.  
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Appendix 7.190: Optimisation of column length  
 
The first separation was performed as described in Appendix 7.173 using the ProPac® MAb 
SCX (4 x 250 mm) column. During each separation 40 µl of recombinant lysostaphin 
(construct 3, preparation 5) was injected onto the column.  
 
The second separation was performed using a ProPac® WCX-10 column (4 x 500 mm) at a 
flow rate of 1.0 ml/min. Prior to injection of 40 µl of recombinant lysostaphin (construct 3, 
preparation 5), an isocratic gradient was maintained for 10 min at 0% B. Separation was 
achieved by applying a 0-48% MAb SCX buffer B over 40.0 min. The column was then 
washed for 10 min using 100% B before reequilibrating at 0% B for 10 min.  
 
Appendix 7.191: SDS-PAGE analysis of resuspended N-terminally His-tagged 
recombinant lysostaphin (construct 1) following IMAC, dialysis and lyophilisation.  
Recombinant lysostaphin was produced using E. coli BL21(DE3) which had been 
cultured in either LB or AIM.  Lane 1: Sigma low molecular weight markers; Lane 2: 
construct 1 expressed in LB (neat); Lane 3: construct 1 expressed in LB (1:10); Lane 
4: construct 1 expressed in LB (1:100); Lane 5: Sigma low molecular weight markers; 
Lane 6: construct 1 expressed in AIM (neat); Lane 7: construct 1 expressed in AIM 
(1:10); Lane 8: construct 1 expressed in AIM (1:100).  
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Appendix 7.192: Expression of recombinant lysostaphin at different post-induction 
temperatures. Three cultures containing 500 ml of LB were inoculated with a starter 
culture harbouring E.coli BL21(DE3) transformed with a plasmid containing N-
terminally His-tagged recombinant lysostaphin (construct 1). Protein expression was 
induced in cultures 1, 2 and 3 at OD600 nm values of 0.847, 0.689, and 1.080 
respectively. Following IPTG induction, each culture was aseptically split and the 
resulting six 250 ml cultures were incubated at 30°C or 20°C. Cell lysates were 
harvested 16 h after induction of protein expression and were analysed by 12% (w/v) 
SDS-PAGE. A) Culture 1. Lane 1: Sigma low molecular weight markers; Lane 2: CFE 
(neat) [20°C]; Lane 3: CFE (1:10) [20°C]; Lane 4: CFE (1:100) [20°C]; Lane 5: CFE in 
solubilising buffer [20°C]; Lane 6: CFE (neat) [30°C]; Lane 7: CFE (1:10) [30°C]; Lane 
8: CFE (1:100) [30°C]; Lane 9: CFE in solubilising buffer [30°C]; Lane 10: Sigma high 
molecular weight markers. B) Culture 2. Lane 1: Sigma low molecular weight markers; 
Lane 2:  CFE (neat) [20°C]; Lane 3: CFE (1:10) [20°C]; Lane 4: CFE (1:100) [20°C]; Lane 
5: CFE in solubilising buffer [20°C]; Lane 6: Sigma high molecular weight markers; 
Lane 7: CFE(neat) [30°C]; Lane 8: CFE (1:10) [30°C]; Lane 9: CFE (1:100) [30°C]; Lane 
10: CFE in solubilising buffer [30°C]. 
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Appendix 7.192 (continued): Expression of recombinant lysostaphin at different post-
induction temperatures. Three cultures containing 500 ml of LB were inoculated with 
a starter culture harbouring E.coli BL21(DE3) transformed with a plasmid containing 
N-terminally His-tagged recombinant lysostaphin (construct 1). Protein expression 
was induced in cultures 1, 2 and 3 at OD600 nm values of 0.847, 0.689, and 1.080 
respectively. Following IPTG induction, each culture was aseptically split and the 
resulting six 250 ml cultures were incubated at 30°C or 20°C. Cell lysates were 
harvested 16 h after induction of protein expression and were analysed by 12% (w/v) 
SDS-PAGE. C) Culture 3. Lane 1: CFE (neat) [20°C]; Lane 2: CFE(1:10) [20°C]; Lane 3: 
CFE (1:100) [20°C]; Lane 4: CFE in solubilising buffer [20°C]; Lane 5: Sigma low 
molecular weight markers; Lane 6: Sigma high molecular weight markers; Lane 7: 
CFE (neat) [30°C]; Lane 8: CFE (1:10) [30°C]; Lane 9: CFE (1:100) [30°C]; Lane 10: CFE 
in solubilising buffer [30°C]. 
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Appendix 7.193: WCX separation of cell lysate containing N-terminally His-tagged 
recombinant lysostaphin (construct 1) following expression at 20°C (Culture 1).  
Fractions 9, 13, 18 and 27 were analysed by SDS-PAGE. 
  
Appendix 7.194: SDS-PAGE analysis of WCX fractions following separation of N-
terminally His-tagged recombinant lysostaphin (construct 1) after expression at 20°C 
(Culture 1).  Lane 1: Sigma low molecular weight markers; Lane 2: Fraction 9; Lane 3: 
Fraction 13; Lane 4: Fraction 18; Lane 5: Fraction 27.  
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Appendix 7.195: WCX separation of cell lysate containing N-terminally His-tagged 
recombinant lysostaphin (construct 1) following expression at 30°C (Culture 1).  
Fractions 5, 12, 16, 19 and 27 were analysed by PAGE. 
 
 
Appendix 7.196: SDS-PAGE analysis of WCX fractions following separation of N-
terminally His-tagged recombinant lysostaphin (construct 1) after expression at 30°C 
(Culture 1).  Lane 1: Fraction 5; Lane 2: Fraction 12; Lane 3: Fraction 16; Lane 4: 
Fraction 19; Lane 5: Fraction 27; Lane 6: Sigma low molecular weight markers. 
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Appendix 7.197: WCX separation of cell lysate containing N-terminally His-tagged 
recombinant lysostaphin (construct 1) following expression at 20°C (Culture 2).  
Fractions 9, 12, 13, 18, 19, 27 and 28 were analysed by SDS-PAGE. 
 
 
Appendix 7.198: SDS-PAGE analysis of WCX fractions following separation of N-
terminally His-tagged recombinant lysostaphin (construct 1) after expression at 20°C 
(Culture 2).  Lane 1: Sigma low molecular weight markers; Lane 2: Fraction 9; Lane 3: 
Fraction 12; Lane 4: Fraction 13; Lane 5: Fraction 18; Lane 6: Fraction 19; Lane 7: 
Fraction 27; Lane 8: Fraction 28; Lane 9: Sigma high molecular weight markers.  
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 Appendix 7.199: WCX separation of cell lysate containing N-terminally His-tagged 
recombinant lysostaphin (construct 1) following expression at 30°C (Culture 2).  
Fractions 13, 17, 19, 27 and 28 were analysed by SDS-PAGE. 
 
 
Appendix 7.200: SDS-PAGE analysis of WCX fractions following separation of N-
terminally His-tagged recombinant lysostaphin (construct 1) after expression at 30°C 
(Culture 2).  Lane 1: Sigma low molecular weight markers; Lane 2: Fraction 13; Lane 3: 
Fraction 17; Lane 4: Fraction 19; Lane 5: Fraction 27; Lane 6: Fraction 28; Lane 7: 
Sigma high molecular weight markers.  
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Appendix 7.201: WCX separation of cell lysate containing N-terminally His-tagged 
recombinant lysostaphin (construct 1) following expression at 20°C (Culture 3).  
Fractions 5, 9, 13, 16, 19 and 27 were analysed by SDS-PAGE. 
 
 
Appendix 7.202: SDS-PAGE analysis of WCX fractions following separation of N-
terminally His-tagged recombinant lysostaphin (construct 1) after expression at 20°C 
(Culture 3).  Lane 1: Fraction 5; Lane 2: Fraction 9; Lane 3: Fraction 13; Lane 4: Sigma 
low molecular weight markers; Lane 5: Sigma low molecular weight markers; Lane 6: 
Fraction 16; Lane 7: Fraction 19; Lane 8: Fraction 27.  
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Appendix 7.203: WCX separation of cell lysate containing N-terminally His-tagged 
recombinant lysostaphin (construct 1) following expression at 30°C (Culture 3).  
Fractions 5, 12, 13, 16, 17, 19, 27 and 28 were analysed by SDS-PAGE. 
 
 
Appendix 7.204: SDS-PAGE analysis of WCX fractions following separation of N-
terminally His-tagged recombinant lysostaphin (construct 1) after expression at 30°C 
(Culture 3).  Lane 1: Fraction 5; Lane 2: Fraction 12; Lane 3: Fraction 13; Lane 4: 
Sigma low molecular weight markers; Lane 5: Sigma low molecular weight markers; 
Lane 6: Fraction 16; Lane 7: Fraction 17; Lane 8: Fraction 19; Lane 9: Fraction 27; 
Lane 10: Fraction 28; Lane 11: Sigma high molecular weight markers.  
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Appendix 7.205: Expression of recombinant lysostaphin at 16°C.  Two cultures 
containing 500 ml of LB were inoculated with a starter culture harbouring E.coli 
BL21(DE3) transformed with a plasmid containing N-terminally His-tagged 
recombinant lysostaphin (construct 1). Protein expression was induced in cultures 1 
and 2 at OD600 nm values of 1.112 and 0.723 respectively. Following IPTG induction, the 
cultures were incubated at 16°C.  Cell lysates were harvested 14 h after induction of 
protein expression and were analysed by SDS-PAGE. A) Culture 1. Lane 1: Sigma low 
molecular weight markers; Lane 2: CFE (neat); Lane 3: CFE (1:10); Lane 4: CFE 
(1:100); B) Culture 2. Lane 1: Sigma high molecular weight markers; Lane 2: CFE 
(neat); Lane 3: CFE (1:10); Lane 4: CFE (1:100).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 7.206: Predicted amino acid sequence of recombinant oxidoreductase from 
Clostridium acetobutylicum (ATCC 8S4) (NP_149166.1).  
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Appendix 7.207: Predicted amino acid sequence of recombinant AyrP1, a 
dehydrogenase from Saccharomyces cerevisiae (S288c) (NP_012142.1).  
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Appendix 7.208: ProtParam analysis of recombinant oxidoreductase from Clostridium 
acetobutylicum (NP_149166.1)  
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Appendix 7.208: ProtParam analysis of recombinant oxidoreductase from Clostridium 
acetobutylicum (NP_149166.1) (continued). 
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Appendix 7.209: ProtParam analysis of recombinant NADPH-dependent 1-acyl 
dihydroxyacetone phosphate reductase (Ayr1p) from Saccharomyces cerevisiae 
(NP_012142.1)  
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Appendix 7.209: ProtParam analysis of recombinant NADPH-dependent 1-acyl 
dihydroxyacetone phosphate reductase (Ayr1p) from Saccharomyces cerevisiae 
(NP_012142.1) (continued). 
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Appendix 7.210: Clustal W alignment of recombinant lysostaphin (construct 1), 
recombinant oxidoreductase and recombinant NADPH-dependent 1-acyl 
dihydroxyacetone phosphate reductase (Ayr1p) sequences. The alignment suggested 
that the sequences shared little homology, with an alignment score of 6.0 being 
achieved between N-terminally His-tagged recombinant lysostaphin (construct 1) and 
recombinant oxidoreductase. A low alignment score of 5.0 was also achieved between 
N-terminally His-tagged recombinant lysostaphin (construct 1) and recombinant 
Ayr1p. Recombinant oxidoreductase and recombinant Ayr1p shared greater sequence 
homology with an alignment score of 20.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
542 
 
Appendix 7.211: SDS-PAGE analysis of cell lysate extracted following expression of 
basic recombinant proteins in E. coli BL21(DE3) cultured in LB. A) Expression of 
recombinant oxidoreductase. Lane 1: Sigma low molecular weight markers; Lane 2: 
CFE (neat); Lane 3: CFE (1:10); Lane 4: CFE (1:100). B) Expression of recombinant 
NADPH-dependent 1-acyl dihydroxyacetone phosphate reductase (Ayr1p). Lane 1: 
Sigma high molecular weight markers; Lane 2: CFE (neat); Lane 3: CFE (1:10); Lane 4: 
CFE (1:100). 
 
 
Appendix 7.212: WCX separation of cell lysate containing recombinant 
oxidoreductase using a ProPac® WCX (4 x 500 mm) column.  Fractions 13-22 were 
analysed by PAGE. 
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Appendix 7.213: SDS-PAGE analysis of fractions collected during WCX separation of 
cell lysate containing recombinant oxidoreductase. Lane 1: Sigma low molecular 
weight markers; Lane 2: Fraction 13; Lane 3: Fraction 14; Lane 4: Fraction 15; Lane 5: 
Fraction 16: Lane 6: Fraction 17: Lane 7: Fraction 18; Lane 8: Fraction 19; Lane 9: 
Fraction 20; Lane 10: Sigma high molecular weight markers; Lane 11: Fraction 21; 
Lane 12: Fraction 22; Lane 13: Sigma low molecular weight markers.  
 
 
 
Appendix 7.214: WCX separation of cell lysate containing recombinant Ayr1p using a 
ProPac® WCX (4 x 500 mm) column.  Fractions 13, 14, 16, 17, 20, 21, 22, 23, 25, 26 and 
28 were analysed by SDS-PAGE. 
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Appendix 7.215: SDS-PAGE analysis of fractions collected during WCX separation of 
cell lysate containing recombinant NADPH-dependent 1-acyl dihydroxyacetone 
phosphate reductase (Ayr1p). Lane 1: Sigma low molecular weight markers; Lane 2: 
Fraction 13; Lane 3: Fraction 14; Lane 4: Fraction 16; Lane 5: Fraction 17; Lane 6: 
Sigma high molecular weight markers; Lane 7: Sigma high molecular weight markers; 
Lane 8: Fraction 20; Lane 9: Fraction 21; Lane 10: Fraction 22; Lane 11: Fraction 23; 
Lane 12: Fraction 25; Lane 13: Fraction 26; Lane 14: Fraction 28. 
 
 
 
Appendix 7.216: SDS-PAGE analysis of cell lysate extracted following expression of 
basic recombinant proteins in E. coli BL21(DE3) cultured in AIM. A) Expression of 
recombinant oxidoreductase. Lane 1: Sigma low molecular weight markers; Lane 2: 
CFE (neat); Lane 3: CFE (1:10); Lane 4: CFE (1:100). B) Expression of recombinant 
NADPH-dependent 1-acyl dihydroxyacetone phosphate reductase (Ayr1p). Lane 1: 
Sigma high molecular weight markers; Lane 2: CFE (neat); Lane 3: CFE (1:10); Lane 4: 
CFE (1:100). 
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Appendix 7.217: WCX separation of cell lysate containing recombinant 
oxidoreductase using a ProPac® WCX (4 x 500 mm) column.  Fractions 12, 13, 14, 15, 
18, 20, 22 and 23 were analysed by SDS-PAGE. 
 
 
Appendix 7.218: SDS-PAGE analysis of fractions collected during WCX separation of 
cell lysate containing recombinant oxidoreductase. Lane 1: Sigma low molecular 
weight markers; Lane 2: Fraction 12; Lane 3: Fraction 13; Lane 4: Fraction 14; Lane 5: 
Fraction 15: Lane 6: Fraction 18: Lane 7: Fraction 20; Lane 8: Fraction 22; Lane 9: 
Fraction 23; Lane 10: Sigma high molecular weight markers. 
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Appendix 7.219: WCX separation of cell lysate containing recombinant NADPH-
dependent 1-acyl dihydroxyacetone phosphate reductase (Ayr1p) using a ProPac® 
WCX (4 x 500 mm) column.  Fractions 9, 11, 12, 13, 14, 15, 18, 19, 20, 21, 22, 23, 24, 26, 
28, 32, 36, 37, 40, 44, 58 and 59 were analysed by SDS-PAGE. 
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Appendix 7.220: SDS-PAGE analysis of fractions collected during WCX separation of 
cell lysate containing recombinant NADPH-dependent 1-acyl dihydroxyacetone 
phosphate reductase (Ayr1p). Lane 1: Sigma low molecular weight markers; Lane 2: 
Fraction 9; Lane 3: Fraction 11; Lane 4: Fraction 12; Lane 5: Fraction 13: Lane 6: 
Fraction 14: Lane 7: Fraction 15; Lane 8: Fraction 18; Lane 9: Fraction 19; Lane 10: 
Sigma high molecular weight markers; Lane 11: Fraction 20; Lane 12: Fraction 21; 
Lane 13: Fraction 22; Lane 14: Fraction 23; Lane 15: Sigma low molecular weight 
markers; Lane 16: Sigma low molecular weight markers; Lane 17: Fraction 24; Lane 
18: Fraction 26; Lane 19: Fraction 28; Lane 20: Fraction 32; Lane 21: Sigma low 
molecular weight markers; Lane 22: Fraction 36; Lane 23: Fraction 37; Lane 24: 
Fraction 40; Lane 25: Fraction 44; Lane 26: Fraction 58; Lane 27: Fraction 59; Lane 28: 
Sigma high molecular weight markers.  
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7.2.3 Rapid analysis of recombinant lysostaphin isoforms  
 
Appendix 7.221: Rapid analysis of recombinant lysostaphin using a ProPac® SCX (2 x 
250 mm) column 
 
SCX analysis was performed using a 0.2 ml/min flow rate and linear gradient from 0-50% 
SCX buffer B in 20 min. Cell lysate containing recombinant lysostaphin (construct 1) was 
harvested as described in Appendix 7.236, before applying 200 µl of cell lysate to the 
column. The gradient remained at 50% B for 2.9 min, before the ProPac® SCX column was 
washed for 3 min by applying 90% B. The column was then equilibrated at 0% B for 11 min.  
 
Appendix 7.222: Influence of optical density at point of induction upon charge 
heterogeneity  
 
Cell lysate containing recombinant lysostaphin (construct 1) was harvested as described in 
Appendix 7.235 before applying 500 µl of cell lysate to the ProPac® SCX (2 x 250 mm) 
column. SCX analysis was performed using a 0.2 ml/min flow rate and linear gradient from 
0-50% SCX buffer B in 20 min. The gradient remained at 50% B for 2.9 min, before the 
ProPac® SCX column was washed for 13 min by applying 90% B. The column was then 
equilibrated at 0% B for 11 min. Fractions were collected every 60 s between 14 and 36 min.  
 
Appendix 7.223: Comparative analysis of cell lysate using a ProPac® SCX (2 x 250 
mm) and ProPac® WCX (4 x 500 mm) columns 
 
Expression was performed as described in Appendix 7.240 using baffled flasks containing 
500 ml LB. Once inoculated into 500 ml LB cultures, protein expression was induced at 
OD600 nm values of 1.060 and 1.041 for cultures derived from colony-based and glycerol 
stock-based inoculation respectively. Twenty-one hours after the induction of protein 
expression, cell lysate was harvested from both cultures, as described in Appendix 7.77. The 
resulting cell lysate (500 µl) was then analysed by SCX and WCX analysis.  
 
SCX analysis was performed using a 0.2 ml/min flow rate and linear gradient from 0-50% 
SCX buffer B in 20 min.  The gradient remained at 50% B for 3 min, before the ProPac® SCX 
column was washed for 13 min by applying 90% B. The column was then equilibrated at 0% 
B for 11 min.  Fraction collection was optionally performed during separation, by collecting 
fractions every 60 s between 14 and 36 min.   
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WCX analysis was performed using a 0.5 ml/min flow rate and linear gradient from 0-50% 
WCX buffer B in 70 min.  Prior to the linear gradient, the column was washed with 100% A 
for 10 min to ensure that cellular contaminants were washed from the column following 
application of cell lysate. Following the linear elution gradient, the ProPac® WCX column was 
washed for 13 min by applying 90% IEX buffer B. The column was then equilibrated at 0% 
IEX buffer B for 15 min.  Fraction collection was optionally performed during separation, by 
collecting fractions every 30 s between 15 and 35 min.   
 
Appendix 7.224: Optimisation of cell lysate preparation during rapid analysis using a 
ProPac® WCX (2 x 250 mm) column 
 
Cell lysate containing recombinant lysostaphin (construct 1) was harvested from 1, 25 or 100 
ml volumes of culture. Expression was performed as described in Appendix 7.76 using 
baffled flasks containing 250 ml LB. Cell lysate was harvested from 1 ml aliquots of culture 
by centrifugation of cells at 4000 x g for 5 min using a benchtop microfuge. The supernatant 
was discarded and the pelleted cells were resuspended in 100 µl of WCX buffer A.  Cell 
lysate was harvested from 25 or 100 ml volumes of culture using conditions described in 
Appendix 7.77.  The harvested cell lysate (100 µl) was then applied to the ProPac® WCX (2 
x 250 mm) column. WCX analysis was performed using a 0.2 ml/min flow rate and linear 
gradient from 0-50% WCX buffer B in 20 min. The gradient remained at 50% B for 2.9 min, 
before the column was washed for 13 min by applying 90% B. The column was then 
equilibrated at 0% B for 11 min.  
 
Appendix 7.225: Rapid analysis of recombinant lysostaphin using a ProPac® WCX (2 x 
500 mm) column 
 
Cell lysate containing recombinant lysostaphin (construct 2) was harvested from 5 x 1L 
cultures. Expression was performed as described in Appendix 7.76 using LB. Cell lysate was 
harvested as described in Appendix 7.77. WCX analysis was performed using a 0.2 ml/min 
flow rate. The harvested cell lysate (100 µl) was then applied to a ProPac® WCX (2 x 500 
mm) column and an isocratic gradient of 0% WCX buffer B was maintained for 10 min.  
Separation was achieved by applying a linear gradient from 0-50% WCX buffer B over 30 
min. The gradient remained at 50% B for 2.9 min, before the column was washed for 13 min 
by applying 90% B. The column was then equilibrated at 0% B for 19 min. 
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Appendix 7.226: Maximising sample through-put during rapid analysis using a 
ProPac® WCX (2 x 500 mm) column 
 
Expression of recombinant lysostaphin (construct 1) was performed as described in 
Appendix 7.76, using multiple flasks containing 100 ml LB. Cell lysate was harvested from 
the cultures, as described in Appendix 7.239, however prior to harvest, the cultures were 
divided into 50 ml volumes. Cell lysate was harvested from one of the 50 ml cultures 
immediately and analysed by WCX. Cell lysate was extracted from the other 50 ml culture 
immediately and the resulting cell lysate was frozen and thawed prior to WCX analysis. 
Alternatively pelleted E. coli was frozen during the preparation of cell lysate so that the cell 
lysate could be fully extracted and analysed later.  
 
WCX analysis was performed using a 0.2 ml/min flow rate. The harvested cell lysate (500 µl) 
was then applied to a ProPac® WCX (2 x 500 mm) column and an isocratic gradient of 0% 
WCX buffer B was maintained for 4 min.  Separation was achieved by applying a linear 
gradient of 0-50% WCX buffer B in 20 min. The gradient remained at 50% B for 2.9 min, 
before the column was washed for 13 min by applying 90% B and then the column was then 
equilibrated at 0% B for 25 min. 
 
Appendix 7.227: Investigation of the influence of optical density at the point of 
induction upon the charge heterogeneity of recombinant lysostaphin 
 
Cell lysate containing recombinant lysostaphin (construct 1) was harvested from twenty-nine 
cultures as described in Appendix 7.239, before applying 200 µl of cell lysate to a ProPac® 
WCX (2 x 500 mm) column. WCX analysis was performed using a 0.2 ml/ min flow rate. 
Following sample injection, an isocratic gradient of 0% WCX buffer B was maintained for 3 
min.  Separation was achieved by applying a linear gradient from 0-50% WCX buffer B in 20 
min. The gradient remained at 50% B for 4 min, before the column was washed for 8 min by 
applying 90% B and the column was then equilibrated at 0% B for 20 min. Fractions were 
collected every 60 s between 15 and 30 min.  Cell lysate was also harvested from cultures 
which had been inoculated directly from glycerol stock (Appendix 7.241).  
 
Appendix 7.228: Optimisation of chromatographic conditions  
 
Chromatographic conditions were gradually optimised by increasing the duration of the initial 
isocratic gradient (0% WCX buffer B) from 3 to 10 min to ensure that unbound cellular 
contaminants were washed from the column following application of cell lysate. The wash 
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period (90% WCX buffer B) was also decreased from 13 to 8 min and the equilibration 
period was extended to 20 min. 
 
Appendix 7.229: Investigation of the influence of time upon the charge heterogeneity 
of recombinant lysostaphin 
 
Cell lysate containing recombinant lysostaphin (construct 1) was harvested periodically from 
a 1 L culture, as described in Appendix 7.237, before applying 500 µl of cell lysate to a 
ProPac® WCX (2 x 500 mm) column. WCX analysis was performed using a 0.2 ml/min flow 
rate.  Following sample injection, an isocratic gradient of 0% WCX buffer B was maintained 
for 10 min.  Separation was achieved by applying a linear gradient from 0-50% WCX buffer 
B in 20 min. The gradient remained at 50% B for 4 min, before the column was washed for 8 
min by applying 90% B and the column was then equilibrated at 0 % B for 20 min. Fractions 
were collected every 60s between 23 and 38 min. The collected fractions were analysed by 
SDS-PAGE as described in Appendix 7.15. 
 
Appendix 7.230: Extended investigation of the influence of time upon the charge 
heterogeneity of recombinant lysostaphin 
 
Cell lysate containing recombinant lysostaphin (construct 1) was harvested periodically from 
a 1 L culture, as described in Appendix 7.238 and, before applying 500 µl of cell lysate to a 
ProPac® WCX (2 x 500 mm). WCX separation was performed as described in Appendix 
7.229. Collected fractions were subjected to SDS-PAGE analysis, as described in Appendix 
7.15. 
  
Appendix 7.231: Rapid analysis of recombinant lysostaphin using a ProPac® MAb 
SCX (4 x 250 mm) column 
 
Cell lysate containing recombinant lysostaphin (construct 1) was harvested periodically from 
a 1 L culture, as described in Appendix 7.237, before applying 500 µl of cell lysate to a 
ProPac® MAb SCX (2 x 500 mm). The separation was performed at 1.0 ml/min and following 
sample injection, an isocratic gradient of 0% MAb SCX buffer B was maintained for 10 min.  
Separation was achieved by applying a linear gradient from 0-50% B in 20 min. The column 
was washed for 5 min by applying 90% B and the column was then equilibrated at 0% B for 
10 min. Fractions were collected every 30 s between 15 and 35 min. The collected fractions 
were analysed by SDS-PAGE as described in Appendix 7.15.  
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Appendix 7.232: Recombinant protein expression using different post-induction 
temperatures 
 
To investigate the influence of post-induction temperatures upon the expression of 
recombinant lysostaphin, recombinant protein expression was performed at different 
temperatures.  Cultures were typically incubated at 30°C following induction of protein 
expression, however in this instance, cultures were incubated at 20°C or 16°C.  In these 
experiments, 500 ml of LB supplemented with kanamycin was inoculated with 5 ml of starter 
culture.  The starter cultures were composed of 10 ml of LB, supplemented with kanamycin, 
which had been inoculated from a glycerol stock containing E. coli BL21(DE3) transformed 
with recombinant pET-28a encoding N-terminally His-tagged recombinant lysostaphin 
(construct 1). The expression cultures were incubated at 37°C and 200 rpm, until 
exponential growth had been achieved, at which point, protein expression was induced 
through the addition of IPTG. In the initial experiment, this was achieved at an OD600 nm value 
of 0.847. The 500 ml culture was aseptically split following the addition of IPTG, so that 250 
ml cultures could be incubated at 30°C and 100 rpm or 20°C and 100 rpm, allowing 
comparison of expression levels and charge heterogeneity at each temperature.  Cell lysates 
were harvested from each culture, 16 h after induction of protein expression and the 
resulting cell lysates were extracted and analysed by PAGE and IEX (Appendix 7.15 and 
Appendix 7.184).      
 
In a subsequent experiment, two cultures were incubated at 16°C following the induction of 
protein expression. As previously, LB starter cultures were inoculated from an E. coli 
BL21(DE3) glycerol stock transformed with a recombinant pET-28a encoding N-terminally 
His-tagged recombinant lysostaphin (construct 1). Two flasks containing 500 ml of LB 
supplemented with kanamycin were inoculated with 5 ml of a starter culture, before 
incubation at 37°C and 200 rpm.  Protein expression was induced in cultures 1 and 2 at 
OD600 nm values of 1.112 and 0.723 respectively. Following induction the cultures were 
incubated at 16°C and 100 rpm for 14 h. After 14 h the cultures were harvested and the 
resulting cell lysates were analysed by PAGE and IEX (Appendix 7.15 and Appendix 7.184). 
 
Appendix 7.233: Monitoring of expression of recombinant lysostaphin (1) 
 
In order to monitor expression of recombinant lysostaphin over time, ten 2 L non-baffled 
flasks containing 50 ml of LB, supplemented with kanamycin, were inoculated with 0.5 ml of 
LB starter culture. The starter culture had been incubated overnight at 37°C and 200 rpm 
following inoculation from a glycerol stock of E. coli BL21(DE3) harbouring recombinant pET-
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28a encoding N-terminally His-tagged recombinant lysostaphin (construct 1). The flasks 
were incubated at 37°C and 200 rpm for 4.5 h. The OD600 nm of a single culture was 
established as being 0.658, therefore IPTG was added to all of the cultures to induce protein 
expression in a synchronised manner. One of the cultures was harvested at the point of 
induction, whilst the remaining cultures were incubated for longer periods of time after 
reducing the incubation temperature and shaking speed to 30°C and 100 rpm respectively. 
The remaining nine cultures were harvested between 2 and 25 h after the induction of 
protein expression. Cytoplasmic cell lysates were extracted and analysed by SDS-PAGE 
(Appendix 7.15). 
 
Appendix 7.234: Monitoring of expression of recombinant lysostaphin (2) 
 
To assess the influence of optical density at the point of induction upon protein expression, 
twenty-nine cultures were analysed following induction at varying optical densities, during 
three separate experiments.  Starter cultures containing 10 ml of LB, supplemented with 
kanamycin were inoculated from a glycerol stock containing E. coli BL21(DE3) transformed 
with recombinant pET-28a encoding N-terminally His-tagged recombinant lysostaphin 
(construct 1). The cultures were incubated overnight at 37°C and 200 rpm, until OD600 nm 
values of 1.651, 1.732, and 1.578 were obtained in experiments 1, 2 and 3 respectively.  At 
which point, 0.5 ml of the starter culture was inoculated into flasks containing 50 ml of LB, 
supplemented with kanamycin. The cultures were incubated at 37°C and 200 rpm until 
protein expression was induced at an OD600 nm value ranging between 0 and 1.6.  Following 
induction, the cultures were incubated at 30°C and 100 rpm for 20 h. At 20 h post-induction, 
the cultures were harvested and the resulting cell lysates were analysed by SDS-PAGE and 
IEX (Appendix 7.15 and Appendix 7.227). Cell lysate was harvested as described in 
Appendix 7.239.  
  
Appendix 7.235: Monitoring of expression of recombinant lysostaphin (3) 
 
To assess the influence of optical density at the point of induction upon protein expression, 
eight cultures were analysed following induction at varying optical densities, during three 
separate experiments.  In each experiment, cultures were harvested either 4 h post -
induction (experiment 1), 12 h post-induction (experiment 2) or 20 h post-induction 
(experiment 3). Starter cultures containing 10 ml of LB, supplemented with kanamycin were 
inoculated from a glycerol stock containing E. coli BL21(DE3) transformed with recombinant 
pET-28a encoding N-terminally His-tagged recombinant lysostaphin (construct 1). The 
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cultures were incubated overnight at 37°C and 200 rpm, before inoculating 1 ml of a single 
starter culture into eight flasks containing 100 ml of LB, supplemented with kanamycin.  The 
cultures were incubated at 37°C and 200 rpm until induction of protein expression, at which 
point incubation temperature and shaking speed were reduced to 30°C and 100 rpm.  
Induction of protein expression was induced at OD600 nm values ranging between 0 and 1.2.  
Cell lysates were harvested at 4, 10 or 20 h following induction of protein expression and the 
resulting lysates were analysed by SDS-PAGE and IEX (Appendix 7.15 and Appendix 
7.222). Cell lysate was harvested as described in Appendix 7.77.  
 
Appendix 7.236: Monitoring of expression of recombinant lysostaphin (4)  
 
To monitor recombinant protein production over the duration of protein expression, a single 
1L shake-flask culture was cultured and analysed until 27 hours after the induction of protein 
expression.  LB starter cultures supplemented with kanamycin, were inoculated from a 
glycerol stock containing E. coli BL21(DE3) transformed with recombinant pET-28a encoding 
N-terminally His-tagged recombinant lysostaphin (construct 1), before being incubated 
overnight at 37°C and 200 rpm. A baffled flask containing 1 L of LB, supplemented with 
kanamycin was inoculated with 10 ml of the starter culture, prior to incubation at 37°C and 
200 rpm.  At an OD600 nm of 0.808, protein expression was induced through the addition of 
IPTG and the incubation conditions were adjusted to 30°C and 100 rpm. Samples (30 ml) of 
the culture were extracted at 2, 3, 19, 20, 21, 22, 23, 24, 25, and 27 h post-induction before 
extracting the cytoplasmic cell lysate and performing analysis by SDS-PAGE and IEX 
(Appendix 7.15 and Appendix 7.221). The cytoplasmic extraction of cell lysate was 
performed using real-time monitoring extraction method (Appendix 7.239). 
 
Appendix 7.237: Monitoring of expression of recombinant lysostaphin (5) 
 
Further analysis of recombinant protein expression and bacterial growth was performed by 
monitoring a single batch culture until 30 h after the induction of protein expression.  An LB 
starter culture supplemented with kanamycin, was inoculated from a glycerol stock 
containing E. coli BL21(DE3) transformed with recombinant pET-28a encoding N-terminally 
His-tagged recombinant lysostaphin (construct 1) and incubated overnight at 37°C and 200 
rpm.  After 7 h of incubation, the starter culture had an OD600 nm of 0.646 and therefore 5 ml 
of the culture was used to inoculate a baffled flask containing 1 L of LB, supplemented with 
kanamycin. The batch culture was incubated at 37°C and 200 rpm, whilst the growth of the 
culture was monitored spectrophotometrically until the point of IPTG induction at an OD600 nm 
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at 0.644. The incubation conditions were adjusted to 30°C and 100 rpm and 50 ml of the 
culture was aseptically extracted at regular intervals between 1.5 and 30 h after the induction 
of protein expression.  At each time-point, the OD600 nm of the culture was recorded and the 
cytoplasmic cell lysate was extracted for analysis by SDS-PAGE and IEX (Appendix 7.15 
and Appendix 7.229).  The cytoplasmic extraction of cell lysate was performed using real-
time monitoring extraction method (Appendix 7.239). 
 
Appendix 7.238: Monitoring of expression of recombinant lysostaphin (6) 
 
Extended culture analysis of recombinant protein expression and bacterial growth was 
performed by monitoring a single batch culture until 85.5 hours after the induction of protein 
expression. An LB starter culture supplemented with kanamycin, was inoculated from a 
glycerol stock containing E. coli BL21(DE3) transformed with recombinant pET-28a encoding 
N-terminally His-tagged recombinant lysostaphin (construct 1) and incubated overnight at 
37°C and 200 rpm. The starter culture was incubated until an OD600 nm of 0.610 had been 
obtained, at which point, 5 ml of the culture was used to inoculate a baffled flask containing 1 
L of LB, supplemented with kanamycin. The batch culture was incubated at 37°C and 200 
rpm, whilst bacterial growth was monitored spectrophotometrically until the point of IPTG 
induction at an OD600 nm of 0.846. The incubation conditions were adjusted to 30°C and 100 
rpm and 50 ml of the culture was aseptically extracted at regular intervals between 12.0 and 
85.5 h after the induction of protein expression.  At each time-point, the OD600 nm of the 
culture was recorded and the cytoplasmic cell lysate was extracted for analysis by SDS-
PAGE and IEX (Appendix 7.15 and Appendix 7.230). The cytoplasmic extraction of cell 
lysate was performed as described in Appendix 7.239.  
 
Appendix 7.239: Cytoplasmic protein extraction during real-time culture analysis   
 
To enable real-time culture analysis, as described in Section 3.5.1, cytoplasmic protein 
extraction was optimised to obtain analysable cell lysates in a shorter period of time. During 
analysis, 50 ml of the culture was harvested by centrifugation at 4000 x g for 10 min at 4°C 
to pellet the cells.  The bacterial cell pellet was resuspended in a suitable volume of an 
appropriate resuspension buffer. The resuspension buffer was selected to facilitate 
subsequent purification or separation of the recombinant protein by chromatography, as 
indicated in Appendix 7.71. The resuspended cells were lysed by sonication at 15 microns 
amplitude at 5 sec intervals for 1 min, whilst on ice.  After sonication, the cells were 
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centrifuged at 24000 x g for 10 min at 4°C and the resulting supernatant (CFE) was 
decanted from the pellet and retained for subsequent analysis.    
 
Appendix 7.240: Expression of recombinant lysostaphin following different modes of 
inoculation 
 
To investigate the influence of inoculation modes upon the expression of recombinant 
lysostaphin, various expression experiments were performed following inoculation with 
colony or glycerol stock derived recombinant E. coli BL21(DE3).  Colonies transformed with 
E. coli BL21(DE3) harbouring recombinant pET-28a encoding N-terminally His-tagged 
recombinant lysostaphin (construct 1) were cultured as described in Appendix 7.75.  
Glycerol stocks containing E. coli BL21(DE3) harbouring recombinant pET-28a encoding N-
terminally His-tagged recombinant lysostaphin (construct 1) were prepared as described in 
Appendix 7.3.  Starter cultures were inoculated with either transformed colonies or a glycerol 
stock using sterile technique and recombinant protein expression was performed as 
described in Appendix 7.76.   
 
Appendix 7.241: Expression of recombinant lysostaphin in the absence of starter 
cultures.   
 
To minimise the growth phase variability during recombinant protein expression, expression 
of recombinant lysostaphin was attempted by inoculating expression media directly from a 
glycerol stock rather than via starter cultures.  During three separate experiments, a total of 
fifteen flasks containing 50 ml of LB supplemented with kanamycin were inoculated directly 
from a glycerol stock containing E. coli BL21(DE3) transformed with recombinant pET-28a 
encoding N-terminally His-tagged recombinant lysostaphin (construct 1). The flasks were 
incubated at 37°C and 200 rpm until induction of protein expression. IPTG was added to the 
cultures at OD600 nm values of between 0.2 and 1.5 and following induction, the cultures were 
incubated at 30°C and 100 rpm.  The cultures were harvested 18 h after induction of protein 
expression and cytoplasmic cell lysates were extracted, as described in Appendix 7.77.  The 
resulting cell lysates were analysed by SDS-PAGE and IEX, as reported in Appendix 7.15 
and Appendix 7.227.  
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Appendix 7.242: Expression of N-terminally His-tagged recombinant lysostaphin over 
time. Lane 1: NZY molecular weight markers; Lane 2: Sample 1 (2 h PI); Lane 3: 
Sample 2 (3 h PI); Lane 4: NZY molecular weight markers; Lane 5: Sample 3 (19 h PI); 
Lane 6: Sample 4 (20 h PI); Lane 7: Sample 5: (21 h PI); Lane 8: Sample 6 (22 h PI); 
Lane 9: Sample 7 (23 h PI); Lane 10: Sample 8 (24 h PI); Lane 11: Sample 9 (25 h PI); 
Lane 12: NZY molecular weight markers; Lane 13: Sample 10 (27 h PI).  
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Appendix 7.243: Expression of recombinant lysostaphin in the absence of starter 
cultures. During three separate experiments, fifteen cultures containing 50 ml LB were 
inoculated with 1.5 ml of a glycerol stock containing E. coli BL21(DE3) transformed 
with N-terminally His-tagged recombinant lysostaphin (construct 1).  The cultures 
were incubated and protein expression was induced at various optical densities.  Cell 
lysates were extracted from the cultures 18 h after the induction of the protein 
expression and analysed by SDS-PAGE. A) Experiment 1. Lane 1: Sigma low 
molecular weight markers; Lane 2: Sample 1; Lane 3: Sample 2; Lane 4: Sample 3; 
Lane 5: Sample 4; Lane 6; Sample 5; Lane 7: Sigma high molecular weight markers. B) 
Experiment 2. Lane 1: Sigma low molecular weight markers; Lane 2: Sample 1; Lane 
3: Sample 2; Lane 4: Sample 3; Lane 5: Sample 4; Lane 6; Sample 5; Lane 7: Sigma 
high molecular weight markers. C) Experiment 3. Lane 1: Sigma low molecular weight 
markers; Lane 2: Sample 1; Lane 3: Sample 2; Lane 4: Sample 3; Lane 5: Sample 4; 
Lane 6; Sample 5; Lane 7: Sigma high molecular weight markers. 
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Appendix 7.244: Optical density measurements recorded following culture inoculation 
and induction of protein expression. 
 
Sample ID Time: Post-Inoculation 
(Hours) 
Time: Post-Induction 
(Hours) 
OD600 nm 
- 2.0 -2.0 0.040 
- 2.5 -1.5 0.133 
- 3.0 -1.0 0.248 
- 3.5 -0.5 0.357 
- 4.0 0.0 0.644 
1 5.5 1.5 0.838 
2 7.0 3.0 0.917 
3 8.5 4.5 0.870 
4 10.0 6.0 1.014 
5 11.5 7.5 1.095 
6 13.0 9.0 1.143 
7 14.5 10.5 1.206 
8 16.0 12.0 1.192 
9 17.5 13.5 1.243 
10 19.0 15.0 1.294 
11 20.5 16.5 1.301 
12 22.0 18.0 1.309 
13 23.5 19.5 1.286 
14 25.0 21.0 1.293 
15 28.0 24.0 1.168 
16 30.5 26.5 1.319 
17 34.0 30.0 1.139 
 
  
560 
 
Appendix 7.245: Growth of E. coli BL21(DE3) pre- and post-induction of recombinant 
lysostaphin expression.  The E. coli was grown in LB media supplemented with 
kanamycin (10 µg/ml) and incubated at 37 ˚C with orbital shaking at 200 rpm. At an 
OD600 nm of 0.644, protein expression was induced (Point of Induction = P.O.I) through 
the addition of IPTG (240 µg/ml) and the culture was incubated at 30˚C with orbital 
shaking at 100 rpm.   
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Appendix 7.246: Growth phases of E. coli BL21(DE3) pre- and post-induction of N-
terminally His-tagged recombinant lysostaphin (construct 1) expression (Point of 
Induction = P.O.I). 
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Appendix 7.247:  Expression of N-terminally His-tagged recombinant lysostaphin 
(construct 1). Samples of the culture were extracted at regular time points after 
induction and the resulting cell lysates were analysed by SDS-PAGE.  Lane 1: Sigma 
low molecular weight markers; Lane 2: Sample 1 (1.5 h PI); Lane 3: Sample 2 (3.0 h 
PI); Lane 4: Sample 3: (4.5 h PI); Lane 5: Sample 4 (6.0 h PI); Lane 6: Sample 5 (7.5 h 
PI); Lane 7: Sample 6 (9.0 h PI); Lane 8: Sample 7 (10.5 h PI); Lane 9: Sample 8 (12.0 h 
PI); Lane 10: Sigma high molecular weight markers; Lane 11: Sigma low molecular 
weight markers; Lane 12: Sample 9 (13.5 h PI); Lane 13: Sample 10 (15 h PI); Lane 14: 
Sample 11 (16.5 h PI); Lane 15: Sample 12 (18.0 h PI); Lane 16: Sample 13 (19.5 h PI); 
Lane 17: Sample 14 (21 h PI); Lane 18: Sample 15 (24.0 h PI); Lane 19: Sigma high 
molecular weight markers.   
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Appendix 7.248: Optical density measurements recorded following culture inoculation 
and induction of protein expression. 
 
Sample ID Time: Post-Inoculation 
(Hours) 
Time: Post-Induction 
(Hours) 
OD600 nm 
1 16.0 12.0 1.062 
2 17.5 13.5 1.060 
3 19.0 15.0 1.096 
4 26.5 22.5 1.142 
5 28.0 24.0 1.191 
6 29.5 25.5 1.204 
7 31.0 27.0 1.245 
8 32.5 28.5 1.349 
9 38.5 34.5 1.395 
10 40.0 36.0 1.410 
11 41.5 37.5 1.466 
12 44.5 40.5 1.514 
13 50.5 46.5 1.520 
14 52.0 48.0 1.525 
15 53.5 49.5 1.479 
16 55.0 51.0 1.465 
17 64.0 60.0 1.384 
18 76.0 72.0 1.245 
19 89.5 85.5 1.214 
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Appendix 7.249: Growth of E. coli BL21(DE3) pre- and post-induction of N-terminally 
His-tagged recombinant lysostaphin (construct 1) expression. The E. coli BL21(DE3) 
was grown in LB media supplemented with kanamycin (10 µg/ml) and incubated at 
37˚C with orbital shaking at 200 rpm.  At an OD600 nm of 0.846, protein expression was 
induced (Point of Induction = P.O.I) through the addition of IPTG (240 µg/ml) and 
culture was incubated 30˚C with orbital shaking at 100 rpm.   
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Appendix 7.250: Growth phases of E. coli BL21(DE3) pre- and post-induction of 
recombinant lysostaphin expression. 
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Appendix 7.251: Extended culture and expression of N-terminally His-tagged 
recombinant lysostaphin (construct 1). Lane 1: Sigma low molecular weight markers; 
Lane 2: Sample 1 (12.0 h PI); Lane 3: Sample 2 (13.5 h PI); Lane 4: Sample 3: (15.0 h 
PI); Lane 5: Sample 4 (22.5 h PI); Lane 6: Sample 5 (24.0 h PI); Lane 7: Sample 6 (25.5 
h PI); Lane 8: Sample 7 (27.0 h PI); Lane 9: Sample 8 (28.5 h PI); Lane 10: Sigma high 
molecular weight markers; Lane 11: Sample 9 (34.5 h PI); Lane 12: Sample 10 (36 h 
PI); Lane 13: Sample 11 (37.5 h PI);  Lane 14: Sample 12 (40.5 h PI); Lane 15: Sigma 
low molecular weight markers; Lane 16: Sigma high molecular weight markers; Lane 
17: Sample 13 (46.5 h PI); Lane 18: Sample 14 (48.0 h PI); Lane 19: Sample 15 (49.5 h 
PI); Lane 20: Sample 16 (51.0 h PI); Lane 21: Sigma low molecular weight markers; 
Lane 21: Sample 17 (60 h PI); Lane 23: Sample 18 (72.0 h PI); Lane 24: Sample 19 (85.5 
h PI) 
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Appendix 7.252: Comparison of growth of E. coli BL21(DE3) pre- and post-induction 
of recombinant lysostaphin expression, during culture analysis (experiments 1 and 2).  
The E. coli BL21(DE3) was grown in LB media supplemented with kanamycin (10 
µg/ml) and incubated at 37 ˚C with orbital shaking at 200 rpm.  At OD600 nm values of 
0.644 and 0.846 , protein expression was induced in cultures 1 and 2 respectively, 
through the addition of IPTG (240 µg/ml).  The cultures were subsequently incubated 
at 30˚C with orbital shaking at 100 rpm.   
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Appendix 7.253: Expression of recombinant lysostaphin at different time-points 
following IPTG induction according to optical density of cultures.  During three 
separate experiments, twenty four cultures containing 100 ml of LB were inoculated 
using LB starter cultures. The LB starter cultures were inoculated using a single 
glycerol stock containing E. coli BL21(DE3) transformed with N-terminally His-tagged 
recombinant lysostaphin (construct 1). The cultures were incubated at 37°C, before 
inducing recombinant protein expression through the addition of IPTG. Each culture 
was induced at a different optical density (OD600 nm) to assess whether the optical 
density of the culture at the point of induction, had an influence on protein 
expression. In each experiment, the cultures were harvested at 4, 10 or 20 h post-
induction (PI) and the resulting cell lysates were analysed by 12% (v/v) SDS-PAGE.  A) 
Experiment 1 – cell lysates harvested at 4 h post-induction. Lane 1: Sigma low 
molecular weight markers; Lane 2: Culture 1; Lane 3: Culture 2: Lane 4: Culture 3: 
Lane 5: Culture 4; Lane 6: Culture 5; Lane 7: Culture 6; Lane 8: Culture 7; Lane 9; 
Culture 8; Lane 10: Sigma high molecular weight markers. B) Experiment 2 – cell 
lysates harvested at 10 h post-induction.  Lane 1: Sigma low molecular weight 
markers; Lane 2: Culture 1; Lane 3: Culture 2:  Lane 4: Culture 3: Lane 5: Culture 4; 
Lane 6: Culture 5; Lane 7: Culture 6; Lane 8: Culture 7; Lane 9; Culture 8; Lane 10: 
Sigma high molecular weight markers.  C) Experiment 3 – cell lysates harvested at 20 
h post-induction. Lane 1: Sigma low molecular weight markers; Lane 2: Culture 1; 
Lane 3: Culture 2: Lane 4: Culture 3: Lane 5: Culture 4; Lane 6: Culture 5; Lane 7: 
Culture 6; Lane 8: Sigma high molecular weight markers; Lane 8: Sigma low 
molecular weight markers; Lane 9: Sigma low molecular weight markers; Lane 10: 
Culture 7; Lane 11: Culture 8.    
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Appendix 7.254: Expression of recombinant lysostaphin following inoculation of LB 
media using LB starter cultures inoculated from glycerol stock or colony. LB starter 
cultures were inoculated using an E.coli BL21(DE3) glycerol stock or colony 
transformed with N-terminally His-tagged recombinant lysostaphin (construct 1).  
Protein expression was induced once OD600 nm values of 1.041 and 1.060 had been 
obtained for glycerol stock-inoculated and colony-inoculated cultures respectively.  
Cell lysate was harvested 21 h after induction of protein expression and was analysed 
by 12% w/v SDS-PAGE.  Lane 1: Sigma low molecular weight markers; Lane 2: CFE 
following colony inoculation (neat); Lane 3: CFE following colony inoculation (1:10); 
Lane 4: CFE following colony inoculation (1:100); Lane 5: Sigma high molecular 
weight markers; Lane 6: CFE following glycerol inoculation (neat); Lane 7: CFE 
following glycerol inoculation (1:10); Lane 8: CFE following glycerol inoculation 
(1:100).    
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Appendix 7.255: Expression of recombinant lysostaphin following IPTG induction 
according to optical density of cultures.  During three separate experiments, twenty 
nine cultures containing 100 ml of LB were inoculated using a single glycerol stock 
containing E. coli BL21(DE3) transformed with N-terminally His-tagged recombinant 
lysostaphin (construct 1).  The cultures were incubated at 37°C, before inducing 
recombinant protein expression through the addition of IPTG.  Each culture was 
induced at a different optical density (OD600 nm) to assess whether the optical density 
of the culture at the point of induction had an influence on protein expression. In each 
experiment, the cultures were harvested at 20 h post-induction (PI) and the resulting 
cell lysates were analysed by 12% (w/v) SDS-PAGE. Arrows indicate over-expression 
of non-recombinant proteins.  A) Experiment 1. Lane 1: Sigma high molecular weight 
markers; Lane 2: Culture 1; Lane 3: Culture 2: Lane 4: Culture 3: Lane 5: Culture 4; 
Lane 6: Sigma high molecular weight markers; Lane 7: Sigma high molecular weight 
markers; Lane 8: Culture 5; Lane 9: Culture 6; Lane 10: Culture 7; Lane 11: Culture 8; 
Lane 12: Culture 9; Lane 13: Culture 10; Lane 14: Sigma high molecular weight 
markers. B) Experiment 2. Lane 1: Culture 1; Lane 2: Culture 2; Lane 3: Sigma high 
molecular weight markers; Lane 4: Culture 3; Lane 5: Culture 4; Lane 6: Culture 5; 
Lane 7: Culture 6; Lane 8: Sigma high molecular weight markers; Lane 9: Sigma high 
molecular weight markers; Lane 10: Culture 7; Lane 11: Culture 8; Lane 12: Sigma 
high molecular weight markers; Lane 13: Culture 9; Lane 14: Culture 10.  
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Appendix 7.255 (continued): Expression of recombinant lysostaphin following IPTG 
induction according to optical density of cultures.  During three separate 
experiments, twenty nine cultures containing 100 ml LB were inoculated using a 
single glycerol stock containing E. coli BL21(DE3) transformed with N-terminally His-
tagged recombinant lysostaphin (construct 1).  The cultures were incubated at 37°C, 
before inducing recombinant protein expression through the addition of IPTG. Each 
culture was induced at a different optical density (OD600 nm) to assess whether the 
optical density of the culture at the point of induction, had an influence on protein 
expression. In each experiment, the cultures were harvested at 20 h post-induction 
(PI) and the resulting cell lysates were analysed by 12% (w/v) SDS-PAGE. Arrows 
indicate over-expression of non-recombinant proteins. C) Experiment 3. Lane 1: 
Sigma low molecular weight markers; Lane 2: Culture 1; Lane 3: Culture 2: Lane 4: 
Culture 3: Lane 5: Culture 4; Lane 6: Culture 5; Lane 7: Sigma high molecular weight 
markers; Lane 8: Sigma low molecular weight markers; Lane 9: Culture 6; Lane 10: 
Culture 7; Lane 11: Culture 8; Lane 12: Culture 9; Lane 13: Sigma high molecular 
weight markers. 
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Appendix 7.256: Comparison of WCX separations of cell lysates harvested between 
1.5 and 4.5 h post-induction.   
 
 
 
Appendix 7.257: Comparison of WCX separations of cell lysates harvested between 
6.0 and 9.0 h post-induction.   
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Appendix 7.258: Comparison of WCX separations of cell lysates harvested between 
10.5 and 18.0 h post-induction.   
 
 
 
Appendix 7.259: Comparison of WCX separations of cell lysates harvested between 
19.5 and 30.0 h post-induction.   
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Appendix 7.260: Analysis of cell lysate harvested at 4.5 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma low molecular weight markers; Lane 
2: Fraction 3; Lane 3: Fraction 4; Lane 4: Fraction 5.      
 
 
Appendix 7.261: Analysis of cell lysate harvested at 6.0 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma low molecular weight markers; Lane 
2: Fraction 5; Lane 3: Sigma low molecular weight markers; Lane 4: Fraction 6; Lane 
5: Fraction 7.      
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Appendix 7.262: Analysis of cell lysate harvested at 7.5 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma low molecular weight markers; Lane 
2: Fraction 6; Lane 3: Fraction 3.  
 
 
Appendix 7.263: Analysis of cell lysate harvested at 9.0 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma low molecular weight markers; Lane 
2: Fraction 6; Lane 3: Fraction 7.  
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Appendix 7.264: Analysis of cell lysate harvested at 10.5 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma low molecular weight markers; Lane 
2: Fraction 6; Lane 3: Fraction 7; Lane 4: Sigma low molecular weight markers; Lane 
5: Fraction 8.  
 
 
Appendix 7.265: Analysis of cell lysate harvested at 12.0 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma low molecular weight markers; Lane 
2: Fraction 6; Lane 3: Fraction 7; Lane 4: Fraction 8.  
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Appendix 7.266: Analysis of cell lysate harvested at 13.5 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma low molecular weight markers; Lane 
2: Fraction 6; Lane 3: Fraction 7; Lane 4: Fraction 8.  
 
 
Appendix 7.267: Analysis of cell lysate harvested at 15.0 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma low molecular weight markers; Lane 
2: Fraction 6; Lane 3: Fraction 7; Lane 4: Fraction 8; Lane 5: Sigma low molecular 
weight markers. 
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Appendix 7.268: Analysis of cell lysate harvested at 16.5 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma low molecular weight markers; Lane 
2: Fraction 6; Lane 3: Fraction 7; Lane 4: Fraction 8. 
 
 
Appendix 7.269: Analysis of cell lysate harvested at 18.0 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma low molecular weight markers; Lane 
2: Fraction 6; Lane 3: Fraction 7; Lane 4: Fraction 8. 
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Appendix 7.270: Analysis of cell lysate harvested at 19.5 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Fraction 7; Lane 2: Fraction 8; Lane 3: 
Sigma low molecular weight markers.  
 
 
Appendix 7.271: Analysis of cell lysate harvested at 21.0 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma low molecular weight markers; Lane 
2: Fraction 6; Lane 3: Fraction 7; Lane 4: Fraction 8.  
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Appendix 7.272: Analysis of cell lysate harvested at 24.0 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma high molecular weight markers; Lane 
2: Fraction 6; Lane 3: Fraction 8.  
 
 
Appendix 7.273:Analysis of cell lysate harvested at 26.5 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma low molecular weight markers; Lane 
2: Fraction 4; Lane 3: Fraction 6; Lane 4: Fraction 7; Lane 5: Fraction 8.   
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Appendix 7.274: Analysis of cell lysate harvested at 13.5 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma high molecular weight markers; Lane 
2: Fraction 6; Lane 3: Fraction 7.  
 
 
Appendix 7.275: Analysis of cell lysate harvested at 15.0 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma high molecular weight markers; Lane 
2: Fraction 6; Lane 3: Fraction 7; Lane 4: Fraction 8.  
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Appendix 7.276: Analysis of cell lysate harvested at 22.5 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Fraction 5; Lane 2: Fraction 6; Lane 3: 
Fraction 7; Lane 4: Fraction 8; Lane 5: Sigma low molecular weight markers.   
 
 
Appendix 7.277: Analysis of cell lysate harvested at 24.0 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma low molecular weight markers; Lane 
2: Fraction 5; Lane 3: Fraction 6; Lane 4: Fraction 7; Lane 5: Fraction 8.    
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Appendix 7.278: Analysis of cell lysate harvested at 27.0 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Fraction 4; Lane 2: Fraction 6; Lane 3: 
Fraction 7; Lane 4: Fraction 8; Lane 5: Sigma low molecular weight markers.  
 
 
Appendix 7.279: Analysis of cell lysate harvested at 28.5 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma low molecular weight markers; Lane 
2: Fraction 4; Lane 3: Fraction 5; Lane 4: Fraction 6; Lane 5: Fraction 7.  
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Appendix 7.280: Analysis of cell lysate harvested at 34.5 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Fraction 4; Lane 2: Fraction 5; Lane 3: 
Fraction 6; Lane 4: Fraction 8; Lane 5: Sigma low molecular weight markers.  
 
 
 
Appendix 7.281: Analysis of cell lysate harvested at 36.0 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma low molecular weight markers; Lane 
2: Fraction 4; Lane 3: Fraction 5; Lane 4: Fraction 6.  
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Appendix 7.282: Analysis of cell lysate harvested at 37.5 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma low molecular weight markers; Lane 
2: Fraction 5; Lane 3: Fraction 6; Lane 4: Fraction 7; Lane 5: Fraction 8.   
 
 
 
Appendix 7.283: Analysis of cell lysate harvested at 40.5 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma high molecular weight markers; Lane 
2: Fraction 4; Lane 3: Fraction 5; Lane 4: Fraction 6; Lane 5: Fraction 7.   
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Appendix 7.284: Analysis of cell lysate harvested at 46.5 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma low molecular weight markers; Lane 
2: Fraction 4; Lane 3: Fraction 5; Lane 4: Fraction 6; Lane 5: Fraction 7; Lane 6: 
Fraction 8.   
 
 
Appendix 7.285: Analysis of cell lysate harvested at 48.0 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Fraction 6; Lane 2: Fraction 4; Lane 3: 
Sigma high molecular weight markers; Lane 4: Fraction 7; Lane 5: Fraction 8; Lane 6: 
Sigma low molecular weight markers.  
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Appendix 7.286: Analysis of cell lysate harvested at 49.5 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma low molecular weight markers; Lane 
2: Fraction 4; Lane 3: Fraction 6; Lane 4: Fraction 7. 
 
 
Appendix 7.287: Analysis of cell lysate harvested at 51.0 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma high molecular weight markers; Lane 
2: Fraction 7.  
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Appendix 7.288: Analysis of cell lysate harvested at 60.0 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma low molecular weight markers; Lane 
2: Fraction 4; Lane 3: Fraction 5; Lane 4: Fraction 6; Lane 5: Fraction 7; Lane 6: 
Fraction 8.  
 
 
 
Appendix 7.289: Analysis of cell lysate harvested at 72.0 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin (construct 1). B) SDS-
PAGE analysis of WCX fractions. Lane 1: Sigma low molecular weight markers; Lane 
2: Fraction 1; Lane 3: Fraction 4; Lane 4: Fraction 7. 
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Appendix 7.290: Analysis of cell lysate harvested at 85.5 h post-induction. A) WCX 
separation of N-terminally His-tagged recombinant lysostaphin. B) SDS-PAGE 
analysis of WCX fractions. Lane 1: Fraction 1; Lane 2: Fraction 2; Lane 3: Sigma low 
molecular weight markers.  
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Appendix 7.291: Dionex customer application note entitled “Rapid Analysis of 
Recombinant Protein Production During Fermentation Using Dionex ProPac SCX 
Columns”.  Available at http://www.dionex.com/en-us/webdocs/109791-CAN110-IC-
RecombinantProtein-Fermentation-19Jan2011-LPN2683.pdf 
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Appendix 7.291: Dionex customer application note entitled “Rapid Analysis of 
Recombinant Protein Production During Fermentation Using Dionex ProPac SCX 
Columns”.  Available at http://www.dionex.com/en-us/webdocs/109791-CAN110-IC-
RecombinantProtein-Fermentation-19Jan2011-LPN2683.pdf (continued). 
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Appendix 7.291: Dionex customer application note entitled “Rapid Analysis of 
Recombinant Protein Production During Fermentation Using Dionex ProPac SCX 
Columns”.  Available at http://www.dionex.com/en-us/webdocs/109791-CAN110-IC-
RecombinantProtein-Fermentation-19Jan2011-LPN2683.pdf (continued). 
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7.3 Characterisation of Recombinant Lysostaphin 
 
7.3.1 Activity of recombinant lysostaphin 
 
Appendix 7.292: Media 
 
Micrococcus nutrient medium (1L) 
 
Peptone      5.0 g  
Beef extract      1.5 g 
Yeast extract      3.0 g  
Glucose      1.0 g 
 
The pH was adjusted to pH 7.4, prior to autoclaving the media.  
 
Micrococcus nutrient medium agar (100 ml) 
 
Micrococcus nutrient medium   100.0 ml 
Agar (bacteriological agar no. 1)  1.2 g  
 
The media was autoclaved to make the agar soluble and allowed to cool to less than 50C, 
before pouring into Petri dishes and leaving to set for ~ 20 min. 
 
Appendix 7.293: Buffers 
Wash buffer (1L)  
 
NaCl (0.15 M)      8.76 g 
KHPO4 (0.01 M)    1.36 g 
 
The pH of the solution was adjusted to pH 7.2 and autoclaved. 
 
Assay buffer (1L)  
 
Tris-HCl (0.05 M)    6.1 g  
NaCl (0.15 M)      8.8 g 
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The pH of the buffer was adjusted to pH 7.5, prior to autoclaving.   
 
IMAC buffer A (1 L)     (as described in Section 2.5.2.1 / Appendix 7.105) 
 
IMAC buffer B (1L)        (as described in Section 2.5.2.1 / Appendix 7.105) 
 
WCX buffer A (1L)      (as described in Section 3.2.1 / Appendix 7.136) 
 
IEX buffer B (1L)     (as described in Section 3.2.1 / Appendix 7.136) 
 
Appendix 7.294: Sample preparation 
 
Experiments were performed using purified, concentrated recombinant lysostaphin samples.  
Purified, concentrated recombinant lysostaphin was harvested from E. coli BL21(DE3) 
cultured in either LB or AIM and purified using either IMAC or HIC and GF.  Following 
purification, the purified protein was concentrated using ultrafiltration. Further details about 
preparation of recombinant lysostaphin is provided in Appendix 7.295. 
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Appendix 7.295: Purified recombinant lysostaphin preparations 
 
Preparation 
ID 
Construct Expression 
media 
Mode of 
purification 
Protein 
concentration 
(µg/µl) 
Related results 
2 3 AIM IMAC 8.67 Figure 2.27 
Appendix 7.141 
Figure 2.26 
3 3 AIM HIC, GF 1.46 Appendix 7.142 
Figure 2.17 
Figure 2.18 
Figure 2.19 
Figure 2.20 
Figure 2.21 
4 1 AIM IMAC 37.80 Appendix 7.143 
Appendix 7.144 
Appendix 7.145 
6 1 AIM IMAC 157.85 Appendix 7.147 
Appendix 7.148 
Appendix 7.149 
14 
 
1 LB IMAC 111.14 Appendix 7.307 
Appendix 7.308 
Appendix 7.309 
15 
 
1 AIM IMAC 203.25 Appendix 7.310 
Appendix 7.311 
Appendix 7.312 
16 
 
1 LB IMAC 312.23 Appendix 7.313 
Appendix 7.314 
Appendix 7.315 
17 
 
1 AIM IMAC 257.74 Appendix 7.316 
Appendix 7.317 
Appendix 7.318 
18 
 
1 LB IMAC 6.23 Appendix 7.319 
Appendix 7.320 
Appendix 7.321 
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Appendix 7.296: Equipment  
 
IMAC purifications and WCX separations using the ProPac® WCX-10 (4 x 500 mm) column 
were performed using an Ultimate™ 3000 Titanium system which consisted of a dual 
gradient pump, a thermal compartment with two column change valves, a VWD detector and 
a WPS-3000 biocompatible autosampler.  The thermal compartment was maintained at 
30°C during separation. The system was fitted with a PEEK fluidic pathway and the 
autosampler was fitted with a 250 µl syringe and a 1 ml injection loop. Small samples 
volumes were loaded onto the system via automated injection, whilst larger sample volumes 
were pumped into the system via buffer line C. Although the autosampler could 
accommodate fractionation, fractionation was performed using an ISCO Foxy® Jr Fraction 
collector in this instance.  Data collection and analysis was performed using Chromeleon® 
Chromatography Data System software with fractionation license.  
  
WCX separations using the ProPac® WCX-10 (2 x 500 mm) column were performed using 
an Ultimate™ 3000 Titanium system which consisted of an analytical titanium pump, a 
thermal compartment with two column change valves, a VWD detector and a WPS-3000 
biocompatible autosampler. The system was fitted with a PEEK fluidic pathway and the 
autosampler was fitted with a 250 µl syringe and a 500 µl injection loop.  Fractionation was 
achieved using the WPS-3000 biocompatible autosampler, which was temperature regulated 
to 10°C. Data collection and analysis was performed using Chromeleon® Chromatography 
Data System software with fractionation license.   
 
Chromatographic separations were performed using a number of analytical columns, as 
described in Appendix 7.297. 
 
Appendix 7.297: Analytical columns and mobile phase compositions used whilst 
investigating the activity of recombinant lysostaphin 
 
Column Chromatographic 
mode 
Dimensions 
(mm) 
Mobile phase conditions 
ProPac® IMAC-10 IMAC 4.0 x 250  IMAC buffer A and B 
ProPac® WCX-10 WCX 2.0 x 500 IEX buffer A and B 
ProPac® WCX-10 WCX 4.0 x 500  IEX buffer A and B  
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Appendix 7.298: Growth of S. aureus for lysostaphin assay 
 
An ampoule of dried culture of S. aureus was rehydrated with micrococcus nutrient media 
and streaked onto micrococcus nutrient media agar plates.  A single colony of S. aureus was 
inoculated from agar into 100 ml of pre-warmed micrococcus nutrient medium using a sterile 
wire loop to create a starter culture.  The starter culture was incubated overnight at 37C 
with orbital shaking at 150 rpm.  Following overnight incubation, the starter culture was 
inoculated into 900 ml of pre-warmed micrococcus nutrient medium and incubated at 37C 
with orbital shaking at 150 rpm.  Growth of the S. aureus was measured 
spectrophotometrically at a wavelength of 600 nm over 24 h, in order to determine the 
optical density at which the end of the exponential phase occurred.   
 
Appendix 7.299: Harvesting of S. aureus for lysostaphin assay  
 
After monitoring the growth of S. aureus spectrophotometrically, it was found that the end of 
the exponential phase occurred at an OD600 nm of 0.8. Therefore S. aureus cells were 
harvested at an OD600 nm of 0.8 by centrifugation of the 900 ml culture at 10,000 x g and 4C.  
The pelleted cells were washed and resuspended in wash buffer and stored at -20C until 
required.  
 
Appendix 7.300: Assay of N-terminally His-tagged recombinant lysostaphin (construct 
1)  
 
Assays were performed as described in Section 4.1.2.7 using preparations 4, 6, 15 and 17 
which had been purified using IMAC (Appendix 7.114) and concentrated by ultrafiltration 
(Appendix 7.120). The protein preparations had been expressed in E. coli BL21(DE3) 
cultured in AIM (Appendix 7.75) and cell lysate was harvested as described in Appendix 
7.77.   
 
Appendix 7.301: Influence of expression media upon the activity of recombinant 
lysostaphin 
 
Assays were performed as described in Section 4.1.2.7 using preparations 14, 15, 16 and 
17, which had been purified using IMAC (Appendix 7.114 or Appendix 7.117) and 
concentrated by ultrafiltration (Appendix 7.120). Preparations 14 and 16 had been expressed 
in E. coli BL21(DE3) cultured in LB (Appendix 7.76), whilst preparations 15 and 17 were 
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expressed in E. coli BL21(DE3) cultured in AIM (Appendix 7.75). Cell lysate was harvested 
as described in Appendix 7.77. Each assay comparison was performed on separate 
occasions, however both experiments were performed on S. aureus substrate cells which 
had been harvested from the same culture.  
 
Appendix 7.302: Influence of expression location upon the activity of recombinant 
lysostaphin 
 
An assay was performed as described in Section 4.1.2.7 using preparation 1 which had 
been purified using IMAC (Appendix 7.114) and concentrated by ultrafiltration (Appendix 
7.120).  The preparation had been expressed in E. coli BL21(DE3) cultured in AIM 
(Appendix 7.75) and cell lysate was harvested as described in Appendix 7.77.  
 
Appendix 7.303: Influence of purification upon the activity of recombinant lysostaphin 
 
Assays were performed as described in Section 4.1.2.7 using preparations 2 and 3, which 
had been purified using HIC and GF or IMAC respectively (Appendix 7.110 and Appendix 
7.111 or Appendix 7.114). Following purification, selected fractions were concentrated by 
ultrafiltration (Appendix 7.120). Preparations 2 and 3 had been expressed in E. coli 
BL21(DE3) cultured in AIM (Appendix 7.75) and cell lysate was harvested as described in 
Appendix 7.77.  
 
Appendix 7.304: Influence of lyophilisation upon the activity of recombinant 
lysostaphin  
 
Assays were performed as described in Section 4.1.2.7 using preparation 10, which had 
been purified using large-scale IMAC purification (Appendix 7.115). Following purification, 
selected eluted protein was dialysed (Appendix 7.118) and lyophilised (Appendix 7.119). 
Lyophilised recombinant lysostaphin was resupended in 18.2 MΩ/cm H2O prior to assay.  
Preparation 10 had been expressed in E. coli BL21(DE3) cultured in LB (Appendix 7.76) and 
cell lysate was harvested as described in Appendix 7.77.  
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Appendix 7.305: Assay of charge variants following WCX separation 
 
Recombinant lysostaphin (preparation 18) was purified from cell lysate which had been 
purified by IMAC, as described in Appendix 7.117. Preparation 18 had been expressed in E. 
coli BL21(DE3) cultured in LB (Appendix 7.76) and cell lysate was harvested as described in 
Appendix 7.77. Following purification selected fractions were desalted and concentrated by 
ultrafiltration (Appendix 7.120). The purified preparation was assayed for activity, as 
indicated in Section 4.1.2.7 and subjected to WCX separation.  
 
WCX separation was performed using a 0.5 ml/ min flow rate and a ProPac® WCX-10 (4 x 
500 mm) column. Purified, concentrated recombinant lysostaphin (300 µg) was applied to 
the column initially, however higher concentrations of recombinant lysostaphin (2.1 mg) were 
applied during the second WCX separation.  Protein isoforms were separated by applying a 
linear gradient of 0-50% B over 70 min. The column was then washed using 90% B for 4 min 
and then the column was equilibrated at 0 % B for 20 min. UV data was acquired at 214 and 
280 nm throughout the separation and fractions were collected by time, every 30 s between 
20 and 70 min.  Following separation, selected fractions were desalted, concentrated and 
assayed for activity, as described in Appendix 7.369 and Section 4.1.2.7.  
 
Appendix 7.306: Assay of charge variants following WCX separation during culture 
analysis 
 
Recombinant lysostaphin was purified from cell lysate which had been harvested during the 
course of expression.  The preparation was produced following expression in E. coli 
BL21(DE3) cultured in LB and cell lysate was harvested as described in Appendix 7.239. 
The cell lysate was subjected to WCX analysis, as described in Appendix 7.230.  Charge 
variants separated by WCX analysis were then assayed for activity as described in Section 
4.1.2.7. 
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Appendix 7.307: SDS-PAGE analysis of cell lysate containing N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 14) expressed in E.coli BL21(DE3) 
cultured in LB.  Lane 1: Sigma low molecular markers; Lane 2: CFE (neat); Lane 3: 
CFE (1:10); Lane 4: CFE (1:100).  
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Appendix 7.308: IMAC purification of recombinant lysostaphin (construct 1, 
preparation 14) using a Chelating Sepharose™ Fast Flow media column and ӒKTA™ 
prime plus system. Fractions were collected every 60 s throughout the separations. 
Cell lysate was applied to the column on two consecutive occasions (A and B). Bound 
protein was eluted by applying an increasing imidazole concentration (20-500 mM).  
Fractions 48-62 collected during purification A and fractions 49-61 collected during 
purification B were pooled and concentrated.   
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Appendix 7.309: SDS-PAGE analysis of purified, concentrated N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 14). Lane 1: Sigma low molecular 
weight markers; Lane 2: concentrated protein (1:100); Lane 3: concentrated protein 
(1:10); Lane 4: concentrated protein (1:1000).  
 
 
 
Appendix 7.310: SDS-PAGE analysis of cell lysate containing N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 15) expressed in E.coli BL21(DE3) 
cultured in AIM. Lane 1: Sigma low molecular markers; Lane 2: CFE (neat); Lane 3: 
CFE (1:10); Lane 4: CFE (1:100).  
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Appendix 7.311: IMAC purification of recombinant lysostaphin (construct 1, 
preparation 15) using a Chelating Sepharose™ Fast Flow media column and ӒKTA™ 
prime plus system. Fractions were collected every 60 s throughout the separations. 
Cell lysate was applied to the column on two consecutive occasions (A and B). Bound 
protein was eluted by applying an increasing imidazole concentration (20-500 mM).  
Fractions 43-59 collected during purification A and fractions 49-59 collected during 
purification B were pooled and concentrated.   
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Appendix 7.312: SDS-PAGE analysis of purified, concentrated N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 15).  Lane 1: Sigma low molecular 
weight markers; Lane 2: concentrated protein (1:10); Lane 3: concentrated protein 
(1:100); Lane 4: concentrated protein (1:1000), Lane 5: Sigma high molecular weight 
markers. 
 
 
Appendix 7.313: SDS-PAGE analysis of cell lysate containing N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 16) expressed in E.coli BL21(DE3) 
cultured in LB. Lane 1: NZY broad-range markers; Lane 2: CFE (1:10). 
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Appendix 7.314: IMAC purification of recombinant lysostaphin (construct 1, 
preparation 16) using a Chelating Sepharose™ Fast Flow media column and ӒKTA™ 
prime plus system. Bound protein was eluted by applying an increasing imidazole 
concentration (20-500 mM).  Fractions were collected every 60 s throughout the 
separation. Fractions 10-34 were pooled and concentrated. 
 
 
Appendix 7.315: SDS-PAGE analysis of purified, concentrated N-terminally His-tagged 
recombinant lysostaphin (construct 1, Preparation 16).  Lane 1: NEB pre-stained 
broad-range markers; Lane 2: concentrated protein (1:10); Lane 3: concentrated 
protein (1:100); Lane 4: concentrated protein (1:1000). 
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Appendix 7.316: SDS-PAGE analysis of cell lysate containing N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 17) expressed in E.coli BL21(DE3) 
cultured in AIM. Lane 1: Sigma low molecular weight markers; Lane 2: CFE (neat); 
Lane 3: CFE (1:10).  
 
Appendix 7.317: IMAC purification of recombinant lysostaphin (construct 1, 
preparation 17) using a Chelating Sepharose™ Fast Flow media column and ӒKTA™ 
prime plus system. Bound protein was eluted by applying an increasing imidazole 
concentration (20-500 mM).  Fractions were collected every 60 s throughout the 
separation. Fractions 46-63 were pooled and concentrated.   
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Appendix 7.318: SDS-PAGE analysis of purified, concentrated N-terminally His-tagged 
recombinant lysostaphin (construct 1, Preparation 17).  Lane 1: NZY broad-range 
markers; Lane 2: concentrated protein (1:10); Lane 3: concentrated protein (1:100); 
Lane 4: concentrated protein (1:1000). 
 
 
Appendix 7.319: SDS-PAGE analysis of cell lysate containing N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 18) expressed in E.coli BL21(DE3) 
cultured in LB. Lane 1: NZY broad range size markers; Lane 2: CFE (neat); Lane 3: 
CFE (1:10); Lane 4: CFE (1:100).  
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Appendix 7.320: IMAC purification of recombinant lysostaphin (construct 1, 
preparation 18) using a ProPac® IMAC-10 column (4.0 x 250 mm) and Ultimate™ 3000 
system.  Fractions were collected by time between 53 and 103 min and fractions 8, 9, 
10, 11, 35, 36, 37 and 38 were analysed by SDS-PAGE.   
 
 
 
Appendix 7.321: SDS-PAGE analysis of IMAC fractions following purification of N-
terminally His-tagged recombinant lysostaphin (construct 1; preparation 18) derived 
from E.coli BL21(DE3) cultured in LB, using the ProPac IMAC-10 (4 x 250 mm) column. 
Lane 1: Sigma low molecular weight markers; Lane 2: Fraction 8; Lane 3: Fraction 9: 
Lane 4: Fraction 10; Lane 5: Fraction 11; Lane 6: Fraction 35; Lane 7: Fraction 36; 
Lane 8: Fraction 37; Lane 9: Fraction 38; Lane 10: Sigma high molecular weight 
markers.   
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Appendix 7.322: Amino acid sequence of mature lysostaphin from Staphylococcus 
staphylolyticus 
 
 
 
Appendix 7.323: Amino acid sequence of glycyl-glycine endopeptidase LytM from 
Staphylococcus aureus (Q99WV0).  Zinc binding domain residues are indicated in red.  
 
 
Appendix 7.324: Spectrophotometric monitoring of the growth of Staphylococcus 
aureus (NCIMB 12703) in liquid culture at 37°C. Bacterial growth in 1 L broth culture 
was monitored spectrophotometrically for over 23 h.  
 
 
 
 
 
 
 
 
 
 
 
  
Time (min) Absorbance at 600 nm 
0 0.000 
60 0.088 
120 0.065 
180 0.123 
240 0.262 
320 0.723 
375 0.804 
435 0.834 
480 0.710 
1390 0.592 
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Appendix 7.325: Percentage lysis of S. aureus cells by N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 4) as determined by turbidometric 
assay 
 
Lysostaphin 
(µg) 
Lysostaphin 
concentration 
(µg/ml) 
Absorbance 
at 620 nm 
Percentage 
change in 
absorbance 
(%) 
T0 T10 
0 0.0 0.725 0.690 4.83 
2 0.4 0.726 0.607 16.39 
4 0.8 0.710 0.455 35.92 
6 1.2 0.700 0.472 32.57 
8 1.6 0.733 0.284 61.26 
10 2.0 0.715 0.272 61.96 
 
Appendix 7.326: Percentage lysis of S. aureus cells by N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 6) as determined by turbidometric 
assay 
 
Lysostaphin 
(µg) 
Lysostaphin 
concentration 
(µg/ml) 
Absorbance 
at 620 nm 
Percentage 
change in 
absorbance 
(%) 
T0 T10 
0 0.0 0.314 0.296 5.73 
2 0.4 0.322 0.128 60.25 
4 0.8 0.327 0.088 73.09 
6 1.2 0.331 0.071 78.55 
8 1.6 0.335 0.070 79.10 
10 2.0 0.328 0.067 79.57 
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Appendix 7.327: Percentage lysis of S. aureus cells by N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 15) as determined by turbidometric 
assay 
 
Lysostaphin 
(µg) 
Lysostaphin 
concentration 
(µg/ml) 
Absorbance 
at 620 nm 
Percentage 
change in 
absorbance 
(%) 
T0 T10 
0 0.0 0.417 0.389 6.71 
2 0.4 0.423 0.354 16.31 
4 0.8 0.427 0.285 33.26 
6 1.2 0.440 0.246 44.09 
8 1.6 0.427 0.208 51.29 
10 2.0 0.420 0.192 54.29 
 
Appendix 7.328: Percentage lysis of S. aureus cells by N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 17) as determined by turbidometric 
assay 
 
Lysostaphin 
(µg) 
Lysostaphin 
concentration 
(µg/ml) 
Absorbance 
at 620 nm 
Percentage 
change in 
absorbance 
(%) 
T0 T10 
0 0.0 0.361 0.311 13.85 
2 0.4 0.370 0.281 24.05 
4 0.8 0.356 0.225 36.80 
6 1.2 0.343 0.205 40.23 
8 1.6 0.357 0.179 49.86 
10 2.0 0.359 0.173 51.81 
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Appendix 7.329: Percentage lysis of S. aureus cells by N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 14) as determined by turbidometric 
assay 
 
Lysostaphin 
(µg) 
Lysostaphin 
concentration 
(µg/ml) 
Absorbance 
at 620 nm 
Percentage 
change in 
absorbance 
(%) 
T0 T10 
0 0.0 0.477 0.404 15.30 
2 0.4 0.440 0.303 31.14 
4 0.8 0.455 0.251 44.84 
6 1.2 0.453 0.230 49.23 
8 1.6 0.430 0.197 54.19 
10 2.0 0.458 0.193 57.86 
 
Appendix 7.330: Percentage lysis of S. aureus cells by N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 16) as determined by turbidometric 
assay 
 
Lysostaphin 
(µg) 
Lysostaphin 
concentration 
(µg/ml) 
Absorbance 
at 620 nm 
Percentage 
change in 
absorbance 
(%) 
T0 T10 
0 0.0 0.363 0.351 3.31 
2 0.4 0.357 0.275 22.97 
4 0.8 0.347 0.238 31.41 
6 1.2 0.322 0.212 34.16 
8 1.6 0.355 0.197 44.51 
10 2.0 0.358 0.176 50.84 
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Appendix 7.331: Percentage lysis of S. aureus cells by C-terminally His-tagged 
recombinant lysostaphin (construct 4, preparation 1) as determined by turbidometric 
assay 
 
Lysostaphin 
(µg) 
Lysostaphin 
concentration 
(µg/ml) 
Absorbance 
at 620 nm 
Percentage 
change in 
absorbance 
(%) 
T0 T10 
0 0.0 0.480 0.451 6.04 
2 0.4 0.468 0.075 85.04 
4 0.8 0.465 0.060 87.10 
6 1.2 0.464 0.052 88.79 
8 1.6 0.472 0.046 90.25 
10 2.0 0.456 0.037 91.89 
 
 
Appendix 7.332: Percentage lysis of S. aureus cells by C-terminally His-tagged 
recombinant lysostaphin (construct 3, preparation 3) as determined by turbidometric 
assay 
 
Lysostaphin 
(µg) 
Lysostaphin 
concentration 
(µg/ml) 
Absorbance 
at 620 nm 
Percentage 
change in 
absorbance 
(%) 
T0 T10 
0 0.0 0.855 0.810 5.26 
2 0.4 0.832 0.339 59.25 
4 0.8 0.825 0.205 75.15 
6 1.2 0.816 0.193 76.15 
8 1.6 0.816 0.193 78.51 
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Appendix 7.333: Percentage lysis of S. aureus cells by C-terminally His-tagged 
recombinant lysostaphin (construct 3, preparation 2) as determined by turbidometric 
assay 
 
Lysostaphin 
(µg) 
Lysostaphin 
concentration 
(µg/ml) 
Absorbance 
at 620 nm 
Percentage 
change in 
absorbance 
(%) 
T0 T10 
0 0.0 0.332 0.299 9.94 
2 0.4 0.353 0.213 39.66 
4 0.8 0.361 0.152 57.89 
6 1.2 0.347 0.117 66.28 
8 1.6 0.342 0.064 81.29 
10 2.0 0.347 0.054 84.44 
 
Appendix 7.334: Percentage lysis of S. aureus cells by N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 10) as determined by turbidometric 
assay 
 
Lysostaphin 
(µg) 
Lysostaphin 
concentration 
(µg/ml) 
Absorbance 
at 620 nm 
Percentage 
change in 
absorbance 
(%) 
T0 T10 
0 0.0 0.298 0.270 9.40 
2 0.4 0.337 0.225 33.23 
4 0.8 0.336 0.171 49.11 
6 1.2 0.330 0.149 54.85 
8 1.6 0.310 0.123 60.32 
10 2.0 0.335 0.110 67.16 
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Appendix 7.335: Percentage lysis of S. aureus cells by N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 18) as determined by turbidometric 
assay. 
 
Lysostaphin 
(µg) 
Lysostaphin 
concentration 
(µg/ml) 
Absorbance 
at 620 nm 
Percentage 
change in 
absorbance 
(%) 
T0 T10 
0 0.0 0.401 0.377 5.99 
2 0.4 0.366 0.250 31.69 
4 0.8 0.380 0.126 66.84 
6 1.2 0.343 0.129 62.39 
8 1.6 0.360 0.093 74.17 
10 2.0 0.396 0.102 74.24 
 
Appendix 7.336: Percentage lysis of S. aureus cells by recombinant lysostaphin 
(fraction 21) following WCX separation. Values determined by turbidometric assay. 
 
Lysostaphin 
(µg) 
Lysostaphin 
concentration 
(µg/ml) 
Absorbance 
at 620 nm 
Percentage 
change in 
absorbance 
(%) 
T0 T10 
0 0.0 0.401 0.377 5.99 
2 0.4 0.352 0.155 55.97 
 
Appendix 7.337: Percentage lysis of S. aureus cells by recombinant lysostaphin 
(fraction 29) following WCX separation. Values determined by turbidometric assay. 
 
Lysostaphin 
(µg) 
Lysostaphin 
concentration 
(µg/ml) 
Absorbance 
at 620 nm 
Percentage 
change in 
absorbance 
(%) 
T0 T10 
0 0.0 0.401 0.377 5.99 
2 0.4 0.339 0.154 54.57 
4 0.8 0.354 0.105 70.34 
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Appendix 7.338: Percentage lysis of S. aureus cells by recombinant lysostaphin 
(fraction 19) following WCX separation. Values determined by turbidometric assay. 
 
Lysostaphin 
(µg) 
Lysostaphin 
concentration 
(µg/ml) 
Absorbance 
at 620 nm 
Percentage 
change in 
absorbance 
(%) 
T0 T10 
0 0.0 0.374 0.349 6.68 
2 0.4 0.373 0.143 61.66 
4 0.8 0.387 0.106 72.61 
6 1.2 0.376 0.083 77.93 
8 1.6 0.367 0.073 80.11 
10 2.0 0.368 0.069 81.25 
 
Appendix 7.339: Percentage lysis of S. aureus cells by recombinant lysostaphin 
(fraction 26) following WCX separation. Values determined by turbidometric assay. 
 
Lysostaphin 
(µg) 
Lysostaphin 
concentration 
(µg/ml) 
Absorbance 
at 620 nm 
Percentage 
change in 
absorbance 
(%) 
T0 T10 
0 0.0 0.306 0.285 6.86 
2 0.4 0.316 0.163 48.42 
4 0.8 0.313 0.080 74.44 
6 1.2 0.298 0.063 78.86 
8 1.6 0.294 0.054 80.61 
10 2.0 0.316 0.060 81.01 
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Appendix 7.340: Percentage lysis of S. aureus cells by recombinant lysostaphin 
(fraction 8) following WCX separation. Values determined by turbidometric assay. 
 
Lysostaphin 
(µg) 
Lysostaphin 
concentration 
(µg/ml) 
Absorbance 
at 620 nm 
Percentage 
change in 
absorbance 
(%) 
T0 T10 
0 0.0 0.306 0.285 6.86 
2 0.4 0.316 0.163 48.42 
4 0.8 0.313 0.080 74.44 
6 1.2 0.298 0.063 78.86 
8 1.6 0.294 0.054 80.61 
10 2.0 0.316 0.060 81.01 
 
Appendix 7.341: Evidence of elastolytic activity following LC-MS/MS analysis of 
tryptically digested N-terminally His-tagged recombinant lysostaphin (construct 1). 
Although the specificity of elastolytic activity is not known, elastolytic enzymes are 
known to catalyse the cleavage of peptide bonds associated with hydrophobic amino 
acids, such as alanine or aromatic amino acids, such as histidine. Acquired LC-
MS/MS spectra were submitted to X!Tandem open source software. Associated data 
not shown.  
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7.3.2 IMAC analysis of recombinant lysostaphin 
 
Appendix 7.342: Buffers 
 
IMAC buffer A (1 L)    (as described in Section 2.5.2.1/ Appendix 7.105) 
IMAC buffer B (1L)      (as described in Section 2.5.2.1/ Appendix 7.105) 
WCX buffer A (1L)    (as described in Section 3.2.1/ Appendix 7.136) 
WCX buffer B (1L)    (as described in Section 3.2.1/ Appendix 7.136 ) 
 
Appendix 7.343: Equipment  
 
IMAC purifications and WCX separations achieved using the ProPac® WCX-10 (4.0 x 500 
mm) column were performed using an Ultimate™ 3000 Titanium system, which consisted of 
an analytical titanium pump, a thermal compartment with two column change valves, a VWD 
detector and a WPS-3000 biocompatible autosampler.  The thermal compartment was 
maintained at 30°C and the autosampler was fitted with a 250 µl syringe and a 1 ml injection 
loop. The system was fitted with a PEEK fluidic pathway. Small samples volumes were 
loaded onto the system via automated injection, whilst larger sample volumes were pumped 
into the system via buffer line C. Although the autosampler could accommodate 
fractionation, fractionation was performed using an ISCO Foxy® Jr Fraction collector in this 
instance.  Data collection and analysis was performed using Chromeleon® Chromatography 
Data System software with fractionation license.   
WCX separations using the ProPac® WCX-10 (2 x 500 mm) column were performed with an 
Ultimate™ 3000 Titanium system which consisted of an analytical titanium pump, a thermal 
compartment with two column change valves, a VWD detector and a WPS-3000 
biocompatible autosampler. The system was fitted with a PEEK fluidic pathway and the 
autosampler was fitted with a 250 µl syringe and a 500 µl injection loop.  Fractionation was 
achieved using the WPS-3000 biocompatible autosampler, which was temperature regulated 
to 10°C. Data collection and analysis was performed using Chromeleon® Chromatography 
Data System software with fractionation license.   
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Chromatographic separations were performed using a number of analytical columns, as 
described in Appendix 7.344.  
 
Appendix 7.344: Analytical columns and mobile phase compositions used whilst 
investigating the retention behaviour of recombinant lysostaphin 
 
Column Chromatographic 
mode 
Dimensions 
 (mm) 
Mobile phase conditions 
ProPac
®
 IMAC-10 IMAC 4.0 x 250  IMAC buffer A and B 
ProPac
®
 WCX-10 WCX 2.0 x 500 IEX buffer A and B 
ProPac
®
 WCX-10 WCX 4.0 x 500  IEX buffer A and B  
 
Appendix 7.345: Sample preparation 
 
Experiments were performed using freshly harvested cell lysate. Cell lysates were harvested 
from E. coli BL21(DE3) which was transformed with a plasmid encoding N-terminally His-
tagged recombinant lysostaphin (construct 1), recombinant lysostaphin (construct 2) or C-
terminally His-tagged recombinant lysostaphin (construct 3). Recombinant protein 
expression was performed as described in Appendix 7.76.  All cultures were grown in LB 
media. 
IMAC purification was performed using freshly harvested cell lysate, which was prepared as 
described in Appendix 7.77.  IMAC purification of N-terminally His-tagged recombinant 
lysostaphin (construct 1) and C-terminally His-tagged recombinant lysostaphin (construct 3) 
was performed on cell lysate harvested from 1 L of culture. IMAC purification of recombinant 
lysostaphin (construct 2) was performed on cell lysate harvested from 1 L of culture initially, 
before harvesting from 5 L of culture prior to the subsequent purification.  During harvesting 
of cell lysate, sample volumes were kept as concentrated as possible, and diluted to a 
minimum volume of 33 ml using IMAC buffer A, prior to IMAC purification.   
WCX separation of recombinant lysostaphin constructs was performed using freshly 
harvested cell lysate, which had been prepared as described in Appendix 7.77.  WCX 
analysis was performed upon 500 µl of cell lysate which was harvested from 100 ml of 
culture.   
 
620 
 
Appendix 7.346: IMAC purification 
 
IMAC purification was performed using a ProPac® IMAC-10 (4.0 x 250 mm) column.  Prior to 
purification, the ProPac® IMAC-10 column was stripped and charged through manual 
injection of 500 µl of EDTA and 1000 µl of NiSO4.  Cell lysate (33 ml) was loaded onto the 
column (via buffer line C) at a flow rate of 1.0 ml/min. Following application of the cell lysate, 
the gradient remained isocratic by applying 0% B to the column for 20 min at a flow rate of 
1.0 ml/min, to remove non-binding proteins and cellular contaminants. The target protein 
was eluted by applying a linear gradient from 0-100% B over 50 min at 0.5 ml/min. The 
column was re-equilibrated for 25 min with 0% B at a flow rate of 1.0 ml/min.  UV 
absorbance was recorded at 214 and 280 nm throughout the purification.  The column eluate 
was collected as fractions in 0.25 ml volumes and stored at 4°C until required for 
subsequent analysis. Fractions thought to contain the target protein were analysed by SDS-
PAGE (Appendix 7.15).  
 
Appendix 7.347: Concentration of IMAC fractions for analysis 
 
Following IMAC purification, selected fractions were either concentrated and desalted using 
Vivaspin 20 ml ultrafiltration columns with a 10 kDa membrane (Appendix 7.120) or Vivaspin 
500 µl columns with 10 kDa membrane.  The Vivaspin 500 µl column was placed into a 
filtrate container and the concentrator column was filled up to the maximum volume of 500 µl 
with IMAC fraction eluent.  The spin column was centrifuged at 14,000 x g until the desired 
volume of sample had been achieved.  The filtrate container was emptied and the 
concentrator was re-filled with 500 µl of 18.2 MΩ/cm H2O and centrifuged at 14,000 x g until 
the volume had reduced to ~50 µl.  This washing and desalting process was performed twice 
more before transferring the concentrated desalted sample from the concentrator column to 
a sterile microtube ready for subsequent analysis. 
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Appendix 7.348: WCX separation of N-terminally His-tagged recombinant lysostaphin 
(construct 1) using ProPac® WCX (2 x 500.0 mm).  Fractions 5, 14, 17, 18, 24, 26, 44 
and 51 were selected for PAGE analysis.  
 
Appendix 7.349: SDS-PAGE analysis of fractions eluted during separation of N-
terminally His-tagged recombinant lysostaphin (construct 1) using ProPac WCX 
column (2 x 500.0 mm). Lane 1: Fraction 5; Lane 2; Fraction 14; Lane 3: Fraction 17; 
Lane 4: Fraction 18; Lane 5: Sigma low molecular weight markers; Lane 6: Sigma low 
molecular weight markers; Lane 7: Fraction 24; Lane 8: Fraction 26; Lane 9: Fraction 
44; Lane 10: Fraction 51; Lane 11: Sigma high molecular weight markers.  
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Appendix 7.350: WCX separation of recombinant lysostaphin (construct 2) using 
ProPac® WCX column (2 x 500.0 mm).  Fractions 12, 13, 17, 45, 50 and 51 were 
selected for PAGE analysis. 
 
Appendix 7.351: SDS-PAGE analysis of fractions eluted during separation of 
recombinant lysostaphin (construct 2) using a ProPac® WCX column (2 x 500.0 mm). 
Lane 1: Fraction 12; Lane 2: Fraction 13; Lane 3: Fraction 17; Lane 4: Sigma low 
molecular weight markers; Lane 5: Fraction 45; Lane 6: Fraction 50; Lane 7: Fraction 
51; Lane 8: Sigma high molecular weight markers.  
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Appendix 7.352: WCX separation of C-terminally His-tagged recombinant lysostaphin 
(construct 3) using ProPac® WCX column (2 x 500.0 mm).  Fractions 13, 14, 15, 17, 18, 
39, 44 and 51 were selected for PAGE analysis.  
 
Appendix 7.353: SDS-PAGE analysis of fractions eluted during separation of C-
terminally His-tagged recombinant lysostaphin (construct 3) using a ProPac® WCX 
column (2 x 500.0 mm). Lane 1: Sigma low molecular weight markers; Lane 2: Fraction 
13; Lane 3: Fraction 14; Lane 4: Fraction 15; Lane 5: Fraction 17; Lane 6: Fraction 18; 
Lane 7: Sigma high molecular weight markers; Lane 8: Fraction 39; Lane 9: Fraction 
44; Lane 10: Fraction 51. 
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7.3.3 GF Analysis of recombinant lysostaphin 
 
Appendix 7.354: Buffers 
 
IMAC buffer A (1 L)     (as described in Section 2.5.2.1/ Appendix 7.105) 
IMAC buffer B (1L)     (as described in Section 2.5.2.1/ Appendix 7.105) 
GF Buffer (1 L) 
NaH2PO4 H2O (200 mM)  27.6 g  
Na2HPO4.H2O (200 mM)   28.4 g 
NaH2PO4.H2O and Na2HPO4.H2O were dissolved in 18.2 M/cm H2O to create two separate 
solutions. Appropriate volumes of each solution were combined to provide a sodium 
phosphate buffer with correct pH. If required, the pH of the buffer was adjusted to pH 8.0 
using NaOH. The stock solution was autoclaved prior to use.  
IMAC denaturing buffer A (1 L)  
Sodium phosphate  (20 mM)  100 ml of 200 mM stock solution  
Imidazole (10 mM)   0.68 g 
NaCl (500 mM)   29.20 g 
Urea (500 mM)   30.03 g 
Sodium phosphate stock solution was diluted with an appropriate volume of 18.2 /cm H2O, 
to account for volumetric displacement following dissolvation of imidazole, NaCl, and urea. 
The pH of the buffer was adjusted to pH 7.4 using NaOH or HCl. The buffer was autoclaved 
prior to use. 
IMAC denaturing buffer B (1L)  
Sodium phosphate (20 mM)  100 ml of 200 mM stock solution  
Imidazole (500 mM)   34.04 g 
NaCl (500 mM)   29.20 g 
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Urea (500 mM)   30.03 g 
Sodium phosphate stock solution was diluted with an appropriate volume of 18.2 /cm H2O, 
to account for volumetric displacement following dissolvation of imidazole, NaCl, and urea. 
The pH of the buffer was adjusted to pH 7.4 using NaOH or HCl. The buffer was autoclaved 
prior to use. 
IEX buffer A (1L)     (as described in Section 3.2.1/ Appendix 7.136) 
IEX buffer B (1L)     (as described in Section 3.2.1/ Appendix 7.136) 
SCX buffer A (1L)   (as described in Section 3.2.1/ Appendix 7.136) 
SCX buffer B (1L)   (as described in Section 3.2.1/ Appendix 7.136) 
 
Appendix 7.355: Equipment 
 
Chromatographic separations were performed using an Ultimate™ 3000 Titanium system 
consisting of an analytical titanium pump, a thermal compartment with two column change 
valves, a VWD detector and a WPS-3000 Biocompatible autosampler. The system was fitted 
with a PEEK fluidic pathway and the autosampler was fitted with a 250 µl syringe and a 1 ml 
injection loop.  Although the autosampler could accommodate fractionation, fractionation 
was performed using an ISCO Foxy® Jr Fraction collector in this instance. Data collection 
and analysis was performed using Chromeleon® Chromatography Data System software 
with fractionation license.   
Chromatographic separations were performed using a number of analytical columns, as 
described in Appendix 7.356.   
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Appendix 7.356: Analytical columns and mobile phase compositions used whilst 
investigating the stability of recombinant lysostaphin 
 
Column Chromatographic 
mode 
Dimensions 
(mm) 
Mobile phase conditions 
ProPac
®
 IMAC-10 IMAC 4.0 x 250  IMAC buffer A and B or 
IMAC denaturing buffer A and B 
Zorbax
®
 GF-250 GF 4.6 x 250 GF buffer  
ProPac
®
 WCX-10 WCX 2.0 x 500 IEX buffer A and B 
ProPac
®
 MAb SCX  SCX 4.0 x 500 SCX Buffer A and B 
 
Appendix 7.357: Sample preparation 
 
Experiments were performed using either purified, concentrated recombinant lysostaphin 
samples, freshly harvested cell lysate or purified, lyophilised recombinant lysostaphin.  
Purified, concentrated recombinant lysostaphin was harvested from E.coli BL21(DE3) 
cultured in either LB or AIM and purified using either IMAC or HIC and GF.  Following 
purification, the purified protein was concentrated using ultrafiltration. Further details about 
preparation of recombinant lysostaphin are provided in Appendix 7.358.  
 
Lyophilised recombinant lysostaphin was prepared following expression of N-terminally His-
tagged recombinant lysostaphin (construct 1) with 15 x 1 L batches of AIM (Appendix 7.75). 
Cell lysate was harvested according to methods described in (Appendix 7.77) and large-
scale IMAC purification was performed as described in Appendix 7.115. Following 
purification, the resulting recombinant lysostaphin was dialysed and lyophilised (Appendix 
7.118 and Appendix 7.119).  
Freshly harvested lysate for IMAC purification was harvested as described in Appendix 7.77, 
whilst cell lysate used during WCX separation was harvested as described in Appendix 
7.239.  All freshly harvested cell lysates were harvested from E. coli BL21(DE3) transformed 
with recombinant pET-28a for expression of N-terminally His-tagged recombinant 
lysostaphin (construct 1) following culture in LB.   
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Appendix 7.358: Purified recombinant lysostaphin preparations 
Preparation 
ID 
Construct Expression 
media 
Mode of 
purification 
Protein 
concentration 
(µg/µl) 
Related results 
3 3 AIM HIC, GF 1.46 Appendix 7.142 
Figure 2.17 
Figure 2.18 
Figure 2.19 
Figure 2.20 
Figure 2.21 
4 3 AIM IMAC 37.80 Appendix 7.143 
Appendix 7.144 
Appendix 7.145 
6 1 AIM IMAC 157.85 Appendix 7.147 
Appendix 7.148 
Appendix 7.149 
13 
 
3 AIM IMAC/GF 19.08 Appendix 7.167 
Figure 2.26 
Figure 2.27 
Figure 2.28 
Figure 2.29 
19 
 
1 AIM IMAC Not determined Appendix 7.362 
Appendix 7.131 
Appendix 7.132 
 
Appendix 7.359: GF of fractions eluted following IMAC purification  
 
IMAC purification was performed on cell lysate containing N-terminally His-tagged 
recombinant lysostaphin (construct 1). IMAC separation was performed as described in 
Appendix 7.117, however due to over-pressure during sample loading, the separation was 
interrupted at 20 min and the separation was recommenced without sample loading.  
Fractions were subsequently collected between 23 and 73 minutes and one of the fractions 
was selected for GF separation. 
 
GF separation was performed using a 0.25 ml/min flow rate and an isocratic gradient over 16 
min.  Manual injection of 250 µl of IMAC fraction 13 was delivered to the system and UV 
data was acquired at 214 and 280 nm throughout the separation. Fractions were collected 
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using a Foxy® Jr fraction collector between 6 and 15 min. Selected fractions were then 
analysed by SDS-PAGE.  
 
Appendix 7.360: GF of fractions eluted following IMAC purification under denaturing 
conditions 
 
IMAC purification was performed on cell lysate containing N-terminally His-tagged 
recombinant lysostaphin (construct 1). IMAC separation was performed as described in 
Appendix 7.117, however the separation was performed using IMAC denaturing start and 
elution buffers.  Fractions were subsequently collected using a Foxy® Jr Fraction collector 
between 53 and 103 min.  Selected fractions were subjected to GF separation, performed as 
described in Appendix 7.359.  
 
Appendix 7.361: GF of fractions eluted following WCX separation of recombinant 
lysostaphin isoforms  
 
WCX separation was performed on cell lysate containing N-terminally His-tagged 
recombinant lysostaphin (construct 1).  WCX separation was performed as described in 
Appendix 7.229 and fractions were subsequently collected between 23 and 38 min.  
Selected fractions were subjected to GF separation, performed as described in Appendix 
7.359.  Comparative SCX separations were performed on the same cell lysates, as 
described in Appendix 7.231, however fractions collected during SCX separation were not 
subjected to GF analysis.  
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Appendix 7.362: SDS-PAGE analysis of cell lysate containing N-terminally His-tagged 
recombinant lysostaphin (construct 1, preparation 19) expressed in E.coli BL21(DE3) 
cultured in AIM. Lane 1: Sigma low molecular weight markers; Lane 2: CFE (neat); 
Lane 3: CFE (1:10); Lane 4: CFE in solubilising buffer; Lane 5: Sigma high molecular 
weight markers.  
 
 
 
  
630 
 
7.3.4 LC-MS analysis of recombinant lysostaphin 
 
Appendix 7.363: Buffers 
 
WCX buffer A (1L)     (as described in Chapter 3.2.1 /Appendix 7.136) 
 
WCX buffer B (1L)     (as described in Chapter 3.2.1 / Appendix 7.136) 
 
RP buffer A (1 L)  
 
Formic acid (0.1% v/v)  1 ml 
 
The buffer was made up to 1 L using LC/MS grade H2O.  
 
RP buffer B (1 L)  
 
Acetonitrile (80% v/v)   800.0 ml 
 
Formic acid (0.05% v/v)  0.5 ml 
 
The buffer was made up to 1 L using LC/MS grade H2O. 
  
Appendix 7.364: Equipment 
 
WCX separation prior to intact MS analysis was performed using the ProPac® WCX-10 (4 x 
500 mm) column and an Ultimate™ 3000 Titanium system, which consisted of an analytical 
titanium pump, a thermal compartment with two column change valves, a VWD detector and 
a WPS-3000 biocompatible autosampler. The system was fitted with a PEEK fluidic 
pathway. The thermal compartment was maintained at 30°C and the autosampler was fitted 
with a 250 µl syringe and a 1 ml injection loop. Although the autosampler could 
accommodate fractionation, fractionation was performed using an ISCO Foxy® Jr Fraction 
collector in this instance.  Data collection and analysis was performed using Chromeleon® 
Chromatography Data System software with fractionation license.   
 
Intact MS analysis was performed using an online MaXis UHR-TOF system (Bruker 
Daltonics, Germany) coupled to an Ultimate™ 3000 LC system with a PepSwift® monolithic 
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PS-DVB column. The Ultimate™ 3000 system featured a flow manager column 
compartment with a flow-splitter cartridge to permit low flow rates and was maintained at 
60°C during separation. The MaXis UHR-TOF system was fitted with an ESI source (Bruker, 
UK).  The instruments were controlled using Hystar™ 3.2 (Build 44) and Esquire Control™ 
Version 6.1 (Build 92) (Bruker Daltonics) software. 
 
Chromatographic separations were performed using a number of analytical columns, as 
described in Appendix 7.365.  
 
Appendix 7.365: Analytical columns and mobile phase compositions used during LC-
MS analysis of recombinant lysostaphin 
 
Column Chromatographic 
mode 
Dimensions 
(mm) 
Mobile phase 
conditions 
ProPac
®
 WCX-10 WCX 4.0 x 500  WCX buffer A and B  
PepSwift
®
 PS-DVB RP 0.2 x 50 RP buffer A and B 
 
Appendix 7.366: Sample preparation 
 
Intact MS analysis was performed upon purified, concentrated recombinant lysostaphin 
which had been harvested from E.coli BL21(DE3) cultured in LB (Appendix 7.76) and 
purified using IMAC (Appendix 7.114). Following purification, the purified protein was 
concentrated using ultrafiltration (Appendix 7.120).  The purified and concentrated 
recombinant lysostaphin was then separated by WCX prior to intact MS analysis. Further 
details about preparation of recombinant lysostaphin is provided in Appendix 7.367. 
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Appendix 7.367: Purified recombinant lysostaphin preparation 
 
 
Appendix 7.368: WCX separation of purified recombinant lysostaphin   
 
WCX separation was performed using a 0.5 ml/min flow rate and a ProPac® WCX-10 (4 x 
500 mm) column.  Following purification and concentration, 31 mg (500 µl) of a 1:5 dilution 
of N-terminally His-tagged recombinant lysostaphin (construct 1, preparation 16) was 
injected onto the column. Protein isoforms were separated by applying a linear gradient of 0-
50% B over 70 min. The column was then washed using 90% B for 4 min and then the 
column was equilibrated at 0% B for 20 min. UV data was acquired at 214 and 280 nm 
throughout the separation and fractions were collected by time, every 30 s between 20 and 
70 min.  Following separation, fractions 14 and 25 were concentrated and desalted as 
described in Appendix 7.369. Samples were stored at 4°C until they could be analysed by 
LC-MS as described in Section 4.4.2.4.   
 
Appendix 7.369: Concentration of WCX fractions for intact MS analysis 
 
Following WCX purification, selected fractions were desalted and concentrated using 
Nanosep® centrifugal devices with a 10 kDa membrane (Pall Gelman Laboratory, USA). The 
Nanosep® device was placed into a filtrate container and the 250 µl of eluted sample was 
pipetted into the concentrator device. The device was centrifuged at 14,000 x g until the 
volume of sample had reached a minimum volume of 20 µl. The sample was washed and 
desalted by applying 500 µl of 18.2 MΩ/cm H2O to device before centrifuging at 14,000 x g 
for 10 min.  This wash procedure was repeated five times before the resulting sample was 
analysed by intact LC-MS (Section 4.4.2.4).  
 
  
Preparation 
ID 
Construct Expression 
media 
Mode of 
purification 
Protein 
concentration 
(µg/µl) 
Related results 
16 1 LB IMAC 312.23 Appendix 7.313 
Appendix 7.314 
Appendix 7.315 
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Appendix 7.370: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with loss of N-terminal methionine1 
 
 
Appendix 7.371: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with loss of N-terminal glycine2 
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Appendix 7.372: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with loss of N-terminal serine3
 
 
 
Appendix 7.373: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with loss of N-terminal serine4
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Appendix 7.374: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with loss of N-terminal histidine5
 
 
 
Appendix 7.375: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with loss of N-terminal histidine6
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Appendix 7.376: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with loss of C-terminal lysine267
 
 
 
Appendix 7.377: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with loss of C-terminal isoleucine266
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Appendix 7.378: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with loss of C-terminal threonine265
 
 
 
Appendix 7.379: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with loss of C-terminal glycine264
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Appendix 7.380: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with loss of C-terminal tryptophan263
 
 
 
Appendix 7.381: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with loss of C-terminal leucine262 
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Appendix 7.382: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with loss of methionine1
 and lysine267
 
 
 
Appendix 7.383: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with loss of methionine1
 and isoleucine266
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Appendix 7.384: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with loss of methionine1
 and threonine265
 
 
 
Appendix 7.385: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with loss of methionine1
 and glycine264
 
 
 
  
641 
 
Appendix 7.386: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with loss of glycine2
 and lysine267
 
 
 
Appendix 7.387: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with loss of glycine2
 and isoleucine266
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Appendix 7.388: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with loss of glycine2
 and threonine265
 
 
 
Appendix 7.389: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with loss of serine3 and lysine267
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Appendix 7.390: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with loss of serine3
 and isoleucine266
 
 
 
Appendix 7.391: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with loss of serine4
 and lysine267
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Appendix 7.392: ProtParam analysis of N-terminally His-tagged recombinant 
lysostaphin (construct 1) with loss of serine4
 and isoleucine266
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Appendix 7.393: Comparison of full-length and N-terminally truncated apoprotein masses (Da) with intact mass measurements 
obtained during LC-MS of protein eluted in Fraction 14 during WCX separation. 
 
 
 
 
 
  
Intact 
Mass (Da) 
Full-length mass  
(29337.8 Da) 
ΔM1  
(29206.7 Da) 
ΔM1-G2 
(29149.6 Da) 
ΔM1-S3 
(29062.5 Da) 
ΔM1-S4 
(28975.4 Da) 
ΔM1-H5 
(28838.3 Da) 
ΔM1-H6 
(28701.2 Da) 
29050.517 -287.3 -156.2 -99.1 -12.0 75.1 212.2 349.3 
29092.348 -245.5 -114.4 -57.3 29.8 116.9 254.0 391.1 
29147.220 -190.6 -59.5 -2.4 84.7 171.8 308.9 446.0 
29182.920 -154.9 -23.8 33.3 120.4 207.5 344.6 481.7 
29235.798 -102.0 29.1 86.2 173.3 260.4 397.5 534.6 
29280.726 -57.1 74.0 131.1 218.2 305.3 442.4 579.5 
29649.793 312.0 443.1 500.2 587.3 674.4 811.5 948.6 
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Appendix 7.394: Comparison of full-length and C-terminally truncated apoprotein masses (Da) with intact mass measurements 
obtained during LC-MS of protein eluted in Fraction 14 during WCX separation 
 
Intact 
Mass (Da) 
Full-length mass  
(29337.8 Da) 
ΔK267 
(29209.7 Da) 
ΔI266-K267 
(29096.5 Da) 
ΔT265-K267 
(28995.4 Da) 
ΔG264-K267 
(28938.4 Da) 
ΔW263-K267 
(28752.1 Da) 
ΔL262-K267 
(28639.0 Da) 
29050.517 -287.3 -159.2 -46.0 55.1 112.1 298.4 411.5 
29092.348 -245.5 -117.4 -4.2 96.9 153.9 340.3 453.3 
29147.220 -190.6 -62.5 50.7 151.8 208.8 395.12 508.2 
29182.920 -154.9 -26.8 86.4 187.5 244.5 430.8 543.9 
29235.798 -102.0 26.1 139.3 240.4 297.4 483.7 596.8 
29280.726 -57.1 71.0 184.2 285.3 342.3 528.6 641.7 
29649.793 312.0 440.1 553.3 654.4 711.4 897.7 1010.8 
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Appendix 7.395: Comparison of full-length and N- and C-terminally truncated apoprotein masses (Da) with intact mass 
measurements obtained during LC-MS of protein eluted in Fraction 14 during WCX separation. 
 
Intact 
Mass (Da) 
Full-length 
mass 
(29337.8 Da) 
ΔM1+ΔK267 
(29078.5 Da) 
ΔM1+ΔI266-K267 
(28965.3 Da) 
ΔM1+ΔT265-K267 
(28864.2 Da) 
ΔM1+ ΔG264-K267 
(28807.2 Da) 
29050.517 -287.3 -28.0 85.2 186.3 243.3 
29092.348 -245.5 13.8 127.0 228.1 285.1 
29147.22 -190.6 68.7 181.9 283.0 340.0 
29182.92 -154.9 104.4 217.6 318.7 375.7 
29235.798 -102.0 157.3 270.5 371.6 428.6 
29280.726 -57.1 202.2 315.4 416.5 473.5 
29649.793 312.0 571.3 684.5 785.6 842.6 
 
Intact 
Mass (Da) 
ΔM1-G2+ΔK267 
(29021.4 Da) 
ΔM1-G2+ΔI266-K267 
(28908.3 Da) 
ΔM1-G2+ΔT265-K267 
(28807.2 Da) 
ΔM1-S3+ΔK267  
(28934.4 Da) 
ΔM1-S3+ ΔI266-K267  
(28821.2 Da) 
ΔM1-S4+ΔK267 
 (28847.3 Da) 
ΔM1-S4+ΔI266-K267 
(28734.1 Da) 
29050.517 29.1 142.2 243.3 116.1 229.3 203.2 316.4 
29092.348 71.0 184.0 285.2 158.0 271.2 245.1 358.3 
29147.22 125.8 238.9 340.0 212.8 326.0 299.9 413.1 
29182.92 161.5 274.6 375.7 248.5 361.7 335.6 448.8 
29235.798 214.4 327.5 428.6 301.4 414.6 388.5 501.7 
29280.726 259.3 372.4 473.5 346.3 459.6 433.4 546.6 
29649.793 628.4 741.5 842.6 715.4 828.6 802.5 915.7 
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Appendix 7.396: Comparison of full-length and N-terminally truncated apoprotein masses (Da) with intact mass measurements 
obtained during LC-MS of protein eluted in Fraction 25 during WCX separation. 
 
  
Intact 
Mass (Da) 
Full-length mass  
(29337.8 Da) 
ΔM1  
(29206.7 Da) 
ΔM1-G2 
(29149.6 Da) 
ΔM1-S3 
(29062.5 Da) 
ΔM1-S4 
(28975.4 Da) 
ΔM1-H5 
(28838.3 Da) 
ΔM1-H6 
(28701.2 Da) 
28829.1 -508.7 -377.6 -320.5 -233.4 -146.3 -9.2 127.9 
28873.4 -464.4 -333.3 -276.2 -189.1 -102.0 35.1 172.2 
28905.1 -432.7 -301.6 -244.5 -157.4 -70.3 66.8 203.9 
29107.7 -230.1 -99.0 -41.9 45.2 132.3 269.4 406.5 
29150.7 -187.1 -56.0 1.1 88.2 175.3 312.4 449.5 
29336.9 -0.9 130.2 187.3 274.4 361.5 498.6 635.7 
29396.6 58.8 189.9 247.0 334.1 421.2 558.3 695.4 
29441.8 104.0 235.1 292.2 379.3 466.4 603.5 740.6 
29477.0 139.2 270.3 327.4 414.5 501.6 638.7 775.8 
29569.7 231.9 363.0 420.1 507.2 594.3 731.4 868.5 
29630.0 292.2 423.3 480.4 567.5 654.6 791.7 928.8 
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Appendix 7.397: Comparison of full-length and C-terminally truncated apoprotein masses (Da) with intact mass measurements 
obtained during LC-MS of protein eluted in Fraction 25 during WCX separation.  
 
 
 
 
  
Intact 
Mass (Da) 
Full-length mass  
(29337.8 Da) 
ΔK267 
(29209.7Da) 
ΔI266-K267 
(29096.5 Da) 
ΔT265-K267 
(28995.4 Da) 
ΔG264-K267 
(28938.4 Da) 
ΔW263-K267 
(28752.1 Da) 
ΔL262-K267 
(28639.0 Da) 
28829.1 -508.7 -380.6 -267.4 -166.3 -109.3 77.0 190.1 
28873.4 -464.4 -336.3 -223.1 -122.0 -65.0 121.3 234.4 
28905.1 -432.7 -304.6 -191.4 -90.3 -33.3 153.0 266.1 
29107.7 -230.1 -102.0 11.2 112.3 169.3 355.6 468.7 
29150.7 -187.1 -59.0 54.2 155.3 212.3 398.6 511.7 
29336.9 -0.9 127.2 240.4 341.5 398.5 584.8 697.9 
29396.6 58.8 186.9 300.1 401.2 458.2 644.5 757.6 
29441.8 104.0 232.1 345.3 446.4 503.4 689.7 802.8 
29477.0 139.2 267.3 380.5 481.6 538.6 724.9 838.0 
29569.7 231.9 360.0 473.2 574.3 631.3 817.6 930.7 
29630.0 292.2 420.3 533.5 634.6 691.6 877.9 991.0 
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Appendix 7.398: Comparison of full-length and N- and C-terminally truncated apoprotein masses (Da) with intact mass 
measurements obtained during LC-MS of protein eluted in Fraction 25 during WCX separation. 
 
Intact 
Mass (Da) 
Full-length 
mass 
(29337.8 Da) 
ΔM1+ΔK267 
(29078.5 Da) 
ΔM1+ΔI266-K267 
(28965.3 Da) 
ΔM1+ΔT265-K267 
(28864.2 Da) 
ΔM1+ ΔG264-K267 
(28807.2 Da) 
28829.1 -508.7 -249.4 -136.2 -35.1 21.9 
28873.4 -464.4 -205.1 -91.9 9.2 66.2 
28905.1 -432.7 -173.4 -60.2 40.9 97.9 
29107.7 -230.1 29.2 142.4 243.5 300.5 
29150.7 -187.1 72.2 185.4 286.5 343.5 
29336.9 -0.9 258.4 371.6 472.7 529.7 
29396.6 58.8 318.1 431.3 532.4 589.4 
29441.8 104.0 363.3 476.5 577.6 634.6 
29477.0 139.2 398.5 511.7 612.8 669.8 
29569.7 231.9 491.2 604.4 705.5 762.5 
29630.0 292.2 551.5 664.7 765.8 822.8 
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Appendix 7.398: Comparison of full-length and N- and C-terminally truncated apoprotein masses (Da) with intact mass 
measurements obtained during LC-MS of protein eluted in Fraction 25 during WCX separation (continued) 
 
Intact 
Mass (Da) 
ΔM1-G2+ΔK267 
(29021.4 Da) 
ΔM1-G2+ΔI266-K267 
(28908.3 Da) 
ΔM1-G2+ΔT265-K267 
(28807.2 Da) 
ΔM1-S3+ΔK267  
(28934.4 Da) 
ΔM1-S3+ ΔI266-K267  
(28821.2 Da) 
ΔM1-S4+ΔK267 
(28847.3 Da) 
ΔM1-S4+ΔI266-K267 
(28734.1 Da) 
28829.1 -192.3 -79.2 21.9 -105.3 7.9 -18.2 95.0 
28873.4 -148.0 -34.9 66.2 -61.0 52.2 26.1 139.3 
28905.1 -116.3 -3.2 97.9 -29.3 83.9 57.8 171.0 
29107.7 86.3 199.4 300.5 173.3 286.5 260.4 373.6 
29150.7 129.3 242.4 343.5 216.3 329.5 303.4 416.6 
29336.9 315.5 428.6 529.7 402.5 515.7 489.6 602.8 
29396.6 375.2 488.3 589.4 462.2 575.4 549.3 662.5 
29441.8 420.4 533.5 634.6 507.4 620.6 594.5 707.7 
29477.0 455.6 568.7 669.8 542.6 655.8 629.7 742.9 
29569.7 548.3 661.4 762.5 635.3 748.5 722.4 835.6 
29630.0 608.6 721.7 822.8 695.6 808.8 782.7 895.9 
 
 
 
 
 
 
